FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Barrault, L
   Gide, J
   Qing, TT
   Lesueur, L
   Tost, J
   Denis, JA
   Cailleret, M
   Aubry, L
   Peschanski, M
   Martinat, C
   Baghdoyan, S
AF Barrault, Laetitia
   Gide, Jacqueline
   Qing, Tingting
   Lesueur, Lea
   Tost, Jorg
   Denis, Jerome Alexandre
   Cailleret, Michel
   Aubry, Laetitia
   Peschanski, Marc
   Martinat, Cecile
   Baghdoyan, Sandrine
TI Expression of miRNAs from the Imprinted DLK1/DIO3 Locus Signals the
   Osteogenic Potential of Human Pluripotent Stem Cells
SO CELLS
LA English
DT Article
DE human pluripotent stem cells; microRNA; imprinting; osteogenic
   differentiation; variability; ACVR2B
ID ENGINEERING BONE TISSUE; CARDIOVASCULAR PROGENITORS; UNIPARENTAL DISOMY;
   DNA METHYLATION; HUMAN ES; DIFFERENTIATION; LINES; GENES; REGENERATION;
   REGULATOR
AB Substantial variations in differentiation properties have been reported among human pluripotent cell lines (hPSC), which could affect their utility and clinical safety. We characterized the variable osteogenic capacity observed between different human pluripotent stem cell lines. By focusing on the miRNA expression profile, we demonstrated that the osteogenic differentiation propensity of human pluripotent stem cell lines could be associated with the methylation status and the expression of miRNAs from the imprinted DLK1/DIO3 locus. More specifically, quantitative analysis of the expression of six different miRNAs of that locus prospectively identified human embryonic stem cells and human-induced pluripotent stem cells with differential osteogenic differentiation capacities. At the molecular and functional levels, we showed that these miRNAs modulated the expression of the activin receptor type 2B and the downstream signal transduction, which impacted osteogenesis. In conclusion, miRNAs of the imprinted DLK1/DIO3 locus appear to have both a predictive value and a functional impact in determining the osteogenic fate of human pluripotent stem cells.
C1 [Barrault, Laetitia; Gide, Jacqueline; Qing, Tingting; Peschanski, Marc] CECS, AFM, I STEM, F-91100 Corbeil Essonnes, France.
   [Lesueur, Lea; Denis, Jerome Alexandre; Cailleret, Michel; Aubry, Laetitia; Peschanski, Marc; Martinat, Cecile; Baghdoyan, Sandrine] Paris Saclay Univ, UEVE, INSERM, UMR 861,I STEM, F-91100 Corbeil Essonnes, France.
   [Tost, Jorg] CEA, CNRGH, LEE, IBFJ 2, F-91000 Evry, France.
RP Martinat, C (corresponding author), Paris Saclay Univ, UEVE, INSERM, UMR 861,I STEM, F-91100 Corbeil Essonnes, France.
EM lbarrault@istem.fr; jgide@istem.fr; tt.qing@gmail.com;
   llesueur@istem.fr; jorg.tost@cng.fr; jerome.denis@aphp.fr;
   mcailleret@istem.fr; laubry@istem.fr; mpeschanski@istem.fr;
   cmartinat@istem.fr; sbaghdoyan@istem.fr
RI Tost, Joerg/H-7129-2019; Martinat, Cecile/F-6777-2010
OI Tost, Joerg/0000-0002-2683-0817; Martinat, Cecile/0000-0002-5234-1064
FU Association Francaise contre les Myopathies (AFM-Telethon); Laboratoire
   d'Excellence Revive (Investissement d'Avenir)French National Research
   Agency (ANR) [ANR-10-LABX-73]; program "investissement d'avenir"
   INGESTEMFrench National Research Agency (ANR)
FX I-Stem is part of the Biotherapies Institute forRare Diseases (BIRD)
   supported by the Association Francaise contre les Myopathies
   (AFM-Telethon). This project was supported by grants from Laboratoire
   d'Excellence Revive (Investissement d'Avenir; ANR-10-LABX-73) and the
   program "investissement d'avenir" INGESTEM.
CR Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118
   Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Attie KM, 2013, MUSCLE NERVE, V47, P416, DOI 10.1002/mus.23539
   Aykul S, 2016, J BIOL CHEM, V291, P10792, DOI 10.1074/jbc.M115.713487
   Bar S, 2017, CELL REP, V19, P957, DOI 10.1016/j.celrep.2017.04.020
   Barreto R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15040-1
   Bastami F, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12321
   Bialek P, 2014, BONE, V60, P162, DOI 10.1016/j.bone.2013.12.002
   Birket MJ, 2015, NAT BIOTECHNOL, V33, P970, DOI 10.1038/nbt.3271
   Bobbs AS, 2012, J BIOL CHEM, V287, P38505, DOI 10.1074/jbc.M112.400598
   Bock C, 2011, CELL, V144, P439, DOI 10.1016/j.cell.2010.12.032
   Butcher LM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10458
   Campbell C, 2017, MUSCLE NERVE, V55, P458, DOI 10.1002/mus.25268
   Cavaille J, 2002, HUM MOL GENET, V11, P1527, DOI 10.1093/hmg/11.13.1527
   Cheng X, 2012, CELL STEM CELL, V10, P371, DOI 10.1016/j.stem.2012.02.024
   Csobonyeiova M, 2017, J ADV RES, V8, P321, DOI 10.1016/j.jare.2017.02.004
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011
   Daluiski A, 2001, NAT GENET, V27, P84
   de Peppo GM, 2013, P NATL ACAD SCI USA, V110, P8680, DOI 10.1073/pnas.1301190110
   Denis JA, 2011, STEM CELLS DEV, V20, P1395, DOI 10.1089/scd.2010.0331
   DiGirolamo DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2014.42
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Gao Y, 2015, FEBS J, V282, P685, DOI 10.1111/febs.13173
   Georgiades P, 2000, DEVELOPMENT, V127, P4719
   Hayashi Kamichika, 2016, BDJ Open, V2, P15007, DOI 10.1038/bdjopen.2015.7
   Hiura H, 2013, BMC GENET, V14, DOI 10.1186/1471-2156-14-32
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Kagami M, 2008, NAT GENET, V40, P237, DOI 10.1038/ng.2007.56
   Keller A, 2018, HUM REPROD UPDATE, V24, P162, DOI 10.1093/humupd/dmx042
   Kim H, 2011, CELL STEM CELL, V8, P695, DOI 10.1016/j.stem.2011.04.002
   Koch P, 2009, P NATL ACAD SCI USA, V106, P3225, DOI 10.1073/pnas.0808387106
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lin SP, 2003, NAT GENET, V35, P97, DOI 10.1038/ng1233
   Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995
   Manley NC, 2017, STEM CELL TRANSL MED, V6, P1917, DOI 10.1002/sctm.17-0065
   Marolt D, 2012, P NATL ACAD SCI USA, V109, P8705, DOI 10.1073/pnas.1201830109
   Matsumoto Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-190
   Menasche P, 2018, J AM COLL CARDIOL, V71, P429, DOI 10.1016/j.jacc.2017.11.047
   Mi HY, 2009, METHODS MOL BIOL, V563, P123, DOI 10.1007/978-1-60761-175-2_7
   Mo CF, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt535
   Nazor KL, 2012, CELL STEM CELL, V10, P620, DOI 10.1016/j.stem.2012.02.013
   Nishizawa M, 2016, CELL STEM CELL, V19, P341, DOI 10.1016/j.stem.2016.06.019
   Olsen OE, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0104-z
   Ortmann D, 2017, CURR OPIN GENET DEV, V46, P179, DOI 10.1016/j.gde.2017.07.004
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pick M, 2009, STEM CELLS, V27, P2686, DOI 10.1002/stem.205
   Quarto N, 2012, P NATL ACAD SCI USA, V109, P215, DOI 10.1073/pnas.1113442109
   Saito A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-017-0754-4
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304
   Senanayake U, 2012, CARCINOGENESIS, V33, P1014, DOI 10.1093/carcin/bgs126
   Sheyn D, 2016, STEM CELL TRANSL MED, V5, P1447, DOI 10.5966/sctm.2015-0311
   Sparks NRL, 2018, STEM CELLS, V36, P349, DOI 10.1002/stem.2746
   Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017
   Sutton VR, 2003, HUM GENET, V113, P447, DOI 10.1007/s00439-003-0981-x
   Tabar V, 2014, NAT REV GENET, V15, P82, DOI 10.1038/nrg3563
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Wang YH, 2009, CELL METAB, V9, P287, DOI 10.1016/j.cmet.2009.01.013
   Wei FL, 2015, STEM CELLS DEV, V24, P312, DOI 10.1089/scd.2014.0191
   Yang DD, 2016, LIFE SCI, V164, P9, DOI 10.1016/j.lfs.2016.09.004
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang Y, 2011, BONE, V48, pS123, DOI 10.1016/j.bone.2011.03.232
   Zhu LL, 2016, J CELL BIOL, V215, P187, DOI 10.1083/jcb.201601061
NR 66
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD DEC
PY 2019
VL 8
IS 12
AR 1523
DI 10.3390/cells8121523
PG 17
WC Cell Biology
SC Cell Biology
GA KB7AN
UT WOS:000506643500051
PM 31779280
OA DOAJ Gold, Green Published
DA 2020-08-12
ER

PT J
AU Nossent, AY
   Ektefaie, N
   Wojta, J
   Eichelberger, B
   Kopp, C
   Panzer, S
   Gremmel, T
AF Nossent, Anne Yael
   Ektefaie, Neda
   Wojta, Johann
   Eichelberger, Beate
   Kopp, Christoph
   Panzer, Simon
   Gremmel, Thomas
TI Plasma Levels of snoRNAs are Associated with Platelet Activation in
   Patients with Peripheral Artery Disease
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE peripheral artery disease; restenosis; angioplasty; snoRNA; platelets
ID ANKLE BRACHIAL INDEX; CIRCULATING MICRORNAS; INHIBITION; EXPRESSION;
   REACTIVITY; MIR-487B; RECOVERY; MARKERS; RISK
AB In addition to supervised walking therapy, antithrombotic therapy and the management of risk factors, the treatment of peripheral artery disease (PAD) is limited to endovascular and surgical interventions, i.e., angioplasty with stent implantation and bypass surgery, respectively. Both are associated with a high restenosis rate. Furthermore, patients with PAD often suffer atherothrombotic events like myocardial infarction, transient ischemic attacks or stroke. Small ribonucleic acids (RNAs) have proven reliable biomarkers because of their remarkable stability. Small nucleolar RNAs (snoRNAs) guide modifications to small nuclear RNAs and ribosomal RNAs, enabling protein synthesis. In the current study, we measured four snoRNAs in 104 consecutive PAD patients who underwent elective infrainguinal angioplasty with stent implantation. We selected snoRNAs that showed significant overexpression in the plasma of end-stage PAD patients in a previous study. All four snoRNAs are transcribed from the 14q32 locus, which is strongly linked to human cardiovascular disease, including PAD and restenosis. We showed that the four selected 14q32 snoRNAs were abundantly expressed in the plasma of PAD patients. The plasma levels of these snoRNAs were not directly associated with target vessel restenosis, however, levels of SNORD113.2 and SNORD114.1 were strongly linked to platelet activation, which is an important determinant of long-term outcome, in PAD, and in cardiovascular disease in general.
C1 [Nossent, Anne Yael] Med Univ Vienna, Dept Lab Med, A-1090 Vienna, Austria.
   [Nossent, Anne Yael; Ektefaie, Neda; Wojta, Johann; Kopp, Christoph; Gremmel, Thomas] Med Univ Vienna, Dept Internal Med 2, A-1090 Vienna, Austria.
   [Nossent, Anne Yael] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands.
   [Nossent, Anne Yael] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, NL-2300 RC Leiden, Netherlands.
   [Wojta, Johann] Med Univ Vienna, Core Facil, A-1090 Vienna, Austria.
   [Wojta, Johann] Ludwig Boltzmann Cluster Cardiovasc Res, A-1090 Vienna, Austria.
   [Eichelberger, Beate; Panzer, Simon] Med Univ Vienna, Dept Blood Grp Serol & Transfus Med, A-1090 Vienna, Austria.
   [Gremmel, Thomas] Landesklinikum Wiener Neustadt, Dept Internal Med Cardiol & Nephrol, A-2700 Wiener Neustadt, Austria.
RP Gremmel, T (corresponding author), Med Univ Vienna, Dept Internal Med 2, A-1090 Vienna, Austria.; Gremmel, T (corresponding author), Landesklinikum Wiener Neustadt, Dept Internal Med Cardiol & Nephrol, A-2700 Wiener Neustadt, Austria.
EM a.y.nossent@lumc.nl; nektefaie@cemm.at; johann.wojta@meduniwien.ac.at;
   thrombozytenlabor@meduniwien.ac.at; christoph.kopp@meduniwien.ac.at;
   simon@wsn.at; thomas.gremmel@meduniwien.ac.at
RI Wojta, Johann/AAC-8433-2020
OI Wojta, Johann/0000-0002-1282-9276; Gremmel, Thomas/0000-0001-9554-7292;
   Nossent, Anne Yael/0000-0002-2155-4286
FU Lise Meitner Grant from the Austrian Science Fund [M2578-B30]
FX A.Y.N. was supported by a Lise Meitner Grant from the Austrian Science
   Fund (M2578-B30).
CR Badrnya S, 2014, ARTERIOSCL THROM VAS, V34, P571, DOI 10.1161/ATVBAHA.113.302919
   Bliden KP, 2008, J AM COLL CARDIOL, V52, P531, DOI 10.1016/j.jacc.2008.04.045
   Cavaille J, 2002, HUM MOL GENET, V11, P1527, DOI 10.1093/hmg/11.13.1527
   Diehm C, 2006, EUR HEART J, V27, P1743, DOI 10.1093/eurheartj/ehl092
   Edelstein LC, 2013, NAT MED, V19, P1609, DOI 10.1038/nm.3385
   Gremmel T, 2016, THROMB HAEMOSTASIS, V115, P615, DOI 10.1160/TH15-07-0598
   Gremmel T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129666
   Gremmel T, 2014, THROMB HAEMOSTASIS, V111, P474, DOI 10.1160/TH13-07-0558
   Gremmel T, 2014, ATHEROSCLEROSIS, V232, P119, DOI 10.1016/j.atherosclerosis.2013.10.027
   Gremmel T, 2011, THROMB HAEMOSTASIS, V106, P211, DOI 10.1160/TH11-03-0137
   Gremmel T, 2009, THROMB RES, V124, P588, DOI 10.1016/j.thromres.2009.06.012
   Gremmel T, 2009, THROMB HAEMOSTASIS, V101, P333, DOI 10.1160/TH08-09-0577
   Hakansson KEJ, 2019, CARDIOVASC RES, V115, P1519, DOI 10.1093/cvr/cvy309
   Hakansson KEJ, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01136
   Hiatt WR, 2015, CIRC RES, V116, P1527, DOI 10.1161/CIRCRESAHA.116.303566
   Hiatt WR, 2008, CIRCULATION, V118, P2826, DOI 10.1161/CIRCULATIONAHA.108.191171
   Jorjani H, 2016, NUCLEIC ACIDS RES, V44, P5068, DOI 10.1093/nar/gkw386
   Jukema JW, 2012, NAT REV CARDIOL, V9, P53, DOI 10.1038/nrcardio.2011.132
   Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617
   Lee AJ, 2004, CIRCULATION, V110, P3075, DOI 10.1161/01.CIR.0000143102.38256.DE
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Nossent AY, 2013, ANN SURG, V258, P743, DOI 10.1097/SLA.0b013e3182a6aac0
   Stather PW, 2013, CIRC-CARDIOVASC GENE, V6, P490, DOI 10.1161/CIRCGENETICS.111.000053
   Stojkovic S, 2018, ATHEROSCLEROSIS, V269, P197, DOI 10.1016/j.atherosclerosis.2018.01.020
   van Ingen E, 2019, MOL THER-NUCL ACIDS, V18, P638, DOI 10.1016/j.omtn.2019.09.021
   Welten GMJM, 2008, J AM COLL CARDIOL, V51, P1588, DOI 10.1016/j.jacc.2007.11.077
   Welten SMJ, 2016, CARDIOVASC RES, V110, P6, DOI 10.1093/cvr/cvw039
   Welten SMJ, 2017, ATHEROSCLEROSIS, V261, P26, DOI 10.1016/j.atherosclerosis.2017.04.011
   Welten SMJ, 2014, CIRC RES, V115, P696, DOI 10.1161/CIRCRESAHA.114.304747
   Wezel A, 2015, ANN SURG, V262, P841, DOI 10.1097/SLA.0000000000001466
   Xi SC, 2013, J CLIN INVEST, V123, P1241, DOI 10.1172/JCI61271
NR 31
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2019
VL 20
IS 23
AR 5975
DI 10.3390/ijms20235975
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA JY5AR
UT WOS:000504428300157
PM 31783567
OA DOAJ Gold, Green Published
DA 2020-08-12
ER

PT J
AU Goossens, EAC
   de Vries, MR
   Simons, KH
   Putter, H
   Quax, PHA
   Nossent, AY
AF Goossens, Eveline A. C.
   de Vries, Margreet R.
   Simons, Kahn H.
   Putter, Hein
   Quax, Paul H. A.
   Nossent, A. Yael
TI miRMap: Profiling 14q32 microRNA Expression and DNA Methylation
   Throughout the Human Vasculature
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE microRNA; DNA methylation; 14q32; DLK1-DIO3; cardiovascular
ID INTERNAL MAMMARY ARTERY; SAPHENOUS-VEIN; INHIBITION; PATHOGENESIS;
   CLUSTER; NEOVASCULARIZATION; ATHEROSCLEROSIS; PROLIFERATION;
   THERAPEUTICS; METASTASIS
AB Aims: MicroRNAs are regulators of (patho)physiological functions with tissue-specific expression patterns. However, little is known about inter-vascular differences in microRNA expression between blood vessel types or vascular beds. Differences in microRNA expression could influence cardiovascular pathophysiology at specific sites in the vasculature. Therefore, we aimed to map expression pro files of vasoaCctive 14q32 microRNAs throughout the human vasculature, as well as expression of vasoactive target genes of the 14q32 microRNAs. Furthermore, we aimed to map the DNA methylation status of the 14q32 locus, which has been linked to cardiovascular disease.
   Methods and Results: We collected 109 samples from different blood vessels, dissected during general surgery. Expression of a representative set of 17 14q32 microRNAs was measured in each sample. All 17 microRNAs showed a unique expression pattern throughout the vasculature. 14q32 microRNA expression was highest in lower limb vessels and lowest in head and neck vessels. All 17 microRNAs were expressed more abundantly in arteries than in veins. Throughout the human vasculature, we observed trends toward an inverse correlation between expression levels of the 14q32 microRNAs and their vasoactive target genes. DNA methylation of the 3 Differentially Methylated Regions (DMRs) along the 14q32 locus did not associate with primary or mature microRNA expression. However, hyper-methylation in venous coronary artery bypass grafts compared to arterial bypass grafts was observed in the Intergenic-DMR and MEG3-DMR. In patients with end-stage peripheral arterial disease we found differential DNA methylation throughout all DMRs in their lower limb veins. These findings were con firmed in a mouse model for vein-graft disease in which we found regulated 14q32 DNA methylation during the active phase of vascular remodeling. In ischemic tissues of a murine hind limb ischemia model we observed an increase in DNA methylation associated with increased ischemia over time.
   Conclusions: We show that 14q32 microRNAs are abundantly expressed in the human vasculature and that expression differs significantly between different blood vessels. 14q32 DNA methylation also varies throughout the vasculature and is associated with vascular health, independently of microRNA levels. These findings could have important implications for future research and for future site-specific targeting of epigenetics-based therapeutics.
C1 [Goossens, Eveline A. C.; de Vries, Margreet R.; Simons, Kahn H.; Quax, Paul H. A.; Nossent, A. Yael] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands.
   [Goossens, Eveline A. C.; de Vries, Margreet R.; Simons, Kahn H.; Quax, Paul H. A.] Leiden Univ, Med Ctr, Einthoven Lab Expt Med, Leiden, Netherlands.
   [Putter, Hein] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands.
   [Nossent, A. Yael] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
   [Nossent, A. Yael] Med Univ Vienna, Dept Internal Med 2, Vienna, Austria.
RP Nossent, AY (corresponding author), Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands.; Nossent, AY (corresponding author), Med Univ Vienna, Dept Lab Med, Vienna, Austria.; Nossent, AY (corresponding author), Med Univ Vienna, Dept Internal Med 2, Vienna, Austria.
EM a.y.nossent@lumc.nl
RI Putter, Hein/C-2244-2018; Goossens, Eveline/V-3981-2018
OI Putter, Hein/0000-0001-5395-1422; Goossens, Eveline/0000-0002-5080-9639;
   Nossent, Anne Yael/0000-0002-2155-4286; Quax, Paul/0000-0002-6853-5760
FU MD/PhD Fellowship from the LUMC
FX This work was supported by an MD/PhD Fellowship from the LUMC to Eveline
   Goossens.
CR Aavik E, 2015, EUR HEART J, V36, P993, DOI 10.1093/eurheartj/ehu437
   Anand Sudarshan, 2011, Genes Cancer, V2, P1134, DOI 10.1177/1947601911423032
   Bonauer A, 2010, CURR DRUG TARGETS, V11, P943, DOI 10.2174/138945010791591313
   Burgess KS, 2015, CLIN PHARMACOL THER, V98, P205, DOI 10.1002/cpt.145
   Cheng YH, 2009, CIRC RES, V105, P158, DOI 10.1161/CIRCRESAHA.109.197517
   Cunningham KS, 2005, LAB INVEST, V85, P9, DOI 10.1038/labinvest.3700215
   Dai RJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153509
   de Vries MR, 2019, J INTERN MED, V285, P59, DOI 10.1111/joim.12821
   de Vries MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047134
   Dmitrijeva M, 2018, NUCLEIC ACIDS RES, V46, P7022, DOI 10.1093/nar/gky498
   El-Maarri O, 2007, HUM GENET, V122, P505, DOI 10.1007/s00439-007-0430-3
   Enterina JR, 2017, EXPERT REV RESP MED, V11, P749, DOI 10.1080/17476348.2017.1355241
   Fan XJ, 2015, GENET MOL RES, V14, P9062, DOI 10.4238/2015.August.7.15
   Gaudino M, 2018, NEW ENGL J MED, V378, P2069, DOI 10.1056/NEJMoa1716026
   Goldman S, 2004, J AM COLL CARDIOL, V44, P2149, DOI 10.1016/j.jacc.2004.08.064
   Golledge J, 2006, ARTERIOSCL THROM VAS, V26, P2605, DOI 10.1161/01.ATV.0000245819.32762.cb
   Gonzalez-Vallinas M, 2018, MOL CANCER RES, V16, P390, DOI 10.1158/1541-7786.MCR-17-0334
   Guo W, 2017, MOL CARCINOGEN, V56, P1924, DOI 10.1002/mc.22650
   Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105
   Heuslein JL, 2019, CARDIOVASC RES, V115, P701, DOI 10.1093/cvr/cvz001
   Iliopoulos D, 2010, J LIPID RES, V51, P1513, DOI 10.1194/jlr.M004812
   Jeltsch A, 2014, TRENDS BIOCHEM SCI, V39, P310, DOI 10.1016/j.tibs.2014.05.002
   Jeon HH, 2018, J PATHOL, V245, P258, DOI 10.1002/path.5075
   Juzenas S, 2017, NUCLEIC ACIDS RES, V45, P9290, DOI 10.1093/nar/gkx706
   Kameswaran V, 2014, CELL METAB, V19, P135, DOI 10.1016/j.cmet.2013.11.016
   Kin K, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.000745
   Kwekel JC, 2017, BIOL SEX DIFFER, V8, DOI 10.1186/s13293-017-0127-9
   Lardenoye JHP, 2002, CIRC RES, V91, P577, DOI 10.1161/01.RES.0000036901.58329.D7
   Liu D, 2015, THROMB RES, V135, P146, DOI 10.1016/j.thromres.2014.10.027
   Liu JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010028
   LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248
   Markus B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161632
   Martinez-Micaelo N, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00648
   Moradi S, 2017, STEM CELL REP, V9, P2081, DOI 10.1016/j.stemcr.2017.10.009
   Nossent AY, 2013, ANN SURG, V258, P743, DOI 10.1097/SLA.0b013e3182a6aac0
   Oshima G, 2019, CANCER RES, V79, P650, DOI 10.1158/0008-5472.CAN-18-0692
   Parahuleva MS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25690-4
   Parsons C, 2018, TRENDS CARDIOVAS MED, V28, P524, DOI 10.1016/j.tcm.2018.05.002
   Pathak S, 2015, ONCOTARGET, V6, P44758, DOI 10.18632/oncotarget.5815
   Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798
   Schober A, 2014, NAT MED, V20, P368, DOI 10.1038/nm.3487
   Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304
   Shayevitch R, 2018, RNA, V24, P1351, DOI 10.1261/rna.064865.117
   Teruel-Montoya R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102259
   Tho LC, 2016, THERANOSTICS, V6, P2068, DOI 10.7150/thno.15007
   Thum T, 2007, CIRCULATION, V116, P258, DOI 10.1161/CIRCULATIONAHA.107.687947
   Thum T, 2012, EMBO MOL MED, V4, P3, DOI 10.1002/emmm.201100191
   Treiber T, 2017, MOL CELL, V66, P270, DOI 10.1016/j.molcel.2017.03.014
   van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103
   van Rooij E, 2012, NAT REV DRUG DISCOV, V11, P860, DOI 10.1038/nrd3864
   van Solingen C, 2009, J CELL MOL MED, V13, P1577, DOI 10.1111/j.1582-4934.2008.00613.x
   Velasco ADR, 2019, MOL THER-NUCL ACIDS, V14, P329, DOI 10.1016/j.omtn.2018.11.017
   Wang P, 2013, MOL CELL BIOL, V33, P3689, DOI 10.1128/MCB.00343-13
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang XH, 2010, CIRCULATION, V122, P1308, DOI 10.1161/CIRCULATIONAHA.110.964684
   Wang YS, 2012, CARDIOVASC RES, V95, P517, DOI 10.1093/cvr/cvs223
   Watson CJ, 2014, HUM MOL GENET, V23, P2176, DOI 10.1093/hmg/ddt614
   Wei YY, 2013, ARTERIOSCL THROM VAS, V33, P449, DOI 10.1161/ATVBAHA.112.300279
   Welten SMJ, 2016, CARDIOVASC RES, V110, P6, DOI 10.1093/cvr/cvw039
   Welten SMJ, 2017, MOL THER-NUCL ACIDS, V7, P61, DOI 10.1016/j.omtn.2017.03.003
   Welten SMJ, 2017, ATHEROSCLEROSIS, V261, P26, DOI 10.1016/j.atherosclerosis.2017.04.011
   Welten SMJ, 2014, CIRC RES, V115, P696, DOI 10.1161/CIRCRESAHA.114.304747
   Wezel A, 2015, ANN SURG, V262, P841, DOI 10.1097/SLA.0000000000001466
   Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519
   Wilhelm K, 2016, NATURE, V529, P216, DOI 10.1038/nature16498
   Xi SC, 2013, J CLIN INVEST, V123, P1241, DOI 10.1172/JCI61271
   Xiao FH, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00107
   Yao GD, 2018, ONCOL LETT, V15, P991, DOI 10.3892/ol.2017.7381
NR 68
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2297-055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD AUG 8
PY 2019
VL 6
AR 113
DI 10.3389/fcvm.2019.00113
PG 22
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA IO3BI
UT WOS:000479255100001
PM 31440517
OA DOAJ Gold, Green Published
DA 2020-08-12
ER

PT J
AU Hakansson, KEJ
   Goossens, EAC
   Trompet, S
   van Ingen, E
   de Vries, MR
   van der Kwast, RVCT
   Ripa, RS
   Kastrup, J
   Hohensinner, PJ
   Kaun, C
   Wojta, J
   Bohringer, S
   Le Cessie, S
   Jukema, JW
   Quax, PHA
   Nossent, AY
AF Hakansson, Kjell E. J.
   Goossens, Eveline A. C.
   Trompet, Stella
   van Ingen, Eva
   de Vries, Margreet R.
   van der Kwast, Reginald V. C. T.
   Ripa, Rasmus S.
   Kastrup, Jens
   Hohensinner, Philipp J.
   Kaun, Christoph
   Wojta, Johann
   Bohringer, Stefan
   Le Cessie, Saskia
   Jukema, J. Wouter
   Quax, Paul H. A.
   Nossent, A. Yael
TI Genetic associations and regulation of expression indicate an
   independent role for 14q32 snoRNAs in human cardiovascular disease
SO CARDIOVASCULAR RESEARCH
LA English
DT Article
DE Non-coding RNA; snoRNA; Cardiovascular disease; 14q32 locus; DLK1-DIO3;
   STEMI; Vessels; Vascular tissue
ID LONG NONCODING RNAS; SMALL NUCLEOLAR RNAS; MICRORNAS; INHIBITION;
   IDENTIFICATION; PRAVASTATIN; RISK
AB Aims We have shown that 14q32 microRNAs are highly involved in vascular remodelling and cardiovascular disease. However, the 14q32 locus also encodes 41 'orphan' small nucleolar RNAs (snoRNAs). We aimed to gather evidence for an independent role for 14q32 snoRNAs in human cardiovascular disease.
   Methods and results We performed a lookup of the 14q32 region within the dataset of a genome wide association scan in 5244 participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Single nucleotide polymorphisms (SNPs) in the snoRNA-cluster were significantly associated with heart failure. These snoRNA-cluster SNPs were not linked to SNPs in the microRNA-cluster or in MEG3, indicating that snoRNAs modify the risk of cardiovascular disease independently. We looked at expression of 14q32 snoRNAs throughout the human cardio-vasculature. Expression profiles of the 14q32 snoRNAs appeared highly vessel specific. When we compared expression levels of 14q32 snoRNAs in human vena saphena magna (VSM) with those in failed VSM-coronary bypasses, we found that 14q32 snoRNAs were up-regulated. SNORD113.2, which showed a 17-fold up-regulation in failed bypasses, was also up-regulated two-fold in plasma samples drawn from patients with ST-elevation myocardial infarction directly after hospitalization compared with 30 days after start of treatment. However, fitting with the genomic associations, 14q32 snoRNA expression was highest in failing human hearts. In vitro studies show that the 14q32 snoRNAs bind predominantly to methyl-transferase Fibrillarin, indicating that they act through canonical mechanisms, but on non-canonical RNA targets. The canonical C/D-box snoRNA seed sequences were highly conserved between humans and mice.
   Conclusion 14q32 snoRNAs appear to play an independent role in cardiovascular pathology. 14q32 snoRNAs are specifically regulated throughout the human vasculature and their expression is up-regulated during cardiovascular disease. Our data demonstrate that snoRNAs merit increased effort and attention in future basic and clinical cardiovascular research.
C1 [Hakansson, Kjell E. J.; Goossens, Eveline A. C.; van Ingen, Eva; de Vries, Margreet R.; van der Kwast, Reginald V. C. T.; Quax, Paul H. A.; Nossent, A. Yael] Leiden Univ, Med Ctr, Dept Surg, K6-R, NL-2333 AA Leiden, Netherlands.
   [Hakansson, Kjell E. J.; Goossens, Eveline A. C.; van Ingen, Eva; de Vries, Margreet R.; van der Kwast, Reginald V. C. T.; Quax, Paul H. A.; Nossent, A. Yael] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, Leiden, Netherlands.
   [Trompet, Stella; Jukema, J. Wouter] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands.
   [Trompet, Stella] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands.
   [Ripa, Rasmus S.; Kastrup, Jens] Univ Copenhagen, Rigshosp, Dept Cardiol, Copenhagen, Denmark.
   [Hohensinner, Philipp J.; Kaun, Christoph; Wojta, Johann] Med Univ Vienna, Dept Internal Med 2, Vienna, Austria.
   [Bohringer, Stefan; Le Cessie, Saskia] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands.
   [Le Cessie, Saskia] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands.
   [Nossent, A. Yael] Ludwig Boltzmann Cluster Cardiovasc Res, Vienna, Austria.
RP Nossent, AY (corresponding author), Leiden Univ, Med Ctr, Dept Surg, K6-R, NL-2333 AA Leiden, Netherlands.; Nossent, AY (corresponding author), Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, Leiden, Netherlands.; Nossent, AY (corresponding author), Ludwig Boltzmann Cluster Cardiovasc Res, Vienna, Austria.
EM a.y.nossent@lumc.nl
RI Goossens, Eveline/V-3981-2018; Wojta, Johann/AAC-8433-2020; Hakansson,
   Kjell EJ/D-3997-2016
OI Goossens, Eveline/0000-0002-5080-9639; Wojta,
   Johann/0000-0002-1282-9276; Hakansson, Kjell EJ/0000-0001-5804-0740;
   Hohensinner, Philipp/0000-0003-4819-3190; Nossent, Anne
   Yael/0000-0002-2155-4286; van der Kwast, Reginald/0000-0002-0436-3621;
   Quax, Paul/0000-0002-6853-5760
FU Netherlands Heart FoundationNetherlands Heart Foundation [2014T102];
   European commissionEuropean Commission Joint Research Centre [223004];
   Netherlands Genomics Initiative [Netherlands Consortium for Healthy
   Aging] [050-060-810]; Danish Council for Independent Research-DFF
   Medical Sciences [6120-00049B]
FX This work was supported by grants from the Netherlands Heart Foundation
   [2014T102]. Support for genotyping within the PROSPER/PHASE study was
   provided by the seventh framework programme of the European commission
   [223004]; and by the Netherlands Genomics Initiative [Netherlands
   Consortium for Healthy Aging 050-060-810]. This work was also supported
   by The Danish Council for Independent Research-DFF Medical Sciences
   [6120-00049B].
CR Archer K, 2015, INT J MOL SCI, V16, P23651, DOI 10.3390/ijms161023651
   Ballantyne MD, 2016, CLIN PHARMACOL THER, V99, P494, DOI 10.1002/cpt.355
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Boon RA, 2016, J AM COLL CARDIOL, V68, P2589, DOI 10.1016/j.jacc.2016.09.949
   Boon RA, 2016, J AM COLL CARDIOL, V67, P1214, DOI 10.1016/j.jacc.2015.12.051
   Brandis KA, 2013, J BIOL CHEM, V288, P35703, DOI 10.1074/jbc.M113.488577
   Busch A, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.06
   Cavaille J, 2002, HUM MOL GENET, V11, P1527, DOI 10.1093/hmg/11.13.1527
   Cavaille J, 1996, BIOCHIMIE, V78, P443, DOI 10.1016/0300-9084(96)84751-1
   Creemers EE, 2016, CIRC RES, V118, P108, DOI 10.1161/CIRCRESAHA.115.305242
   Dechamethakun S, 2017, J HUM GENET, V62, P97, DOI 10.1038/jhg.2016.70
   Devaux Y, 2015, NAT REV CARDIOL, V12, P415, DOI 10.1038/nrcardio.2015.55
   Ender C, 2008, MOL CELL, V32, P519, DOI 10.1016/j.molcel.2008.10.017
   Falaleeva M, 2015, GENE, V572, P266, DOI 10.1016/j.gene.2015.07.023
   Gordon FE, 2010, ENDOCRINOLOGY, V151, P2443, DOI 10.1210/en.2009-1151
   Kishore S, 2010, HUM MOL GENET, V19, P1153, DOI 10.1093/hmg/ddp585
   KISS T, 1995, GENE DEV, V9, P1411, DOI 10.1101/gad.9.11.1411
   Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617
   Lorenzen JM, 2016, NAT REV NEPHROL, V12, P360, DOI 10.1038/nrneph.2016.51
   Machiela MJ, 2018, BIOINFORMATICS, V34, P887, DOI 10.1093/bioinformatics/btx561
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Michalik KM, 2014, CIRC RES, V114, P1389, DOI 10.1161/CIRCRESAHA.114.303265
   Michel CI, 2011, CELL METAB, V14, P33, DOI 10.1016/j.cmet.2011.04.009
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Nossent AY, 2013, ANN SURG, V258, P743, DOI 10.1097/SLA.0b013e3182a6aac0
   Ounzain S, 2015, J MOL CELL CARDIOL, V89, P17, DOI 10.1016/j.yjmcc.2015.09.013
   Philippen LE, 2015, J MOL CELL CARDIOL, V89, P51, DOI 10.1016/j.yjmcc.2015.03.014
   Ploner A, 2009, RNA, V15, P1797, DOI 10.1261/rna.1740009
   Ripa RS, 2006, CIRCULATION, V113, P1983, DOI 10.1161/CIRCULATIONAHA.105.610469
   Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X
   Shepherd J, 1999, AM J CARDIOL, V84, P1192, DOI 10.1016/S0002-9149(99)00533-0
   Simons KH, 2017, J INTERN MED, V282, P522, DOI 10.1111/joim.12679
   Taulli R, 2012, J CLIN INVEST, V122, P2765, DOI 10.1172/JCI63549
   Taylor J, 2005, BIOSTATISTICS, V7, P167
   Thum T, 2015, CIRC RES, V116, P751, DOI 10.1161/CIRCRESAHA.116.303549
   Trompet S, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-131
   Uchida T, 2004, BLOOD, V104, P2081, DOI 10.1182/blood-2004-02-0715
   Valleron W, 2012, LEUKEMIA, V26, P2052, DOI 10.1038/leu.2012.111
   van der Kwast RVCT, 2018, CIRC RES, V122, P444, DOI 10.1161/CIRCRESAHA.117.312345
   Vitali P, 2005, J CELL BIOL, V169, P745, DOI 10.1083/jcb.200411129
   Welten SMJ, 2016, CARDIOVASC RES, V110, P6, DOI 10.1093/cvr/cvw039
   Welten SMJ, 2017, ATHEROSCLEROSIS, V261, P26, DOI 10.1016/j.atherosclerosis.2017.04.011
   Welten SMJ, 2014, CIRC RES, V115, P696, DOI 10.1161/CIRCRESAHA.114.304747
   Wezel A, 2015, ANN SURG, V262, P841, DOI 10.1097/SLA.0000000000001466
NR 44
TC 5
Z9 5
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008-6363
EI 1755-3245
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD AUG 1
PY 2019
VL 115
IS 10
BP 1519
EP 1532
DI 10.1093/cvr/cvy309
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA JH6CB
UT WOS:000492854700016
PM 30544252
DA 2020-08-12
ER

PT J
AU Huan, TX
   Mendelson, M
   Joehanes, R
   Yao, C
   Liu, CY
   Song, C
   Bhattachary, A
   Rong, J
   Tanriverdi, K
   Keefe, J
   Murabito, JM
   Courchesne, P
   Larson, MG
   Freedman, JE
   Levy, D
AF Huan, Tianxiao
   Mendelson, Michael
   Joehanes, Roby
   Yao, Chen
   Liu, Chunyu
   Song, Ci
   Bhattachary, Anindya
   Rong, Jian
   Tanriverdi, Kahraman
   Keefe, Joshua
   Murabito, Joanne M.
   Courchesne, Paul
   Larson, Martin G.
   Freedman, Jane E.
   Levy, Daniel
TI Epigenome-wide association study of DNA methylation and microRNA
   expression highlights novel pathways for human complex traits
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; microRNA; miR-eQTM; eQTM; complex traits; age at
   menarche
ID MENDELIAN RANDOMIZATION ANALYSIS; GENE-EXPRESSION; HEART; EPIGENETICS;
   SIGNATURES; DISCOVERY; SEQUENCE; DESIGN; ORIGIN; CANCER
AB DNA methylation (DNAm) and microRNAs (miRNAs) have been implicated in a wide-range of human diseases. While often studied in isolation, DNAm and miRNAs are not independent. We analyzed associations of expression of 283 miRNAs with DNAm at >400K CpG sites in whole blood obtained from 3565 individuals and identified 227 CpGs at which differential methylation was associated with the expression of 40 nearby miRNAs (cis-miR-eQTMs) at FDR<0.01, including 91 independent CpG sites at r(2) cis-miR-eQTMs were enriched for CpGs in promoter and polycomb-repressed state regions, and 60% were inversely associated with miRNA expression. Bidirectional Mendelian randomization (MR) analysis further identified 58 cis-miR-eQTMCpG-miRNA pairs where DNAm changes appeared to drive miRNA expression changes and opposite directional effects were unlikely. Integration of genetic variants in joint analyses revealed an average partial between cis-miR-eQTM CpGs and miRNAs of 2% after conditioning on site-specific genetic variation, suggesting that DNAm is an important epigenetic regulator of miRNA expression. Finally, two-step MR analysis was performed to identify putatively causal CpGs driving miRNA expression in relation to human complex traits. We found that an imprinted region on 14q32 that was previously identified in relation to age at menarche is enriched with cis-miR-eQTMs. Nine CpGs and three miRNAs at this locus tested causal for age at menarche, reflecting novel epigenetic-driven molecular pathways underlying this complex trait. Our study sheds light on the joint genetic and epigenetic regulation of miRNA expression and provides insights into the relations of miRNAs to their targets and to complex phenotypes.
C1 [Huan, Tianxiao; Mendelson, Michael; Joehanes, Roby; Yao, Chen; Liu, Chunyu; Song, Ci; Keefe, Joshua; Murabito, Joanne M.; Courchesne, Paul; Larson, Martin G.; Levy, Daniel] Boston Univ, Framingham Heart Study, NHLBI, Framingham, MA USA.
   [Huan, Tianxiao; Mendelson, Michael; Joehanes, Roby; Yao, Chen; Liu, Chunyu; Song, Ci; Keefe, Joshua; Courchesne, Paul; Levy, Daniel] NHLBI, Populat Sci Branch, Div Intramural Res, Bldg 10, Bethesda, MD 20892 USA.
   [Liu, Chunyu] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Bhattachary, Anindya] Univ Calif San Diego, Dept Comp Sci & Engn, San Diego, CA 92103 USA.
   [Rong, Jian; Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
   [Tanriverdi, Kahraman; Freedman, Jane E.] Univ Massachusetts, Med Sch, Dept Med, Worcester, MA USA.
   [Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Sect Gen Internal Med, Boston, MA 02118 USA.
RP Huan, TX; Levy, D (corresponding author), Framingham Heart Dis Epidemiol Study, 73 Mt Wayte Ave, Framingham, MA 01702 USA.
EM Tianxiao.huan@nih.gov; levyd@nhlbi.nih.gov
RI Mendelson, Michael/I-2874-2014
OI Mendelson, Michael/0000-0001-7590-3958; Huan,
   Tianxiao/0000-0001-5840-9413; Levy, Daniel/0000-0003-1843-8724; yao,
   chen/0000-0002-3944-7788
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [N01-HC-25195,
   HHSN268201500001I, R56AG029451]
FX This work was supported by the National Heart, Lung, and Blood Institute
   [N01-HC-25195, HHSN268201500001I, and R56AG029451].
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844
   Astuti D, 2005, BRIT J CANCER, V92, P1574, DOI 10.1038/sj.bjc.6602478
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bonder MJ, 2017, NAT GENET, V49, P131, DOI 10.1038/ng.3721
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Chen DJ, 2014, NUCLEIC ACIDS RES, V42, P3028, DOI 10.1093/nar/gkt1294
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684
   Cordes KR, 2009, CIRC RES, V104, P724, DOI 10.1161/CIRCRESAHA.108.192872
   Day FR, 2017, NAT GENET, V49, P834, DOI 10.1038/ng.3841
   EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709
   Enright AJ, 2004, GENOME BIOL, V5
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067
   FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gao YQ, 2015, P NATL ACAD SCI USA, V112, P13627, DOI 10.1073/pnas.1511448112
   Gaunt TR, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0926-z
   Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352
   Hannon E, 2016, NAT NEUROSCI, V19, P48, DOI 10.1038/nn.4182
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Hedman AK, 2017, CIRC-CARDIOVASC GENE, V10, DOI 10.1161/CIRCGENETICS.116.001487
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Huan T, 2018, AM SOC HUM GEN 68 AN
   Huan T, 2015, ARTERIOSCLER THROMB, V114
   Huan TX, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7601
   Irvin M. R, 2014, CIRCULATION, V114
   Jang JS, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-144
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Jensen SG, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-435
   Joehanes R, 2016, CIRC-CARDIOVASC GENE, V9, P436, DOI 10.1161/CIRCGENETICS.116.001506
   Joehanes R, 2013, ARTERIOSCL THROM VAS, V33, P1418, DOI 10.1161/ATVBAHA.112.301169
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Kagami M, 2008, NAT GENET, V40, P237, DOI 10.1038/ng.2007.56
   Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1
   Khoury H, 2010, BLOOD
   Kong A, 2009, NATURE, V462, P868, DOI 10.1038/nature08625
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329
   Lee Rosalind, 2004, Cell, VS116, pS89, DOI 10.1016/S0092-8674(04)00035-2
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Lemire M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7326
   Levy D, 2009, NAT GENET, V41, P677, DOI 10.1038/ng.384
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Ligthart S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1119-5
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu C, 2016, MOL PSYCHIATR, V21, P4, DOI [10.1038/mp.2016.192, 10.1038/mp.2015.95]
   Liu YM, 2013, HUM MOL GENET, V22, P5065, DOI 10.1093/hmg/ddt356
   Loginov VI, 2015, BIOCHEMISTRY-MOSCOW+, V80, P145, DOI 10.1134/S0006297915020029
   MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133
   Marsico A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r84
   McClay JL, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0842-7
   McManus DD, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3533-9
   McRae AF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35871-w
   Mendelson MM, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002215
   Perry JRB, 2014, NATURE, V514, P92, DOI 10.1038/nature13545
   Pidsley R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-293
   Richardson TG, 2017, AM J HUM GENET, V101, P590, DOI 10.1016/j.ajhg.2017.09.003
   Sakajiri S, 2005, LEUKEMIA, V19, P1404, DOI 10.1038/sj.leu.2403832
   Shi JX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4365
   Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783
   Splansky GL, 2007, AM J EPIDEMIOL, V165, P1328, DOI 10.1093/aje/kwm021
   Thum T, 2007, CIRCULATION, V116, P258, DOI 10.1161/CIRCULATIONAHA.107.687947
   Volkmar M, 2012, EMBO J, V31, P1405, DOI 10.1038/emboj.2011.503
   Wagner JR, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r37
   Wallace C, 2010, NAT GENET, V42, P68, DOI 10.1038/ng.493
   Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797
   Wu H, 2014, CELL, V156, P45, DOI 10.1016/j.cell.2013.12.019
NR 71
TC 1
Z9 1
U1 1
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD FEB 1
PY 2020
VL 15
IS 1-2
BP 183
EP 198
DI 10.1080/15592294.2019.1640547
EA JUL 2019
PG 16
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA KB4DR
UT WOS:000476331700001
PM 31282290
OA Green Published
DA 2020-08-12
ER

PT J
AU Huo, KG
   Richer, C
   Berillo, O
   Mahjoub, N
   Fraulob-Aquino, JC
   Barhoumi, T
   Ouerd, S
   Coelho, SC
   Sinnett, D
   Paradis, P
   Schiffrin, EL
AF Huo, Ku-Geng
   Richer, Chantal
   Berillo, Olga
   Mahjoub, Nada
   Fraulob-Aquino, Julio C.
   Barhoumi, Tlili
   Ouerd, Sofiane
   Coelho, Suellen C.
   Sinnett, Daniel
   Paradis, Pierre
   Schiffrin, Ernesto L.
TI miR-431-5p Knockdown Protects Against Angiotensin II-Induced
   Hypertension and Vascular Injury
SO HYPERTENSION
LA English
DT Article
DE angiotensin II; blood pressure; genes; microRNAs
ID SMOOTH-MUSCLE-CELLS; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; OPPOSING
   ROLES; MESSENGER-RNA; DIFFERENTIATION; MICRORNAS; HYPOMETHYLATION;
   MECHANISMS; EXPRESSION
AB Vascular injury is an early manifestation in hypertension and a cause of end-organ damage. MicroRNAs play an important role in cardiovascular disease, but their implication in vascular injury in hypertension remains unclear. This study revealed using an unbiased approach, microRNA and mRNA sequencing with molecular interaction analysis, a microRNA-transcription factor coregulatory network involved in vascular injury in mice made hypertensive by 14-day Ang II (angiotensin II) infusion. A candidate gene approach identified upregulated miR-431-5p encoded in the conserved 12qF1 (14q32 in humans) microRNA cluster, whose expression correlated with blood pressure, and which has been shown to be upregulated in human atherosclerosis, as a potential key regulator in Ang II-induced vascular injury. Gain-and loss-of-function in human vascular smooth muscle cells demonstrated that miR-431-5p regulates in part gene expression by targeting ETS homologous factor. In vivo miR-431-5p knockdown delayed Ang II-induced blood pressure elevation and reduced vascular injury in mice, which demonstrated its potential as a target for treatment of hypertension and vascular injury.
C1 [Huo, Ku-Geng; Berillo, Olga; Mahjoub, Nada; Fraulob-Aquino, Julio C.; Barhoumi, Tlili; Ouerd, Sofiane; Coelho, Suellen C.; Paradis, Pierre; Schiffrin, Ernesto L.] McGill Univ, Lady Davis Inst Med Res, Vasc & Hypertens Res Unit, Montreal, PQ, Canada.
   [Schiffrin, Ernesto L.] McGill Univ, Dept Med, Sir Mortimer B Davis Jewish Gen Hosp, Montreal, PQ, Canada.
   [Richer, Chantal; Sinnett, Daniel] Univ Montreal, Ctr Hosp Univ St Justine, Div Hematol Oncol, Res Ctr, Montreal, PQ, Canada.
   [Sinnett, Daniel] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ, Canada.
RP Schiffrin, EL (corresponding author), Sir Mortimer B Davis Jewish Hosp, B-127,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.
EM ernesto.schiffrin@mcgill.ca
RI Berillo, Olga/AAH-2549-2020; Schiffrin, Ernesto L/AAB-9061-2019;
   sinnett, daniel/S-4589-2017
OI Berillo, Olga/0000-0002-3767-7627; Schiffrin, Ernesto
   L/0000-0002-4502-2823; sinnett, daniel/0000-0003-3625-6676
FU Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR) [123465]; CIHR First Pilot Foundation [143348];
   Canada Research Chair (CRC) on Hypertension and Vascular Research by CRC
   Government of Canada/CIHR Program; Canada Fund for InnovationCanada
   Foundation for Innovation; Terry Fox New Frontiers Program [217967];
   Science without Borders [CsF] of the National Council for Scientific and
   Technological Development [CNPq] of Brazil; Societe quebecoise
   d'hypertension arterielle; Richard and Edith Strauss Postdoctoral
   Fellowship; CIHR Canada Graduate ScholarshipCanadian Institutes of
   Health Research (CIHR)
FX This work was supported by Canadian Institutes of Health Research (CIHR)
   grant 123465 and CIHR First Pilot Foundation Grant 143348, a Canada
   Research Chair (CRC) on Hypertension and Vascular Research by the CRC
   Government of Canada/CIHR Program, and by the Canada Fund for
   Innovation, all to E.L. Schiffrin; by a Terry Fox New Frontiers Program
   grant 217967 to D. Sinnett; and by fellowships to J.C. Fraulob-Aquino
   and S.C. Coelho from Science without Borders [CsF] of the National
   Council for Scientific and Technological Development [CNPq] of Brazil;
   to O. Berillo and T. Barhoumi from Societe quebecoise d'hypertension
   arterielle, and T. Barhoumi also from Richard and Edith Strauss
   Postdoctoral Fellowship; and to S. Ouerd (CIHR Canada Graduate
   Scholarship).
CR Aavik E, 2015, EUR HEART J, V36, P993, DOI 10.1093/eurheartj/ehu437
   Albino D, 2012, CANCER RES, V72, P2889, DOI 10.1158/0008-5472.CAN-12-0212
   Albinsson S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018869
   Babiarz JE, 2012, STEM CELLS DEV, V21, P1956, DOI 10.1089/scd.2011.0357
   Bei YH, 2016, ONCOTARGET, V7, P1584, DOI 10.18632/oncotarget.6444
   Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8
   Boettger T, 2009, J CLIN INVEST, V119, P2634, DOI 10.1172/JCI38864
   Caillon A, 2019, BRIT J PHARMACOL, V176, P1818, DOI 10.1111/bph.14427
   Cho HM, 2013, J HYPERTENS, V31, P1406, DOI 10.1097/HJH.0b013e3283610fed
   Cho JH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-8
   Fan Y, 2016, BBA-MOL BASIS DIS, V1862, P2119, DOI 10.1016/j.bbadis.2016.08.015
   Fang Y, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4708516
   Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Han XR, 2018, J CELL PHYSIOL, V233, P5895, DOI 10.1002/jcp.26394
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Ho JY, 2017, ONCOTARGET, V8, P22443, DOI 10.18632/oncotarget.12338
   Hu YW, 2015, ARTERIOSCL THROM VAS, V35, P87, DOI 10.1161/ATVBAHA.114.304296
   Idris-Khodja N, 2014, EUR HEART J, V35, P1238, DOI 10.1093/eurheartj/ehu119
   Kriegel AJ, 2010, NUCLEIC ACIDS RES, V38, P8338, DOI 10.1093/nar/gkq718
   Lee KP, 2015, GENE DEV, V29, P1605, DOI 10.1101/gad.263574.115
   Londin E, 2015, P NATL ACAD SCI USA, V112, pE1106, DOI 10.1073/pnas.1420955112
   Luk JM, 2011, J BIOL CHEM, V286, P30706, DOI 10.1074/jbc.M111.229831
   Marques FZ, 2011, HYPERTENSION, V58, P1093, DOI 10.1161/HYPERTENSIONAHA.111.180729
   Norlander AE, 2018, J EXP MED, V215, P21, DOI 10.1084/jem.20171773
   Nossent AY, 2013, ANN SURG, V258, P743, DOI 10.1097/SLA.0b013e3182a6aac0
   Palao T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137027
   Paradis P, 2009, CONTEMP CARDIOL, P35, DOI 10.1007/978-1-60761-186-8_5
   Park JB, 2001, J HYPERTENS, V19, P921, DOI 10.1097/00004872-200105000-00013
   Ritchie RH, 2017, PHARMACOL RES, V116, P57, DOI 10.1016/j.phrs.2016.12.017
   Ross SP, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00087
   Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010
   Schiffrin EL, 2015, CLIN INVEST MED, V38, pE394
   Schiffrin EL, 2012, HYPERTENSION, V59, P367, DOI 10.1161/HYPERTENSIONAHA.111.187021
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sun KX, 2015, FEBS OPEN BIO, V5, P900, DOI 10.1016/j.fob.2015.11.001
   Sun W, 2010, ANNU REV BIOMED ENG, V12, P1, DOI 10.1146/annurev-bioeng-070909-105314
   Synnergren J, 2011, PHYSIOL GENOMICS, V43, P581, DOI 10.1152/physiolgenomics.00074.2010
   Takeda Y, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008281
   Wang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126319
   Wang S, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12462
   Wertz MH, 2016, HUM MOL GENET, V25, P2168, DOI 10.1093/hmg/ddw084
   Wu RM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8713
   Wu WH, 2011, AM J HYPERTENS, V24, P1087, DOI 10.1038/ajh.2011.116
   Xin M, 2009, GENE DEV, V23, P2166, DOI 10.1101/gad.1842409
   Yang F, 2017, MOL MED REP, V15, P1031, DOI 10.3892/mmr.2017.6122
   Zhang SK, 2018, AM J CANCER RES, V8, P120
   Zini R, 2016, STEM CELLS DEV, V25, P1433, DOI 10.1089/scd.2016.0150
NR 48
TC 4
Z9 4
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0194-911X
EI 1524-4563
J9 HYPERTENSION
JI Hypertension
PD MAY
PY 2019
VL 73
IS 5
BP 1007
EP 1017
DI 10.1161/HYPERTENSIONAHA.119.12619
PG 11
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA IA1WE
UT WOS:000469352400019
PM 30929512
DA 2020-08-12
ER

PT J
AU Zhang, C
   Xu, D
   Chen, WN
   Li, JL
   Gao, QH
   Li, SJ
AF Zhang, Cui
   Xu, Da
   Chen, Weina
   Li, Junliang
   Gao, Qinghua
   Li, Shijie
TI <bold>LINC24065</bold> is a monoallelically expressed long intergenic
   noncoding RNA located in the cattle <bold>DLK1-DIO3</bold> cluster
SO JOURNAL OF GENETICS
LA English
DT Article
DE long intergenic noncoding RNA; cattle; LNC24065 gene; monoallelic
   expression; spliced variants
ID LANDSCAPE; TRANSCRIPTION; EVOLUTION; REVEALS; GENE
AB Long noncoding RNAs (lncRNAs) are important regulators of biological processes, and regulate genomic imprinting in cis and/or trans to induce monoallelic expression with parent-origin-specific pattern. DLK1-DIO3 domain is one of the largest imprinted clusters in mammals, and maternally expressed noncoding RNAs of this region is related to the pluripotency of the embryonic stem cells. Previously, we sequenced the cDNA of two maternally expressed noncoding RNAs, MEG8 and MEG9, and mapped a lncRNA (LINC24061) between the two genes in the cattle DLK1-DIO3 domain on chromosome 21. In this study, we identified LINC24065, a novel long intergenic noncoding RNA (lincRNA), which was also located between MEG8 and MEG9. We identified four variants of LINC24065 (LINC24065-v1, LINC24065-v2, LINC24065-v3 and LINC24065-v4) that were a result of alternative splicing from 18 exons. LINC24065-v1 and LINC24065-v2 showed tissue-specific expression patterns in adult bovine tissues, and LINC24065-v3 and LINC24065-v4 were detected in all eight analysed tissues (heart, liver, spleen, lung, kidney, skeletal muscle, adipose and brain). Using single-nucleotide polymorphism (SNP)-based method, LINC24065 was identified to have monoallelic expression in adult tissues, suggesting that it is imprinted in cows. These results provide a foundation for further investigation about whether LINC24065 plays a role in regulating imprinting of the DLK1-DIO3 domain.
C1 [Zhang, Cui; Xu, Da; Chen, Weina; Li, Junliang; Li, Shijie] Hebei Agr Univ, Dept Biochem & Mol Biol, Coll Life Sci, Baoding 071001, Peoples R China.
   [Chen, Weina] Hebei Univ, Coll Tradit Chinese Med, Baoding 071000, Peoples R China.
   [Gao, Qinghua] Hebei Acad Sci, Inst Microbiol, Baoding 071051, Peoples R China.
RP Li, SJ (corresponding author), Hebei Agr Univ, Dept Biochem & Mol Biol, Coll Life Sci, Baoding 071001, Peoples R China.
EM lishijie20005@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31372312]; Hebei province Natural Science
   Foundation of ChinaNatural Science Foundation of Hebei Province
   [C2016204092]
FX This study was supported by National Natural Science Foundation of China
   (grant no. 31372312), Hebei province Natural Science Foundation of China
   (grant no. C2016204092).
CR Barlow DP, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018382
   Bartolomei MS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002592
   Benetatos L, 2014, CELL MOL LIFE SCI, V71, P4421, DOI 10.1007/s00018-014-1698-9
   Calle AS, 2018, CANCER SCI, V109, P2093, DOI 10.1111/cas.13642
   Cao JN, 2014, BIOL PROCED ONLINE, V16, DOI 10.1186/1480-9222-16-11
   Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011
   Deniz E, 2017, FUNCT INTEGR GENOMIC, V17, P135, DOI 10.1007/s10142-016-0524-x
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Edwards CA, 2008, PLOS BIOL, V6, P1292, DOI 10.1371/journal.pbio.0060135
   Enfield KSS, 2016, ONCOTARGET, V7, P80957, DOI 10.18632/oncotarget.13133
   Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149
   Enterina JR, 2017, EXPERT REV RESP MED, V11, P749, DOI 10.1080/17476348.2017.1355241
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192
   Johnsson P, 2014, BBA-GEN SUBJECTS, V1840, P1063, DOI 10.1016/j.bbagen.2013.10.035
   Kanduri C, 2016, BBA-GENE REGUL MECH, V1859, P102, DOI 10.1016/j.bbagrm.2015.05.006
   Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995
   Marchese FP, 2014, EPIGENETICS-US, V9, P21, DOI 10.4161/epi.27472
   Meseure D, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/320214
   Mo CF, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt535
   Moradi S, 2017, STEM CELL REP, V9, P2081, DOI 10.1016/j.stemcr.2017.10.009
   Morcos L, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r25
   Partida GC, 2018, HUM MOL GENET, V27, P2927, DOI 10.1093/hmg/ddy206
   Qu ZP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042638
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020
   Zhang FW, 2011, J MOL HISTOL, V42, P333, DOI 10.1007/s10735-011-9337-3
   Zhang MY, 2017, GENETICA, V145, P1, DOI 10.1007/s10709-016-9939-5
NR 28
TC 0
Z9 0
U1 1
U2 2
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0022-1333
EI 0973-7731
J9 J GENET
JI J. Genet.
PD MAR
PY 2019
VL 98
IS 1
AR 30
DI 10.1007/s12041-019-1076-3
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA HO1VA
UT WOS:000460698200003
DA 2020-08-12
ER

PT J
AU Dill, TL
   Naya, FJ
AF Dill, Tiffany L.
   Naya, Francisco J.
TI A Hearty Dose of Noncoding RNAs: The Imprinted DLK1-DIO3 Locus in
   Cardiac Development and Disease
SO JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE
LA English
DT Review
DE cardiac; proliferation; hypertrophy; fibrosis; microRNA; long noncoding
   RNA; imprinting; epigenetics
ID MUSCLE-CELL PROLIFERATION; CIRCULATING MICRORNAS; EXPRESSION PROFILE;
   SKELETAL-MUSCLE; CARDIOMYOCYTE PROLIFERATION; MYOCARDIAL-INFARCTION;
   POLAR OVERDOMINANCE; UNIPARENTAL DISOMY; DOWN-REGULATION; CLUSTER
AB The imprinted Dlk1-Dio3 genomic region harbors a noncoding RNA cluster encoding over fifty microRNAs (miRNAs), three long noncoding RNAs (lncRNAs), and a small nucleolar RNA (snoRNA) gene array. These distinct noncoding RNAs (ncRNAs) are thought to arise from a single polycistronic transcript that is subsequently processed into individual ncRNAs, each with important roles in diverse cellular contexts. Considering these ncRNAs are derived from a polycistron, it is possible that some coordinately regulate discrete biological processes in the heart. Here, we provide a comprehensive summary of Dlk1-Dio3 miRNAs and lncRNAs, as they are currently understood in the cellular and organ-level context of the cardiovascular system. Highlighted are expression profiles, mechanistic contributions, and functional roles of these ncRNAs in heart development and disease. Notably, a number of these ncRNAs are implicated in processes often perturbed in heart disease, including proliferation, differentiation, cell death, and fibrosis. However, most literature falls short of characterizing precise mechanisms for many of these ncRNAs, warranting further investigation. Taken together, the Dlk1-Dio3 locus represents a largely unexplored noncoding regulator of cardiac homeostasis, harboring numerous ncRNAs that may serve as therapeutic targets for cardiovascular disease.
C1 [Dill, Tiffany L.; Naya, Francisco J.] Boston Univ, Dept Biol, Program Cell & Mol Biol, Boston, MA 02215 USA.
RP Naya, FJ (corresponding author), Boston Univ, Dept Biol, Program Cell & Mol Biol, Boston, MA 02215 USA.
EM tiffdill@bu.edu; fnaya@bu.edu
FU Boston University
FX This work was supported by funds provided by Boston University.
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bernardo B. C., 2016, SCI REP, V6, P1
   Bidwell CA, 2014, ANIM GENET, V45, P51, DOI 10.1111/age.12132
   Boon RA, 2016, J AM COLL CARDIOL, V67, P1214, DOI 10.1016/j.jacc.2015.12.051
   Caiment F, 2010, GENOME RES, V20, P1651, DOI 10.1101/gr.108787.110
   Cakmak HA, 2015, J CARDIOVASC MED, V16, P431, DOI 10.2459/JCM.0000000000000233
   Carr MS, 2007, GENOMICS, V89, P280, DOI 10.1016/j.ygeno.2006.10.005
   Castel D., 2018, SCI REP, V8, P1
   Charlier C, 2001, NAT GENET, V27, P367, DOI 10.1038/86856
   Chen JF, 2008, P NATL ACAD SCI USA, V105, P2111, DOI 10.1073/pnas.0710228105
   Chen JH, 2012, J MOL CELL CARDIOL, V52, P949, DOI 10.1016/j.yjmcc.2012.01.012
   Chen SM, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-87
   Christodoulou C, 2011, J CLIN INVEST, V121, P2313, DOI 10.1172/JCI43853
   Chu C, 2004, AM J MED GENET A, V127A, P167, DOI 10.1002/ajmg.a.20618
   Clark AL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151515
   Clark AL, 2015, J BIOL CHEM, V290, P23162, DOI 10.1074/jbc.M115.672659
   Coffey S, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002150
   Creemers EE, 2012, CIRC RES, V110, P483, DOI 10.1161/CIRCRESAHA.111.247452
   Cruz FM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.255
   Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011
   Das PP, 2015, CELL REP, V12, P1456, DOI 10.1016/j.celrep.2015.07.053
   Dentice M, 2011, J ENDOCRINOL, V209, P273, DOI 10.1530/JOE-11-0002
   Devaux Y, 2015, NAT REV CARDIOL, V12, P415, DOI 10.1038/nrcardio.2015.55
   Dong P, 2018, EUR REV MED PHARMACO, V22, P2052, DOI 10.26355/eurrev_201804_14735
   Eulalio A, 2012, NATURE, V492, P376, DOI 10.1038/nature11739
   Falix FA, 2012, BBA-MOL BASIS DIS, V1822, P988, DOI 10.1016/j.bbadis.2012.02.003
   Fiore R, 2009, EMBO J, V28, P697, DOI 10.1038/emboj.2009.10
   Gao YQ, 2015, P NATL ACAD SCI USA, V112, P13627, DOI 10.1073/pnas.1511448112
   Georgiades P, 2000, DEVELOPMENT, V127, P4719
   Gong LC, 2018, J CELL BIOCHEM, V119, P1429, DOI 10.1002/jcb.26304
   Greco CM, 2015, NAT REV CARDIOL, V12, P488, DOI 10.1038/nrcardio.2015.71
   Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012
   Guntrum M, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0138-0
   Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352
   Han P, 2014, NATURE, V514, P102, DOI 10.1038/nature13596
   He FC, 2014, MOL CELL BIOCHEM, V394, P137, DOI 10.1007/s11010-014-2089-0
   Hoelscher SC, 2017, J THORAC DIS, V9, pS64, DOI 10.21037/jtd.2017.03.149
   Huang ZP, 2010, ARTERIOSCL THROM VAS, V30, P2575, DOI 10.1161/ATVBAHA.110.213306
   Ioannides Y, 2014, J MED GENET, V51, P495, DOI 10.1136/jmedgenet-2014-102396
   Janssen R, 2013, ENDOCRINOLOGY, V154, P1973, DOI 10.1210/en.2012-2017
   Joladarashi D, 2015, J AM COLL CARDIOL, V66, P2214, DOI 10.1016/j.jacc.2015.09.009
   Kaneko S, 2014, MOL CELL, V53, P290, DOI 10.1016/j.molcel.2013.11.012
   Kim JY, 2014, AGING-US, V6, P524, DOI 10.18632/aging.100677
   Labialle S, 2014, EMBO J, V33, P2216, DOI 10.15252/embj.201387038
   Li D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106318
   Li SH, 2015, ONCOTARGET, V6, P10045, DOI 10.18632/oncotarget.3541
   Liang J., 2016, STEM CELLS, V35, P1459
   Lin SP, 2007, DEVELOPMENT, V134, P417, DOI 10.1242/dev.02726
   Lin ZQ, 2009, P NATL ACAD SCI USA, V106, P12103, DOI 10.1073/pnas.0811371106
   Liu F., 2014, CELL DEATH DIS, V5, P1
   Liu HL, 2014, CELL BIOCHEM BIOPHYS, V70, P635, DOI 10.1007/s12013-014-9967-7
   Liu HS, 2016, BIOMED REP, V5, P332, DOI 10.3892/br.2016.726
   Liu N, 2010, DEV CELL, V18, P510, DOI 10.1016/j.devcel.2010.03.010
   Liu N, 2008, GENE DEV, V22, P3242, DOI 10.1101/gad.1738708
   Lu YM, 2015, INT J CLIN EXP MED, V8, P845
   Matsumoto S, 2012, BIOCHEM BIOPH RES CO, V427, P280, DOI 10.1016/j.bbrc.2012.09.039
   Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480
   Mohnle P, 2014, BIOCHEM BIOPH RES CO, V451, P516, DOI 10.1016/j.bbrc.2014.08.008
   Morrison JL, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1693-z
   Muthusamy S, 2014, J BIOL CHEM, V289, P29665, DOI 10.1074/jbc.M114.578682
   Ogata T, 2016, J HUM GENET, V61, P87, DOI 10.1038/jhg.2015.113
   Ogata Tsutomu, 2008, Clin Pediatr Endocrinol, V17, P103, DOI 10.1297/cpe.17.103
   Peters J, 2014, NAT REV GENET, V15, P517, DOI 10.1038/nrg3766
   Piccoli MT, 2017, CIRC RES, V121, P575, DOI 10.1161/CIRCRESAHA.117.310624
   Porrello ER, 2011, CIRC RES, V109, P670, DOI 10.1161/CIRCRESAHA.111.248880
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Scheuermann JC, 2013, EMBO J, V32, P1805, DOI 10.1038/emboj.2013.134
   Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304
   Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783
   Snyder CM, 2013, DEVELOPMENT, V140, P31, DOI 10.1242/dev.081851
   Song GS, 2008, NUCLEIC ACIDS RES, V36, P5727, DOI 10.1093/nar/gkn567
   Stevenson DA, 2004, AM J MED GENET A, V130A, P88, DOI 10.1002/ajmg.a.30200
   Su Q, 2017, CELL PHYSIOL BIOCHEM, V43, P1012, DOI 10.1159/000481699
   Sun LY, 2016, CELL BIOL INT, V40, P1271, DOI 10.1002/cbin.10655
   Sun ZX, 2017, CELL PHYSIOL BIOCHEM, V42, P2569, DOI 10.1159/000480218
   Takahashi N, 2009, HUM MOL GENET, V18, P1879, DOI 10.1093/hmg/ddp108
   Tho LC, 2016, THERANOSTICS, V6, P2068, DOI 10.7150/thno.15007
   Tian Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010841
   Vacchi-Suzzi C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052442
   Valdmanis PN, 2015, ONCOGENE, V34, P94, DOI 10.1038/onc.2013.523
   van der Bom T, 2011, NAT REV CARDIOL, V8, P50, DOI 10.1038/nrcardio.2010.166
   van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105
   van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089
   Wamstad JA, 2012, CELL, V151, P206, DOI 10.1016/j.cell.2012.07.035
   Wang J, 2010, DEV CELL, V19, P903, DOI 10.1016/j.devcel.2010.10.022
   Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596
   Wang X., 2018, CELL MOL BIOL LETT, V23, P1
   Wang XH, 2010, CIRCULATION, V122, P1308, DOI 10.1161/CIRCULATIONAHA.110.964684
   Wang ZH, 2016, NAT MED, V22, P1131, DOI 10.1038/nm.4179
   Weber K, 2015, MOL CELL BIOCHEM, V402, P171, DOI 10.1007/s11010-014-2324-8
   Welten SMJ, 2014, CIRC RES, V115, P696, DOI 10.1161/CIRCRESAHA.114.304747
   Wen Z., 2014, PLOS ONE, V9
   Wu YH, 2015, INT J MOL SCI, V16, P25199, DOI 10.3390/ijms161025199
   Wust S, 2018, CELL METAB, V27, P1026, DOI 10.1016/j.cmet.2018.02.022
   Xiao JJ, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-159
   Yamada S., 2017, EP EUR, V20, pf37
   Yang F, 2018, J CELL BIOCHEM, V119, P2427, DOI 10.1002/jcb.26405
   Yang VK, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1350088
   Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011
   Zhao YF, 2017, BBA-MOL BASIS DIS, V1863, P2871, DOI 10.1016/j.bbadis.2017.07.034
   Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030
   Zhou Y, 2007, J BIOL CHEM, V282, P24731, DOI 10.1074/jbc.M702029200
   Zhou YL, 2012, J MOL ENDOCRINOL, V48, pR45, DOI 10.1530/JME-12-0008
   Zhou YL, 2010, DEVELOPMENT, V137, P2643, DOI 10.1242/dev.045724
   Zhu BQ, 2018, BIOCHEM BIOPH RES CO, V495, P2125, DOI 10.1016/j.bbrc.2017.11.185
   Zhu XH, 2016, EUR REV MED PHARMACO, V20, P3653
   Zhu XD, 2016, CAN J CARDIOL, V32, P1249, DOI 10.1016/j.cjca.2015.11.012
NR 107
TC 9
Z9 9
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2308-3425
J9 J CARDIOVASC DEV DIS
JI J. Cardiovasc. Dev. Dis.
PD SEP
PY 2018
VL 5
IS 3
AR 37
DI 10.3390/jcdd5030037
PG 21
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA HG7OY
UT WOS:000455183000003
PM 29996488
OA DOAJ Gold, Green Published
DA 2020-08-12
ER

PT J
AU Fiorillo, AA
   Tully, CR
   Damsker, JM
   Nagaraju, K
   Hoffman, EP
   Heier, CR
AF Fiorillo, Alyson A.
   Tully, Christopher R.
   Damsker, Jesse M.
   Nagaraju, Kanneboyina
   Hoffman, Eric P.
   Heier, Christopher R.
TI Muscle miRNAome shows suppression of chronic inflammatory miRNAs with
   both prednisone and vamorolone
SO PHYSIOLOGICAL GENOMICS
LA English
DT Article
DE Duchenne muscular dystrophy; inflammation; miRNA; muscle; steroids
ID NF-KAPPA-B; DUCHENNE-MUSCULAR-DYSTROPHY; BOWEL-DISEASE;
   ALZHEIMERS-DISEASE; CARDIAC FIBROSIS; DOWN-REGULATION; TGF-BETA;
   EXPRESSION; MICRORNAS; CELLS
AB Corticosteroids are highly prescribed and effective anti-inflammatory drugs but the burden of side effects with chronic use significantly detracts from patient quality of life, particularly in children. Developing safer steroids amenable to long-term use is an important goal for treatment of chronic inflammatory diseases such as Duchenne muscular dystrophy (DMD). We have developed vamorolone (VBP15), a first-in-class dissociative glucocorticoid receptor (GR) ligand that shows the anti-inflammatory efficacy of corticosteroids without key steroid side effects in animal models. miRNAs are increasingly recognized as key regulators of inflammatory responses. To define effects of prednisolone and vamorolone on the muscle miRNAome, we performed a preclinical discovery study in the mdx mouse model of DMD. miRNAs associated with inflammation were highly elevated in mdx muscle. Both vamorolone and prednisolone returned these toward wild-type levels (miR-142-5p, miR-142-3p, miR-146a, miR-301a, miR-324-3p, miR-455-5p, miR-455-3p, miR-497, miR-652). Effects of vamorolone were largely limited to reduction of proinflammatory miRNAs. In contrast, prednisolone activated a separate group of miRNAs associated with steroid side effects and a noncoding RNA cluster homologous to human chromosome 14q32. Effects were validated for inflammatory miRNAs in a second, independent preclinical study. For the anti-inflammatory miRNA signature, bioinformatic analyses showed all of these miRNAs are directly regulated by, or in turn activate, the inflammatory transcription factor NF-kappa B. Moving forward miR-146a and miR-142 are of particular interest as biomarkers or novel drug targets. These data validate NF-kappa B signaling as a target of dissociative GR-ligand efficacy in vivo and provide new insight into miRNA signaling in chronic inflammation.
C1 [Fiorillo, Alyson A.; Tully, Christopher R.; Heier, Christopher R.] Childrens Natl Med Ctr, Ctr Genet Med Res, 111 Michigan Ave NW, Washington, DC 20010 USA.
   [Fiorillo, Alyson A.; Heier, Christopher R.] George Washington Univ, Sch Med & Hlth Sci, Dept Genom & Precis Med, Washington, DC 20052 USA.
   [Damsker, Jesse M.; Nagaraju, Kanneboyina; Hoffman, Eric P.] ReveraGen BioPharma Inc, Rockville, MD USA.
   [Nagaraju, Kanneboyina; Hoffman, Eric P.] SUNY Binghamton, Sch Pharm & Pharmaceut Sci, Binghamton, NY USA.
RP Heier, CR (corresponding author), Childrens Natl Med Ctr, Ctr Genet Med Res, 111 Michigan Ave NW, Washington, DC 20010 USA.
EM cheier@childrensnational.org
OI Fiorillo, Alyson/0000-0003-3458-8036; Hoffman, Eric/0000-0001-6470-5139;
   Heier, Christopher/0000-0001-7914-2068
FU Foundation to Eradicate Duchenne; Clark Charitable Foundation; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Department of
   DefenseUnited States Department of Defense [W81XWH-17-1-047]; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [1L40-AR-070539-01, R00-HL-130035, U54-HD-090254,
   L40-AR-068727]
FX This work was funded by the Foundation to Eradicate Duchenne, the Clark
   Charitable Foundation, and the National Institutes of Health. A.
   Fiorillo is funded by the Department of Defense (W81XWH-17-1-047) and
   the NIH (1L40-AR-070539-01). C. Heier is funded by the NIH
   (R00-HL-130035, U54-HD-090254, L40-AR-068727). Both A. Fiorillo and C.
   Heier are additionally funded by the Clark Charitable Foundation and the
   Foundation to Eradicate Duchenne.
CR Bello L, 2015, NEUROLOGY, V85, P1048, DOI 10.1212/WNL.0000000000001950
   Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027
   Chapman CG, 2015, THER ADV GASTROENTER, V8, P4, DOI 10.1177/1756283X14547360
   Charlier C, 2001, GENOME RES, V11, P850, DOI 10.1101/gr.172701
   Chen X, 2017, SCI REP-UK, V7, DOI 10.1038/srep40958
   Chen Y, 2014, CELL REP, V7, P1982, DOI 10.1016/j.celrep.2014.05.007
   Chen YW, 2005, NEUROLOGY, V65, P826, DOI 10.1212/01.wnl.0000173836.09176.c4
   Christopher Ajay Francis, 2016, Perspect Clin Res, V7, P68, DOI 10.4103/2229-3485.179431
   Curtale G, 2010, BLOOD, V115, P265, DOI 10.1182/blood-2009-06-225987
   Czimmerer Z, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0315-y
   Davis TE, 2013, ARTHRITIS RHEUM-US, V65, P1882, DOI 10.1002/art.37966
   Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157
   Dharap A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079467
   Duijvis NW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185097
   Eisenberg I, 2008, P NATL ACAD SCI USA, V105, P399, DOI 10.1073/pnas.0711290105
   Eisenberg I, 2007, P NATL ACAD SCI USA, V104, P17016, DOI 10.1073/pnas.0708115104
   Fasseu M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013160
   Fiorillo AA, 2015, CELL REP, V12, P1678, DOI 10.1016/j.celrep.2015.07.066
   Fordham JB, 2015, J LEUKOCYTE BIOL, V98, P195, DOI 10.1189/jlb.1A1014-519RR
   Ghorpade DS, 2013, J BIOL CHEM, V288, P33037, DOI 10.1074/jbc.M113.492496
   Grounds MD, 2011, BIOESSAYS, V33, P458, DOI 10.1002/bies.201000136
   He C, 2016, GUT, V65, P1938, DOI 10.1136/gutjnl-2015-309389
   He FC, 2014, MOL CELL BIOCHEM, V394, P137, DOI 10.1007/s11010-014-2089-0
   Heier CR, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.49
   Heier CR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112477
   Heier CR, 2013, EMBO MOL MED, V5, P1569, DOI 10.1002/emmm.201302621
   Hoffman EP, 2018, STEROIDS, V134, P43, DOI 10.1016/j.steroids.2018.02.010
   Hu XJ, 2015, BIOCHEM BIOPH RES CO, V468, P781, DOI 10.1016/j.bbrc.2015.11.032
   Israeli D, 2016, SCI REP-UK, V6, DOI 10.1038/srep28097
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kramer NJ, 2015, BLOOD, V125, P3720, DOI 10.1182/blood-2014-10-603951
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Kumar S, 2017, HUM MOL GENET, V26, P3808, DOI 10.1093/hmg/ddx267
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lu JY, 2013, NEUROSCI LETT, V555, P85, DOI 10.1016/j.neulet.2013.09.014
   Lu ZX, 2011, EMBO J, V30, P57, DOI 10.1038/emboj.2010.296
   Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200
   Lukiw WJ, 2007, NEUROREPORT, V18, P297, DOI 10.1097/WNR.0b013e3280148e8b
   Ma XD, 2011, J MOL CELL BIOL, V3, P159, DOI 10.1093/jmcb/mjr007
   Ma XT, 2014, INT J MED SCI, V11, P810, DOI 10.7150/ijms.8647
   Maciotta S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043464
   Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176
   Mechtler P, 2015, ONCOTARGET, V6, P17097, DOI 10.18632/oncotarget.4005
   Meerson A, 2010, J MOL NEUROSCI, V40, P47, DOI 10.1007/s12031-009-9252-1
   Mildner A, 2013, BLOOD, V121, P1016, DOI 10.1182/blood-2012-07-445999
   Milosevic J, 2012, AM J RESP CELL MOL, V47, P879, DOI 10.1165/rcmb.2011-0377OC
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Monici MC, 2003, NEUROLOGY, V60, P993, DOI 10.1212/01.WNL.0000049913.27181.51
   Monk CE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013669
   Olivieri F, 2013, AGE, V35, P1157, DOI 10.1007/s11357-012-9440-8
   Palmieri O, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071580
   Panguluri SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008760
   Pekow JR, 2012, INFLAMM BOWEL DIS, V18, P187, DOI 10.1002/ibd.21691
   Piccoli MT, 2017, CIRC RES, V121, P575, DOI 10.1161/CIRCRESAHA.117.310624
   Pilbrow AP, 2014, INT J CARDIOL, V176, P375, DOI 10.1016/j.ijcard.2014.07.068
   Plumb-Rudewiez N, 2004, HEPATOLOGY, V40, P1266, DOI 10.1002/hep.20459
   Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200
   Quattrocelli M, 2017, J CLIN INVEST, V127, P2418, DOI 10.1172/JCI91445
   RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752
   Recchiuti A, 2011, FASEB J, V25, P544, DOI 10.1096/fj.10-169599
   Rieu I, 2009, PLANT CELL, V21, P1031, DOI 10.1105/tpc.109.066001
   Roderburg C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032999
   Sato T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5597
   Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304
   Sonkoly E, 2009, INT REV IMMUNOL, V28, P535, DOI 10.3109/08830180903208303
   STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0
   Su SC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9523
   Swingler TE, 2012, ARTHRITIS RHEUM-US, V64, P1909, DOI 10.1002/art.34314
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tho LC, 2016, THERANOSTICS, V6, P2068, DOI 10.7150/thno.15007
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Vasa-Nicotera M, 2011, ATHEROSCLEROSIS, V217, P326, DOI 10.1016/j.atherosclerosis.2011.03.034
   Walden TB, 2009, J CELL PHYSIOL, V218, P444, DOI 10.1002/jcp.21621
   Wang HW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147067
   Wang J, 2012, GENOME RES, V22, P1798, DOI 10.1101/gr.139105.112
   Wang WX, 2011, ACTA NEUROPATHOL, V121, P193, DOI 10.1007/s00401-010-0756-0
   Wang YL, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1158-z
   Wei L, 2004, ANN INTERN MED, V141, P764, DOI 10.7326/0003-4819-141-10-200411160-00007
   White BD, 2007, CURR BIOL, V17, pR923, DOI 10.1016/j.cub.2007.08.062
   Yue X, 2016, NEURO-ONCOLOGY, V18, P1288, DOI 10.1093/neuonc/now044
   Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5
   Zhang XR, 2016, EUR J PHARMACOL, V779, P46, DOI 10.1016/j.ejphar.2016.03.011
   Zhang ZQ, 2015, FEBS LETT, V589, P3671, DOI 10.1016/j.febslet.2015.09.032
   Zhou L, 2006, NEUROMUSCULAR DISORD, V16, P32, DOI 10.1016/j.nmd.2005.09.009
   Zhou M, 2018, MOL NEUROBIOL, V55, P917, DOI 10.1007/s12035-016-0365-6
NR 85
TC 7
Z9 7
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1094-8341
EI 1531-2267
J9 PHYSIOL GENOMICS
JI Physiol. Genomics
PD SEP
PY 2018
VL 50
IS 9
BP 735
EP 745
DI 10.1152/physiolgenomics.00134.2017
PG 11
WC Cell Biology; Genetics & Heredity; Physiology
SC Cell Biology; Genetics & Heredity; Physiology
GA GT1VR
UT WOS:000444265300010
PM 29883261
OA Other Gold, Green Published
DA 2020-08-12
ER

PT J
AU Ushijima, K
   Yatsuga, S
   Matsumoto, T
   Nakamura, A
   Fukami, M
   Kagami, M
AF Ushijima, Kikumi
   Yatsuga, Syuichi
   Matsumoto, Takako
   Nakamura, Akie
   Fukami, Maki
   Kagami, Masayo
TI A severely short-statured girl with 47,XX,+14/46,XX,upd(14) mat,
   mosaicism
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID MATERNAL UNIPARENTAL DISOMY; 14Q32.2 IMPRINTED REGION; TRISOMY 14;
   CHROMOSOME-14; EPIMUTATIONS
AB The predominant symptoms of trisomy 14 mosaicism are prenatal and postnatal growth failure, ear abnormalities, congenital heart disease, developmental delay, and genitourinary abnormalities. Maternal uniparental disomy of chromosome 14 (upd (14) mat) presents discernible clinical features such as prenatal and postnatal growth failure, hypotonia, precocious puberty, and obesity. Given the small number of previously reported patients with a combination of trisomy 14 mosaicism and upd (14) mat, the detailed clinical features of these patients remain to be elucidated. Here we report a severely short-statured girl with feeding difficulties and failure to thrive, ear abnormalities, deafness, small hands, and developmental delay. Karyotyping, FISH analysis, methylation analysis, and microsatellite marker analysis using her leukocytes and buccal cells showed that she had a combination of trisomy 14 mosaicism and upd(14) mat. Furthermore, a comparison of the clinical features of this patient with those of previously reported patients with genetic anomalies including the combination of trisomy 14 mosaicism and upd(14) mat or upd(14) mat suggested that the severe short stature observed in patients with a combination of trisomy 14 mosaicism and upd(14) mat stemmed from the synergic effect of these two events. In severely short-statured patients with trisomy 14 mosaicism, we should be aware of the possible coexistence of upd(14) mat.
C1 [Ushijima, Kikumi; Nakamura, Akie; Fukami, Maki; Kagami, Masayo] Natl Res Inst Child Hlth & Dev, Dept Mol Endocrinol, Tokyo, Japan.
   [Ushijima, Kikumi; Yatsuga, Syuichi; Matsumoto, Takako] Kurume Univ, Dept Pediat & Child Hlth, Sch Med, Fukuoka, Japan.
RP Kagami, M (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Mol Endocrinol, Tokyo, Japan.
EM kagami-ms@ncchd.go.jp
OI Kagami, Masayo/0000-0003-3020-455X
FU Japan Society for the Promotion of Science (JSPS)Ministry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [15K15096]; National Center for Child Health
   and DevelopmentUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [28-6]; Japan Agency for Medical Research and Development (AMED)Japan
   Agency for Medical Research and Development (AMED) [16ek0109030h0003,
   16ek0109141h0002]; Takeda Science FoundationTakeda Science Foundation
   (TSF); Japanese Society for Pediatric Endocrinology Future Development
   Grant
FX We are grateful to the patient and her parents for their cooperation.
   This work was supported by Grants from the Japan Society for the
   Promotion of Science (JSPS) (15K15096), the National Center for Child
   Health and Development (28-6), the Japan Agency for Medical Research and
   Development (AMED) (16ek0109030h0003, 16ek0109141h0002), The Takeda
   Science Foundation, and The Japanese Society for Pediatric Endocrinology
   Future Development Grant.
CR ANTONARAKIS SE, 1993, AM J HUM GENET, V52, P1145
   Balbeur S, 2016, CLIN CASE REP, V4, P265, DOI 10.1002/ccr3.501
   Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011
   FUJIMOTO A, 1992, AM J MED GENET, V44, P189, DOI 10.1002/ajmg.1320440214
   Hoffmann K, 2011, BEST PRACT RES CL EN, V25, P77, DOI 10.1016/j.beem.2010.09.004
   Hur Yun Jung, 2012, Korean J Pediatr, V55, P393, DOI 10.3345/kjp.2012.55.10.393
   Ioannides Y, 2014, J MED GENET, V51, P495, DOI 10.1136/jmedgenet-2014-102396
   Kagami M, 2008, NAT GENET, V40, P237, DOI 10.1038/ng.2007.56
   Kagami M, 2017, GENET MED, V19, P1356, DOI 10.1038/gim.2017.53
   Kagami M, 2015, EUR J HUM GENET, V23, P1062, DOI 10.1038/ejhg.2014.234
   Kagami M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000992
   Kayashima T, 2002, AM J MED GENET, V111, P38, DOI 10.1002/ajmg.10511
   Salas-Labadia C, 2014, MOL CYTOGENET, V7, DOI 10.1186/s13039-014-0065-8
   SERRA A, 1978, HUM GENET, V41, P157
   TEMPLE IK, 1991, J MED GENET, V28, P511, DOI 10.1136/jmg.28.8.511
   Zhang SJ, 2016, MOL CYTOGENET, V9, DOI 10.1186/s13039-016-0274-4
NR 16
TC 2
Z9 2
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD MAR
PY 2018
VL 63
IS 3
BP 377
EP 381
DI 10.1038/s10038-017-0381-z
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA FX5DY
UT WOS:000426099500014
PM 29311684
DA 2020-08-12
ER

PT J
AU Guo, W
   Dong, ZM
   Liu, SN
   Qiao, YL
   Kuang, G
   Guo, YL
   Shen, SP
   Liang, J
AF Guo, Wei
   Dong, Zhiming
   Liu, Shengnan
   Qiao, Yiling
   Kuang, Gang
   Guo, Yanli
   Shen, Supeng
   Liang, Jia
TI Promoter hypermethylation-mediated downregulation of miR-770 and its
   host gene MEG3, a long non-coding RNA, in the development of gastric
   cardia adenocarcinoma
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE expression; gastric cardia adenocarcinoma; MEG3; methylation; miR-770
ID ESOPHAGOGASTRIC JUNCTION; CELL-PROLIFERATION; INTRONIC MICRORNAS; CPG
   METHYLATION; CANCER; EXPRESSION; REGION; CHINA; PCR; P53
AB Maternally expressed gene 3 (MEG3) is an imprinted gene located at 14q32 which encodes an lncRNA and is downregulated in an expanding list of cancer cell lines and primary human cancers. The miR-770 is transcribed from the intronic sequence of MEG3 and MEG3 may be the host gene for miR-770. However, the biological role of MEG3 and miR-770 in gastric cardia adenocarcinoma (GCA) development and prognosis is poorly defined. The present study was to investigate the function and methylation status of MEG3 in GCA, and further to detect the functional association of miR-770 and its host gene MEG3 in GCA carcinogenesis and prognosis. MEG3 and miR-770 was significantly downregulated in GCA patients and cell lines, and their expression was associated with TNM stage and lymph node metastasis. Overexpression of MEG3 and miR-770 inhibited gastric cancer cell proliferation and invasion in vitro. Furthermore, the expression level of MEG3 and miR-770 was significantly increased in cancer cells after treated with 5-Aza-dC. The aberrant hypermethylation of proximal promoter and enhancer region of MEG3 was detected in GCA tissues. In addition, the proximal promoter and enhancer region hypermethylation and dysregulation of MEG3 and miR-770 were associated with poorer GCA patients' survival. These findings suggest that miR-770 and its host gene MEG3 may play tumor suppressor role and hypermethylation of proximal promoter and enhancer region may be one of the critical mechanisms in inactivation of MEG3 and miR-770 in GCA development. MEG3 and miR-770 may be used as potential biomarkers in predicting GCA patients' prognosis.
C1 [Guo, Wei; Dong, Zhiming; Liu, Shengnan; Kuang, Gang; Guo, Yanli; Shen, Supeng; Liang, Jia] Hebei Med Univ, Hosp 4, Pathol Lab, Hebei Canc Inst, Jiankang Rd 12, Shijiazhuang 050011, Hebei, Peoples R China.
   [Qiao, Yiling] Special Care Hosp Hebei Prov, Shijiazhuang, Hebei, Peoples R China.
RP Dong, ZM (corresponding author), Hebei Med Univ, Hosp 4, Pathol Lab, Hebei Canc Inst, Jiankang Rd 12, Shijiazhuang 050011, Hebei, Peoples R China.
EM guowei7303@163.com
FU National Natural Science FoundationNational Natural Science Foundation
   of China [81472335, 81572441]; Natural Science Foundation of Hebei
   ProvinceNatural Science Foundation of Hebei Province [H2015206196,
   H2015206420]
FX National Natural Science Foundation, Grant numbers: 81472335, 81572441;
   Natural Science Foundation of Hebei Province, Grant numbers:
   H2015206196, H2015206420
CR Anwar SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049462
   Augoff K, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-5
   Balik V, 2013, J NEURO-ONCOL, V112, P1, DOI 10.1007/s11060-012-1038-6
   Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905
   Benetatos L, 2008, CLIN LYMPHOMA MYELOM, V8, P171, DOI 10.3816/CLM.2008.n.021
   Benetatos L, 2011, INT J CANCER, V129, P773, DOI 10.1002/ijc.26052
   Benetatos L, 2010, LEUKEMIA RES, V34, P148, DOI 10.1016/j.leukres.2009.06.019
   Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193
   Brown Linda Morris, 2002, Surg Oncol Clin N Am, V11, P235, DOI 10.1016/S1055-3207(02)00002-9
   Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279
   Gao Y, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-269
   Gejman R, 2008, J CLIN ENDOCR METAB, V93, P4119, DOI 10.1210/jc.2007-2633
   Jia LF, 2014, INT J CANCER, V135, P2282, DOI 10.1002/ijc.28667
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu KH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-461
   Lutter D, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-224
   Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999
   Qiu MT, 2013, TUMOR BIOL, V34, P613, DOI 10.1007/s13277-013-0658-6
   Sasaki M, 2003, BIOCHEM BIOPH RES CO, V309, P305, DOI 10.1016/j.bbrc.2003.08.005
   Sheng XJ, 2014, ONCOL REP, V32, P277, DOI 10.3892/or.2014.3208
   Siewert JR, 1998, BRIT J SURG, V85, P1457
   Sun M, 2015, ENDOCR REV, V36, P25, DOI 10.1210/er.2014-1034
   Tano Keiko, 2012, Frontiers in Genetics, V3, P219, DOI 10.3389/fgene.2012.00219
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang LD, 2003, WORLD J GASTROENTERO, V9, P1156, DOI 10.3748/wjg.v9.i6.1156
   Wang PJ, 2012, J CELL BIOCHEM, V113, P1868, DOI 10.1002/jcb.24055
   Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k
   Zhang H, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-37
   Zhang X, 2010, CANCER RES, V70, P2350, DOI 10.1158/0008-5472.CAN-09-3885
   Zhao J, 2005, J CLIN ENDOCR METAB, V90, P2179, DOI 10.1210/jc.2004-1848
   Zhao J, 2006, INT J BIOCHEM CELL B, V38, P1808, DOI 10.1016/j.biocel.2006.05.004
   Zhou Y, 2007, J BIOL CHEM, V282, P24731, DOI 10.1074/jbc.M702029200
   Zhu Y, 2012, NUCLEIC ACIDS RES, V40, P4615, DOI 10.1093/nar/gkr1278
NR 35
TC 29
Z9 32
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD AUG
PY 2017
VL 56
IS 8
BP 1924
EP 1934
DI 10.1002/mc.22650
PG 11
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA EZ7IM
UT WOS:000404896500007
PM 28345805
DA 2020-08-12
ER

PT J
AU Wang, GN
   Yang, WZ
   Xu, D
   Li, DJ
   Zhang, C
   Chen, WN
   Li, SJ
AF Wang, Guan-Nan
   Yang, Wen-Zhi
   Xu, Da
   Li, Dong-Jie
   Zhang, Cui
   Chen, Wei-Na
   Li, Shi-Jie
TI Aberrant expression of MICO1 and MICO1OS in deceased somatic cell
   nuclear transfer calves
SO MOLECULAR REPRODUCTION AND DEVELOPMENT
LA English
DT Article
DE DLK1-DIO3 domain; DNA methylation; genomic imprinting; MICO 1/MICO1OS;
   SCNT
ID IMPRINTED GENE-EXPRESSION; UNIPARENTAL DISOMY; GTL2; TRANSCRIPTS;
   CLONING; GENERATION; DEFECTS; CLUSTER; REGION; DOMAIN
AB Incomplete reprogramming of a donor nucleus following somatic cell nuclear transfer (SCNT) results in aberrant expression of developmentally important genes, and is the primary source of the phenotypic abnormalities observed in cloned animals. Expression of non-coding RNAs in the murine Dlk1-Dio3 imprinted domain was previously shown to correlate with the pluripotency of mouse induced pluripotent stem cells. In this study, we examined the transcription of the bovine orthologs from this locus, MICO1 (Maternal intergenic circadian oscillating 1) and MICO1OS (MICO1 opposite strand), in tissues from artificially inseminated and SCNT calves that died during the perinatal period. A single-nucleotide polymorphism (SNP), a T-to-C transition, was used to analyze the allelic transcription of MICO1. Our results indicate monoallelic expression of the MICO1C allele among the six analyzed tissues (heart, liver, spleen, lung, kidney, and brain) of artificially inseminated calves, indicating that this gene locus may be imprinted in bovine. Conversely, we observed variable allelic transcription of MICO1 in SCNT calves. We asked if DNA methylation regulated the monoallelic expression of MICO1 and MICO1OS by evaluating the methylation levels of six regions within or around this locus in tissues with normal or aberrant MICO1 transcription; all of the samples from either artificially inseminated or SCNT calves exhibited hypermethylation, implying that DNA methylation may not be involved in regulating its monoallelic expression. Furthermore, three imprinted genes (GTL2, MEG9, and DIO3) nearby MICO1 showed monoallelic expression in SCNT calves with aberrant MICO1 transcription, indicating that not all of the genes in the bovine DLK1-DIO3 domain are mis-regulated.
C1 [Wang, Guan-Nan; Yang, Wen-Zhi; Xu, Da; Zhang, Cui; Li, Shi-Jie] Hebei Agr Univ, Coll Life Sci, Dept Biochem & Mol Biol, Baoding 071001, Peoples R China.
   [Li, Dong-Jie] Hebei Sci & Technol Univ, Coll Life Sci & Life Engn, Shijiazhuang, Peoples R China.
   [Chen, Wei-Na] Hebei Univ, Dept Tradit Chinese Med, Baoding, Peoples R China.
RP Li, SJ (corresponding author), Hebei Agr Univ, Coll Life Sci, Dept Biochem & Mol Biol, Baoding 071001, Peoples R China.
EM lishijie20005@163.com
FU Hebei province Natural Science Foundation of ChinaNatural Science
   Foundation of Hebei Province [C2016204092]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [31372312]
FX Hebei province Natural Science Foundation of China, Grant number:
   C2016204092; The National Natural Science Foundation of China, Grant
   number: 31372312
CR Aston KI, 2010, CELL REPROGRAM, V12, P23, DOI 10.1089/cell.2009.0042
   Barlow DP, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018382
   Bartolomei MS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002592
   Charlier C, 2001, GENOME RES, V11, P850, DOI 10.1101/gr.172701
   Chen ZY, 2016, EPIGENETICS-US, V11, P501, DOI 10.1080/15592294.2016.1184805
   de la Casa-Esperon E, 2003, ANNU REV GENET, V37, P349, DOI 10.1146/annurev.genet.37.110801.143741
   Farin CE, 2004, J ANIM SCI, V82, P53
   Georgiades P, 2000, DEVELOPMENT, V127, P4719
   Gong GC, 2004, SCI CHINA SER C, V47, P183, DOI 10.1360/03yc0015
   Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352
   Hill JR, 2000, BIOL REPROD, V63, P1787, DOI 10.1095/biolreprod63.6.1787
   Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402
   Humphreys D, 2002, P NATL ACAD SCI USA, V99, P12889, DOI 10.1073/pnas.192433399
   Kota SK, 2014, DEV CELL, V31, P19, DOI 10.1016/j.devcel.2014.08.009
   Labialle S, 2008, EPIGENETICS-US, V3, P322, DOI 10.4161/epi.3.6.7109
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Li SJ, 2005, BIOL REPROD, V72, P258, DOI 10.1095/biolreprod.104.029462
   Lin SP, 2003, NAT GENET, V35, P97, DOI 10.1038/ng1233
   Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995
   Long CR, 2014, MOL REPROD DEV, V81, P183, DOI 10.1002/mrd.22271
   Mesquita FS, 2013, ANIM REPROD SCI, V136, P231, DOI 10.1016/j.anireprosci.2012.10.030
   Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008
   Niemann H, 2012, REPROD DOMEST ANIM, V47, P2, DOI 10.1111/j.1439-0531.2012.02121.x
   Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206
   Schmidt JV, 2000, GENE DEV, V14, P1997
   Sekita Y, 2006, CYTOGENET GENOME RES, V113, P223, DOI 10.1159/000090836
   Stadtfeld M, 2012, NAT GENET, V44, P398, DOI 10.1038/ng.1110
   Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017
   Steshina EY, 2006, BMC GENET, V7, DOI 10.1186/1471-2156-7-44
   Sutton VR, 2003, HUM GENET, V113, P447, DOI 10.1007/s00439-003-0981-x
   Takada S, 2002, HUM MOL GENET, V11, P77, DOI 10.1093/hmg/11.1.77
   Takada S, 2000, CURR BIOL, V10, P1135, DOI 10.1016/S0960-9822(00)00704-1
   Wang JC, 2008, PROG BIOCHEM BIOPHYS, V35, P1183
   Wrenzycki C, 2001, BIOL REPROD, V65, P309, DOI 10.1095/biolreprod65.1.309
   Yevtodiyenko A, 2002, MAMM GENOME, V13, P633, DOI 10.1007/s00335-002-2208-1
   Zhang K, 2014, ANIM GENET, V45, P660, DOI 10.1111/age.12195
   Zhou XQ, 2015, CELL MOL LIFE SCI, V72, P1175, DOI 10.1007/s00018-014-1744-7
NR 37
TC 0
Z9 0
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1040-452X
EI 1098-2795
J9 MOL REPROD DEV
JI Mol. Reprod. Dev.
PD JUN
PY 2017
VL 84
IS 6
BP 517
EP 524
DI 10.1002/mrd.22807
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology;
   Reproductive Biology
SC Biochemistry & Molecular Biology; Cell Biology; Developmental Biology;
   Reproductive Biology
GA EX4RZ
UT WOS:000403223700007
PM 28383772
DA 2020-08-12
ER

PT J
AU Zhang, MY
   Zhao, YP
   Wang, GN
   Li, DJ
   Chen, WN
   Zhang, C
   Li, SJ
AF Zhang, Mingyue
   Zhao, Yupeng
   Wang, Guannan
   Li, Dongjie
   Chen, Weina
   Zhang, Cui
   Li, Shijie
TI An imprinted long noncoding RNA located between genes Meg8 and Meg9 in
   the cattle Dlk1-Dio3 domain
SO GENETICA
LA English
DT Article
DE Cows; LINC24061; Splice variants; lncRNA; Allele expression
ID HUMAN TRANSCRIPTOME; ENCODE PROJECT; STEM-CELLS; EXPRESSION; GENOME;
   PLURIPOTENCY; LANDSCAPE; GTL2; DNA
AB The Dlk1-Dio3 imprinted domain is located on the cattle chromosome 21 and contains three paternally expressed protein-coding genes and a number of maternally expressed short or long noncoding RNA genes. We have previously obtained two maternally expressed long noncoding RNA genes, Meg8 and Meg9, from the cattle. In this study, we identified a novel noncoding RNA located between Meg8 and Meg9 known as LINC24061 according to the GENCODE annotated bibliography. Two alternatively spliced transcripts (LINC24061-v1 and LINC24061-v2) were obtained using RT-PCR and RACE, and the expression pattern of LINC24061-v1 and LINC24061-v2 was shown to be tissue-specific. The LINC24061-v1 splice variant was expressed in only three types of tissues: heart, kidney and muscle; in contrast, LINC24061-v2 was expressed in all eight tissues examined, including heart, liver, spleen, lung, kidney, skeletal muscle, subcutaneous fat, and brain of adult cattle. The allele-specific expression of LINC24061 was identified based on a single nucleotide polymorphism (SNP) in exon 2 of LINC24061. The results showed that LINC24061 exhibited monoallelic expression in all the examined cattle tissues.
C1 [Zhang, Mingyue; Wang, Guannan; Zhang, Cui; Li, Shijie] Agr Univ Hebei, Coll Life Sci, Dept Biochem & Mol Biol, Baoding, Peoples R China.
   [Zhao, Yupeng] Hebei North Univ, Zhangjiakou, Peoples R China.
   [Li, Dongjie] Hebei Univ Sci & Technol, Coll Life Sci & Life Engn, Shijiazhuang, Peoples R China.
   [Chen, Weina] Hebei Univ, Coll Med Sci, Baoding, Peoples R China.
RP Li, SJ (corresponding author), Agr Univ Hebei, Coll Life Sci, Dept Biochem & Mol Biol, Baoding, Peoples R China.
EM lishijie20005@163.com
FU National Natural Science foundation of ChinaNational Natural Science
   Foundation of China [31372312, 30972098]; Natural Science foundation of
   HebeiNatural Science Foundation of Hebei Province [C2016204092]
FX This study was supported by National Natural Science foundation of China
   (31372312 and 30972098) and Natural Science foundation of Hebei
   (C2016204092).
CR Barlow DP, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018382
   Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Charlier C, 2001, GENOME RES, V11, P850, DOI 10.1101/gr.172701
   Damiani G, 2008, RIV BIOL-BIOL FORUM, V101, P375
   Dinger ME, 2008, GENOME RES, V18, P1433, DOI 10.1101/gr.078378.108
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Han ZB, 2013, MOL CELLS, V35, P285, DOI 10.1007/s10059-013-2275-z
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Hou XH, 2011, RUSS J GENET+, V47, P994, DOI 10.1134/S1022795411080096
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192
   Kanduri C, 2016, BBA-GENE REGUL MECH, V1859, P102, DOI 10.1016/j.bbagrm.2015.05.006
   Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995
   Mercer TR, 2008, P NATL ACAD SCI USA, V105, P716, DOI 10.1073/pnas.0706729105
   Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259
   Pennisi E, 2012, SCIENCE, V337, P1159, DOI 10.1126/science.337.6099.1159
   Qu ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029641
   Ravasi T, 2006, GENOME RES, V16, P11, DOI 10.1101/gr.4200206
   Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017
   Su H, 2011, ANIM REPROD SCI, V127, P23, DOI 10.1016/j.anireprosci.2011.07.002
   Yao X, 2010, MOL IMMUNOL, V48, P153, DOI 10.1016/j.molimm.2010.08.014
   Zhang FW, 2011, J MOL HISTOL, V42, P333, DOI 10.1007/s10735-011-9337-3
   Zhang K, 2014, ANIM GENET, V45, P660, DOI 10.1111/age.12195
NR 23
TC 3
Z9 5
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0016-6707
EI 1573-6857
J9 GENETICA
JI Genetica
PD FEB
PY 2017
VL 145
IS 1
BP 1
EP 7
DI 10.1007/s10709-016-9939-5
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA EL1GU
UT WOS:000394369300001
PM 27858207
DA 2020-08-12
ER

PT J
AU Liang, JL
   Huang, W
   Cai, WF
   Wang, L
   Guo, LL
   Paul, C
   Yu, XY
   Wang, YG
AF Liang, Jialiang
   Huang, Wei
   Cai, Wenfeng
   Wang, Lei
   Guo, Linlin
   Paul, Christian
   Yu, Xi-Yong
   Wang, Yigang
TI Inhibition of microRNA-495 Enhances Therapeutic Angiogenesis of Human
   Induced Pluripotent Stem Cells
SO STEM CELLS
LA English
DT Article
DE Induced pluripotent stem cells; Endothelial differentiation;
   Angiogenesis; Neovascularization; microRNAs; Myocardial infarction
ID ENDOTHELIAL-CELLS; INFARCTED MYOCARDIUM; PROGENITOR CELLS; CARDIAC
   REPAIR; DIFFERENTIATION; EXPRESSION; REGENERATION; MECHANISMS; GENE; RNA
AB Therapeutic angiogenesis has emerged as a promising strategy to regenerate the damaged blood vessels resulting from ischemic diseases such as myocardial infarction (MI). However, the functional integration of implanted endothelial cells (ECs) in infarcted heart remains challenging. We herein develop an EC generation approach by inhibiting microRNA-495 (miR-495) in human induced pluripotent stem cells (hiPSCs) and assess the angiogenic potential for MI treatment. The anti-angiogenic miR-495 belonging to Dlk1-Dio3 miR cluster was identified through expression profiling and computational analysis. Loss-of-function experiments for miR-495 were performed using a lentiviral transfer of antisense sequence in hiPSCs. The pluripotency of hiPSCs was not impacted by the genetic modification. Induced with differentiation medium, miR-495 inhibition enhanced the expression of EC genes of hiPSCs, as well as the yield of ECs. Newly derived ECs displayed prominent angiogenic characteristics including tube formation, cell migration, and proliferation. Mechanistically, miR-495 mediated the expression of endothelial or angiogenic genes by directly targeting vascular endothelial zinc finger 1. After transplantation in immunodeficient MI mice, the derived ECs significantly increased neovascularization in the infarcted heart, prevented functional worsening, and attenuated expansion of infarct size. The functional integration of the implanted ECs into coronary networks was also enhanced by inhibiting miR-495. miR-495 represents a new target not only for promoting EC generation from hiPSCs but also for enhancing angiogenesis and engraftment of hiPSC-derived ECs in ischemic heart.
C1 [Liang, Jialiang; Huang, Wei; Cai, Wenfeng; Wang, Lei; Guo, Linlin; Paul, Christian; Wang, Yigang] Univ Cincinnati, Med Ctr, Coll Med, Dept Pathol, Cincinnati, OH 45267 USA.
   [Liang, Jialiang; Huang, Wei; Cai, Wenfeng; Wang, Lei; Guo, Linlin; Paul, Christian; Wang, Yigang] Univ Cincinnati, Med Ctr, Coll Med, Dept Lab Med, Cincinnati, OH 45267 USA.
   [Yu, Xi-Yong] Guangzhou Med Univ, Inst Mol & Clin Pharmacol, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
RP Wang, YG (corresponding author), Univ Cincinnati, Med Ctr, Dept Pathol & Lab Med, Coll Med, 231 Albert Sabin Way, Cincinnati, OH 54267 USA.; Yu, XY (corresponding author), Guangzhou Med Univ, Sch Pharmaceut Sci, Jingxiu Rd,Univ Campus A1-656, Guangzhou 511436, Guangdong, Peoples R China.
EM yuxycn@aliyun.com; yi-gang.wang@uc.edu
RI LIANG, JIALIANG/L-5865-2015
OI LIANG, JIALIANG/0000-0001-8033-741X; Liang, Jialiang/0000-0002-1556-7195
FU American Heart AssociationAmerican Heart Association [15POST25150010];
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HL110740, HL107957];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81330007, 81120108003]; Guangdong Science and
   Technology Programs [2014A050503047, 2015B020225006]
FX We thank Dr. Carolyn M. Lutzko (Cincinnati Children's Hospital) for
   providing human iPS cell lines. This work was supported by the American
   Heart Association award 15POST25150010 (J.L.) and funded by the National
   Institutes of Health grants HL110740 and HL107957 (Y.W.), the National
   Natural Science Foundation of China grants 81330007 and 81120108003
   (X.Y.Y.), and the Guangdong Science and Technology Programs
   2014A050503047 and 2015B020225006 (X.Y.Y.).
CR Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9
   Aitsebaomo J, 2001, J BIOL CHEM, V276, P39197, DOI 10.1074/jbc.M105166200
   Bautch VL, 2011, NAT MED, V17, P1437, DOI 10.1038/nm.2539
   Beers J, 2012, NAT PROTOC, V7, P2029, DOI 10.1038/nprot.2012.130
   Behfar A, 2014, NAT REV CARDIOL, V11, P232, DOI 10.1038/nrcardio.2014.9
   Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8
   Bolli R, 1999, PHYSIOL REV, V79, P609
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chen GK, 2011, NAT METHODS, V8, P424, DOI [10.1038/NMETH.1593, 10.1038/nmeth.1593]
   Choi KD, 2009, STEM CELLS, V27, P559, DOI 10.1634/stemcells.2008-0922
   Christoforou N, 2008, J CLIN INVEST, V118, P894, DOI 10.1172/JCI33942
   Cochain C, 2013, ANTIOXID REDOX SIGN, V18, P1100, DOI 10.1089/ars.2012.4849
   COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U
   Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011
   Dai B, 2011, J AM COLL CARDIOL, V58, P2118, DOI 10.1016/j.jacc.2011.06.062
   Dickson J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000804
   Esau CC, 2008, METHODS, V44, P55, DOI 10.1016/j.ymeth.2007.11.001
   Fadini GP, 2012, CIRC RES, V110, P624, DOI 10.1161/CIRCRESAHA.111.243386
   Frangogiannis NG, 2006, ANTIOXID REDOX SIGN, V8, P1907, DOI 10.1089/ars.2006.8.1907
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Gordon FE, 2010, ENDOCRINOLOGY, V151, P2443, DOI 10.1210/en.2009-1151
   Gowher H, 2012, P NATL ACAD SCI USA, V109, P2370, DOI 10.1073/pnas.1121538109
   Gu MX, 2012, CIRC RES, V111, P882, DOI 10.1161/CIRCRESAHA.112.269001
   Haga CL, 2012, J BIOL CHEM, V287, P42695, DOI 10.1074/jbc.M112.387761
   Heinrich EM, 2012, CIRC RES, V110, P1014, DOI 10.1161/CIRCRESAHA.111.243394
   Howard L, 2011, VASC PHARMACOL, V55, P69, DOI 10.1016/j.vph.2011.08.002
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Jakobsson L, 2006, DEV CELL, V10, P625, DOI 10.1016/j.devcel.2006.03.009
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Kane NM, 2012, STEM CELLS, V30, P643, DOI 10.1002/stem.1026
   Kane NM, 2010, ARTERIOSCL THROM VAS, V30, P1389, DOI 10.1161/ATVBAHA.110.204800
   Kattman SJ, 2006, DEV CELL, V11, P723, DOI 10.1016/j.devcel.2006.10.002
   Kishimoto K, 2005, ONCOGENE, V24, P445, DOI 10.1038/sj.onc.1208223
   Kuhnert F, 2005, DEV BIOL, V283, P140, DOI 10.1016/j.ydbio.2005.04.003
   Li ZJ, 2011, STEM CELLS DEV, V20, P1701, DOI 10.1089/scd.2010.0426
   Liang JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046158
   Luo ZL, 2013, STEM CELLS, V31, P1749, DOI 10.1002/stem.1448
   Malek A, 2010, CLIN EXP METASTAS, V27, P261, DOI 10.1007/s10585-010-9324-1
   Marcelo KL, 2013, CIRC RES, V112, P1272, DOI 10.1161/CIRCRESAHA.113.300506
   Matouk CC, 2008, CIRC RES, V102, P873, DOI 10.1161/CIRCRESAHA.107.171025
   Miyashita H, 2004, ARTERIOSCL THROM VAS, V24, P878, DOI 10.1161/01.ATV.0000126373.52450.32
   Mo CF, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt535
   Orlova VV, 2014, NAT PROTOC, V9, P1514, DOI 10.1038/nprot.2014.102
   Park C, 2013, CIRC RES, V112, P1380, DOI 10.1161/CIRCRESAHA.113.301078
   Pauli A, 2011, NAT REV GENET, V12, P136, DOI 10.1038/nrg2904
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702
   Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304
   Shigematsu Satoshi, 1999, Endocrine Journal, V46, pS59, DOI 10.1507/endocrj.46.Suppl_S59
   Shiojima I, 2005, J CLIN INVEST, V115, P2108, DOI 10.1172/JCI24682
   Simons M, 2015, CIRC RES, V116, pE99, DOI 10.1161/RES.0000000000000054
   Snyder CM, 2013, DEVELOPMENT, V140, P31, DOI 10.1242/dev.081851
   Sone M, 2007, ARTERIOSCL THROM VAS, V27, P2127, DOI 10.1161/ATVBAHA.107.143149
   Stadtfeld M, 2012, NAT GENET, V44, P398, DOI 10.1038/ng.1110
   Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494
   Walchli T, 2015, NAT PROTOC, V10, P53, DOI 10.1038/nprot.2015.002
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang XH, 2014, J MOL CELL CARDIOL, V74, P139, DOI 10.1016/j.yjmcc.2014.05.001
   Wang YG, 2006, J MOL CELL CARDIOL, V40, P736, DOI 10.1016/j.yjmcc.2006.02.004
   Welten SMJ, 2014, CIRC RES, V115, P696, DOI 10.1161/CIRCRESAHA.114.304747
   Wen ZL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104666
   Wilson KD, 2015, JAMA-J AM MED ASSOC, V313, P1613, DOI 10.1001/jama.2015.1846
   Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103
   Yang DD, 2014, STEM CELL RES, V12, P550, DOI 10.1016/j.scr.2014.01.005
   Zou ZM, 2010, ARTERIOSCL THROM VAS, V30, P1378, DOI 10.1161/ATVBAHA.109.200428
NR 67
TC 19
Z9 21
U1 3
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD FEB
PY 2017
VL 35
IS 2
BP 337
EP 350
DI 10.1002/stem.2477
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA EJ9UT
UT WOS:000393573300007
PM 27538588
OA Bronze
DA 2020-08-12
ER

PT J
AU Monteiro, RAC
   de Freitas, ML
   Vianna, GS
   de Oliveira, VT
   Pietra, RX
   Ferreira, LCA
   Rocha, PPO
   Goncalves, MD
   Cesar, GD
   Lima, JD
   Medeiros, PFV
   Mazzeu, JF
   Jehee, FS
AF Monteiro, Rejane A. C.
   de Freitas, Mariana L.
   Vianna, Gabrielle S.
   de Oliveira, Valdirene T.
   Pietra, Rafaella X.
   Ferreira, Luana C. A.
   Rocha, Patricia P. O.
   Goncalves, Michele da S.
   Cesar, Giovana da C.
   Lima, Joziele de S.
   Medeiros, Paula F. V.
   Mazzeu, Juliana F.
   Jehee, Fernanda S.
TI Major Contribution of Genomic Copy Number Variation in Syndromic
   Congenital Heart Disease: The Use of MLPA as the First Genetic Test
SO MOLECULAR SYNDROMOLOGY
LA English
DT Article
DE Copy number variation; Heart disease; MLPA; SLC2A3; SNP array
ID DEPENDENT PROBE AMPLIFICATION; DE-NOVO; CHROMOSOMAL IMBALANCES;
   MICRODELETION SYNDROME; DEVELOPMENTAL DELAY; MENTAL-RETARDATION;
   ARRAY-CGH; DEFECTS; DELETION; CHILDREN
AB Congenital heart disease (CHD) is the most common congenital disorder among live births. When associated with extracardiac abnormalities, it is characterized as a syndromic heart disease (syndromic CHD) and corresponds to 25% of all liveborn infants with a heart defect. The etiology in about 65% of the cases still remains unknown, and in about 35% of the patients, it is associated with genetic factors. In the present study, MLPA and SNP-array techniques were used to investigate a group of 47 patients with syndromic CHD. In total, 16 defects (34%) were identified, of which 12 (25.5%) were classified as pathogenic or probably pathogenic. The most frequent abnormalities were 22q11.2 deletion (22q11.2 deletion syndrome) and 7q11.23 deletion (Williams-Beuren syndrome). We also show that rarer malformations may be associated with syndromic CHD, such as 14q32.33 deletion 12p13.31 (SLC2A3) duplications. The present study demonstrates that CNVs are important causal factors and should be studied in patients with syndromic CHD. Furthermore, the use of MLPA as a first screening test was appropriate, as this less expensive technology detected 11 of the 12 pathogenic abnormalities (91.6%). (C) 2017 S. Karger AG, Basel
C1 [Monteiro, Rejane A. C.; de Freitas, Mariana L.; Vianna, Gabrielle S.; de Oliveira, Valdirene T.; Pietra, Rafaella X.; Ferreira, Luana C. A.; Rocha, Patricia P. O.; Goncalves, Michele da S.; Cesar, Giovana da C.; Lima, Joziele de S.; Medeiros, Paula F. V.; Mazzeu, Juliana F.; Jehee, Fernanda S.] Inst Educ & Res Santa Casa Belo Horizonte, Human Genet Lab, Belo Horizonte, MG, Brazil.
RP Monteiro, RAC (corresponding author), Inst Educ & Res Santa Casa Belo Horizonte, Human Genet Lab, Belo Horizonte, MG, Brazil.
EM rejane.alvesdecarvalho@gmail.com
RI mazzeu, Juliana forte/H-4279-2016
OI mazzeu, Juliana forte/0000-0002-6161-0510
FU Fundacao de Amparo a Pesquisa de Minas Gerais/FAPEMIGMinas Gerais State
   Research Foundation (FAPEMIG); Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior/CAPESCAPES; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico/CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX The authors would like to express their gratitude to all patients and
   their families for their participation in the study. This work was
   supported by the Fundacao de Amparo a Pesquisa de Minas Gerais/FAPEMIG,
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/CAPES,
   and the Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico/CNPq.
CR Abdelmoity AT, 2012, J DEV BEHAV PEDIATR, V33, P570, DOI 10.1097/DBP.0b013e31826052ae
   Aracena A. Mariana, 2003, Rev. chil. pediatr., V74, P426, DOI 10.4067/S0370-41062003000400014
   BERNSTEIN D, 2004, NELSON TXB PEDIAT, P1481
   Breckpot J, 2012, AM J MED GENET A, V158A, P574, DOI 10.1002/ajmg.a.35217
   Burnside R, 2011, HUM GENET, V130, P517, DOI 10.1007/s00439-011-0970-4
   Cardoso C, 2009, NEUROLOGY, V72, P784, DOI 10.1212/01.wnl.0000336339.08878.2d
   Cowan JR, 2015, CLIN PERINATOL, V42, P373, DOI 10.1016/j.clp.2015.02.009
   Cox DM, 2015, INT J MOL SCI, V16, P4068, DOI 10.3390/ijms16024068
   Digilio M, 2001, Images Paediatr Cardiol, V3, P19
   El Malti R, 2016, EUR J HUM GENET, V24, P228, DOI 10.1038/ejhg.2015.105
   Engels H, 2012, AM J MED GENET A, V158A, P695, DOI 10.1002/ajmg.a.35256
   Engels H, 2009, EUR J HUM GENET, V17, P1592, DOI 10.1038/ejhg.2009.90
   Glessner JT, 2014, CIRC RES, V115, P884, DOI 10.1161/CIRCRESAHA.115.304458
   Hightower HB, 2015, CARDIOL YOUNG, V25, P1155, DOI 10.1017/S1047951114001838
   Holder JL, 2012, AM J MED GENET A, V158A, P1962, DOI 10.1002/ajmg.a.35289
   Jehee FS, 2011, EUR J MED GENET, V54, pE425, DOI 10.1016/j.ejmg.2011.03.007
   Kerstjens-Frederikse WS, 2013, AANGEBOREN HARTAFWIJ, P233
   Landis BJ, 2016, FRONT CARDIOVASC MED, V3, DOI 10.3389/fcvm.2016.00022
   Lukusa T, 2010, GENET COUNSEL, V21, P25
   Maurin ML, 2006, AM J MED GENET A, V140A, P2324, DOI 10.1002/ajmg.a.31438
   Mayr JA, 2011, AM J HUM GENET, V89, P806, DOI 10.1016/j.ajhg.2011.11.007
   MILLER BA, 1992, AM J MED GENET, V44, P635, DOI 10.1002/ajmg.1320440521
   Nakayama J, 2002, ANN NEUROL, V52, P654, DOI 10.1002/ana.10347
   O'Roak BJ, 2012, NATURE, V485, P246, DOI 10.1038/nature10989
   Osoegawa K, 2014, AM J MED GENET A, V164, P397, DOI 10.1002/ajmg.a.36291
   Payne AR, 2012, PEDIATR CARDIOL, V33, P757, DOI 10.1007/s00246-012-0208-9
   Probst FJ, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0291-0
   Richards AA, 2010, CURR CARDIOL REV, V6, P91, DOI 10.2174/157340310791162703
   Campos CMR, 2015, ARQ BRAS CARDIOL, V104, P24, DOI 10.5935/abc.20140169
   Shaikh TH, 2007, GENOME RES, V17, P482, DOI 10.1101/gr.5986507
   Sorensen KM, 2012, AM J MED GENET A, V158A, P720, DOI 10.1002/ajmg.a.35214
   Stoll G, 2013, NAT NEUROSCI, V16, P1228, DOI 10.1038/nn.3484
   Thienpont B, 2007, EUR HEART J, V28, P2778, DOI 10.1093/eurheartj/ehl560
   Thorsson T, 2015, CONGENIT HEART DIS, V10, P193, DOI 10.1111/chd.12179
   Torrezan GT, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-55
   van Karnebeek CDM, 2002, AM J MED GENET, V110, P65, DOI 10.1002/ajmg.10207
   van Karnebeek CDM, 1999, AM J MED GENET, V84, P158, DOI 10.1002/(SICI)1096-8628(19990521)84:2<158::AID-AJMG13>3.0.CO;2-5
   Vanlerberghe C, 2015, EUR J MED GENET, V58, P140, DOI 10.1016/j.ejmg.2015.01.002
   Wang J, 2013, FETAL DIAGN THER, V34, P110, DOI 10.1159/000350272
   Warburton D, 2014, HUM GENET, V133, P11, DOI 10.1007/s00439-013-1353-9
   Ware S.M., 2012, J CLIN EXP CARDIOL S, VS8, P003, DOI [10.4172/2155-9880.S8-003, DOI 10.4172/2155-9880.S8-003]
   Wu Y, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-72
   Zollino M, 2009, AM J MED GENET A, V149A, P1116, DOI 10.1002/ajmg.a.32831
   Zweier M, 2011, MOL SYNDROMOL, V2, P164, DOI 10.1159/000337496
NR 44
TC 7
Z9 7
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1661-8769
EI 1661-8777
J9 MOL SYNDROMOL
JI Mol. Syndromol.
PY 2017
VL 8
IS 5
BP 227
EP 235
DI 10.1159/000477226
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA FC9NF
UT WOS:000407167600002
PM 28878606
OA Green Published, Bronze
DA 2020-08-12
ER

PT J
AU Janssen, R
   Muller, A
   Simonides, WS
AF Janssen, Rob
   Muller, Alice
   Simonides, Warner S.
TI Cardiac Thyroid Hormone Metabolism and Heart Failure
SO EUROPEAN THYROID JOURNAL
LA English
DT Review
DE Thyroid hormone; Deiodinase; Ventricular remodeling; Heart failure
ID TYPE-2 IODOTHYRONINE DEIODINASE; DLK1-DIO3 GENOMIC REGION;
   MYOCARDIAL-INFARCTION; MOUSE HEART; GENE-EXPRESSION;
   CARDIOVASCULAR-DISEASE; DILATED CARDIOMYOPATHY; MICRORNA THERAPEUTICS;
   CELL-PROLIFERATION; RECEPTOR ALPHA-1
AB The heart is a principal target of thyroid hormone, and a reduction of cardiac thyroid hormone signaling is thought to play a role in pathological ventricular remodeling and the development of heart failure. Studies in various rodent models of heart disease have identified increased activity of cardiac type III deiodinase as a possible cause of diminished levels and action of thyroid hormone. Recent data indicate novel mechanisms underlying the induction of this thyroid hormone-degrading enzyme in the heart as well as post-transcriptional regulation of its expression by microRNAs. In addition, the relevance of diminished thyroid hormone signaling for cardiac remodeling is suggested to include miRNA-mediated effects on pathological signaling pathways. These and other recent studies are reviewed and discussed in the context of other processes and factors that have been implicated in the reduction of cardiac thyroid hormone signaling in heart failure. (C) 2017 European Thyroid Association Published by S. Karger AG, Basel
C1 [Janssen, Rob; Muller, Alice; Simonides, Warner S.] Vrije Univ Amsterdam, Med Ctr, Inst Cardiovasc Res, Physiol Lab, De Boelelaan 1118, NL-1081 HV Amsterdam, Netherlands.
RP Simonides, WS (corresponding author), Vrije Univ Amsterdam, Med Ctr, Inst Cardiovasc Res, Physiol Lab, De Boelelaan 1118, NL-1081 HV Amsterdam, Netherlands.
EM ws.simonides@vumc.nl
CR Accorroni A, 2016, HEART FAIL REV, V21, P373, DOI 10.1007/s10741-016-9553-8
   Auden A, 2006, GENE EXPR PATTERNS, V6, P964, DOI 10.1016/j.modgep.2006.03.011
   Aurora AB, 2012, J CLIN INVEST, V122, P1222, DOI 10.1172/JCI59327
   Belke DD, 2007, ENDOCRINOLOGY, V148, P2870, DOI 10.1210/en.2007-0009
   Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8
   Bernardo BC, 2010, PHARMACOL THERAPEUT, V128, P191, DOI 10.1016/j.pharmthera.2010.04.005
   Boelen A, 2008, THYROID, V18, P123, DOI 10.1089/thy.2007.0253
   Boelen A, 2011, ENDOCR REV, V32, P670, DOI 10.1210/er.2011-0007
   Boguslawska J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024541
   Brent GA, 2012, J CLIN INVEST, V122, P3035, DOI 10.1172/JCI60047
   Buermans HPJ, 2005, PHYSIOL GENOMICS, V21, P314, DOI 10.1152/physiolgenomics.00185.2004
   Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165
   Callis TE, 2009, J CLIN INVEST, V119, P2772, DOI 10.1172/JCI36154
   Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007
   Cokkinos DV, 2016, HEART FAIL REV, V21, P365, DOI 10.1007/s10741-016-9554-7
   Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011
   Danzi S, 2002, THYROID, V12, P467, DOI 10.1089/105072502760143836
   Danzi S, 2014, ENDOCRIN METAB CLIN, V43, P517, DOI 10.1016/j.ecl.2014.02.005
   de Vries EM, 2015, J ENDOCRINOL, V225, pR67, DOI 10.1530/JOE-15-0133
   Dentice M, 2014, CELL METAB, V20, P1038, DOI 10.1016/j.cmet.2014.10.009
   Dentice M, 2013, EXPERT OPIN THER TAR, V17, P1369, DOI 10.1517/14728222.2013.833189
   Dentice M, 2011, J ENDOCRINOL, V209, P273, DOI 10.1530/JOE-11-0002
   Di Girolamo D, 2016, J CLIN INVEST, V126, P2308, DOI 10.1172/JCI84465
   Diniz GP, 2013, MOL CELL ENDOCRINOL, V374, P117, DOI 10.1016/j.mce.2013.04.010
   Dorn GW, 2007, HYPERTENSION, V49, P962, DOI 10.1161/HYPERTENSIONAHA.106.079426
   Drexler H, 2010, CARDIOLOGY, P923
   Escobar-Morreale HF, 1999, BIOCHIMIE, V81, P453, DOI 10.1016/S0300-9084(99)80095-9
   Friesema ECH, 2003, J BIOL CHEM, V278, P40128, DOI 10.1074/jbc.M300909200
   Friesema ECH, 2008, MOL ENDOCRINOL, V22, P1357, DOI 10.1210/me.2007-0112
   Galton VA, 2009, ENDOCRINOLOGY, V150, P2957, DOI 10.1210/en.2008-1572
   Gerdes AM, 2015, AM J PHYSIOL-HEART C, V308, pH1, DOI 10.1152/ajpheart.00704.2014
   Gerdes AM, 2010, CIRCULATION, V122, P385, DOI 10.1161/CIRCULATIONAHA.109.917922
   Gereben B, 2008, ENDOCR REV, V29, P898, DOI 10.1210/er.2008-0019
   Hernandez A, 2007, ENDOCRINOLOGY, V148, P3968, DOI 10.1210/en.2007-0029
   Janssen R, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00022
   Janssen R, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00171
   Janssen R, 2013, ENDOCRINOLOGY, V154, P1973, DOI 10.1210/en.2012-2017
   Kawase Y, 2008, J AM COLL CARDIOL, V51, P1112, DOI 10.1016/j.jacc.2007.12.014
   Kenessey A, 2006, J BIOL CHEM, V281, P20666, DOI 10.1074/jbc.M512671200
   Kester MHA, 2009, ENDOCRINOLOGY, V150, P540, DOI 10.1210/en.2008-0344
   Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707
   Li M, 2014, STEM CELL RES, V13, P582, DOI 10.1016/j.scr.2014.07.001
   Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995
   Lowes BD, 2002, NEW ENGL J MED, V346, P1357, DOI 10.1056/NEJMoa012630
   Maillet M, 2013, NAT REV MOL CELL BIO, V14, P38, DOI 10.1038/nrm3495
   Mourouzis I, 2013, MOL CELL BIOCHEM, V379, P97, DOI 10.1007/s11010-013-1631-9
   Muller J, 2014, ENDOCRINOLOGY, V155, P315, DOI 10.1210/en.2013-1800
   Olivares EL, 2007, ENDOCRINOLOGY, V148, P4786, DOI 10.1210/en.2007-0043
   Pachucki J, 2001, ENDOCRINOLOGY, V142, P13, DOI 10.1210/en.142.1.13
   Pantos C, 2007, EUR J ENDOCRINOL, V156, P415, DOI 10.1530/EJE-06-0707
   Pantos C, 2011, HEART FAIL REV, V16, P79, DOI 10.1007/s10741-010-9185-3
   Pingitore A, 2016, HEART FAIL REV, V21, P391, DOI 10.1007/s10741-016-9545-8
   Pol CJ, 2011, ENDOCRINOLOGY, V152, P669, DOI 10.1210/en.2010-0431
   Pol CJ, 2010, HEART FAIL REV, V15, P133, DOI 10.1007/s10741-008-9133-7
   Porrello ER, 2011, SCIENCE, V331, P1078, DOI 10.1126/science.1200708
   Rajabi M, 2007, HEART FAIL REV, V12, P331, DOI 10.1007/s10741-007-9034-1
   Rajagopalan V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151413
   Salvatore D, 2014, NAT REV ENDOCRINOL, V10, P206, DOI 10.1038/nrendo.2013.238
   Schutkowski A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112118
   Simonides WS, 2008, J CLIN INVEST, V118, P975, DOI 10.1172/JCI32824
   Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511
   Trivieri MG, 2006, P NATL ACAD SCI USA, V103, P6043, DOI 10.1073/pnas.0601072103
   Ueta CB, 2012, MOL ENDOCRINOL, V26, P809, DOI 10.1210/me.2011-1325
   van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089
   van Rooij E, 2014, EMBO MOL MED, V6, P851, DOI 10.15252/emmm.201100899
   van Rooij E, 2012, NAT REV DRUG DISCOV, V11, P860, DOI 10.1038/nrd3864
   Visser WE, 2008, TRENDS ENDOCRIN MET, V19, P50, DOI 10.1016/j.tem.2007.11.003
   Wagner MS, 2003, J MOL ENDOCRINOL, V31, P541, DOI 10.1677/jme.0.0310541
   Wahlquist C, 2014, NATURE, V508, P531, DOI 10.1038/nature13073
   Wang YY, 2010, CARDIOVASC RES, V87, P636, DOI 10.1093/cvr/cvq133
   Wassen FWJS, 2002, ENDOCRINOLOGY, V143, P2812, DOI 10.1210/en.143.7.2812
   Weltman NY, 2014, MOL MED, V20, P302, DOI 10.2119/molmed.2013.00040
   Weltman NY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046655
NR 73
TC 13
Z9 15
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 2235-0640
EI 2235-0802
J9 EUR THYROID J
JI Eur. Thyroid J.
PY 2017
VL 6
IS 3
BP 130
EP 137
DI 10.1159/000469708
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA FA0FD
UT WOS:000405105800002
PM 28785539
OA Other Gold, Green Published
DA 2020-08-12
ER

PT J
AU Trompet, S
   de Vries, M
   Welten, S
   van der Kwast, R
   Jukema, W
   Agrawal, S
   Quax, P
   Nossent, AY
AF Trompet, Stella
   de Vries, Margreet
   Welten, Sabine
   van der Kwast, Reginald
   Jukema, Wouter
   Agrawal, Sudhir
   Quax, Paul
   Nossent, Anne Yael
TI C/D Box Small Nucleolar RNAs of the 14q32 Noncoding RNA Gene Cluster
   Play an Important Role in Human Cardiovascular Disease
SO CIRCULATION
LA English
DT Meeting Abstract
CT Scientific Sessions of the American-Heart-Association / Resuscitation
   Science Symposium
CY NOV 12-16, 2016
CL New Orleans, LA
SP Amer Heart Assoc
DE Genome-wide association studies (GWAS); Angiogenesis; Arteriogenesis;
   Vein graft disease
RI Quax, Paul/W-8520-2019
NR 0
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD NOV 11
PY 2016
VL 134
SU 1
MA 18654
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA EO6QC
UT WOS:000396816606088
DA 2020-08-12
ER

PT J
AU Jones, AK
   Safarulla, A
AF Jones, Anwar Krishna
   Safarulla, Azif
TI Trisomy 14 with diaphragmatic hernia
SO JOURNAL OF CLINICAL NEONATOLOGY
LA English
DT Article
DE Amniocentesis; diaphragmatic hernia; karyotype; Trisomy 14
ID MOSAICISM; DIAGNOSIS; ANOMALIES
AB The patient was a 38 week female infant who was prenatally detected to have left sided diaphragmatic hernia which has not been previously described in literature. Diaphragmatic hernia is associated with chromosomal disorders. Multiple case reports have described Mosaic Trisomy 14 with distinctive characteristics. The patient shared few of the reported clinical features and had some novel phenotypic features. The patient was a term female infant who was prenatally detected to have left-sided diaphragmatic hernia at 34 weeks along with polyhydramnios, clover-shaped skull, and shortening of long bones. On delivery, the patient was noted to have multiple distinct features. The patient received maximal cardiorespiratory support but succumbed to the disease process after 6 days. Amniocentesis was performed on mother, and fluorescence in situ hybridization revealed duplication 14q24.2.2q32.33 and deletion 14q32.33. Karyotype on peripheral blood of the patient revealed partial Trisomy 14, by virtue of extra 14q32 region.
C1 [Jones, Anwar Krishna; Safarulla, Azif] Augusta Univ, Med Coll Georgia, Div Neonatol, Dept Pediat, Augusta, GA USA.
RP Safarulla, A (corresponding author), 1120 15th St,BIW 6033, Augusta, GA 30912 USA.
EM asafarulla@augusta.edu
CR Borys D, 2004, PEDIATR DEVEL PATHOL, V7, P35, DOI 10.1007/s10024-003-2133-7
   Fagerberg CR, 2012, CLIN DYSMORPHOL, V21, P45, DOI 10.1097/MCD.0b013e32834a0436
   Faivre L, 1998, PRENATAL DIAG, V18, P1055, DOI 10.1002/(SICI)1097-0223(1998100)18:10<1055::AID-PD405>3.0.CO;2-I
   FUJIMOTO A, 1992, AM J MED GENET, V44, P189, DOI 10.1002/ajmg.1320440214
   Holder AM, 2007, AM J HUM GENET, V80, P825, DOI 10.1086/513442
   Howe DT, 1996, PRENATAL DIAG, V16, P1003, DOI 10.1002/(SICI)1097-0223(199611)16:11<1003::AID-PD995>3.0.CO;2-D
   JOHNSON VP, 1979, AM J MED GENET, V3, P331, DOI 10.1002/ajmg.1320030404
   Lurie IW, 2003, GENET COUNSEL, V14, P75
   Lynch M Fran, 2004, J Perinatol, V24, P121
   PECILE V, 1990, CLIN GENET, V37, P271
   Shinawi M, 2008, AM J MED GENET A, V146A, P1395, DOI 10.1002/ajmg.a.32287
   Tonks A, 2004, PRENATAL DIAG, V24, P596, DOI 10.1002/pd.908
   van Dooren MF, 2004, AM J MED GENET A, V127A, P194, DOI 10.1002/ajmg.a.20613
NR 13
TC 0
Z9 0
U1 1
U2 1
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 2249-4847
EI 1658-6093
J9 J CLIN NEONATOL
JI J. Clin. Neonatol.
PD JUL-SEP
PY 2016
VL 5
IS 3
BP 199
EP 201
DI 10.4103/2249-4847.191266
PG 3
WC Pediatrics
SC Pediatrics
GA ED2KH
UT WOS:000388672600012
DA 2020-08-12
ER

PT J
AU Welten, SMJ
   Goossens, EAC
   Quax, PHA
   Nossent, AY
AF Welten, S. M. J.
   Goossens, E. A. C.
   Quax, P. H. A.
   Nossent, A. Y.
TI The multifactorial nature of microRNAs in vascular remodelling
SO CARDIOVASCULAR RESEARCH
LA English
DT Review
DE MicroRNA; Vascular remodelling; Angiogenesis; Atherosclerosis
ID SMOOTH-MUSCLE-CELLS; HUMAN ATHEROSCLEROTIC PLAQUES; ACUTE
   MYOCARDIAL-INFARCTION; NEOINTIMAL LESION FORMATION;
   CORONARY-ARTERY-DISEASE; VEIN ENDOTHELIAL-CELLS; INFLAMMATORY RESPONSE;
   GROWTH-FACTOR; IN-VITRO; ADAPTIVE NEOVASCULARIZATION
AB Vascular remodelling is a multifactorial process that involves both adaptive and maladaptive changes of the vessel wall through, among others, cell proliferation and migration, but also apoptosis and necrosis of the various cell types in the vessel wall. Vascular remodelling can be beneficial, e.g. during neovascularization after ischaemia, as well as pathological, e.g. during atherosclerosis and aneurysm formation. In recent years, it has become clear that microRNAs are able to target many genes that are involved in vascular remodelling processes and either can promote or inhibit structural changes of the vessel wall. Since many different processes of vascular remodelling are regulated by similar mechanisms and factors, both positive and negative vascular remodelling can be affected by the same microRNAs. A large number of microRNAs has been linked to various aspects of vascular remodelling and indeed, several of these microRNAs regulate multiple vascular remodelling processes, including both the adaptive processes angiogenesis and arteriogenesis as well as maladaptive processes of atherosclerosis, restenosis and aneurysm formation. Here, we discuss the multifactorial role of microRNAs and microRNA clusters that were reported to play a role in multiple forms of vascular remodelling and are clearly linked to cardiovascular disease (CVD). The microRNAs reviewed are miR-126, miR-155 and the microRNA gene clusters 17-92, 23/24/27, 143/145 and 14q32. Understanding the contribution of these microRNAs to the entire spectrum of vascular remodelling processes is important, especially as these microRNAs may have great potential as therapeutic targets for treatment of various CVDs.
C1 [Welten, S. M. J.; Goossens, E. A. C.; Quax, P. H. A.; Nossent, A. Y.] Leiden Univ, Med Ctr, Dept Surg, D6-28,POB 9600, NL-2300 RC Leiden, Netherlands.
   [Welten, S. M. J.; Goossens, E. A. C.; Quax, P. H. A.; Nossent, A. Y.] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, D6-28,POB 9600, NL-2300 RC Leiden, Netherlands.
RP Nossent, AY (corresponding author), Leiden Univ, Med Ctr, Dept Surg, D6-28,POB 9600, NL-2300 RC Leiden, Netherlands.; Nossent, AY (corresponding author), Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, D6-28,POB 9600, NL-2300 RC Leiden, Netherlands.
EM a.y.nossent@lumc.nl
RI Quax, Paul/W-8520-2019; Goossens, Eveline/V-3981-2018
OI Goossens, Eveline/0000-0002-5080-9639; Quax, Paul/0000-0002-6853-5760;
   Nossent, Anne Yael/0000-0002-2155-4286
FU Dutch Heart FoundationNetherlands Heart Foundation [2014T102];
   Netherlands Institute for Regenerative Medicine [FES0908]
FX This study was supported by grants of the Dutch Heart Foundation (Dr. E.
   Dekker Senior Postdoc, 2014T102) and by the Netherlands Institute for
   Regenerative Medicine (FES0908).
CR Aavik E, 2015, EUR HEART J, V36, P993, DOI 10.1093/eurheartj/ehu437
   Anand Sudarshan, 2011, Genes Cancer, V2, P1134, DOI 10.1177/1947601911423032
   Bang C, 2012, MICROCIRCULATION, V19, P208, DOI 10.1111/j.1549-8719.2011.00153.x
   Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8
   Boettger T, 2009, J CLIN INVEST, V119, P2634, DOI 10.1172/JCI38864
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   Boon RA, 2011, TRENDS CARDIOVAS MED, V21, P172, DOI 10.1016/j.tcm.2012.05.005
   Boucher JM, 2011, J BIOL CHEM, V286, P28312, DOI 10.1074/jbc.M111.221945
   Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106
   Chamorro-Jorganes A, 2016, CIRC RES, V118, P38, DOI 10.1161/CIRCRESAHA.115.307408
   Cheng YH, 2009, CIRC RES, V105, P158, DOI 10.1161/CIRCRESAHA.109.197517
   Cipollone F, 2011, STROKE, V42, P2556, DOI 10.1161/STROKEAHA.110.597575
   Climent M, 2015, CIRC RES, V116, P1753, DOI 10.1161/CIRCRESAHA.116.305178
   Concepcion CP, 2012, CANCER J, V18, P262, DOI 10.1097/PPO.0b013e318258b60a
   Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195
   Corsten MF, 2012, CIRC RES, V111, P415, DOI 10.1161/CIRCRESAHA.112.267443
   Davis-Dusenbery BN, 2011, J BIOL CHEM, V286, P28097, DOI 10.1074/jbc.M111.236950
   de Boer HC, 2013, EUR HEART J, V34, P3451, DOI 10.1093/eurheartj/eht007
   Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855
   Dimmeler S, 2014, CIRC RES, V115, P680, DOI 10.1161/CIRCRESAHA.114.304973
   Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812
   Donners MMPC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035877
   Ella L, 2009, CELL DEATH DIFFER, V16, P1590, DOI 10.1038/cdd.2009.153
   Epstein SE, 2004, CIRCULATION, V109, P2826, DOI 10.1161/01.CIR.0000132468.82942.F5
   Fichtlscherer S, 2010, CIRC RES, V107, P677, DOI 10.1161/CIRCRESAHA.109.215566
   Fiedler J, 2014, ANTIOXID REDOX SIGN, V21, P1167, DOI 10.1089/ars.2013.5418
   Fiedler J, 2011, CIRCULATION, V124, P720, DOI 10.1161/CIRCULATIONAHA.111.039008
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Gatsiou A, 2012, CURR VASC PHARMACOL, V10, P524, DOI 10.2174/157016112801784611
   GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431
   Gordon FE, 2010, ENDOCRINOLOGY, V151, P2443, DOI 10.1210/en.2009-1151
   Hakimzadeh N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137035
   Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105
   He FC, 2014, MOL CELL BIOCHEM, V394, P137, DOI 10.1007/s11010-014-2089-0
   Hergenreider E, 2012, NAT CELL BIOL, V14, P249, DOI 10.1038/ncb2441
   Hoekstra M, 2010, BIOCHEM BIOPH RES CO, V394, P792, DOI 10.1016/j.bbrc.2010.03.075
   Huang RS, 2010, J INVEST MED, V58, P961, DOI 10.231/JIM.0b013e3181ff46d7
   Iaconetti C, 2015, CARDIOVASC RES, V107, P522, DOI 10.1093/cvr/cvv141
   Iaconetti C, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-012-0296-y
   Iliopoulos D, 2010, J LIPID RES, V51, P1513, DOI 10.1194/jlr.M004812
   Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986
   Jiang YG, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-36
   Jickling GC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099283
   Kaluza D, 2013, ARTERIOSCL THROM VAS, V33, P533, DOI 10.1161/ATVBAHA.112.300415
   Kasza Z, 2013, J BIOL CHEM, V288, P25956, DOI 10.1074/jbc.M113.484360
   Katare R, 2016, ENDOCRINOLOGY, V157, P432, DOI 10.1210/en.2015-1799
   Kin K, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.000745
   Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916
   La Rocca G, 2009, CELL CYCLE, V8, P2255, DOI 10.4161/cc.8.14.9026
   Laffont B, 2016, THROMB HAEMOSTASIS, V115, P311, DOI 10.1160/TH15-05-0389
   Landskroner-Eiger S, 2015, P NATL ACAD SCI USA, V112, P12812, DOI 10.1073/pnas.1507094112
   Leeper NJ, 2011, J CELL PHYSIOL, V226, P1035, DOI 10.1002/jcp.22422
   Li CJ, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-16
   Li LJ, 2014, MOL MED REP, V10, P527, DOI 10.3892/mmr.2014.2172
   Li P, 2013, CIRC RES, V113, P1117, DOI 10.1161/CIRCRESAHA.113.301306
   Liu D, 2015, THROMB RES, V135, P146, DOI 10.1016/j.thromres.2014.10.027
   Liu DH, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0188-x
   Liu F, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.141
   Liu K, 2015, INT J MOL MED, V36, P817, DOI 10.3892/ijmm.2015.2277
   Lovren F, 2012, CIRCULATION, V126, pS81, DOI 10.1161/CIRCULATIONAHA.111.084186
   Loyer X, 2014, CIRC RES, V114, P434, DOI 10.1161/CIRCRESAHA.114.302213
   Lu LF, 2009, IMMUNITY, V30, P80, DOI 10.1016/j.immuni.2008.11.010
   Maegdefessel L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6214
   Maegdefessel L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003441
   Maegdefessel L, 2012, J CLIN INVEST, V122, P497, DOI 10.1172/JCI61598
   Mandolini C, 2015, NUTR METAB CARDIOVAS, V25, P202, DOI 10.1016/j.numecd.2014.09.005
   Matsumoto S, 2012, BIOCHEM BIOPH RES CO, V427, P280, DOI 10.1016/j.bbrc.2012.09.039
   Mocharla P, 2013, BLOOD, V121, P226, DOI 10.1182/blood-2012-01-407106
   Mohnle P, 2014, BIOCHEM BIOPH RES CO, V451, P516, DOI 10.1016/j.bbrc.2014.08.008
   Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123
   Nazari-Jahantigh M, 2012, J CLIN INVEST, V122, P4190, DOI 10.1172/JCI61716
   Neth P, 2013, CARDIOVASC RES, V99, P294, DOI 10.1093/cvr/cvt096
   Ng R, 2014, HEPATOLOGY, V60, P554, DOI 10.1002/hep.27153
   Ni CW, 2011, AM J PHYSIOL-HEART C, V300, pH1762, DOI 10.1152/ajpheart.00829.2010
   Nossent AY, 2013, ANN SURG, V258, P743, DOI 10.1097/SLA.0b013e3182a6aac0
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   Pankratz F, 2015, CIRCULATION, V131, P1575, DOI 10.1161/CIRCULATIONAHA.114.014579
   Qian X, 2013, CELL CYCLE, V12, P1385, DOI 10.4161/cc.24477
   Qin XM, 2010, P NATL ACAD SCI USA, V107, P3240, DOI 10.1073/pnas.0914882107
   Raitoharju E, 2011, ATHEROSCLEROSIS, V219, P211, DOI 10.1016/j.atherosclerosis.2011.07.020
   Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798
   Ramirez CM, 2011, ARTERIOSCL THROM VAS, V31, P2707, DOI 10.1161/ATVBAHA.111.232066
   Rayner KJ, 2011, NATURE, V478, P404, DOI 10.1038/nature10486
   Rayner KJ, 2011, J CLIN INVEST, V121, P2921, DOI 10.1172/JCI57275
   Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862
   Sahoo S, 2011, CIRC RES, V109, P724, DOI 10.1161/CIRCRESAHA.111.253286
   Sala F, 2014, THROMB HAEMOSTASIS, V112, P796, DOI 10.1160/TH13-11-0905
   Schmitt MMN, 2014, CIRCULATION, V129, P66, DOI 10.1161/CIRCULATIONAHA.113.004149
   Schober A, 2014, NAT MED, V20, P368, DOI 10.1038/nm.3487
   Sethupathy P, 2007, AM J HUM GENET, V81, P405, DOI 10.1086/519979
   Stanczyk J, 2008, ARTHRITIS RHEUM, V58, P1001, DOI 10.1002/art.23386
   Stoneman VEA, 2004, CLIN SCI, V107, P343, DOI 10.1042/CS20040086
   Tian FJ, 2014, CARDIOVASC RES, V103, P100, DOI 10.1093/cvr/cvu070
   Torella D, 2011, CIRC RES, V109, P880, DOI 10.1161/CIRCRESAHA.111.240150
   Turner M, 2008, BIOCHEM SOC T, V36, P531, DOI 10.1042/BST0360531
   Urbich C, 2012, BLOOD, V119, P1607, DOI 10.1182/blood-2011-08-373886
   van Solingen C, 2011, CARDIOVASC RES, V92, P449, DOI 10.1093/cvr/cvr227
   van Solingen C, 2009, J CELL MOL MED, V13, P1577, DOI 10.1111/j.1582-4934.2008.00613.x
   Vengrenyuk Y, 2015, ARTERIOSCL THROM VAS, V35, P535, DOI 10.1161/ATVBAHA.114.304029
   Vickers KC, 2013, HEPATOLOGY, V57, P533, DOI 10.1002/hep.25846
   Villeneuve LM, 2010, DIABETES, V59, P2904, DOI 10.2337/db10-0208
   Wang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107012
   Wang KC, 2010, P NATL ACAD SCI USA, V107, P3234, DOI 10.1073/pnas.0914825107
   Wang P, 2013, MOL CELL BIOL, V33, P3689, DOI 10.1128/MCB.00343-13
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang YS, 2014, J MOL CELL CARDIOL, V66, P94, DOI 10.1016/j.yjmcc.2013.08.007
   Weber M, 2010, BIOCHEM BIOPH RES CO, V393, P643, DOI 10.1016/j.bbrc.2010.02.045
   Wei YY, 2013, AM J PHYSIOL-HEART C, V304, pH1050, DOI 10.1152/ajpheart.00267.2012
   Welten SMJ, 2015, CIRCULATION, V132, pe375, DOI 10.1161/CIRCULATIONAHA.115.018275
   Welten SMJ, 2014, CIRC RES, V115, P696, DOI 10.1161/CIRCRESAHA.114.304747
   Wen ZL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104666
   Wezel A, 2015, ANN SURG, V262, P841, DOI 10.1097/SLA.0000000000001466
   Wu W, 2011, CIRCULATION, V124, P633, DOI 10.1161/CIRCULATIONAHA.110.005108
   Xin M, 2009, GENE DEV, V23, P2166, DOI 10.1101/gad.1842409
   Yang K, 2011, FEBS LETT, V585, P854, DOI 10.1016/j.febslet.2011.02.009
   Young JA, 2013, BLOOD, V122, P2911, DOI 10.1182/blood-2012-12-473017
   Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610
   Zhang CF, 2015, CURR VASC PHARMACOL, V13, P405, DOI 10.2174/1570161112666141118094612
   Zhang CX, 2009, CELL CYCLE, V8, P3469, DOI 10.4161/cc.8.21.9837
   Zhang H, 2014, ONCOGENE, V33, P387, DOI 10.1038/onc.2012.574
   Zhang M, 2014, ATHEROSCLEROSIS, V234, P54, DOI 10.1016/j.atherosclerosis.2014.02.008
   Zhou J, 2013, CIRC RES, V113, P40, DOI 10.1161/CIRCRESAHA.113.280883
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zhu GF, 2013, MOL CELL BIOCHEM, V382, P253, DOI 10.1007/s11010-013-1741-4
   Zhu N, 2011, ATHEROSCLEROSIS, V215, P286, DOI 10.1016/j.atherosclerosis.2010.12.024
   Zou C, 2012, CELL CYCLE, V11, P2137, DOI 10.4161/cc.20598
NR 126
TC 69
Z9 71
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008-6363
EI 1755-3245
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD MAY 1
PY 2016
VL 110
IS 1
BP 6
EP 22
DI 10.1093/cvr/cvw039
PG 17
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA DM1MP
UT WOS:000376109700004
PM 26912672
OA Bronze
DA 2020-08-12
ER

PT J
AU Yuan, HM
   Xie, YJ
   Li, Q
   Hu, XZ
   Li, XW
   Sun, XF
   Zhao, WW
AF Yuan, Haiming
   Xie, Yingjun
   Li, Qian
   Hu, Xizi
   Li, Xinwei
   Sun, Xiaofang
   Zhao, Weiwei
TI Paternal Uniparental Disomy of Chromosome 14 with Hypospadias
SO CYTOGENETIC AND GENOME RESEARCH
LA English
DT Article
DE ESR2; Hypospadias; Imprinted genes; Paternal uniparental disomy 14
ID ESTROGEN-RECEPTORS-ALPHA; ENDOCRINE DISRUPTION; IMPRINTED GENE; ESR2;
   POLYMORPHISMS; ASSOCIATION; PATIENT; REGIONS; 14Q32; RISK
AB Paternal uniparental disomy 14 (patUPD14) is a distinct, clinically recognizable syndrome. Using a clinical SNP microarray, we identified patUPD14 in a boy with a normal karyotype presenting cardiomyopathy and facial anomalies, a specific configuration of the thoracic ribs ('coat hanger sign'), and hypospadias. Analyses of polymorphic microsatellites confirmed the diagnosis of patUPD14. We discuss the functions of the genes included in the rearrangement and their involvement in the pathogenesis of these disorders, especially hypospadias. ESR2 single nucleotide polymorphisms (rs944050; 2681-4A>G) have been associated with an increased risk of hypospadias in previous studies. The patient's ESR2 (rs944050) genotype is GG, whereas the parents both exhibit an AG genotype. This report sheds light on the genetic phenomenon in which the combination of a polymorphism and UPD can lead to new phenotypes, such as hypospadias. (C) 2016 S. Karger AG, Basel
C1 [Yuan, Haiming; Li, Xinwei; Zhao, Weiwei] Guangzhou KingMed Ctr Clin Lab Co Ltd, Guangzhou, Guangdong, Peoples R China.
   [Yuan, Haiming; Zhao, Weiwei] Guangzhou Med Univ, KingMed Sch Lab Med, Guangzhou, Guangdong, Peoples R China.
   [Xie, Yingjun; Sun, Xiaofang] Guangzhou Med Univ, Affiliated Hosp 3, Key Lab Reprod & Genet Guangdong Higher Educ Inst, Key Lab Major Obstet Dis Guangdong Prov, Guangzhou, Guangdong, Peoples R China.
   [Li, Qian] Affymetrix Biotech Shanghai Ltd, Shanghai, Peoples R China.
   [Hu, Xizi] Fairmont Preparatory Acad, Anaheim, CA USA.
RP Xie, YJ (corresponding author), Guangzhou Med Univ, Affiliated Hosp 3, 63 Duobao Rd, Guangzhou 510150, Guangdong, Peoples R China.
EM fairyfareyj@sina.com
CR Ban S, 2008, HUM REPROD, V23, P1466, DOI 10.1093/humrep/den098
   Baskin LS, 2001, ENVIRON HEALTH PERSP, V109, P1175, DOI 10.2307/3454866
   Beleza-Meireles A, 2006, J ENDOCRINOL INVEST, V29, P5, DOI 10.1007/BF03349170
   Beleza-Meireles A, 2007, J CLIN ENDOCR METAB, V92, P3712, DOI 10.1210/jc.2007-0543
   Brown WM, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2014-094073
   Ge YZ, 2014, J ASSIST REPROD GEN, V31, P601, DOI 10.1007/s10815-014-0212-5
   Hannula-Jouppi K, 2014, EPIGENETICS-US, V9, P351, DOI 10.4161/epi.27160
   Haudry C, 2012, MOL GENET METAB, V107, P700, DOI 10.1016/j.ymgme.2012.10.008
   Hsieh Michael H, 2008, Curr Urol Rep, V9, P137
   Kagami M, 2012, EPIGENETICS-US, V7, P1142, DOI 10.4161/epi.21937
   Laverdure N, 2014, CLIN RES HEPATOL GAS, V38, P604, DOI 10.1016/j.clinre.2014.01.011
   Liehr Thomas, 2014, Mol Cytogenet, V7, pI21, DOI 10.1186/1755-8166-7-S1-I21
   Lucas TFG, 2008, BIOL REPROD, V78, P101, DOI 10.1095/biolreprod.107.063909
   Rosenfeld JA, 2015, AM J MED GENET A, V167, P345, DOI 10.1002/ajmg.a.36866
   Sargar KM, 2014, J PERINATOL, V34, P723, DOI 10.1038/jp.2014.24
   Scariano JK, 2008, J RECEPT SIG TRANSD, V28, P285, DOI [10.1080/10799890802084614, 10.1080/10799890802084614 ]
   Sekita Y, 2008, NAT GENET, V40, P243, DOI 10.1038/ng.2007.51
   Shin EH, 2016, BRAIN DEV
   Steinhardt GF, 2004, ADV EXP MED BIOL, V545, P203
   Sutton VR, 2002, AM J MED GENET, V112, P23, DOI 10.1002/ajmg.10703
   Tohyama J, 2011, AM J MED GENET A, V155A, P2584, DOI 10.1002/ajmg.a.34224
   Tsezou A, 2008, BREAST, V17, P159, DOI 10.1016/j.breast.2007.08.007
   Watanabe T, 2015, J OBSTET GYNAECOL RE, V41, P1133, DOI 10.1111/jog.12665
   Xie YJ, 2015, J CHILD NEUROL, V30, P371, DOI 10.1177/0883073814535492
NR 24
TC 2
Z9 2
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1424-8581
EI 1424-859X
J9 CYTOGENET GENOME RES
JI Cytogenet. Genome Res.
PY 2016
VL 148
IS 4
BP 256
EP 261
DI 10.1159/000446783
PG 6
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA DW5SB
UT WOS:000383706100003
PM 27300571
DA 2020-08-12
ER

PT J
AU Zhang, H
   Jin, PF
   Niu, LL
   Li, L
   Wang, LJ
   Chen, Y
   Zhang, GJ
   Zhang, HP
   Zhong, T
AF Zhang, H.
   Jin, P. F.
   Niu, L. L.
   Li, L.
   Wang, L. J.
   Chen, Y.
   Zhang, G. J.
   Zhang, H. P.
   Zhong, T.
TI Methylation differences and expression profiles of the caprine DIO3 gene
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE DIO3; Chinese Nanjiang Yellow goat; Methylation; Gene expression;
   Correlation
ID TYPE-3 IODOTHYRONINE DEIODINASE; THYROID-HORMONE; DNA METHYLATION;
   MAMMALIAN DEVELOPMENT; MOLECULAR-CLONING; MOUSE; CELLS; INACTIVATION;
   METABOLISM; MATURATION
AB gene, located in the DLK1-DIO3 (delta-like 1 homologtype 3 iodothyronine deiodinase) imprinted domain, and is potentially involved in degrading excessive amounts of thyroid hormone to protect embryogenesis. However, the underlying regulatory mechanism of the imprinted DIO3 gene expression during fetal and neonatal development in goats has not been elucidated. In this study, we explored the DNA methylation patterns of the caprine DIO3 intragenic CpG island and quantified gene expression level in six tissues from Chinese Nanjiang Yellow 3-day old kids. The expression of the DIO3 gene was determined using quantitative reverse transcription-polymerase chain reactions (qRT-PCRs), while the identification of methylation patterns was determined using bisulfite-sequencing PCRs. Modest, and non-significant (P > 0.05), methylation patterns were noted for the DIO3 CpG island methylation in the brain, heart, liver, kidney, lung, and longissimus dorsi tissues (ranging from 26.48 to 34.92%). The expression level of the DIO3 mRNA was significantly higher (P < 0.05) in the liver tissue than in the other five tissues. Pearson's correlation analysis revealed that there was no significant relationship between methylation and gene expression (P > 0.05), which indicated that the expression of the caprine DIO3 gene was likely modified by other regulatory elements. This study identified DNA methylation and expression patterns of the DIO3 gene in goats and provided insights into further regulatory mechanisms of expression and imprinting in the DLK1-DIO3 domain.
C1 [Zhang, H.; Jin, P. F.; Niu, L. L.; Li, L.; Wang, L. J.; Zhang, H. P.; Zhong, T.] Sichuan Agr Univ, Coll Anim Sci & Technol, Farm Anim Genet Resources Explorat & Innovat Key, Chengdu, Peoples R China.
   [Chen, Y.; Zhang, G. J.] Inst Nanjiang Yellow Goat Breeding Sci, Bazhong, Peoples R China.
RP Zhong, T (corresponding author), Sichuan Agr Univ, Coll Anim Sci & Technol, Farm Anim Genet Resources Explorat & Innovat Key, Chengdu, Peoples R China.
EM zhongtao@sicau.edu.cn
RI Li, Li/T-4353-2017
OI Li, Li/0000-0003-2459-3499
FU Education Department of Sichuan Province, China [13ZA0264]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [31301945, 31501936]; Technology Support Program of Sichuan
   Province [2014NZ0001, 2015NZ0112]; Chinese Domestic Animal Germplasm
   Resources Infrastructure
FX Research supported by the Education Department of Sichuan Province,
   China (#13ZA0264), the National Natural Science Foundation of China
   (#31301945 and #31501936), the Technology Support Program of Sichuan
   Province (#2014NZ0001 and #2015NZ0112), and the Chinese Domestic Animal
   Germplasm Resources Infrastructure.
CR Barca-Mayo O, 2011, P NATL ACAD SCI USA, V108, pE1321, DOI 10.1073/pnas.1109926108
   Bestor TH, 2015, P NATL ACAD SCI USA, V112, P6796, DOI 10.1073/pnas.1415301111
   Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38
   Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848
   Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886
   Charalambous Marika, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P3, DOI 10.1097/MED.0b013e328013daa2
   Colosimo A, 2009, ANIM GENET, V40, P900, DOI 10.1111/j.1365-2052.2009.01939.x
   Connor EE, 2005, ANIM GENET, V36, P240, DOI 10.1111/j.1365-2052.2005.01282.x
   Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011
   Dong Y, 2013, NAT BIOTECHNOL, V31, P135, DOI 10.1038/nbt.2478
   Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020
   Fonseca TL, 2014, DIABETES, V63, P1594, DOI 10.2337/db13-1768
   Forrest D, 2002, CURR OPIN NEUROBIOL, V12, P49, DOI 10.1016/S0959-4388(02)00289-1
   Galton VA, 1999, J CLIN INVEST, V103, P979, DOI 10.1172/JCI6073
   Hernandez A, 2006, J CLIN INVEST, V116, P476, DOI 10.1172/JCI26240
   Hernandez A, 2002, ENDOCRINOLOGY, V143, P4483, DOI 10.1210/en.2002-220800
   Lin SP, 2007, DEVELOPMENT, V134, P417, DOI 10.1242/dev.02726
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martinez ME, 2014, MOL ENDOCRINOL, V28, P1875, DOI 10.1210/me.2014-1210
   McAninch EA, 2014, ANN NY ACAD SCI, V1311, P77, DOI 10.1111/nyas.12374
   Medina MC, 2011, ENDOCRINOLOGY, V152, P3717, DOI 10.1210/en.2011-1210
   Monk D, 2015, AM J OBSTET GYNECOL, V213, pS152, DOI 10.1016/j.ajog.2015.06.032
   Ng L, 2010, J NEUROSCI, V30, P3347, DOI 10.1523/JNEUROSCI.5267-09.2010
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Peeters R, 2001, AM J PHYSIOL-ENDOC M, V281, pE54
   Qiao M, 2012, MOL BIOL REP, V39, P2329, DOI 10.1007/s11033-011-0983-z
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Renfree MB, 2008, REPRODUCTION, V136, P523, DOI 10.1530/REP-08-0264
   STGERMAIN DL, 1994, TRENDS ENDOCRIN MET, V5, P36, DOI 10.1016/1043-2760(94)90119-8
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Tsai CE, 2002, CURR BIOL, V12, P1221, DOI 10.1016/S0960-9822(02)00951-X
   Walker CG, 2013, PHYSIOL GENOMICS, V45, P276, DOI 10.1152/physiolgenomics.00145.2012
   Wang DX, 2014, GENE, V547, P351, DOI 10.1016/j.gene.2014.06.059
   Wang HM, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15014240
   Wang XS, 2013, GENET MOL RES, V12, P6228, DOI 10.4238/2013.December.4.10
   Wilkinson LS, 2007, NAT REV NEUROSCI, V8, P832, DOI 10.1038/nrn2235
   Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279
   Zhong T, 2016, FUNCT INTEGR GENOMIC, V16, P419, DOI 10.1007/s10142-016-0493-0
NR 38
TC 1
Z9 1
U1 0
U2 1
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2016
VL 15
IS 3
AR 15038678
DI 10.4238/gmr.15038678
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DY1VD
UT WOS:000384881600033
PM 27706705
OA Bronze
DA 2020-08-12
ER

PT J
AU Briggs, TA
   Lokulo-Sodipe, K
   Chandler, KE
   Mackay, DJG
   Temple, IK
AF Briggs, Tracy A.
   Lokulo-Sodipe, Kemi
   Chandler, Kate E.
   Mackay, Deborah J. G.
   Temple, I. Karen
TI Temple Syndrome as a Result of Isolated Hypomethylation of the 14q32
   Imprinted DLK1/MEG3 Region
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE temple syndrome; epigenetics; imprinting; chromosome 14q32
ID MATERNAL UNIPARENTAL DISOMY; CHROMOSOME 14Q32.2; EPIMUTATION; DELETION
AB We present a Caucasian female, who was diagnosed at 13 years of age with Temple syndrome ( formerly referred to as "maternal UPD 14 phenotype") due to an epigenetic loss of methylation at IG-DMR/MEG3-DMR at the chromosome 14q32 imprinted locus. Clinical features were typical and included intra-uterine growth retardation ( IUGR), low birth weight, hypotonia, and poor feeding in the neonatal period; and failure to thrive and developmental delay-particularly in relation to speech-in early childhood. Premature puberty, with short stature and truncal obesity, but normal intelligence, were the key features in teenage years. To date only eight patients with Temple syndrome due to an epigenetic error have been described and the etiology of the methylation defect is currently undetermined. In view of a tendency towards central obesity, patients are at potential risk of early-onset type 2 diabetes mellitus, as well as cardiovascular disease and they, therefore, require appropriate monitoring. (C) 2015 Wiley Periodicals, Inc.
C1 [Briggs, Tracy A.; Chandler, Kate E.] Univ Manchester, St Marys Hosp, Manchester Ctr Genom Med, Manchester M13 0JH, Lancs, England.
   [Lokulo-Sodipe, Kemi; Mackay, Deborah J. G.; Temple, I. Karen] Univ Southampton, Fac Med, Acad Unit Human Dev & Hlth, Southampton SO9 5NH, Hants, England.
   [Lokulo-Sodipe, Kemi; Temple, I. Karen] Univ Hosp Southampton NHS Fdn Trust, Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England.
RP Temple, IK (corresponding author), Princess Anne Hosp, Wessex Clin Genet Serv, Coxford Rd, Southampton SO16 5YA, Hants, England.
EM ikt@soton.ac.uk
RI ; Mackay, Deborah JG/B-2879-2015
OI Lokulo-Sodipe, Kemi (Oluwakemi)/0000-0002-8169-3384; Briggs,
   Tracy/0000-0001-5208-2691; Mackay, Deborah JG/0000-0003-3088-4401;
   Temple, Isabel Karen/0000-0002-6045-1781
FU NIHR Research; Wessex Clinical Research; National Institute for Health
   ResearchNational Institute for Health Research (NIHR) [2295,
   PB-PG-1111-26003]
FX Grant sponsor: NIHR Research; Grant sponsor: Wessex Clinical Research.
CR Bastepe M, 2005, NAT GENET, V37, P25, DOI 10.1038/ng1487
   Buiting K, 2008, HUM MUTAT, V29, P1141, DOI 10.1002/humu.20771
   Hosoki K, 2008, EUR J HUM GENET, V16, P1019, DOI 10.1038/ejhg.2008.90
   Ioannides Y, 2014, J MED GENET, V51, P495, DOI 10.1136/jmedgenet-2014-102396
   Kagami M, 2008, NAT GENET, V40, P237, DOI 10.1038/ng.2007.56
   Kagami M, 2015, EUR J HUM GENET, V23, P1062, DOI 10.1038/ejhg.2014.234
   Mitter D, 2006, AM J MED GENET A, V140A, P2039, DOI 10.1002/ajmg.a.31414
   Poole RL, 2013, AM J MED GENET A, V161, P2174, DOI 10.1002/ajmg.a.36049
   Temple IK, 2007, J MED GENET, V44, P637, DOI 10.1136/jmg.2007.050807
   TEMPLE IK, 1991, J MED GENET, V28, P511, DOI 10.1136/jmg.28.8.511
   Zechner U, 2009, CLIN GENET, V75, P251, DOI 10.1111/j.1399-0004.2008.01116.x
NR 11
TC 17
Z9 18
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD JAN
PY 2016
VL 170
IS 1
BP 170
EP 175
DI 10.1002/ajmg.a.37400
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA DA6RT
UT WOS:000367933600022
PM 26395259
OA Green Accepted
DA 2020-08-12
ER

PT J
AU Cruz, FM
   Tome, M
   Bernal, JA
   Bernad, A
AF Cruz, F. M.
   Tome, M.
   Bernal, J. A.
   Bernad, A.
TI miR-300 mediates Bmi1 function and regulates differentiation in
   primitive cardiac progenitors
SO CELL DEATH & DISEASE
LA English
DT Article
ID CELL SELF-RENEWAL; ACTIVATED PROTEIN-KINASE; CANCER STEM-CELLS;
   CARDIOMYOPATHY; REGENERATION; EXPRESSION; INK4A/ARF; PATHWAY; DISEASE;
   RNAS
AB B lymphoma Mo-MLV insertion region 1 (Bmi1) is a polycomb-family transcriptional factor critical for self-renewal in many adult stem cells and human neoplasia. We sought to identify microRNAs regulated by Bmi1 that could play a role in multipotent cardiac progenitor cell (CPC) decisions. We found that miR-300, a poorly characterized microRNA mapping in the Dlk1-Dio3 microRNA cluster, was positively regulated by Bmi1 in CPCs. Forced expression of miR-300 in CPCs promoted an improved stemness signature with a significant increase in Oct4 levels, a reduction in senescence progression and an enhanced proliferative status via p19 activation and inhibition of p16 accumulation. Endothelial and cardiogenic differentiation were clearly compromised by sustained miR-300 expression. Additionally, RNA and protein analysis revealed a significant reduction in key cardiac transcription factors, including Nkx2.5 and Tbx5. Collectively, these results suggest that some functions attributed to Bmi1 are due to induction of miR-300, which decreases the cardiogenic differentiation potential of multipotent CPCs in vitro and promotes self-renewal.
C1 [Cruz, F. M.; Tome, M.; Bernal, J. A.; Bernad, A.] Ctr Nacl Invest Cardiovasc CNIC, Dept Cardiovasc Dev & Repair, Madrid, Spain.
   [Tome, M.; Bernad, A.] Spanish Natl Ctr Biotechnol CNB CSIC, Dept Immunol & Oncol, Madrid 28049, Spain.
RP Bernad, A (corresponding author), Spanish Natl Ctr Biotechnol CNB CSIC, Dept Immunol & Oncol, Campus Univ Autonoma Madrid, Madrid 28049, Spain.
EM abernad@cnb.csic.es
RI Bernal, Juan A/N-4544-2014
OI Bernal, Juan A/0000-0002-9933-5550
FU Ministry of Science and InnovationSpanish Government [SAF2012-34327,
   PLE2009-0147, PSE-010000-2009-3]; Comunidad Autonoma de MadridComunidad
   de Madrid [S2010/BMD-2420]; Instituto de Salud Carlos III
   (RETICS.TERCEL)Instituto de Salud Carlos III; European
   CommissionEuropean Commission Joint Research Centre [242038,
   BFU2012-35258, RYC-2009-04341, FPU-AP2010-5951]
FX This study was supported by grants from the Ministry of Science and
   Innovation (SAF2012-34327, PLE2009-0147, and PSE-010000-2009-3), the
   Comunidad Autonoma de Madrid (S2010/BMD-2420), the Instituto de Salud
   Carlos III (RETICS.TERCEL), and the European Commission (Proposal
   242038) to AB, (BFU2012-35258 and RYC-2009-04341) to JAB, and fellowship
   FPU-AP2010-5951 to FMC. We thank JL Toran and S Mendez-Ferrer for
   critical discussions of the manuscript; RM Carmona for help with the
   animal procedure; Fatima Sanchez Cabo for statistic and bioinformatic
   assistance, and K. McCreath for editorial support.
CR Allegra E, 2014, ONCOLOGY-BASEL, V86, P199, DOI 10.1159/000358598
   Bailey B, 2012, CIRC RES, V111, P750, DOI 10.1161/CIRCRESAHA.112.274662
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Behfar A, 2002, FASEB J, V16, P1558, DOI 10.1096/fj.02-0072com
   Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8
   Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552
   Biehs B, 2013, NAT CELL BIOL, V15, P846, DOI 10.1038/ncb2766
   Bolli R, 2011, LANCET, V378, P1847, DOI 10.1016/S0140-6736(11)61590-0
   Bras-Rosario L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063041
   Chatoo W, 2009, J NEUROSCI, V29, P529, DOI 10.1523/JNEUROSCI.5303-08.2009
   Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931
   Ellison GM, 2013, CELL, V154, P827, DOI 10.1016/j.cell.2013.07.039
   Fazzio TG, 2008, CELL, V134, P162, DOI 10.1016/j.cell.2008.05.031
   Fu XB, 2003, WORLD J GASTROENTERO, V9, P2036, DOI 10.3748/wjg.v9.i9.2036
   Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003
   Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915
   Izarra A, 2014, STEM CELL REP, V3, P1029, DOI 10.1016/j.stemcr.2014.10.010
   Jacobs JJL, 1999, NATURE, V397, P164
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Li YX, 2006, EUR J PHARMACOL, V549, P98, DOI 10.1016/j.ejphar.2006.08.006
   Makkar RR, 2012, LANCET, V379, P895, DOI 10.1016/S0140-6736(12)60195-0
   Malliaras K, 2014, EMBO MOL MED, V6, P760, DOI 10.1002/emmm.201303626
   Martin-Puig S, 2008, CELL STEM CELL, V2, P320, DOI 10.1016/j.stem.2008.03.010
   Matheu A, 2005, J BIOL CHEM, V280, P42433, DOI 10.1074/jbc.M508270200
   Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060
   Nimmo R, 2013, DEV CELL, V26, P237, DOI 10.1016/j.devcel.2013.06.023
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2
   Piccinato CA, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/369828
   Robson LG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027116
   Rosenblatt-Velin N, 2005, J CLIN INVEST, V115, P1724, DOI 10.1172/JCI23418
   Royo H, 2008, BIOL CELL, V100, P149, DOI 10.1042/BC20070126
   Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165
   Sangiorgi E, 2009, P NATL ACAD SCI USA, V106, P7101, DOI 10.1073/pnas.0902508106
   Schoeftner S, 2013, STEM CELLS, V31, P717, DOI 10.1002/stem.1315
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Shyh-Chang N, 2013, CELL, V155, P778, DOI 10.1016/j.cell.2013.09.059
   Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Tanaka T, 2013, NAT CELL BIOL, V15, P511, DOI 10.1038/ncb2719
   Torres R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019794
   Trohatou O, 2014, STEM CELL TRANSL MED, V3, P54, DOI 10.5966/sctm.2013-0081
   Urbanek K, 2006, P NATL ACAD SCI USA, V103, P9226, DOI 10.1073/pnas.0600635103
   van Berlo JH, 2014, NATURE, V509, P337, DOI 10.1038/nature13309
   VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757
   Williamson D, 2003, J PHYSIOL-LONDON, V547, P977, DOI 10.1113/jphysiol.2002.036673
   Xie X, 2014, ONCOGENE, V33, P2040, DOI 10.1038/onc.2013.173
   Zacharek SJ, 2011, CELL STEM CELL, V9, P272, DOI 10.1016/j.stem.2011.07.007
NR 48
TC 12
Z9 13
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT
PY 2015
VL 6
AR e1953
DI 10.1038/cddis.2015.255
PG 10
WC Cell Biology
SC Cell Biology
GA CZ5NU
UT WOS:000367150100036
PM 26512961
OA DOAJ Gold, Green Published
DA 2020-08-12
ER

PT J
AU Warsame, R
   Kumar, SK
   Gertz, MA
   Lacy, MQ
   Buadi, FK
   Hayman, SR
   Leung, N
   Dingli, D
   Lust, JA
   Ketterling, RP
   Lin, Y
   Russell, S
   Hwa, L
   Kapoor, P
   Go, RS
   Zeldenrust, SR
   Kyle, RA
   Rajkumar, SV
   Dispenzieri, A
AF Warsame, R.
   Kumar, S. K.
   Gertz, M. A.
   Lacy, M. Q.
   Buadi, F. K.
   Hayman, S. R.
   Leung, N.
   Dingli, D.
   Lust, J. A.
   Ketterling, R. P.
   Lin, Y.
   Russell, S.
   Hwa, L.
   Kapoor, P.
   Go, R. S.
   Zeldenrust, S. R.
   Kyle, R. A.
   Rajkumar, S. V.
   Dispenzieri, A.
TI Abnormal FISH in patients with immunoglobulin light chain amyloidosis is
   a risk factor for cardiac involvement and for death
SO BLOOD CANCER JOURNAL
LA English
DT Article
ID PRIMARY SYSTEMIC AMYLOIDOSIS; MULTIPLE-MYELOMA; PROGNOSTIC-FACTOR;
   TRANSLOCATIONS; SURVIVAL; IMPACT
AB Importance of interphase fluorescent in situ hybridization (FISH) with cytoplasmic staining of immunoglobulin FISH (cIg-FISH) on bone marrow is not well understood in light chain amyloidosis (AL). This is in contrast with multiple myeloma where prognostic and treatment related decisions are dependent on cytogenetic testing. This retrospective study reviewed 401 AL patients with cIg-FISH testing performed at our institution between 2004 and 2012. Eighty-one percent of patients had an abnormal cIg-FISH. Common abnormalities involved translocations of chromosome 14q32 (52%), specifically: t(11;14) (43%), t(14;16) (3%) and t(4;14) (2%). Other common abnormalities include monosomy 13/deletion 13q (30%), trisomies 9 (20%), 15 (14%), 11 (10%) and 3 (10%). Median overall survival for this cohort of patients is 3.5 years. When plasma cell burden was greater than 10% trisomies predicted for worse survival (44 vs 19 months), and when it was. 10% t(11; 14) predicted for worse survival (53 months vs not reached). Abnormal cIg-FISH was significantly associated with advanced cardiac involvement, and remained a prognostic factor on multivariate analysis. This large AL cohort demonstrates that abnormal FISH at diagnosis is prognostic for survival and advanced cardiac disease. Particularly, trisomies and t(11;14) affect survival when degree of plasma cell burden is considered.
C1 Mayo Clin, Div Hematol, Rochester, MN 55905 USA.
   Mayo Clin, Dept Pathol, Rochester, MN 55905 USA.
RP Dispenzieri, A (corresponding author), Mayo Clin, Div Hematol, Dept Internal Med, 200 First St SW, Rochester, MN 55905 USA.
EM dispenzieri.angela@mayo.edu
RI Gertz, Morie/K-2873-2019; Kumar, Shaji K/A-9853-2008
OI Kumar, Shaji K/0000-0001-5392-9284; Dispenzieri,
   Angela/0000-0001-8780-9512; Ketterling, Rhett/0000-0001-6479-7897
FU JABBS foundation; Predolin Foundation; Robert A Kyle Hematologic
   Malignancies Fund
FX This work was supported in part by the JABBS foundation, the Predolin
   Foundation and the Robert A Kyle Hematologic Malignancies Fund. This was
   also supported in part by a generous gift from Mr Howard Weitzman's 2011
   Gala in Support of Amyloid Research and Awareness.
CR Bochtler T, 2014, AMYLOID, V21, P9, DOI 10.3109/13506129.2013.854766
   Bochtler T, 2011, BLOOD, V117, P3809, DOI 10.1182/blood-2010-02-268987
   Boyd KD, 2012, LEUKEMIA, V26, P349, DOI 10.1038/leu.2011.204
   Bryce AH, 2009, HAEMATOL-HEMATOL J, V94, P380, DOI 10.3324/haematol.13369
   Dispenzieri A, 2001, J CLIN ONCOL, V19, P3350, DOI 10.1200/JCO.2001.19.14.3350
   Dispenzieri A, 2004, J CLIN ONCOL, V22, P3751, DOI 10.1200/JCO.2004.03.029
   Fonseca R, 2003, BLOOD, V102, P2562, DOI 10.1182/blood-2003-02-0493
   Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876
   Harrison CJ, 2002, BRIT J HAEMATOL, V117, P427, DOI 10.1046/j.1365-2141.2002.03438.x
   Hayman SR, 2001, BLOOD, V98, P2266, DOI 10.1182/blood.V98.7.2266
   Kourelis TV, 2013, J CLIN ONCOL, V31, P4319, DOI 10.1200/JCO.2013.50.8499
   Kumar S, 2012, BLOOD, V119, P2100, DOI 10.1182/blood-2011-11-390658
   Kumar S, 2010, BLOOD, V116, P5126, DOI 10.1182/blood-2010-06-290668
   Mikhael JR, 2013, MAYO CLIN PROC, V88, P360, DOI 10.1016/j.mayocp.2013.01.019
   Perfetti V, 2001, AM J PATHOL, V158, P1599, DOI 10.1016/S0002-9440(10)64115-6
   Rajkumar SV, 2013, LEUKEMIA, V27, P1738, DOI 10.1038/leu.2013.86
   Wuilleme S, 2005, LEUKEMIA, V19, P275, DOI 10.1038/sj.leu.2403586
NR 17
TC 33
Z9 35
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-5385
J9 BLOOD CANCER J
JI Blood Cancer J.
PD MAY
PY 2015
VL 5
AR e310
DI 10.1038/bcj.2015.34
PG 7
WC Oncology; Hematology
SC Oncology; Hematology
GA CJ2AG
UT WOS:000355285800002
PM 25933374
OA DOAJ Gold, Green Published
DA 2020-08-12
ER

PT J
AU Aavik, E
   Lumivuori, H
   Leppanen, O
   Wirth, T
   Hakkinen, SK
   Brasen, JH
   Beschorner, U
   Zeller, T
   Braspenning, M
   van Criekinge, W
   Makinen, K
   Yla-Herttuala, S
AF Aavik, Einari
   Lumivuori, Henri
   Leppanen, Olli
   Wirth, Thomas
   Hakkinen, Sanna-Kaisa
   Braesen, Jan-Hinrich
   Beschorner, Ulrich
   Zeller, Thomas
   Braspenning, Maarten
   van Criekinge, Wim
   Makinen, Kimmo
   Yla-Herttuala, Seppo
TI Global DNA methylation analysis of human atherosclerotic plaques reveals
   extensive genomic hypomethylation and reactivation at imprinted locus
   14q32 involving induction of a miRNA cluster
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Atherosclerosis; DNA methylation; Epigenetics; Peripheral vascular
   disease
ID GENE-EXPRESSION; GROWTH; CELLS; REPRESSION; ARTERIES; DISEASE; LESIONS;
   TUMOR
AB Aims Genetics can explain just above 10% of the observed heritability in cardiovascular diseases. Epigenetics is about to provide some further explanations, but the information needed for that is in the accumulation phase. Genome-wide DNA methylation analysis has revealed thousands of genes, which are epigenetically differentially regulated in atherosclerotic plaques. Our results point to an additional level of complexity that needs to be integrated into the aetiology of atherogenesis.We conducted a genome-wide analysis to identify differentially methylated genes in atherosclerotic lesions.
   Methods DNA methylation at promoters, exons and introns was identified by massive parallel sequencing. Gene expression was analysed by microarrays, qPCR, immunohistochemistry and western blots.
   Results Globally, hypomethylation of chromosomal DNA predominates in atherosclerotic plaques and two-thirds of genes showing over 2.5-fold differential in DNA methylation are up-regulated in comparison to healthy mammary arteries. The imprinted chromatin locus 14q32 was identified for the first time as an extensively hypomethylated area in atherosclerosis with highly induced expression of miR127, -136, -410, -431, -432, -433 and capillary formation-associated gene RTL1. The top 100 list of hypomethylated promoters exhibited over 1000-fold enrichment for miRNAs, many of which mapped to locus 14q32. Unexpectedly, also gene body hypermethylation was found to correlate with stimulated mRNA expression.
   Conclusion Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases.
C1 [Aavik, Einari; Lumivuori, Henri; Wirth, Thomas; Hakkinen, Sanna-Kaisa; Yla-Herttuala, Seppo] Univ Eastern Finland, Dept Biotechnol & Mol Med, AI Virtanen Inst Kuopio, FIN-70211 Kuopio, Finland.
   [Leppanen, Olli] Uppsala Univ, Cty Council Gavleborg, Ctr R&D, Gavle, Sweden.
   [Braesen, Jan-Hinrich] Hannover Med Sch, Inst Pathol, D-30623 Hannover, Germany.
   [Beschorner, Ulrich; Zeller, Thomas] Univ Herzzentrum Freiburg Bad Krozingen, Dept Angiol, Bad Krozingen, Germany.
   [Braspenning, Maarten] NXT Dx, Ghent, Belgium.
   [van Criekinge, Wim] Univ Ghent, Lab Bioinformat & Computat Genom, B-9000 Ghent, Belgium.
   [Makinen, Kimmo] Kuopio Univ Hosp, Vasc Surg Unit, SF-70210 Kuopio, Finland.
   [Yla-Herttuala, Seppo] Kuopio Univ Hosp, Sci Serv Ctr, SF-70210 Kuopio, Finland.
   [Yla-Herttuala, Seppo] Kuopio Univ Hosp, Gene Therapy Unit, SF-70210 Kuopio, Finland.
RP Yla-Herttuala, S (corresponding author), Univ Eastern Finland, Dept Biotechnol & Mol Med, AI Virtanen Inst Kuopio, POB 1627 Neulaniementie 2, FIN-70211 Kuopio, Finland.
EM seppo.ylaherttuala@uef.fi
OI Yla-Herttuala, Seppo/0000-0001-7593-2708
FU Academy of FinlandAcademy of Finland; University of Eastern Finland
   spearhead program, Kuopio University Hospital; Sigrid Juselius
   FoundationSigrid Juselius Foundation
FX This work was supported by the Academy of Finland, University of Eastern
   Finland spearhead program, Kuopio University Hospital, and Sigrid
   Juselius Foundation.
CR Aran D, 2011, HUM MOL GENET, V20, P670, DOI 10.1093/hmg/ddq513
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   BARKER DJP, 1986, LANCET, V1, P1077
   Bell AC, 2000, NATURE, V405, P482
   Broadbent HM, 2008, HUM MOL GENET, V17, P806, DOI 10.1093/hmg/ddm352
   Castillo-Diaz SA, 2010, INT J MOL MED, V26, P691, DOI 10.3892/ijmm_00000515
   Cipollone F, 2011, STROKE, V42, P2556, DOI 10.1161/STROKEAHA.110.597575
   Davis E, 2005, CURR BIOL, V15, P743, DOI 10.1016/j.cub.2005.02.060
   de la Cuesta F, 2013, J PROTEOMICS, V82, P155, DOI 10.1016/j.jprot.2013.01.032
   Deloukas P, 2013, NAT GENET, V45, P25, DOI 10.1038/ng.2480
   EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Han DKM, 1996, J CLIN INVEST, V97, P1276, DOI 10.1172/JCI118543
   Hiltunen M, 2002, VASC MED, V7, P5, DOI 10.1191/1358863x02vm418oa
   Krawetz S, 2000, BIOINFORMATICS METHO
   Laukkanen MO, 1999, ARTERIOSCL THROM VAS, V19, P2171, DOI 10.1161/01.ATV.19.9.2171
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Lin X, 2013, LEUKEMIA, V27, P344, DOI 10.1038/leu.2012.224
   Matouk CC, 2008, CIRC RES, V102, P873, DOI 10.1161/CIRCRESAHA.107.171025
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nemlich Y, 2013, J CLIN INVEST, V123, P2703, DOI 10.1172/JCI62980
   OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0
   Perini G, 2005, P NATL ACAD SCI USA, V102, P12117, DOI 10.1073/pnas.0409097102
   Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sekita Y, 2008, NAT GENET, V40, P243, DOI 10.1038/ng.2007.51
   Sixt S, 2010, VASA, V39, P229, DOI 10.1024/0301-1526/a000034
   Slomp J, 1997, DIFFERENTIATION, V61, P305, DOI 10.1046/j.1432-0436.1997.6150305.x
   Tobi EW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037933
   Turunen MP, 2009, BBA-GEN SUBJECTS, V1790, P886, DOI 10.1016/j.bbagen.2009.02.008
   Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x
   Yla-Herttuala S, 2014, EMBO REP, V15, P125, DOI 10.1002/embr.201338030
   Yla-Herttuala S, 2013, EUR HEART J, V34, P3251, DOI 10.1093/eurheartj/eht301
   Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693
   Zhu SK, 2005, CIRCULATION, V112, P1353, DOI 10.1161/CIRCULATIONAHA.104.519025
NR 37
TC 58
Z9 64
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD APR 21
PY 2015
VL 36
IS 16
BP 993
EP U23
DI 10.1093/eurheartj/ehu437
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CG8GC
UT WOS:000353544300012
PM 25411193
OA Bronze
DA 2020-08-12
ER

PT J
AU Riegel, M
   Moreira, LMA
   Santo, LDE
   Toralles, MBP
   Schinzel, A
AF Riegel, Mariluce
   Moreira, Lilia M. A.
   Espirito Santo, Layla D.
   Toralles, Maria Betania P.
   Schinzel, Albert
TI Interstitial 14q24.3 to q31.3 deletion in a 6-year-old boy with a
   non-specific dysmorphic phenotype
SO MOLECULAR CYTOGENETICS
LA English
DT Article
DE Genotype-phenotype correlation; 14q interstitial deletion; Array-CGH
ID CONGENITAL HEART-DEFECTS; FEATURES; HUMAN-CHROMOSOME-14; CHROMOSOMES;
   PATIENT; CHILD
AB Background: Few patients with interstitial deletions in the distal long arm of chromosome 14 have been reported, and these patients showed rather indistinct features, including growth and mental retardation and phenotypic alterations.
   Results: We describe a de novo 14q interstitial deletion in a 6-year-old boy with dysmorphic facial traits such as hypertelorism, short and narrow palpebral fissures, broad nose with anteverted nostrils, long philtrum, thin upper lip with cupid's bow, prominent and everted lower lip, mildly low-set ears, as well as moderate developmental delay and mild mental retardation. Array-CGH mapped the deletion to the region 14q24.3 to 14q31.3, including 13.11 Mb, proximal to the imprinted genomic region of 14q32.
   Conclusion: This mild phenotypic presentation suggests that the deleted segment does not contain essential genes for early organ development. Twenty-two genes with known functions, including Neurexin III (NRXN3, OMIM 600567), map to the region deleted in the propositus.
C1 [Riegel, Mariluce] Hosp Clin Porto Alegre, Med Genet Serv, BR-90035003 Porto Alegre, RS, Brazil.
   [Riegel, Mariluce] Univ Fed Rio Grande do Sul, Postgrad Program Genet & Mol Biol, Porto Alegre, RS, Brazil.
   [Riegel, Mariluce; Schinzel, Albert] Univ Zurich, Inst Med Genet, Zurich, Switzerland.
   [Moreira, Lilia M. A.; Espirito Santo, Layla D.] Fed Univ Bahia UFBA, Inst Biol, Genet & Soc Program, Lab Human Genet & Mutagenesis, Salvador, BA, Brazil.
   [Toralles, Maria Betania P.] Fed Univ Bahia UFBA, Inst Hlth Sci, Postgrad Studies Program Interact Proc Organs & S, Salvador, BA, Brazil.
RP Riegel, M (corresponding author), Hosp Clin Porto Alegre, Med Genet Serv, Rua Ramiro Barcelos 2350, BR-90035003 Porto Alegre, RS, Brazil.
EM mriegel@hcpa.ufrgs.br
RI Riegel, Mariluce/E-8162-2010
OI Riegel, Mariluce/0000-0002-6397-1301
FU Brazilian Network of Reference; Information in Microdeletion Syndromes
   (RedeBRIM); CNPq/BrazilNational Council for Scientific and Technological
   Development (CNPq) [402012/2010-0]; Swiss National FoundationSwiss
   National Science Foundation (SNSF) [320030-113635]
FX The authors thank the patient's family for their kind cooperation in all
   stages of this study. The investigation was supported by the Brazilian
   Network of Reference and Information in Microdeletion Syndromes
   (RedeBRIM), CNPq/Brazil grant number: 402012/2010-0 and Swiss National
   Foundation, Grant number: 320030-113635.
CR Brisset S, 2014, MOL CYTOGENET, V7, DOI 10.1186/1755-8166-7-17
   BYTH BC, 1995, J MED GENET, V32, P564, DOI 10.1136/jmg.32.7.564
   Cingoz S, 2011, AM J MED GENET A, V155A, P203, DOI 10.1002/ajmg.a.33766
   Gimelli S, 2013, J APPL GENET, V54, P361, DOI 10.1007/s13353-013-0150-4
   Guilherme RS, 2013, CYTOGENET GENOME RES, V141, P317, DOI 10.1159/000353302
   Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348
   Kamnasaran D, 2002, J MED GENET, V39, P81, DOI 10.1136/jmg.39.2.81
   KARNITIS SA, 1992, AM J MED GENET, V44, P153, DOI 10.1002/ajmg.1320440207
   Le Meur N, 2005, AM J MED GENET A, V134A, P439, DOI 10.1002/ajmg.a.30660
   Martinez-Frias ML, 2014, AM J MED GENET A, V164, P639, DOI 10.1002/ajmg.a.36330
   Oehl-Jaschkowitz B, 2014, AM J MED GENET A, V164, P620, DOI 10.1002/ajmg.a.36321
   Piccione M, 2010, EUR J PEDIATR, V169, P845, DOI 10.1007/s00431-009-1128-4
   Rossi E, 2008, J MED GENET, V45, P147, DOI 10.1136/jmg.2007.054007
   Schlade-Bartusiak K, 2008, AM J MED GENET A, V146A, P117, DOI 10.1002/ajmg.a.32064
   Shimada S, 2012, AM J MED GENET A, V158A, P1771, DOI 10.1002/ajmg.a.35431
   Sutton VR, 2000, AM J MED GENET, V93, P381, DOI 10.1002/1096-8628(20000828)93:5<381::AID-AJMG7>3.0.CO;2-9
   Vaags AK, 2012, AM J HUM GENET, V90, P133, DOI 10.1016/j.ajhg.2011.11.025
   YEN FS, 1989, J MED GENET, V26, P130, DOI 10.1136/jmg.26.2.130
   Zollino M, 2009, AM J MED GENET A, V149A, P1116, DOI 10.1002/ajmg.a.32831
   Zorzi JL, 2004, PROC PROTOCOLO OBSER
NR 20
TC 3
Z9 4
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755-8166
J9 MOL CYTOGENET
JI Mol. Cytogenet.
PD NOV 19
PY 2014
VL 7
DI 10.1186/s13039-014-0077-4
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA AU7PT
UT WOS:000345793300001
PM 25426167
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-08-12
ER

PT J
AU Welten, SMJ
   Bastiaansen, AJNM
   de Jong, RCM
   de Vries, MR
   Peters, EAB
   Boonstra, MC
   Sheikh, SP
   La Monica, N
   Kandimalla, ER
   Quax, PHA
   Nossent, AY
AF Welten, Sabine M. J.
   Bastiaansen, Antonius J. N. M.
   de Jong, Rob C. M.
   de Vries, Margreet R.
   Peters, Erna A. B.
   Boonstra, Martin C.
   Sheikh, Soren P.
   La Monica, Nicola
   Kandimalla, Ekambar R.
   Quax, Paul H. A.
   Nossent, A. Yael
TI Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494, and miR-495
   Increases Neovascularization and Blood Flow Recovery After Ischemia
SO CIRCULATION RESEARCH
LA English
DT Article
DE collateral blood circulation; microRNAs; peripheral arterial disease;
   physiologic angiogenesis
ID ENDOTHELIAL-CELLS; EXPRESSION; GENE; ANGIOGENESIS; MIGRATION;
   ARTERIOGENESIS; PROLIFERATION; RECEPTOR-2; ACTIVATION; MECHANISMS
AB Rationale: Effective neovascularization is crucial for recovery after cardiovascular events.
   Objective: Because microRNAs regulate expression of up to several hundred target genes, we set out to identify microRNAs that target genes in all pathways of the multifactorial neovascularization process. Using www.targetscan.org, we performed a reverse target prediction analysis on a set of 197 genes involved in neovascularization. We found enrichment of binding sites for 27 microRNAs in a single microRNA gene cluster. Microarray analyses showed upregulation of 14q32 microRNAs during neovascularization in mice after single femoral artery ligation.
   Methods and Results: Gene silencing oligonucleotides (GSOs) were used to inhibit 4 14q32 microRNAs, miR-329, miR-487b, miR-494, and miR-495, 1 day before double femoral artery ligation. Blood flow recovery was followed by laser Doppler perfusion imaging. All 4 GSOs clearly improved blood flow recovery after ischemia. Mice treated with GSO-495 or GSO-329 showed increased perfusion already after 3 days (30% perfusion versus 15% in control), and those treated with GSO-329 showed a full recovery of perfusion after 7 days (versus 60% in control). Increased collateral artery diameters (arteriogenesis) were observed in adductor muscles of GSO-treated mice, as well as increased capillary densities (angiogenesis) in the ischemic soleus muscle. In vitro, treatment with GSOs led to increased sprout formation and increased arterial endothelial cell proliferation, as well as to increased arterial myofibroblast proliferation.
   Conclusions: The 14q32 microRNA gene cluster is highly involved in neovascularization. Inhibition of 14q32 microRNAs miR-329, miR-487b, miR-494, and miR-495 provides a promising tool for future therapeutic neovascularization.
C1 [Welten, Sabine M. J.; Bastiaansen, Antonius J. N. M.; de Jong, Rob C. M.; de Vries, Margreet R.; Peters, Erna A. B.; Boonstra, Martin C.; Quax, Paul H. A.; Nossent, A. Yael] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands.
   [Welten, Sabine M. J.; Bastiaansen, Antonius J. N. M.; de Jong, Rob C. M.; de Vries, Margreet R.; Peters, Erna A. B.; Quax, Paul H. A.; Nossent, A. Yael] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, NL-2300 RC Leiden, Netherlands.
   [Sheikh, Soren P.] Odense Univ Hosp, Dept Biochem & Pharmacol, DK-5000 Odense, Denmark.
   [La Monica, Nicola; Kandimalla, Ekambar R.] Idera Pharmaceut, Cambridge, MA USA.
RP Nossent, AY (corresponding author), Leiden Univ, Med Ctr, Dept Surg, D6-28,POB 9600, NL-2300 RC Leiden, Netherlands.
EM a.y.nossent@lumc.nl
RI Quax, Paul/W-8520-2019
OI Nossent, Anne Yael/0000-0002-2155-4286; Quax, Paul/0000-0002-6853-5760
FU Netherlands Organization for Scientific ResearchNetherlands Organization
   for Scientific Research (NWO) [Veni 916.12.041]; Leiden University
   Fund/Nypels-van der Zee Fund [2219/5-4-12\NZ]; BioMedical Materials,
   Dutch Ministry of Economic Affairs, Agriculture and Innovation
   (BMM-PENT) [P1.03]; Netherlands Institute for Regenerative Medicine
   [FES0908]
FX This study was supported by grants from the Netherlands Organization for
   Scientific Research (Veni 916.12.041), the Leiden University
   Fund/Nypels-van der Zee Fund (2219/5-4-12\NZ), BioMedical Materials,
   Dutch Ministry of Economic Affairs, Agriculture and Innovation
   (BMM-PENT; P1.03), and by the Netherlands Institute for Regenerative
   Medicine (FES0908).
CR Baker M, 2012, NAT PROTOC, V7, P89, DOI 10.1038/nprot.2011.435
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8
   Bhagat L, 2011, J MED CHEM, V54, P3027, DOI 10.1021/jm200113t
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   Cai WJ, 2009, MOL CELL BIOCHEM, V322, P161, DOI 10.1007/s11010-008-9953-8
   Caporali A, 2012, CARDIOL RES PRACT, V2012, DOI 10.1155/2012/486702
   Caporali A, 2011, TRENDS CARDIOVAS MED, V21, P162, DOI 10.1016/j.tcm.2012.05.003
   Chamorro-Jorganes A, 2011, ARTERIOSCL THROM VAS, V31, P2595, DOI 10.1161/ATVBAHA.111.236521
   Chen Z, 2008, MED RES REV, V28, P185, DOI 10.1002/med.20101
   de Groot D, 2011, J MOL CELL CARDIOL, V50, P25, DOI 10.1016/j.yjmcc.2010.08.006
   Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196
   Germani A, 2009, CARDIOVASC THER, V27, P289, DOI 10.1111/j.1755-5922.2009.00105.x
   Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980
   Gordon FE, 2010, ENDOCRINOLOGY, V151, P2443, DOI 10.1210/en.2009-1151
   Grundmann S, 2011, CIRCULATION, V123, P999, DOI 10.1161/CIRCULATIONAHA.110.000323
   Gupta R, 2009, CIRC RES, V105, P724, DOI 10.1161/CIRCRESAHA.109.200386
   Hazarika S, 2013, CIRCULATION, V127, P1818, DOI 10.1161/CIRCULATIONAHA.112.000860
   Hellingman AA, 2010, EUR J VASC ENDOVASC, V40, P796, DOI 10.1016/j.ejvs.2010.07.009
   Hwang-Verslues WW, 2011, ONCOGENE, V30, P2463, DOI 10.1038/onc.2010.618
   Ikeda S, 2005, CIRC RES, V96, P467, DOI 10.1161/01.RES.0000158286.51045.16
   Jiang X, 2012, P NATL ACAD SCI USA, V109, P19397, DOI 10.1073/pnas.1217519109
   Kagami M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000992
   Katsu M, 2009, J VASC SURG, V49, P192, DOI 10.1016/j.jvs.2008.08.007
   Korff T, 2008, BLOOD, V112, P73, DOI 10.1182/blood-2007-12-128835
   Li ZR, 2012, CANCER LETT, V323, P41, DOI 10.1016/j.canlet.2012.03.029
   Nossent AY, 2013, ANN SURG, V258, P743, DOI 10.1097/SLA.0b013e3182a6aac0
   Nossent AY, 2011, AM J HYPERTENS, V24, P999, DOI 10.1038/ajh.2011.92
   Ohdaira H, 2012, CELL PROLIFERAT, V45, P32, DOI 10.1111/j.1365-2184.2011.00798.x
   Olieslagers S, 2011, CARDIOVASC RES, V91, P510, DOI 10.1093/cvr/cvr100
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304
   Semo J, 2014, EUR HEART J, V35, P3212, DOI 10.1093/eurheartj/eht041
   Snyder CM, 2013, DEVELOPMENT, V140, P31, DOI 10.1242/dev.081851
   Spinetti G, 2013, CIRC RES, V112, DOI 10.1161/CIRCRESAHA.111.300418
   Tille JC, 2001, J PHARMACOL EXP THER, V299, P1073
   Troyan SL, 2009, ANN SURG ONCOL, V16, P2943, DOI 10.1245/s10434-009-0594-2
   van Oostrom MC, 2008, J LEUKOCYTE BIOL, V84, P1379, DOI 10.1189/jlb.0508281
   van Solingen C, 2009, J CELL MOL MED, V13, P1577, DOI 10.1111/j.1582-4934.2008.00613.x
   Wang P, 2013, MOL CELL BIOL, V33, P3689, DOI 10.1128/MCB.00343-13
   Wang XH, 2010, CIRCULATION, V122, P1308, DOI 10.1161/CIRCULATIONAHA.110.964684
   Xi SC, 2013, J CLIN INVEST, V123, P1241, DOI 10.1172/JCI61271
   Yin KJ, 2012, J BIOL CHEM, V287, P27055, DOI 10.1074/jbc.M112.364414
   Zhao W, 2012, CELL BIOCHEM FUNCT, V30, P108, DOI 10.1002/cbf.1823
   Zhou YL, 2010, DEVELOPMENT, V137, P2643, DOI 10.1242/dev.045724
NR 45
TC 75
Z9 79
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD SEP 26
PY 2014
VL 115
IS 8
BP 696
EP +
DI 10.1161/CIRCRESAHA.114.304747
PG 49
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA AP5UQ
UT WOS:000342144600007
PM 25085941
OA Bronze
DA 2020-08-12
ER

PT J
AU Ioannides, Y
   Lokulo-Sodipe, K
   Mackay, DJG
   Davies, JH
   Temple, IK
AF Ioannides, Yiannis
   Lokulo-Sodipe, Kemi
   Mackay, Deborah J. G.
   Davies, Justin H.
   Temple, I. Karen
TI Temple syndrome: improving the recognition of an underdiagnosed
   chromosome 14 imprinting disorder: an analysis of 51 published cases
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID MATERNAL UNIPARENTAL DISOMY; PRADER-WILLI-SYNDROME; INTRAUTERINE
   GROWTH-RETARDATION; PRECOCIOUS PUBERTY; NORMAL KARYOTYPE; CLINICAL
   REPORT; RUSSELL-SILVER; PHENOTYPE; METHYLATION; 14Q32.2
AB Chromosome 14 harbours an imprinted locus at 14q32. Maternal uniparental disomy of chromosome 14, paternal deletions and loss of methylation at the intergenic differentially methylated region (IG-DMR) result in a human phenotype of low birth weight, hypotonia, early puberty and markedly short adult stature. The analysis of the world literature of 51 cases identifies the key features that will enhance diagnosis and potentially improve treatment. We found a median birth weight SD score (SDS) of -1.88 and median adult final height of -2.04 SDS. Hypotonia and motor delay were reported in 93% and 83% of cases, respectively. Early puberty was reported in 86% of cases with the mean age of menarche at 10 years and 2 months of age. Small hands and feet were reported frequently (87% and 96%, respectively). Premature birth was common (30%) and feeding difficulties frequently reported (n = 22). There was evidence of mildly reduced intellectual ability (measured IQ 75-95). Obesity was reported in 49% of cases, and three patients developed type 2 diabetes mellitus. Two patients were reported to have recurrent hypoglycaemia, and one of these patients was subsequently demonstrated to be growth hormone deficient and started replacement therapy. We propose the use of the name 'Temple syndrome' for this condition and suggest that improved diagnosis and long-term monitoring, especially of growth and cardiovascular risk factors, is required.
C1 [Ioannides, Yiannis; Lokulo-Sodipe, Kemi; Mackay, Deborah J. G.; Davies, Justin H.; Temple, I. Karen] Univ Southampton, Fac Med, Acad Unit Human Dev & Hlth, Human Genet & Genom Med Grp, Southampton SO9 5NH, Hants, England.
   [Lokulo-Sodipe, Kemi; Temple, I. Karen] Princess Anne Hosp, Wessex Clin Genet Serv, Univ Hosp Southampton NHS Fdn Trust, Southampton SO16 5YA, Hants, England.
   [Mackay, Deborah J. G.] Salisbury NHS Fdn Trust, Wessex Reg Genet Lab, Salisbury, Wilts, England.
   [Davies, Justin H.] Univ Hosp Southampton NHS Fdn Trust, Dept Paediat Endocrinol, Southampton, Hants, England.
RP Temple, IK (corresponding author), Princess Anne Hosp, Wessex Clin Genet Serv, Coxford Rd, Southampton SO16 5YA, Hants, England.
EM ikt@soton.ac.uk
RI Ioannides, Yannis M/A-1026-2010; temple, isabel K/K-2391-2015; Mackay,
   Deborah JG/B-2879-2015
OI Ioannides, Yannis M/0000-0001-9282-643X; Davies,
   Justin/0000-0001-7560-6320; Lokulo-Sodipe, Kemi
   (Oluwakemi)/0000-0002-8169-3384; Temple, Isabel
   Karen/0000-0002-6045-1781; Mackay, Deborah JG/0000-0003-3088-4401
FU NIHRNational Institute for Health Research (NIHR); National Institute
   for Health ResearchNational Institute for Health Research (NIHR)
   [PB-PG-1111-26003]
FX KL-S is supported by a NIHR Research for Patient Benefit grant. KL-S,
   DJGM and IKT are members of the COST Action BM1208.
CR ANTONARAKIS SE, 1993, AM J HUM GENET, V52, P1145
   Aretz S, 2005, AM J MED GENET A, V135A, P336, DOI 10.1002/ajmg.a.30755
   Azzi S, 2009, HUM MOL GENET, V18, P4724, DOI 10.1093/hmg/ddp435
   BARTON DE, 1996, AM J HUM GENET S, V59, P698
   Bena F, 2010, HUM MOL GENET, V19, P1967, DOI 10.1093/hmg/ddq075
   Berends MJW, 1999, AM J MED GENET, V84, P76, DOI 10.1002/(SICI)1096-8628(19990507)84:1<76::AID-AJMG16>3.0.CO;2-F
   Buiting K, 2008, HUM MUTAT, V29, P1141, DOI 10.1002/humu.20771
   Cassidy SB, 2009, EUR J HUM GENET, V17, P3, DOI 10.1038/ejhg.2008.165
   Coviello D. A., 1996, Acta Geneticae Medicae et Gemellologiae, V45, P169
   Cox H, 2004, AM J MED GENET A, V127A, P21, DOI 10.1002/ajmg.a.20611
   Desilets VA, 1997, AM J HUM GENET S, V61, pA122
   Eggermann T, 2001, J MED GENET, V38, P86, DOI 10.1136/jmg.38.2.86
   Falk MJ, 2005, PEDIATR NEUROL, V32, P116, DOI 10.1016/j.pediatrneurol.2004.07.007
   Fokstuen S, 1999, J PEDIATR-US, V134, P689, DOI 10.1016/S0022-3476(99)70282-9
   Giunti L, 2002, EUR J HUM GENET, V10, P120
   Gunay-Aygun M, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.5.e92
   HARRISON KJ, 1998, AM J HUM GENET S, V63, P51
   HEALEY S, 1994, AM J MED GENET, V51, P147, DOI 10.1002/ajmg.1320510213
   Hordijk R, 1999, J MED GENET, V36, P782, DOI 10.1136/jmg.36.10.782
   Hosoki K, 2008, EUR J HUM GENET, V16, P1019, DOI 10.1038/ejhg.2008.90
   Hosoki K, 2009, J PEDIATR-US, V155, P900, DOI 10.1016/j.jpeds.2009.06.045
   Kagami M, 2008, NAT GENET, V40, P237, DOI 10.1038/ng.2007.56
   Kayashima T, 2002, AM J MED GENET, V111, P38, DOI 10.1002/ajmg.10511
   Linck L, 1997, AM J HUM GENET S, V59, pA124
   Manzoni MF, 2000, CLIN GENET, V57, P406, DOI 10.1034/j.1399-0004.2000.570514.x
   Martin RA, 1999, J MED GENET, V36, P633
   McCandless SE, 2011, PEDIATRICS, V127, P195, DOI 10.1542/peds.2010-2820
   Mitter D, 2006, AM J MED GENET A, V140A, P2039, DOI 10.1002/ajmg.a.31414
   Miyoshi O, 1998, J HUM GENET, V43, P138, DOI 10.1007/s100380050056
   Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002
   Netchine I, 2007, J CLIN ENDOCR METAB, V92, P3148, DOI 10.1210/jc.2007-0354
   Papenhausen P, 2001, AM J HUM GENET, V69, P313
   PENTAO L, 1992, AM J HUM GENET, V50, P690
   Poole RL, 2013, AM J MED GENET A, V161, P2174, DOI 10.1002/ajmg.a.36049
   ROBINSON WP, 1994, AM J HUM GENET, V54, P290
   Sanlaville D, 2000, J MED GENET, V37, P525, DOI 10.1136/jmg.37.7.525
   Schmidt JV, 2000, GENE DEV, V14, P1997
   Schneider A, 2008, EUR J HUM GENET, V16, P680, DOI 10.1038/sj.ejhg.5201977
   Sekita Y, 2008, NAT GENET, V40, P243, DOI 10.1038/ng.2007.51
   Splitt MP, 1997, AM J MED GENET, V72, P239, DOI 10.1002/(SICI)1096-8628(19971017)72:2<239::AID-AJMG21>3.0.CO;2-N
   Takahashi I, 2005, TOHOKU J EXP MED, V207, P333, DOI 10.1620/tjem.207.333
   Temple IK, 2007, J MED GENET, V44, P637, DOI 10.1136/jmg.2007.050807
   TEMPLE IK, 1991, J MED GENET, V28, P511, DOI 10.1136/jmg.28.8.511
   Tomkins DJ, 1996, EUR J HUM GENET, V4, P153
   Wakeling EL, 2010, J MED GENET, V47, P760, DOI 10.1136/jmg.2010.079111
   Worley KA, 2001, AM J HUM GENET, V69, P309
   Zechner U, 2009, CLIN GENET, V75, P251, DOI 10.1111/j.1399-0004.2008.01116.x
NR 47
TC 94
Z9 95
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD AUG
PY 2014
VL 51
IS 8
BP 495
EP 501
DI 10.1136/jmedgenet-2014-102396
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA AL6VM
UT WOS:000339271200001
PM 24891339
OA Green Accepted
DA 2020-08-12
ER

PT J
AU Nossent, AY
   Eskildsen, TV
   Andersen, LB
   Bie, P
   Bronnum, H
   Schneider, M
   Andersen, DC
   Welten, SMJ
   Jeppesen, PL
   Hamming, JF
   Hansen, JL
   Quax, PH
   Sheikh, SP
AF Nossent, A. Yael
   Eskildsen, Tilde V.
   Andersen, Lene B.
   Bie, Peter
   Bronnum, Hasse
   Schneider, Mikael
   Andersen, Ditte C.
   Welten, Sabine M. J.
   Jeppesen, Pia L.
   Hamming, Jaap F.
   Hansen, Jakob L.
   Quax, Paul H.
   Sheikh, Soren P.
TI The 14q32 MicroRNA-487b Targets the Antiapoptotic Insulin Receptor
   Substrate 1 in Hypertension-Induced Remodeling of the Aorta
SO ANNALS OF SURGERY
LA English
DT Article
DE aneurysm; angiotensin II; aorta; hypertension; insulin receptor
   substrate 1; microRNA-487b
ID BLOOD-PRESSURE; IRS-1; PHOSPHORYLATION; SENSITIVITY; RESISTANCE;
   PROTEINS; SURVIVAL
AB Objectives: To study the role of microRNAs in hypertension-induced vascular pathology before the onset of symptoms of severe cardiovascular disease.
   Background: MicroRNAs play a crucial role in cardiovascular disease. However, microRNAs are often studied in full-blown cardiovascular disease models, not during development of cardiovascular pathology.
   Methods: Angiotensin II was infused into healthy adult rats, inducing chronic hypertension, and microRNA expression profiles were obtained. The most prominently regulated microRNA, miR-487b, was further investigated, using primary cultures of rat aortic and human umbilical cord arterial cells.
   Results: MiR-487b is predicted to target insulin receptor substrate 1 (IRS1). IRS1 plays an important role in both insulin signaling and cell proliferation and survival. IRS1 mRNA and protein levels were downregulated in aortae of hypertensive rats. MiR-487b binds directly to both rat and human IRS1 3' UTR and inhibits reporter gene expression in vitro. In primary rat and human arterial adventitial fibroblasts, inhibition of miR-487b leads to upregulation of IRS1 expression. Upregulation of miR-487b had the opposite effect, confirming direct targeting of IRS1 by miR-487b.
   Immunohistochemistry of aortic cross sections and rt/qPCR analyses of the separate aortic wall layers showed that both IRS1 and miR-487b were present mainly in the adventitia and less or not at all in the intima and tunica media. IRS1 expression in adventitial fibroblasts was predominantly nuclear and nuclear IRS1 is known to have antiapoptotic effects. Indeed, inhibition of miR-487b protected adventitial fibroblasts, and also medial smooth muscle cells, against serum starvation-induced apoptosis and increased cell survival.
   Conclusions: Angiotensin II-induced hypertension leads to upregulation of miR-487b, which targets IRS1. Via downregulation of IRS1, miR-487b can contribute to cell death and loss of adventitial and medial integrity during hypertension-induced vascular pathology.
C1 [Nossent, A. Yael; Welten, Sabine M. J.; Hamming, Jaap F.; Quax, Paul H.] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands.
   [Nossent, A. Yael; Welten, Sabine M. J.; Hamming, Jaap F.; Quax, Paul H.] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, NL-2300 RC Leiden, Netherlands.
   [Nossent, A. Yael; Eskildsen, Tilde V.; Andersen, Lene B.; Bie, Peter; Bronnum, Hasse; Schneider, Mikael; Andersen, Ditte C.; Jeppesen, Pia L.; Sheikh, Soren P.] Univ Southern Denmark, Renal & Cardiovasc Sect, Inst Mol Med, Odense, Denmark.
   [Nossent, A. Yael; Eskildsen, Tilde V.; Andersen, Lene B.; Bie, Peter; Bronnum, Hasse; Schneider, Mikael; Andersen, Ditte C.; Jeppesen, Pia L.; Sheikh, Soren P.] Odense Univ Hosp, DK-5000 Odense, Denmark.
   [Nossent, A. Yael; Hansen, Jakob L.] Univ Copenhagen, Dept Biomed Sci, Copenhagen, Denmark.
   [Nossent, A. Yael; Hansen, Jakob L.] Univ Copenhagen, Danish Natl Res Fdn Ctr Cardiac Arrhythmia, Copenhagen, Denmark.
   [Hansen, Jakob L.] Novo Nordisk AS, Diabet NBEs, Malov, Denmark.
   [Hansen, Jakob L.] Novo Nordisk AS, Obes Biol, Malov, Denmark.
RP Nossent, AY (corresponding author), Leiden Univ, Med Ctr, Dept Surg, D6-28,POB 9600, NL-2300 RC Leiden, Netherlands.
EM a.y.nossent@lumc.nl
RI Schneider, Mikael/AAC-2742-2019; Schneider, Mikael/C-2036-2008; Quax,
   Paul/W-8520-2019; Andersen, Ditte/P-4523-2014
OI Schneider, Mikael/0000-0002-3379-0235; Andersen,
   Ditte/0000-0003-4940-7912; Nossent, Anne Yael/0000-0002-2155-4286; Quax,
   Paul/0000-0002-6853-5760
FU Birthe and John Meyer Foundation in Denmark; BioMedical Materials, Dutch
   Ministry of Economic Affairs, Agriculture and Innovation (BMM-PENT)
   [P1.03]; Netherlands Organization for Scientific Research
   (NWO)Netherlands Organization for Scientific Research (NWO) [Veni
   916.12.041]
FX The authors received financial support from Birthe and John Meyer
   Foundation in Denmark, the BioMedical Materials, Dutch Ministry of
   Economic Affairs, Agriculture and Innovation (BMM-PENT; P1.03), and The
   Netherlands Organization for Scientific Research (NWO) (Veni
   916.12.041). The authors declare no conflicts of interest.
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Boon RA, 2011, TRENDS CARDIOVAS MED, V21, P172, DOI 10.1016/j.tcm.2012.05.005
   Boon RA, 2011, CIRC RES, V109, P1115, DOI 10.1161/CIRCRESAHA.111.255737
   Bruneau BG, 2005, NATURE, V436, P181, DOI 10.1038/436181a
   Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200
   Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019
   Hitomi H, 2011, AM J PHYSIOL-CELL PH, V301, pC1415, DOI 10.1152/ajpcell.00017.2011
   Huang D, 2007, AM J PHYSIOL-CELL PH, V292, pC1339, DOI 10.1152/ajpcell.00144.2006
   Jeppesen PL, 2011, BRIT J PHARMACOL, V164, P394, DOI 10.1111/j.1476-5381.2011.01375.x
   Kin K, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.000745
   Lawes CMM, 2008, LANCET, V371, P1513, DOI 10.1016/S0140-6736(08)60655-8
   Machado-Neto JA, 2011, BBA-MOL CELL RES, V1813, P1404, DOI 10.1016/j.bbamcr.2011.04.002
   Maegdefessel L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003441
   Maegdefessel L, 2012, J CLIN INVEST, V122, P497, DOI 10.1172/JCI61598
   Miranda S, 2010, CELL SIGNAL, V22, P645, DOI 10.1016/j.cellsig.2009.11.019
   Nawano M, 1999, METABOLISM, V48, P1248, DOI 10.1016/S0026-0495(99)90263-9
   Nossent AY, 2011, AM J HYPERTENS, V24, P999, DOI 10.1038/ajh.2011.92
   Pahl MC, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-25
   Reiss K, 2012, J CELL PHYSIOL, V227, P2992, DOI 10.1002/jcp.24019
   Sloniger JA, 2005, METABOLISM, V54, P1659, DOI 10.1016/j.metabol.2005.06.016
   Tseng YH, 2002, J BIOL CHEM, V277, P31601, DOI 10.1074/jbc.M202932200
   Ueno H, 2000, MOL BIOL CELL, V11, P735, DOI 10.1091/mbc.11.2.735
   Van Rooij E, 2007, J CLIN INVEST, V117, P2369, DOI 10.1172/JCI33099
   Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490
   Walker RJ, 2012, MOL VIS, V18, P271
   White MK, 2002, EXP CELL RES, V280, P270, DOI 10.1006/excr.2002.5646
NR 26
TC 25
Z9 29
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-4932
EI 1528-1140
J9 ANN SURG
JI Ann. Surg.
PD NOV
PY 2013
VL 258
IS 5
BP 743
EP 753
DI 10.1097/SLA.0b013e3182a6aac0
PG 11
WC Surgery
SC Surgery
GA 300LS
UT WOS:000330466000014
PM 24096771
DA 2020-08-12
ER

PT J
AU Thun, GA
   Imboden, M
   Ferrarotti, I
   Kumar, A
   Obeidat, M
   Zorzetto, M
   Haun, M
   Curjuric, I
   Alves, AC
   Jackson, VE
   Albrecht, E
   Ried, JS
   Teumer, A
   Lopez, LM
   Huffman, JE
   Enroth, S
   Bosse, Y
   Hao, K
   Timens, W
   Gyllensten, U
   Polasek, O
   Wilson, JF
   Rudan, I
   Hayward, C
   Sandford, AJ
   Deary, IJ
   Koch, B
   Reischl, E
   Schulz, H
   Hui, J
   James, AL
   Rochat, T
   Russi, EW
   Jarvelin, MR
   Strachan, DP
   Hall, IP
   Tobin, MD
   Dahl, M
   Nielsen, SF
   Nordestgaard, BG
   Kronenberg, F
   Luisetti, M
   Probst-Hensch, NM
AF Thun, Gian Andri
   Imboden, Medea
   Ferrarotti, Ilaria
   Kumar, Ashish
   Obeidat, Ma'en
   Zorzetto, Michele
   Haun, Margot
   Curjuric, Ivan
   Alves, Alexessander Couto
   Jackson, Victoria E.
   Albrecht, Eva
   Ried, Janina S.
   Teumer, Alexander
   Lopez, Lorna M.
   Huffman, Jennifer E.
   Enroth, Stefan
   Bosse, Yohan
   Hao, Ke
   Timens, Wim
   Gyllensten, Ulf
   Polasek, Ozren
   Wilson, James F.
   Rudan, Igor
   Hayward, Caroline
   Sandford, Andrew J.
   Deary, Ian J.
   Koch, Beate
   Reischl, Eva
   Schulz, Holger
   Hui, Jennie
   James, Alan L.
   Rochat, Thierry
   Russi, Erich W.
   Jarvelin, Marjo-Riitta
   Strachan, David P.
   Hall, Ian P.
   Tobin, Martin D.
   Dahl, Morten
   Nielsen, Sune Fallgaard
   Nordestgaard, Borge G.
   Kronenberg, Florian
   Luisetti, Maurizio
   Probst-Hensch, Nicole M.
TI Causal and Synthetic Associations of Variants in the SERPINA Gene
   Cluster with Alpha1-antitrypsin Serum Levels
SO PLOS GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; OBSTRUCTIVE PULMONARY-DISEASE; LUNG-FUNCTION;
   MOLECULAR CHARACTERIZATION; MZ HETEROZYGOTES; RARE VARIANTS;
   AIR-POLLUTION; ALPHA(1)-ANTITRYPSIN; SUSCEPTIBILITY; DEFICIENCY
AB Several infrequent genetic polymorphisms in the SERPINA1 gene are known to substantially reduce concentration of alpha1-antitrypsin (AAT) in the blood. Since low AAT serum levels fail to protect pulmonary tissue from enzymatic degradation these polymorphisms also increase the risk for early onset chronic obstructive pulmonary disease (COPD). The role of more common SERPINA1 single nucleotide polymorphisms (SNPs) in respiratory health remains poorly understood. We present here an agnostic investigation of genetic determinants of circulating AAT levels in a general population sample by performing a genome-wide association study (GWAS) in 1392 individuals of the SAPALDIA cohort. Five common SNPs defined by showing minor allele frequencies (MAFs) >5% reached genome-wide significance all located in the SERPINA gene cluster at 14q32.13. The top-ranking genotyped SNP rs4905179 was associated with an estimated effect of beta = 20.068 g/L per minor allele (P = 1.20*10(-12)). But denser SERPINA1 locus genotyping in 5569 participants with subsequent stepwise conditional analysis as well as exon-sequencing in a subsample (N = 410) suggested that AAT serum level is causally determined at this locus by rare (MAF<1%) and low-frequent (MAF 1-5%) variants only in particular by the well-documented protein inhibitor S and Z (PI S PI Z) variants. Replication of the association of rs4905179 with AAT serum levels in the Copenhagen City Heart Study (N = 8273) was successful (P<0.0001) as was the replication of its synthetic nature (the effect disappeared after adjusting for PI S and Z P = 0.57). Extending the analysis to lung function revealed a more complex situation. Only in individuals with severely compromised pulmonary health (N = 397) associations of common SNPs at this locus with lung function were driven by rarer PI S or Z variants. Overall our meta-analysis of lung function in ever-smokers does not support a functional role of common SNPs in the SERPINA gene cluster in the general population.
C1 [Thun, Gian Andri; Imboden, Medea; Kumar, Ashish; Curjuric, Ivan; Probst-Hensch, Nicole M.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Thun, Gian Andri; Imboden, Medea; Kumar, Ashish; Curjuric, Ivan; Probst-Hensch, Nicole M.] Univ Basel, Basel, Switzerland.
   [Ferrarotti, Ilaria; Zorzetto, Michele; Luisetti, Maurizio] Univ Pavia, IRCCS San Matteo Hosp Fdn, Inst Resp Dis, Ctr Diag Inherited Antitrypsin Deficiency Alpha1, I-27100 Pavia, Italy.
   [Kumar, Ashish] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Obeidat, Ma'en; Sandford, Andrew J.] Univ British Columbia, Inst Heart & Lung Hlth, James Hogg Res Ctr, Vancouver, BC V5Z 1M9, Canada.
   [Haun, Margot; Kronenberg, Florian] Med Univ Innsbruck, Dept Med Genet, Div Genet Epidemiol, A-6020 Innsbruck, Austria.
   [Alves, Alexessander Couto; Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London, England.
   [Jackson, Victoria E.; Tobin, Martin D.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England.
   [Jackson, Victoria E.; Tobin, Martin D.] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England.
   [Albrecht, Eva; Ried, Janina S.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany.
   [Teumer, Alexander] Univ Med Greifswald, Interfac Inst Genet & Funct Genom, Greifswald, Germany.
   [Lopez, Lorna M.; Deary, Ian J.] Univ Edinburgh, Dept Psychol, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland.
   [Huffman, Jennifer E.; Hayward, Caroline] Univ Edinburgh, Inst Genet & Mol Med, MRC Human Genet, Edinburgh, Midlothian, Scotland.
   [Enroth, Stefan; Gyllensten, Ulf] Uppsala Univ, SciLifeLab, Rudbeck Lab, Dept Immunol Genet & Pathol, Uppsala, Sweden.
   [Bosse, Yohan] Univ Laval, Dept Mol Med, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada.
   [Hao, Ke] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, Dept Genet & Genom Sci, New York, NY USA.
   [Timens, Wim] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, GRIAC Res Inst, Groningen, Netherlands.
   [Polasek, Ozren] Univ Split, Fac Med, Dept Publ Hlth, Split, Croatia.
   [Wilson, James F.; Rudan, Igor] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland.
   [Koch, Beate] Univ Med Greifswald, Dept Internal Med B, Greifswald, Germany.
   [Reischl, Eva] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany.
   [Schulz, Holger] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany.
   [Hui, Jennie] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia.
   [Hui, Jennie] Univ Western Australia, Perth, WA 6009, Australia.
   [Hui, Jennie] Busselton Populat Med Res Fdn, Perth, WA, Australia.
   [James, Alan L.] West Australian Sleep Disorders Res Inst, Perth, WA, Australia.
   [James, Alan L.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia.
   [Rochat, Thierry] Univ Hosp Geneva, Div Pulm Med, Geneva, Switzerland.
   [Russi, Erich W.] Univ Zurich Hosp, Div Pulm, CH-8091 Zurich, Switzerland.
   [Jarvelin, Marjo-Riitta] Univ Oulu, Inst Hlth Sci, Oulu, Finland.
   [Jarvelin, Marjo-Riitta] Univ Oulu, Bioctr Oulu, Oulu, Finland.
   [Jarvelin, Marjo-Riitta] Oulu Univ Hosp, Unit Primary Care, Oulu, Finland.
   [Jarvelin, Marjo-Riitta] Natl Inst Hlth & Welf, Dept Children & Young People & Families, Oulu, Finland.
   [Strachan, David P.] Univ London, Div Populat Hlth Sci & Educ, London, England.
   [Hall, Ian P.] Queens Med Ctr, Div Therapeut & Mol Med, Nottingham NG7 2UH, England.
   [Dahl, Morten] Univ Copenhagen Hosp, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark.
   [Nielsen, Sune Fallgaard; Nordestgaard, Borge G.] Copenhagen Univ Hosp, Herlev Hosp, Dept Clin Biochem, Herlev, Denmark.
RP Thun, GA (corresponding author), Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
EM nicole.probst@unibas.ch
RI Wilson, James F F/A-5704-2009; Rudan, Igor/I-1467-2012; Hui,
   Jennie/A-9543-2013; Hayward, Caroline/M-8818-2016; Reischl,
   Eva/B-9311-2013; Kronenberg, Florian/B-1736-2008; Jackson,
   Victoria/L-5782-2019; Dahl, Morten/F-4219-2014; Schulz,
   Holger/J-5643-2015; Deary, Ian J/C-6297-2009; Enroth,
   Stefan/C-7396-2009; Lopez, Lorna/AAR-4912-2020; Zorzetto,
   Michele/K-2281-2015; Teumer, Alexander/S-7438-2019; Polasek,
   Ozren/B-6002-2011; Timens, Wim/K-5570-2013
OI Wilson, James F F/0000-0001-5751-9178; Rudan, Igor/0000-0001-6993-6884;
   Hui, Jennie/0000-0002-1653-2496; Hayward, Caroline/0000-0002-9405-9550;
   Reischl, Eva/0000-0003-4055-8060; Kronenberg,
   Florian/0000-0003-2229-1120; Jackson, Victoria/0000-0002-9758-9784;
   Dahl, Morten/0000-0002-6686-312X; Schulz, Holger/0000-0002-1157-200X;
   Deary, Ian J/0000-0002-1733-263X; Enroth, Stefan/0000-0002-5056-9137;
   Lopez, Lorna/0000-0002-0241-9783; Zorzetto, Michele/0000-0002-7826-3666;
   Teumer, Alexander/0000-0002-8309-094X; Polasek,
   Ozren/0000-0002-5765-1862; Timens, Wim/0000-0002-4146-6363; Kumar,
   Ashish/0000-0002-7075-5930; Couto Alves, Alex/0000-0001-8519-7356;
   Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Thun, Gian
   Andri/0000-0003-4436-3455; Hall, Ian/0000-0001-9933-3216; Tobin,
   Martin/0000-0002-3596-7874
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF) [33CS30_134276/1, 33CSCO-108796, 3247BO-104283, 3247BO104288,
   3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532,
   4026-028099, 3233-054996, PDFMP3-123171]; Federal Office for Forest,
   Environment and Landscape; Federal Office of Public Health; Federal
   Office of Roads and Transport; canton's government of Aargau,
   Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais and Zurich;
   Swiss Lung League; the canton's Lung League of Basel Stadt, Basel
   Landschaft, Geneva, Ticino, Valais and Zurich; Schweizerische
   Unfallversicherungsanstalt (SUVA); Freiwillige Akademische Gesellschaft;
   UBS Wealth Foundation; Talecris Biotherapeutics GmbH; Grifols; Abbott
   Diagnostics; Kedrion S.p.A.; IRCCS (Istituto di ricovero e cura a
   carattere scientifico) Foundation San Matteo Hospital; Cariplo
   FoundationFondazione Cariplo; European CommissionEuropean Commission
   Joint Research Centre [018996]; Wellcome TrustWellcome Trust [WT
   084703MA, 076113/B/04/Z, 068545/Z/02]; Medical Research CouncilMedical
   Research Council UK (MRC) [G0000934]; National Institute of Diabetes and
   Digestive and Kidney Diseases (NIDDK)United States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National
   Institute of Allergy and Infectious Diseases (NIAID)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Human Genome Research Institute (NHGRI)United States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Human Genome Research Institute (NHGRI); National Institute of
   Child Health and Human Development (NICHD)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD); Juvenile Diabetes Research Foundation International
   (JDRF)Juvenile Diabetes Research Foundation; Juvenile Diabetes Research
   Foundation InternationalJuvenile Diabetes Research Foundation; National
   Institute for Health Research Cambridge Biomedical Research
   CentreNational Institute for Health Research (NIHR); Wellcome Trust
   Strategic AwardWellcome Trust [079895]; European Commission Framework
   Programme 6European Union (EU) [018996]; French Ministry of
   ResearchMinistry of Research, France; Healthway; Danish Heart
   Foundation; Danish Lung Foundation; Medical Research Council (UK)Medical
   Research Council UK (MRC); Ministry of Science, Education, and Sport of
   the Republic of CroatiaMinistry of Science, Education and Sports,
   Republic of Croatia; European Union framework program 6 European Special
   Populations Research Network projectEuropean Union (EU)
   [LSHG-CT-2006-018947]; Merck Research LaboratoriesMerck & Company;
   Helmholtz Zentrum Munchen-German Research Center for Environmental
   HealthHelmholtz Association; German Federal Ministry of Education and
   ResearchFederal Ministry of Education & Research (BMBF); State of
   Bavaria; Munich Center of Health Sciences (MC Health),
   Ludwig-Maximilians-Universitat; Competence Network ASCONET, subnetwork
   COSYCONET [FKZ 01GI0882]; Research Into Ageing [251]; University of
   Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology; cross
   council Lifelong Health and Wellbeing Initiative [G0700704/84698];
   Biotechnology and Biological Sciences Research Council
   (BBSRC)Biotechnology and Biological Sciences Research Council (BBSRC)
   [BB/F019394/1]; BBSRCBiotechnology and Biological Sciences Research
   Council (BBSRC); Engineering and Physical Sciences Research Council
   (EPSRC)Engineering & Physical Sciences Research Council (EPSRC);
   Economic and Social Research Council (ESRC)Economic & Social Research
   Council (ESRC); Medical Research Council (MRC)Medical Research Council
   UK (MRC); Division of Lung Diseases of the National Heart, Lung, and
   Blood InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [N01-HR-46002]; Academy of FinlandAcademy of
   Finland [104781, 120315, 129269, 1114194, 24300796]; University Hospital
   Oulu, Biocenter; University of Oulu, Finland [75617]; NHLBIUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [5R01HL087679-02,
   1RL1MH083268-01]; NIH/NIMHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [5R01MH63706: 02]; ENGAGE project
   [HEALTH-F4-2007-201413]; Medical Research Council, UKMedical Research
   Council UK (MRC) [G0500539, G0600705, G1002319]; Academy of Finland and
   Biocentrum HelsinkiAcademy of Finland; Northern Swedish Population
   Health Study; Swedish Medical Research CouncilSwedish Medical Research
   Council (SMRC) [K2007-66X-20270-01-3]; Foundation for Strategic
   Research; European Commission Sixth Framework Programme Specific
   Targeted Research ProjectsEuropean Union (EU) [01947,
   LSHG-CT-2006-01947]; Chief Scientist Office of the Scottish Government;
   Royal SocietyRoyal Society of London; European Union Framework Programme
   6 EUROSPAN projectEuropean Union (EU) [LSHG-CT-2006-018947]; Federal
   Ministry of Education and ResearchFederal Ministry of Education &
   Research (BMBF) [01ZZ9603, 01ZZ0103, 01ZZ0403, 03ZIK012]; Ministry of
   Cultural Affairs; Social Ministry of the Federal State of
   Mecklenburg-West Pomerania; networks 'Greifswald Approach to
   Individualized Medicine' [03IS2061A]; COSYCONET [01GI0883]; Siemens
   Healthcare, Erlangen, Germany; Federal State of Mecklenburg-West
   Pomerania; Biotechnology and Biological Sciences Research
   CouncilBiotechnology and Biological Sciences Research Council (BBSRC)
   [BB/F019394/1]; Medical Research CouncilMedical Research Council UK
   (MRC) [G1002319, G1000861, 1192912, MR/K026992/1, G0700704, G0902313,
   G0600705]; Chief Scientist Office [CZB/4/710]
FX This SAPALDIA project was supported by the Swiss National Science
   Foundation (grants: 33CS30_134276/1, 33CSCO-108796, 3247BO-104283,
   3247BO104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720,
   3200-042532, 4026-028099, 3233-054996, PDFMP3-123171); the Federal
   Office for Forest, Environment and Landscape; the Federal Office of
   Public Health; the Federal Office of Roads and Transport; the canton's
   government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino,
   Valais and Zurich; the Swiss Lung League; the canton's Lung League of
   Basel Stadt, Basel Landschaft, Geneva, Ticino, Valais and Zurich;
   Schweizerische Unfallversicherungsanstalt (SUVA); Freiwillige
   Akademische Gesellschaft; UBS Wealth Foundation; Talecris
   Biotherapeutics GmbH; Grifols; Abbott Diagnostics; Kedrion S.p.A.; IRCCS
   (Istituto di ricovero e cura a carattere scientifico) Foundation San
   Matteo Hospital; and Cariplo Foundation 2006 projects. Genotyping in the
   GABRIEL framework was supported by European Commission (018996) and
   Wellcome Trust (WT 084703MA). Individual studies: The British 1958 Birth
   Cohort DNA collection was funded by the Medical Research Council grant
   G0000934 and the Wellcome Trust grant 068545/Z/02. Genotyping for the
   B58C-WTCCC subset was funded by the Wellcome Trust grant 076113/B/04/Z.
   The B58C-T1DGC genotyping utilized resources provided by the Type 1
   Diabetes Genetics Consortium, a collaborative clinical study sponsored
   by the National Institute of Diabetes and Digestive and Kidney Diseases
   (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID),
   National Human Genome Research Institute (NHGRI), National Institute of
   Child Health and Human Development (NICHD), and Juvenile Diabetes
   Research Foundation International (JDRF) and supported by U01 DK062418.
   B58C-T1DGC GWAS data were deposited by the Diabetes and Inflammation
   Laboratory, Cambridge Institute for Medical Research (CIMR), University
   of Cambridge, which is funded by Juvenile Diabetes Research Foundation
   International, the Wellcome Trust and the National Institute for Health
   Research Cambridge Biomedical Research Centre; the CIMR is in receipt of
   a Wellcome Trust Strategic Award (079895). The B58C-GABRIEL genotyping
   was supported by a contract from the European Commission Framework
   Programme 6 (018996) and grants from the French Ministry of Research.
   The 1994-95 Busselton Health Study is funded by Healthway. The
   Copenhagen City Heart Study is funded by the Danish Heart Foundation and
   the Danish Lung Foundation. The CROATIA-Korcula, CROATIA-Vis and
   CROATIA-Split studies in the Croatian islands of Korcula and Vis and
   mainland city of Split were supported by grants from the Medical
   Research Council (UK); the Ministry of Science, Education, and Sport of
   the Republic of Croatia (grant number 108-1080315-0302); and the
   European Union framework program 6 European Special Populations Research
   Network project (contract LSHG-CT-2006-018947). The eQTL-Study,
   including for this project the University of British Columbia and the
   University of Groningen, was funded by Merck Research Laboratories. The
   KORA research platform (KORA, Cooperative Health Research in the Region
   of Augsburg) was initiated and financed by the Helmholtz Zentrum
   Munchen-German Research Center for Environmental Health which is funded
   by the German Federal Ministry of Education and Research and by the
   State of Bavaria. Furthermore, KORA research was supported within the
   Munich Center of Health Sciences (MC Health),
   Ludwig-Maximilians-Universitat, as part of LMUinnovativ.; Further
   support was provided by the Competence Network ASCONET, subnetwork
   COSYCONET (FKZ 01GI0882). The Lothian Birth Cohort 1936 data collection
   was funded by Research Into Ageing (Ref. 251). The work was undertaken
   by The University of Edinburgh Centre for Cognitive Ageing and Cognitive
   Epidemiology, part of the cross council Lifelong Health and Wellbeing
   Initiative (Ref. G0700704/84698). The whole genome association study was
   funded by the Biotechnology and Biological Sciences Research Council
   (BBSRC) (Ref. BB/F019394/1). Funding from the BBSRC, Engineering and
   Physical Sciences Research Council (EPSRC), Economic and Social Research
   Council (ESRC) and Medical Research Council (MRC) is gratefully
   acknowledged. The Lung Health Study was supported by contract
   N01-HR-46002 from the Division of Lung Diseases of the National Heart,
   Lung, and Blood Institute. The rs4905179 data were from Gene-Environment
   Association Studies (GENEVA). The Northern Finland Birth Cohort 1966
   received financial support from the Academy of Finland (project grants
   104781, 120315, 129269, 1114194, 24300796, Center of Excellence in
   Complex Disease Genetics and SALVE), University Hospital Oulu,
   Biocenter, University of Oulu, Finland (75617), NHLBI grant
   5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), NIH/NIMH
   (5R01MH63706: 02), ENGAGE project and grant agreement
   HEALTH-F4-2007-201413, and the Medical Research Council, UK (G0500539,
   G0600705, G1002319, PrevMetSyn/SALVE). The DNA extractions, sample
   quality controls, biobank up-keeping and aliquotting was performed in
   the National Public Health Institute, Biomedicum Helsinki, Finland and
   supported financially by the Academy of Finland and Biocentrum Helsinki.
   The Northern Swedish Population Health Study was funded by the Swedish
   Medical Research Council (Project K2007-66X-20270-01-3), and the
   Foundation for Strategic Research. NSPHS, as part of European Special
   Populations Research Network, was also supported by European Commission
   Sixth Framework Programme Specific Targeted Research Projects Grant
   01947 (LSHG-CT-2006-01947). The Orkney Complex Disease Study was
   supported by the Chief Scientist Office of the Scottish Government, the
   Royal Society, and the European Union Framework Programme 6 EUROSPAN
   project (contract LSHG-CT-2006-018947). The Study of Health in Pomerania
   is part of the Community Medicine Research net of the University of
   Greifswald, Germany, which is funded by the Federal Ministry of
   Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403),
   the Ministry of Cultural Affairs, as well as the Social Ministry of the
   Federal State of Mecklenburg-West Pomerania, and the networks
   'Greifswald Approach to Individualized Medicine' (GANI_MED, grant no.
   03IS2061A) and COSYCONET (grant no. 01GI0883), both funded by the
   Federal Ministry of Education and Research. Genome-wide data have been
   supported by the Federal Ministry of Education and Research (grant no.
   03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany
   and the Federal State of Mecklenburg-West Pomerania. The University of
   Greifswald is a member of the 'Center of Knowledge Interchange' program
   of the Siemens AG and the Cache 'Campus program of the InterSystems
   GmbH. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ackermann-Liebrich U, 2005, SOZ PRAVENTIV MED, V50, P245, DOI 10.1007/s00038-005-4075-5
   Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Amer Thoracic Soc European Respir, 2003, AM J RESP CRIT CARE, V168, P818, DOI 10.1164/rccm.168.7.818
   Aulchenko YS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-134
   Aulchenko YS, 2009, NAT GENET, V41, P47, DOI 10.1038/ng.269
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BRANTLY ML, 1991, CHEST, V100, P703, DOI 10.1378/chest.100.3.703
   Carter KW, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-60
   Chappell S, 2006, HUM MUTAT, V27, P103, DOI 10.1002/humu.20275
   Chappell S, 2008, HEPATOLOGY, V47, P127, DOI 10.1002/hep.21979
   Coassin S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001239
   Dahl M, 2005, EUR RESPIR J, V26, P67, DOI 10.1183/09031936.05.00135704
   Dahl M, 2002, ANN INTERN MED, V136, P270, DOI 10.7326/0003-4819-136-4-200202190-00006
   Dickson SP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000294
   Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758
   FABER JP, 1994, AM J HUM GENET, V55, P1113
   Ferrarotti I, 2012, THORAX, V67, P669, DOI 10.1136/thoraxjnl-2011-201321
   Fra AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038405
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Galarneau G, 2010, NAT GENET, V42, P1049, DOI 10.1038/ng.707
   Gibson G, 2012, NAT REV GENET, V13, P135, DOI 10.1038/nrg3118
   Gorrini M, 2006, CLIN CHEM, V52, P899, DOI 10.1373/clinchem.2005.062059
   GRAHAM A, 1989, HUM GENET, V84, P55, DOI 10.1007/BF00210671
   Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029
   Heath SC, 2008, EUR J HUM GENET, V16, P1413, DOI 10.1038/ejhg.2008.210
   Heid IM, 2006, DIABETES, V55, P375, DOI 10.2337/diabetes.55.02.06.db05-0747
   Hemminger BM, 2006, BIOINFORMATICS, V22, P626, DOI 10.1093/bioinformatics/btk025
   Hersh CP, 2004, THORAX, V59, P843, DOI 10.1136/thx.2004.022541
   HOLMES MD, 1990, AM REV RESPIR DIS, V142, P1185, DOI 10.1164/ajrccm/142.5.1185
   Imboden M, 2012, J ALLERGY CLIN IMMUN, V129, P1218, DOI 10.1016/j.jaci.2012.01.074
   Inouye M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002907
   Johansen CT, 2010, NAT GENET, V42, P684, DOI 10.1038/ng.628
   Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564
   Kong XY, 2011, AM J RESP CRIT CARE, V183, P43, DOI 10.1164/rccm.201004-0541OC
   Kronenberg F, 2013, J INTERN MED, V273, P6, DOI 10.1111/j.1365-2796.2012.02592.x
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Lappalainen T, 2011, AM J HUM GENET, V89, P459, DOI 10.1016/j.ajhg.2011.08.004
   Law RHP, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-216
   Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   LIEBERMAN J, 1986, CHEST, V89, P370, DOI 10.1378/chest.89.3.370
   Lin JP, 2009, ATHEROSCLEROSIS, V206, P228, DOI 10.1016/j.atherosclerosis.2009.02.039
   LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0
   Luisetti M, 2004, THORAX, V59, P164, DOI 10.1136/thorax.2003.006494
   Martin BW, 1997, SOZ PRAVENTIV MED, V42, P67, DOI 10.1007/BF01318136
   MIYAKE K, 1979, JPN J HUM GENET, V24, P55, DOI 10.1007/BF01888921
   Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312
   NUKIWA T, 1987, J BIOL CHEM, V262, P11999
   Obeidat M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019382
   OKAYAMA H, 1991, AM J HUM GENET, V48, P1154
   Oosterveer DM, 2013, EUR J HUM GENET, V21, P563, DOI 10.1038/ejhg.2012.207
   Poller W, 1999, EUR J HUM GENET, V7, P321, DOI 10.1038/sj.ejhg.5200304
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Qiu WL, 2012, AM J RESP CRIT CARE, V185, P373, DOI 10.1164/rccm.201108-1382OC
   Rivas MA, 2011, NAT GENET, V43, P1066, DOI 10.1038/ng.952
   Rollini P, 1999, P NATL ACAD SCI USA, V96, P10308, DOI 10.1073/pnas.96.18.10308
   Sandford AJ, 2001, AM J RESP CRIT CARE, V163, P469, DOI 10.1164/ajrccm.163.2.2006158
   Sanna S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002198
   Senn O, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-35
   SILVERMAN EK, 1990, AM REV RESPIR DIS, V142, P1015, DOI 10.1164/ajrccm/142.5.1015
   Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941
   Sorheim IC, 2010, CHEST, V138, P1125, DOI 10.1378/chest.10-0746
   Thun GA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042728
   Trynka G, 2011, NAT GENET, V43, P1193, DOI 10.1038/ng.998
   Wilk JB, 2012, AM J RESP CRIT CARE, V186, P622, DOI 10.1164/rccm.201202-0366OC
   Zorzetto M, 2008, CLIN CHEM, V54, P1331, DOI 10.1373/clinchem.2007.102798
NR 68
TC 33
Z9 33
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD AUG
PY 2013
VL 9
IS 8
AR e1003585
DI 10.1371/journal.pgen.1003585
PG 16
WC Genetics & Heredity
SC Genetics & Heredity
GA 210KB
UT WOS:000323830300003
PM 23990791
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-08-12
ER

PT J
AU Janssen, R
   Zuidwijk, M
   Muller, A
   Mulders, J
   Oudejans, CBM
   Simonides, WS
AF Janssen, Rob
   Zuidwijk, Marian
   Muller, Alice
   Mulders, Joyce
   Oudejans, Cees B. M.
   Simonides, Warner S.
TI Cardiac Expression of Deiodinase type 3 (Dio3) Following Myocardial
   Infarction Is Associated With the Induction of a Pluripotency microRNA
   Signature from the Dlk1-Dio3 Genomic Region
SO ENDOCRINOLOGY
LA English
DT Article
ID MOUSE; REGENERATION; HEART; HYPERTROPHY; BIOLOGY; MIRNAS; DOMAIN; MODEL
AB The adult heart has almost completely lost the proliferative potential of the fetal heart. Instead, loss of cardiomyocytes due to myocardial infarction (MI) leads to a limited, and often insufficient, hypertrophic response of cardiomyocytes in the spared myocardium. This response is still characterized by a partial reexpression of the fetal gene program. Because of the suggested involvement of microRNAs (miRNAs) in cardiac remodeling, we examined the miRNA expression profile of the spared left ventricular myocardium using a MI mouse model. C57Bl/6J mice of either sex were randomly assigned to the sham-operated group or MI group. MI was induced by ligation of the left coronary artery. One week after surgery RNA was isolated from the left ventricle. MiRNA analysis was performed using the Taqman Megaplex rodent array. Unexpectedly, we found a set of 29 up-regulated miRNAs originating from the Dlk1-Dio3 genomic imprinted region, which has been identified as a hallmark of pluripotency and proliferation. This miRNA signature was associated with a 6-fold increase in expression of the deiodinase type 3 gene (Dio3) located in this region. Dio3 is a fetally expressed thyroid hormone-inactivating enzyme associated with cell proliferation, which was shown to be up-regulated in cardiomyocytes creating a local hypothyroid condition in the spared myocardium in this model. These data suggest that a regenerative process is initiated, but not completed, in adult cardiomyocytes after MI. The identified miRNA signature could provide new ways to manipulate the in vivo response of adult cardiomyocytes to stress and to increase the regenerative capacity of the injured myocardium.
C1 [Janssen, Rob; Zuidwijk, Marian; Muller, Alice; Simonides, Warner S.] Vrije Univ Amsterdam Med Ctr, Physiol Lab, NL-1081 BT Amsterdam, Netherlands.
   [Mulders, Joyce; Oudejans, Cees B. M.] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, NL-1081 BT Amsterdam, Netherlands.
   [Mulders, Joyce; Oudejans, Cees B. M.] Vrije Univ Amsterdam Med Ctr, Dept Clin Chem, NL-1081 BT Amsterdam, Netherlands.
RP Simonides, WS (corresponding author), Vrije Univ Amsterdam Med Ctr, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.
EM ws.simonides@vumc.nl
CR Bagnall RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044744
   Benetatos L, 2012, CRIT REV EUKAR GENE, V22, P1
   Bernardo BC, 2010, PHARMACOL THERAPEUT, V128, P191, DOI 10.1016/j.pharmthera.2010.04.005
   Bersell K, 2009, CELL, V138, P257, DOI 10.1016/j.cell.2009.04.060
   Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011
   Davis E, 2005, CURR BIOL, V15, P743, DOI 10.1016/j.cub.2005.02.060
   de Waard MC, 2007, CIRC RES, V100, P1079, DOI 10.1161/01.RES.0000262655.16373.37
   Dentice M, 2010, J CLIN INVEST, V120, P4021, DOI 10.1172/JCI43670
   Eulalio A, 2012, NATURE, V492, P376, DOI 10.1038/nature11739
   Gereben B, 2008, ENDOCR REV, V29, P898, DOI 10.1210/er.2008-0019
   Jopling C, 2011, NAT REV MOL CELL BIO, V12, P79, DOI 10.1038/nrm3043
   Jorgensen S, 2010, METHODS, V52, P375, DOI 10.1016/j.ymeth.2010.07.002
   Laflamme MA, 2011, NATURE, V473, P326, DOI 10.1038/nature10147
   Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995
   Pol CJ, 2011, ENDOCRINOLOGY, V152, P669, DOI 10.1210/en.2010-0431
   Porrello ER, 2011, SCIENCE, V331, P1078, DOI 10.1126/science.1200708
   Port JD, 2011, PHYSIOL GENOMICS, V43, P1087, DOI 10.1152/physiolgenomics.00074.2011
   Simonides WS, 2008, J CLIN INVEST, V118, P975, DOI 10.1172/JCI32824
   Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783
   Thum T, 2007, CIRCULATION, V116, P258, DOI 10.1161/CIRCULATIONAHA.107.687947
   van den Bos EJ, 2005, AM J PHYSIOL-HEART C, V289, pH1291, DOI 10.1152/ajpheart.00111.2005
   van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105
   Yang KC, 2012, J MOL CELL CARDIOL, V53, P101, DOI 10.1016/j.yjmcc.2012.04.012
NR 23
TC 22
Z9 22
U1 0
U2 7
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUN
PY 2013
VL 154
IS 6
BP 1973
EP 1978
DI 10.1210/en.2012-2017
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 147YO
UT WOS:000319208200006
PM 23554452
OA Bronze
DA 2020-08-12
ER

PT J
AU Zeng, TB
   He, HJ
   Zhang, FW
   Han, ZB
   Huang, ZJ
   Liu, Q
   Wu, Q
AF Zeng, Tie-Bo
   He, Hong-Juan
   Zhang, Feng-Wei
   Han, Zheng-Bin
   Huang, Zhi-Jun
   Liu, Qi
   Wu, Qiong
TI Expression analysis of AK003491, an imprinted noncoding RNA, during
   mouse development
SO GENES & GENETIC SYSTEMS
LA English
DT Article
DE AK003491; Dlk1-Dio3 domain; genomic imprinting; in situ hybridization;
   long noncoding RNA
ID DLK1-DIO3 DOMAIN; CHROMOSOME 12QF1; STEM-CELLS; GENES;
   MOUSE-CHROMOSOME-12; CLUSTER; IDENTIFICATION; TRANSCRIPTS; REGION; LOCUS
AB The Dlk1-Dio3 imprinted domain on mouse chromosome 12qF1 contains three paternally expressed protein-coding genes and multiple maternally expressed long or short noncoding RNA genes. All these imprinted genes are regulated by IG-DMR located between Dlk1 and Meg3/Gtl2. Recently, several novel imprinted noncoding RNAs were identified in the intergenic region of this domain, although the exact number of imprinted genes within the region is unclear. Here, we report that a novel noncoding RNA, AK003491, located between Meg3/Gtl2 and Meg8, is maternally expressed in E15.5 brain, tongue, heart, lung, liver and kidney tissues. In situ hybridization analysis at E15.5 shows AK003491 is predominantly expressed in forebrain, tongue, thymus, somites, lung and liver. Quantitative real-time RT-PCR analysis confirms this expression pattern and detects highest expression in tongue. While the AK003491 expression pattern at postnatal day 1 is similar to E15.5, AK003491 expression at postnatal day 30 is mainly restricted to the brain. These results expand the number of known imprinted long noncoding RNAs in this domain, and contribute to further investigation of their regulatory mechanism and function.
C1 [Zeng, Tie-Bo; He, Hong-Juan; Zhang, Feng-Wei; Han, Zheng-Bin; Huang, Zhi-Jun; Liu, Qi; Wu, Qiong] Harbin Inst Technol, Sch Life Sci & Technol, State Key Lab Urban Water Resources & Environm, Harbin 150001, Heilongjiang, Peoples R China.
RP Wu, Q (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, State Key Lab Urban Water Resources & Environm, Harbin 150001, Heilongjiang, Peoples R China.
EM kigo@hit.edu.cn
OI Zeng, Tie-Bo/0000-0002-8999-2952
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31171383, 31100934]; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities [HIT.NSRIF.2010027]
FX This study was supported by grants from the National Natural Science
   Foundation of China (Nos. 31171383 and 31100934), and the Fundamental
   Research Funds for the Central Universities (No. HIT.NSRIF.2010027).
CR Bartolomei MS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002592
   Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011
   Davis E, 2005, CURR BIOL, V15, P743, DOI 10.1016/j.cub.2005.02.060
   Edwards CA, 2007, CURR OPIN CELL BIOL, V19, P281, DOI 10.1016/j.ceb.2007.04.013
   Gu TT, 2011, J MOL HISTOL, V42, P105, DOI 10.1007/s10735-011-9312-z
   Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352
   Labialle S, 2008, EPIGENETICS-US, V3, P322, DOI 10.4161/epi.3.6.7109
   Lin SP, 2003, NAT GENET, V35, P97, DOI 10.1038/ng1233
   Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995
   Miyoshi N, 2000, GENES CELLS, V5, P211, DOI 10.1046/j.1365-2443.2000.00320.x
   Schmidt JV, 2000, GENE DEV, V14, P1997
   Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304
   Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171
   Song GS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003574
   Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017
   Takada S, 2002, HUM MOL GENET, V11, P77, DOI 10.1093/hmg/11.1.77
   Takada S, 2000, CURR BIOL, V10, P1135, DOI 10.1016/S0960-9822(00)00704-1
   Tierling S, 2006, GENOMICS, V87, P225, DOI 10.1016/j.ygeno.2005.09.018
   Zhang FW, 2011, J MOL HISTOL, V42, P333, DOI 10.1007/s10735-011-9337-3
   Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011
NR 20
TC 4
Z9 5
U1 0
U2 9
PU GENETICS SOC JAPAN
PI SHIZUOKA-KEN
PA NATIONAL INST GENETICS YATA 1111, MISHIMA, SHIZUOKA-KEN, 411-8540, JAPAN
SN 1341-7568
EI 1880-5779
J9 GENES GENET SYST
JI Genes Genet. Syst.
PD APR
PY 2013
VL 88
IS 2
BP 127
EP 133
DI 10.1266/ggs.88.127
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 206PS
UT WOS:000323535200006
PM 23832304
OA Bronze
DA 2020-08-12
ER

PT J
AU Engels, H
   Schuler, HM
   Zink, AM
   Wohlleber, E
   Brockschmidt, A
   Hoischen, A
   Drechsler, M
   Lee, JA
   Ludwig, KU
   Kubisch, C
   Schwanitz, G
   Weber, RG
   Leube, B
   Hennekam, RCM
   Rudnik-Schoneborn, S
   Kreiss-Nachtsheim, M
   Reutter, H
AF Engels, Hartmut
   Schueler, Herdit M.
   Zink, Alexander M.
   Wohlleber, Eva
   Brockschmidt, Antje
   Hoischen, Alexander
   Drechsler, Matthias
   Lee, Jennifer A.
   Ludwig, Kerstin U.
   Kubisch, Christian
   Schwanitz, Gesa
   Weber, Ruthild G.
   Leube, Barbara
   Hennekam, Raoul C. M.
   Rudnik-Schoeneborn, Sabine
   Kreiss-Nachtsheim, Martina
   Reutter, Heiko
TI A Phenotype Map for 14q32.3 Terminal Deletions
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE 14q terminal deletion syndrome; molecular karyotyping;
   genotype-phenotype correlation; intellectual disability
ID MOLECULAR CYTOGENETIC CHARACTERIZATION; SYNAPTIC PLASTICITY; 14Q;
   PROTEIN; TRANSLOCATION; RETARDATION; TRAFFICKING; DELINEATION;
   MECHANISM; INTERACTS
AB Detailedmolecular-cytogenetic studies combined with thorough clinical characterization are needed to establish genotype-phenotype correlations for specific chromosome deletion syndromes. Although many patients with subtelomeric deletions have been reported, the phenotype maps for many of the corresponding syndromes, including the terminal deletion 14q syndrome, are only slowly emerging. Here, we report on five patients with terminal partial monosomy of 14q32.3 and characteristic features of terminal deletion 14q syndrome. Four of the patients carry de novo terminal deletions of 14q, three of which have not yet been reported. One patient carries an unbalanced translocation der(14) t(9; 14)(q34.3;q32.3). Minimum deletion sizes as determined by molecular karyotyping and FISH are 5.82, 5.56, 4.17, 3.54, and 3.29 Mb, respectively. Based on our findings and a comprehensive review of the literature, we refine the phenotype map for typical clinical findings of the terminal deletion 14q syndrome (i.e., intellectual disability/developmental delay, muscular hypotonia, postnatal growth retardation, microcephaly, congenital heart defects, genitourinary malformations, ocular coloboma, and several dysmorphic signs). Combining this phenotype map with benign copy-number variation data available from the Database of Genomic Variants, we propose a small region critical for certain features of the terminal deletion 14q syndrome which contains only seven RefSeq genes. (C) 2012 Wiley Periodicals, Inc.
C1 [Engels, Hartmut] Univ Bonn, Inst Human Genet, Biomed Ctr, D-53105 Bonn, Germany.
   [Schueler, Herdit M.; Rudnik-Schoeneborn, Sabine] Rhein Westfal TH Aachen, Inst Human Genet, Aachen, Germany.
   [Hoischen, Alexander] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
   [Drechsler, Matthias; Leube, Barbara] Univ Duesseldorf, Inst Human Genet, Dusseldorf, Germany.
   [Lee, Jennifer A.; Ludwig, Kerstin U.] Univ Bonn, Life & Brain Ctr, Dept Genom, D-53105 Bonn, Germany.
   [Kubisch, Christian] Univ Ulm, Inst Human Genet, Ulm, Germany.
   [Weber, Ruthild G.] Hannover Med Sch, Dept Human Genet, D-3000 Hannover, Germany.
   [Hennekam, Raoul C. M.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
   [Hennekam, Raoul C. M.] UCL, Inst Neurol, London, England.
   [Reutter, Heiko] Univ Bonn, Childrens Hosp, Dept Neonatol, D-53105 Bonn, Germany.
RP Engels, H (corresponding author), Univ Bonn, Inst Human Genet, Biomed Ctr, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM hartmut.engels@uni-bonn.de
RI Hoischen, Alexander/D-1282-2013; Rudnik-Schoneborn, Sabine/F-8473-2015;
   Weber, Ruthild/E-2906-2015; Kubisch, Christian/F-1893-2011; Ludwig,
   Kerstin U/H-7828-2019; Zink, Alexander/B-2305-2013
OI Hoischen, Alexander/0000-0002-8072-4476; Kubisch,
   Christian/0000-0003-4220-0978; Ludwig, Kerstin U/0000-0002-8541-2519;
   Weber, Ruthild/0000-0001-6610-1080
FU German Mental Retardation Network (MRNET); National Genome Research
   Network (NGFNplus) [01GS08164]; Medical Faculty of Rheinische
   Friedrich-Wilhelms-University, Bonfor program, Bonn [O-249.0004]; German
   Federal Ministry of Education and Research (BMBF)Federal Ministry of
   Education & Research (BMBF) [01GM08107]; "German Mental Retardation
   Network" (MRNET), a part of the German Federal Ministry of Education and
   Research (Bundesministerium fur Bildung und Forschung, BMBF) National
   Genome Research Network (NGFNplus); BONFOR of the Medical Faculty of
   Rheinische Friedrich-Wilhelms-University, Bonn [O-249.0004]
FX Grant sponsor: German Mental Retardation Network (MRNET); Grant sponsor:
   National Genome Research Network (NGFNplus); Grant number: 01GS08164;
   Grant sponsor: Medical Faculty of Rheinische
   Friedrich-Wilhelms-University, Bonfor program, Bonn; Grant number:
   O-249.0004; Grant sponsor: German Federal Ministry of Education and
   Research (BMBF); Grant number: 01GM08107.; We thank the patients and
   their families for their kind cooperation. HE, EW and AZ are funded by
   the "German Mental Retardation Network" (MRNET), a part of the German
   Federal Ministry of Education and Research (Bundesministerium fur
   Bildung und Forschung, BMBF) National Genome Research Network (NGFNplus,
   www.ngfn.de, grant number 01GS08164). HE was also supported by the
   BONFOR program of the Medical Faculty of Rheinische
   Friedrich-Wilhelms-University, Bonn, grant number O-249.0004. HR is
   supported by the German Federal Ministry of Education and Research
   (BMBF, grant 01GM08107).
CR Aksu F, 1980, KINDERARZT, V11, P119
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Brandt I, 1986, HUMAN GROWTH, P415
   Brenk CH, 2007, EUR J HUM GENET, V15, P35, DOI 10.1038/sj.ejhg.5201718
   Chung I, 2006, J PEDIAT OPHTH STRAB, V43, P104
   de Vries BBA, 2003, J MED GENET, V40, P385, DOI 10.1136/jmg.40.6.385
   Engels H, 2009, EUR J HUM GENET, V17, P1592, DOI 10.1038/ejhg.2009.90
   Fredriks AM, 2003, EUR J PEDIATR, V162, P788, DOI 10.1007/s00431-003-1292-x
   HEMPE JM, 1991, P NATL ACAD SCI USA, V88, P9671, DOI 10.1073/pnas.88.21.9671
   HREIDARSSON SJ, 1983, J MED GENET, V20, P147, DOI 10.1136/jmg.20.2.147
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   Jakobsson M, 2008, NATURE, V451, P998, DOI 10.1038/nature06742
   Kagami M, 2008, NAT GENET, V40, P237, DOI 10.1038/ng.2007.56
   Kasri NN, 2008, METHOD ENZYMOL, V439, P255, DOI 10.1016/S0076-6879(07)00419-3
   Kaufman L, 2010, J NEURODEV DISORD, V2, P182, DOI 10.1007/s11689-010-9055-2
   Kleefstra T, 2006, AM J HUM GENET, V79, P370, DOI 10.1086/505693
   Kottgen M, 2005, EMBO J, V24, P705, DOI 10.1038/sj.emboj.7600566
   Leube B, 2003, CLIN DYSMORPHOL, V12, P261, DOI 10.1097/00019605-200310000-00010
   MASADA CT, 1989, AM J MED GENET, V34, P528, DOI 10.1002/ajmg.1320340415
   Maurin ML, 2006, AM J MED GENET A, V140, P2324
   Merritt JL, 2005, AM J MED GENET A, V133A, P99, DOI 10.1002/ajmg.a.30462
   Meschede D, 1998, AM J MED GENET, V80, P443, DOI 10.1002/(SICI)1096-8628(19981228)80:5<443::AID-AJMG2>3.0.CO;2-Y
   Ortigas AP, 1997, J MED GENET, V34, P515, DOI 10.1136/jmg.34.6.515
   Rittinger O, 2002, DYSMORPHIESYNDROME G, P144
   Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026
   Schlade-Bartusiak K, 2005, AM J MED GENET A, V138A, P218, DOI 10.1002/ajmg.a.30942
   Schlade-Bartusiak K, 2009, AM J MED GENET A, V149A, P1012, DOI 10.1002/ajmg.a.32752
   Schneider A, 2008, EUR J HUM GENET, V16, P680, DOI 10.1038/sj.ejhg.5201977
   Sun XJ, 2008, CIRC RES, V102, P831, DOI 10.1161/CIRCRESAHA.107.166488
   Talukder AH, 2004, MOL CELL BIOL, V24, P6581, DOI 10.1128/mcb.24.15.6581-6591.2004
   TELFORD N, 1990, J MED GENET, V27, P261, DOI 10.1136/jmg.27.4.261
   Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346
   van Ham M, 2003, GENES CELLS, V8, P631, DOI 10.1046/j.1365-2443.2003.00660.x
   van Karnebeek CDM, 2002, AM J MED GENET, V110, P65, DOI 10.1002/ajmg.10207
   WANG HS, 1992, ANN GENET-PARIS, V35, P171
   WINTLE RF, 1995, HUM GENET, V95, P495
   Wu Y, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-72
   Zhou JM, 2005, BIOCHEM BIOPH RES CO, V333, P344, DOI 10.1016/j.bbrc.2005.05.115
   Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8
   Zollino M, 2009, AM J MED GENET A, V149A, P1116, DOI 10.1002/ajmg.a.32831
NR 40
TC 10
Z9 10
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD APR
PY 2012
VL 158A
IS 4
BP 695
EP 706
DI 10.1002/ajmg.a.35256
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 922JW
UT WOS:000302544200003
PM 22367666
DA 2020-08-12
ER

PT J
AU Zhang, FW
   Zeng, TB
   Han, ZB
   He, HJ
   Chen, Y
   Gu, N
   Jiang, HJ
   Wu, Q
AF Zhang, Feng Wei
   Zeng, Tie Bo
   Han, Zheng Bin
   He, Hong Juan
   Chen, Yan
   Gu, Ning
   Jiang, Hui Jie
   Wu, Qiong
TI Imprinting and expression analysis of a non-coding RNA gene in the mouse
   Dlk1-Dio3 domain
SO JOURNAL OF MOLECULAR HISTOLOGY
LA English
DT Article
DE B830012L14Rik; Imprinting; Dlk1-Dio3 domain; Northern blot; In situ
   hybridization; Real-time quantitative RT-PCR
ID IN-SITU HYBRIDIZATION; UNIPARENTAL DISOMY; TISSUE-SECTIONS;
   MESSENGER-RNA; IDENTIFICATION; CLUSTER; MOUSE-CHROMOSOME-12; GENOME
AB The Dlk1-Dio3 imprinted domain not only is implicated growth and development of the embryo and placenta, but also affects adult metabolism and brain function. In this study, we identified the imprinting status of a mouse non-coding RNA gene, B830012L14Rik, mapped to the Dlk1-Dio3 domain by the polymorphism- and sequencing-based approach. Imprinting analysis showed that the gene was expressed maternally at E15.5, E18.5 and postnatal day 1 mice. Two transcripts of approximately 1.9 and 3.5 kb were detected by northern blot. Furthermore, we examined the spatiotemporal expression patterns of the gene during the mouse development. In situ hybridization analysis showed that B830012L14Rik was mainly expressed in forebrain, pituitary, cartilage primordium of spinal column, lung and liver at E13.5 and E15.5. The results of real-time quantitative RT-PCR showed that the B830012L14Rik expression in brain, heart, lung and liver was higher at E15.5 than at E12.5 and E18.5. Furthermore, the gene expression increased progressively in brain from E12.5 to E15.5 whereas decreased from E15.5 to E19.5. This study may provide further insights into the imprinting, genomic features and expression regulation of the Dlk1-Dio3 imprinted cluster.
C1 [Zhang, Feng Wei; Zeng, Tie Bo; Han, Zheng Bin; He, Hong Juan; Chen, Yan; Gu, Ning; Wu, Qiong] Harbin Inst Technol, Dept Life Sci & Engn, Harbin 150001, Peoples R China.
   [Jiang, Hui Jie] Princess Margaret Hosp, Cell Therapy Program, Toronto, ON M5G 2M9, Canada.
   [Jiang, Hui Jie] Ludong Univ, Coll Life Sci, Yantai 264025, Peoples R China.
RP Wu, Q (corresponding author), Harbin Inst Technol, Dept Life Sci & Engn, Harbin 150001, Peoples R China.
EM kigo@hit.edu.cn
OI Zeng, Tie-Bo/0000-0002-8999-2952
FU Heilongjiang Province Science Foundation for Youths [QC2010052];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [30971645]
FX The study was supported by the Heilongjiang Province Science Foundation
   for Youths (No. QC2010052) and the National Natural Science Foundation
   of China (No. 30971645).
CR da Rocha ST, 2007, DEV BIOL, V306, P810, DOI 10.1016/j.ydbio.2007.02.043
   Da Rocha ST, 2008, TRENDS GENET, V24, P306, DOI 10.1016/j.tig.2008.03.011
   Edwards CA, 2008, PLOS BIOL, V6, P1292, DOI 10.1371/journal.pbio.0060135
   Gao MY, 2009, J MOL HISTOL, V40, P227, DOI 10.1007/s10735-009-9234-1
   Georgiades P, 2000, DEVELOPMENT, V127, P4719
   Georgiades P, 2001, P NATL ACAD SCI USA, V98, P4522, DOI 10.1073/pnas.081540898
   Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352
   Hatada I, 2001, J BIOCHEM, V130, P187, DOI 10.1093/oxfordjournals.jbchem.a002971
   Isles AR, 2005, EARLY HUM DEV, V81, P73, DOI 10.1016/j.earlhumdev.2004.10.006
   Kawahara M, 2007, FEBS LETT, V581, P5178, DOI 10.1016/j.febslet.2007.10.004
   Kobayashi H, 2009, GENOMICS, V93, P461, DOI 10.1016/j.ygeno.2008.12.012
   Lin SP, 2007, DEVELOPMENT, V134, P417, DOI 10.1242/dev.02726
   Lin SP, 2003, NAT GENET, V35, P97, DOI 10.1038/ng1233
   Moorman AFM, 2001, J HISTOCHEM CYTOCHEM, V49, P1
   Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008
   Okamura K, 2000, GENOME RES, V10, P1878, DOI 10.1101/gr.139200
   Ono R, 2003, GENOME RES, V13, P1696, DOI 10.1101/gr.906803
   Peters Jo, 2004, Briefings in Functional Genomics & Proteomics, V2, P320, DOI 10.1093/bfgp/2.4.320
   Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Schulz R, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl461
   Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Takada S, 2002, HUM MOL GENET, V11, P77, DOI 10.1093/hmg/11.1.77
   Tevendale M, 2006, CYTOGENET GENOME RES, V113, P215, DOI 10.1159/000090835
   Tierling S, 2006, GENOMICS, V87, P225, DOI 10.1016/j.ygeno.2005.09.018
   WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361
NR 27
TC 3
Z9 5
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1567-2379
EI 1567-2387
J9 J MOL HISTOL
JI J. Mol. Histol.
PD AUG
PY 2011
VL 42
IS 4
BP 333
EP 339
DI 10.1007/s10735-011-9337-3
PG 7
WC Cell Biology
SC Cell Biology
GA 793PP
UT WOS:000292835900005
PM 21706278
DA 2020-08-12
ER

PT J
AU Enquobahrie, DA
   Abetew, DF
   Sorensen, TK
   Willoughby, D
   Chidambaram, K
   Williams, MA
AF Enquobahrie, Daniel A.
   Abetew, Dejene F.
   Sorensen, Tanya K.
   Willoughby, David
   Chidambaram, Kumaravel
   Williams, Michelle A.
TI Placental microRNA expression in pregnancies complicated by preeclampsia
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE expression; microRNA; placenta; preeclampsia
ID GROWTH-FACTOR-I; GENE-EXPRESSION; RECEPTOR; HYPOXIA; CLUSTER; WOMEN
AB OBJECTIVE: The role of posttranscription regulation in preeclampsia is largely unknown. We investigated preeclampsia-related placental microRNA (miRNA) expression using microarray and confirmatory quantitative real-time polymerase chain reaction experiments.
   STUDY DESIGN: Placental expressions of characterized and novel miRNAs (1295 probes) were measured in samples collected from 20 preeclampsia cases and 20 controls. Differential expression was evaluated using Student t test and fold change analyses. In pathway analysis, we examined functions/functional relationships of targets of differentially expressed miRNAs.
   RESULTS: Eight miRNAs were differentially expressed (1 up-regulated and 7 down-regulated) among preeclampsia cases compared with controls. These included previously identified candidates (miR-210, miR-1, and a miRNA in the 14q32.31 cluster region) and others that are novel (miR-584 and miR-34c-5p). These miRNAs target genes that participate in organ/system development (cardiovascular and reproductive system), immunologic dysfunction, cell adhesion, cell cycle, and signaling.
   CONCLUSION: Expression of miRNAs that target genes in diverse pathophysiological processes is altered in the setting of preeclampsia.
C1 [Enquobahrie, Daniel A.; Abetew, Dejene F.; Sorensen, Tanya K.; Williams, Michelle A.] Univ Washington, Ctr Perinatal Studies, Swedish Med Ctr, Seattle, WA 98104 USA.
   [Enquobahrie, Daniel A.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98104 USA.
   [Enquobahrie, Daniel A.; Williams, Michelle A.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA.
   [Willoughby, David; Chidambaram, Kumaravel] Oceanridge Biosci, Palm Beach Gardens, FL USA.
RP Enquobahrie, DA (corresponding author), Univ Washington, Ctr Perinatal Studies, Swedish Med Ctr, 1124 Columbia St,Suite 750, Seattle, WA 98104 USA.
EM danenq@u.washington.edu
FU National Institute of Child Health and Human Development, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [HD/HL R01-32562]; March of DimesMarch of Dimes [1 FY08-425]
FX This work was supported by grants from the National Institute of Child
   Health and Human Development, National Institutes of Health (HD/HL
   R01-32562); the March of Dimes (#1 FY08-425); and a gift from Sarah and
   Chuck Genuardi through the Mourning Dove Foundation.
CR Askie LM, 2007, LANCET, V369, P1791, DOI 10.1016/S0140-6736(07)60712-0
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Burney RO, 2009, MOL HUM REPROD, V15, P625, DOI 10.1093/molehr/gap068
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585
   Eickhoff B, 1999, Nucleic Acids Res, V27, pe33, DOI 10.1093/nar/27.22.e33
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Enquobahrie DA, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.020
   Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200
   Founds SA, 2009, PLACENTA, V30, P15, DOI 10.1016/j.placenta.2008.09.015
   Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928
   Grill S, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-70
   Hu YL, 2009, CLIN CHEM LAB MED, V47, P923, DOI 10.1515/CCLM.2009.228
   Huppertz B, 2008, HYPERTENSION, V51, P970, DOI 10.1161/HYPERTENSIONAHA.107.107607
   Ikeda S, 2009, MOL CELL BIOL, V29, P2193, DOI 10.1128/MCB.01222-08
   Liao Y, 2010, INT J BIOCHEM CELL B, V42, P1363, DOI 10.1016/j.biocel.2009.07.019
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046
   Ning Y, 2004, CLIN BIOCHEM, V37, P968, DOI 10.1016/j.clinbiochem.2004.07.009
   Oudejans CBM, 2008, PLACENTA, V29, pS78, DOI 10.1016/j.placenta.2007.09.005
   Ozkan S, 2008, J MATERN-FETAL NEO M, V21, P831, DOI 10.1080/14767050802251024
   Pineles BL, 2007, AM J OBSTET GYNECOL, V196, P261, DOI 10.1016/j.ajog.2007.01.008
   Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726
   Saito S, 2007, MOL ASPECTS MED, V28, P192, DOI 10.1016/j.mam.2007.02.006
   Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304
   Sharov AA, 2005, BIOINFORMATICS, V21, P2548, DOI 10.1093/bioinformatics/bti343
   Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5
   Sitras V, 2009, PLACENTA, V30, P424, DOI 10.1016/j.placenta.2009.01.012
   Soleymanlou N, 2005, J CLIN ENDOCR METAB, V90, P4299, DOI 10.1210/jc.2005-0078
   Suzuki YA, 2005, CELL MOL LIFE SCI, V62, P2560, DOI 10.1007/s00018-005-5371-1
   Thway TM, 2004, CIRCULATION, V110, P1612, DOI 10.1161/01.CIR.0000142855.68398.3A
   Urakubo A, 2001, SCHIZOPHR RES, V47, P27, DOI 10.1016/S0920-9964(00)00032-3
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   Vaiman D, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-111
   Wang ZQ, 2010, GYNECOL ENDOCRINOL, V26, P96, DOI 10.3109/09513590903184100
   Zhang CX, 2008, PHYSIOL GENOMICS, V33, P139, DOI 10.1152/physiolgenomics.00034.2008
   Zhang YQ, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.057
   Zhu XM, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.045
NR 39
TC 89
Z9 96
U1 5
U2 26
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD FEB
PY 2011
VL 204
IS 2
AR 178.e12
DI 10.1016/j.ajog.2010.09.004
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 715HV
UT WOS:000286874900042
PM 21093846
OA Green Accepted
DA 2020-08-12
ER

PT J
AU Dong, CH
   Beecham, A
   Slifer, S
   Wang, LY
   Blanton, SH
   Wright, CB
   Rundek, T
   Sacco, RL
AF Dong, Chuanhui
   Beecham, Ashley
   Slifer, Susan
   Wang, Liyong
   Blanton, Susan H.
   Wright, Clinton B.
   Rundek, Tatjana
   Sacco, Ralph L.
TI Genomewide Linkage and Peakwide Association Analyses of Carotid Plaque
   in Caribbean Hispanics
SO STROKE
LA English
DT Article
DE association; Caribbean Hispanics; carotid plaque; heritability; linkage
ID INTIMA-MEDIA THICKNESS; POPULATION-BASED TWIN; CARDIOVASCULAR-DISEASE;
   NORTHERN MANHATTAN; PRINCIPAL-COMPONENTS; HEART-DISEASE; ARTERY PLAQUE;
   HIGH-RISK; FAMILY; STROKE
AB Background and Purpose-Atherosclerosis is a complex subclinical cardiovascular disorder with a substantial genetic component. This study sought to identify genetic loci influencing carotid plaque in 2 independent samples.
   Methods-B-mode ultrasound was performed to determine the presence and area of carotid plaque. Variance components analysis was used to test for linkage using 383 autosomal microsatellite markers in 1308 subjects from 100 Dominican families. Multiple linear and logistic regression models were used to investigate the association between plaque traits and 18 904 single nucleotide polymorphisms under the 1-logarithm of odds unit down regions of linkage peaks in an independent community-based data set (N=941, 41% Dominicans) from the Northern Manhattan Study.
   Results-After adjustment for age, hypertension, diabetes mellitus, cigarette pack-years, body mass index, and waist-to-hip ratio, significant heritability was detected for plaque presence (h(2)=0.50 +/- 0.14, P<0.0001) and plaque area (h(2)=0.17 +/- 0.04, P<0.0001). Quantitative and dichotomous trait linkage analyses obtained similar results and identified 4 regions with multipoint logarithm of odds scores >= 2.00 on 7q36, 11p15, 14q32, and 15q23. In the association analysis of the 4 linkage peaks, several single nucleotide polymorphisms in or near SOX6, FSD2, AP3S2, EFTUD1, and MYOD1 were associated with carotid plaque traits with a nominal P <= 0.0005 in the Northern Manhattan Study data set and with a P <= 0.01 in Northern Manhattan Study Dominican subset.
   Conclusions-Carotid plaque has considerable heritability and may be influenced by loci on chromosomes 11p15, 14q32, and 15q23. The SOX6 gene within the bone morphogenic protein pathway could be a candidate for carotid plaque. Larger independent studies are needed to validate these findings. (Stroke. 2010;41:2750-2756.)
C1 [Dong, Chuanhui; Blanton, Susan H.; Wright, Clinton B.; Rundek, Tatjana; Sacco, Ralph L.] Univ Miami, Evelyn F McKnight Ctr Age Related Memory Loss, Dept Neurol, Miller Sch Med, Miami, FL 33136 USA.
   [Beecham, Ashley; Slifer, Susan; Wang, Liyong; Blanton, Susan H.; Sacco, Ralph L.] Univ Miami, John P Hussman Inst Human Genom, John T McDonald Dept Human Genet, Miller Sch Med, Miami, FL 33136 USA.
   [Wright, Clinton B.; Rundek, Tatjana; Sacco, Ralph L.] Univ Miami, Dept Epidemiol, Miller Sch Med, Miami, FL 33136 USA.
RP Sacco, RL (corresponding author), Univ Miami, Evelyn F McKnight Ctr Age Related Memory Loss, Dept Neurol, Miller Sch Med, 1120 NW 14th St, Miami, FL 33136 USA.
EM rsacco@med.miami.edu
RI Sacco, Ralph/Y-9278-2019
OI rundek, tatjana/0000-0002-7115-9815
FU National Institute of Neurologic Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS40807, R01NS047655, R37NS29993]; Evelyn F. McKnight Center for
   Age-related Memory Loss
FX This work was supported by the National Institute of Neurologic
   Disorders and Stroke (R01NS40807 to R.L.S., R01NS047655 to T.R.,
   R37NS29993 to R.L.S) and the Evelyn F. McKnight Center for Age-related
   Memory Loss.
CR Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844
   Bak S, 2002, STROKE, V33, P769, DOI 10.1161/hs0302.103619
   Bowden DW, 2008, ANN HUM GENET, V72, P598, DOI 10.1111/j.1469-1809.2008.00446.x
   BRASS LM, 1992, STROKE, V23, P221, DOI 10.1161/01.STR.23.2.221
   BULTMANN A, J MOL CELL CARDIOL
   Cohen-Barak O, 2003, NUCLEIC ACIDS RES, V31, P5941, DOI 10.1093/nar/gkg807
   Duggirala R, 1997, GENET EPIDEMIOL, V14, P987, DOI 10.1002/(SICI)1098-2272(1997)14:6<987::AID-GEPI71>3.0.CO;2-G
   Hagiwara N, 2000, P NATL ACAD SCI USA, V97, P4180, DOI 10.1073/pnas.97.8.4180
   Hunt KJ, 2002, STROKE, V33, P2775, DOI 10.1161/01.STR.0000043827.03966.EF
   Husten L, 1998, LANCET, V352, P1530, DOI 10.1016/S0140-6736(05)60342-X
   Iguchi H, 2005, J BIOL CHEM, V280, P37669, DOI 10.1074/jbc.M505392200
   Jartti L, 2002, ARTERIOSCL THROM VAS, V22, P832, DOI 10.1161/01.ATV.0000013313.70875.A7
   Johnsen Stein Harald, 2009, Curr Cardiol Rep, V11, P21
   Lange LA, 2002, ARTERIOSCL THROM VAS, V22, P418, DOI 10.1161/hq0302.105721
   Li RL, 2000, GENET EPIDEMIOL, V18, P236, DOI 10.1002/(SICI)1098-2272(200003)18:3<236::AID-GEPI4>3.0.CO;2-0
   Liu YZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006827
   Lloyd-Jones DM, 2004, JAMA-J AM MED ASSOC, V291, P2204, DOI 10.1001/jama.291.18.2204
   Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666
   Moskau S, 2005, STROKE, V36, P5, DOI 10.1161/01.STR.0000149936.33498.83
   Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740
   Nicodemus KK, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-S1-S78
   North KE, 2002, ARTERIOSCL THROM VAS, V22, P1698, DOI 10.1161/01.ATV.0000032656.91352.5E
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   O'Donnell CJ, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S4
   Pankow JS, 2004, HUM HERED, V57, P80, DOI 10.1159/000077545
   Pollex Rebecca L, 2006, Curr Atheroscler Rep, V8, P206, DOI 10.1007/s11883-006-0075-z
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rundek T, 2008, NEUROLOGY, V70, P1200, DOI 10.1212/01.wnl.0000303969.63165.34
   Sacco RL, 2007, ETHNIC DIS, V17, P351
   Sacco RL, 2009, J AM COLL CARDIOL, V54, P2303, DOI 10.1016/j.jacc.2009.07.047
   Sacco RL, 2009, STROKE, V40, pE110
   Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X
   Spence JD, 2006, INT J STROKE, V1, P216, DOI 10.1111/j.1747-4949.2006.00068.x
   Sun L, 2002, HUM HERED, V54, P99, DOI 10.1159/000067666
   Swan L, 2003, ATHEROSCLEROSIS, V166, P137, DOI 10.1016/S0021-9150(02)00317-9
   Tobin JF, 2006, DRUG DISCOV TODAY, V11, P405, DOI 10.1016/j.drudis.2006.03.016
   Williams JT, 2004, ANN HUM GENET, V68, P620, DOI 10.1046/j.1529-8817.2004.00128.x
   Zhao JY, 2008, ATHEROSCLEROSIS, V197, P814, DOI 10.1016/j.atherosclerosis.2007.07.030
NR 39
TC 25
Z9 26
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD DEC
PY 2010
VL 41
IS 12
BP 2750
EP 2756
DI 10.1161/STROKEAHA.110.596981
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 686GU
UT WOS:000284685600012
PM 20966410
OA Bronze, Green Accepted, Green Published
DA 2020-08-12
ER

PT J
AU Smith, NL
   Chen, MH
   Dehghan, A
   Strachan, DP
   Basu, S
   Soranzo, N
   Hayward, C
   Rudan, I
   Sabater-Lleal, M
   Bis, JC
   de Maat, MPM
   Rumley, A
   Kong, XX
   Yang, Q
   Williams, FMK
   Vitart, V
   Campbell, H
   Malarstig, A
   Wiggins, KL
   Van Duijn, CM
   McArdle, WL
   Pankow, JS
   Johnson, AD
   Silveira, A
   McKnight, B
   Uitterlinden, AG
   Aleksic, N
   Meigs, JB
   Peters, A
   Koenig, W
   Cushman, M
   Kathiresan, S
   Rotter, JI
   Bovill, EG
   Hofman, A
   Boerwinkle, E
   Tofler, GH
   Peden, JF
   Psaty, BM
   Leebeek, F
   Folsom, AR
   Larson, MG
   Spector, TD
   Wright, AF
   Wilson, JF
   Hamsten, A
   Lumley, T
   Witteman, JCM
   Tang, WH
   O'Donnell, CJ
AF Smith, Nicholas L.
   Chen, Ming-Huei
   Dehghan, Abbas
   Strachan, David P.
   Basu, Saonli
   Soranzo, Nicole
   Hayward, Caroline
   Rudan, Igor
   Sabater-Lleal, Maria
   Bis, Joshua C.
   de Maat, Moniek P. M.
   Rumley, Ann
   Kong, Xiaoxiao
   Yang, Qiong
   Williams, Frances M. K.
   Vitart, Veronique
   Campbell, Harry
   Maelarstig, Anders
   Wiggins, Kerri L.
   Van Duijn, Cornelia M.
   McArdle, Wendy L.
   Pankow, James S.
   Johnson, Andrew D.
   Silveira, Angela
   McKnight, Barbara
   Uitterlinden, Andre G.
   Aleksic, Nena
   Meigs, James B.
   Peters, Annette
   Koenig, Wolfgang
   Cushman, Mary
   Kathiresan, Sekar
   Rotter, Jerome I.
   Bovill, Edwin G.
   Hofman, Albert
   Boerwinkle, Eric
   Tofler, Geoffrey H.
   Peden, John F.
   Psaty, Bruce M.
   Leebeek, Frank
   Folsom, Aaron R.
   Larson, Martin G.
   Spector, Timothy D.
   Wright, Alan F.
   Wilson, James F.
   Hamsten, Anders
   Lumley, Thomas
   Witteman, Jacqueline C. M.
   Tang, Weihong
   O'Donnell, Christopher J.
CA Wellcome Trust Case Control Consor
TI Novel Associations of Multiple Genetic Loci With Plasma Levels of Factor
   VII, Factor VIII, and von Willebrand Factor The CHARGE (Cohorts for
   Heart and Aging Research in Genome Epidemiology) Consortium
SO CIRCULATION
LA English
DT Article
DE genetic variation; factor VII; factor VIII; von Willebrand factor;
   epidemiology; meta-analysis; thrombosis; hemostasis
ID CARDIOVASCULAR RISK-FACTORS; CORONARY-ARTERY-DISEASE;
   COAGULATION-FACTOR-VII; C-REACTIVE PROTEIN; ABO BLOOD-GROUP; WIDE
   ASSOCIATION; ATHEROSCLEROSIS RISK; MYOCARDIAL-INFARCTION; TRIGLYCERIDE
   LEVELS; MOLECULAR-GENETICS
AB Background-Plasma levels of coagulation factors VII (FVII), VIII (FVIII), and von Willebrand factor (vWF) influence risk of hemorrhage and thrombosis. We conducted genome-wide association studies to identify new loci associated with plasma levels.
   Methods and Results-The setting of the study included 5 community-based studies for discovery comprising 23 608 European-ancestry participants: Atherosclerosis Risk In Communities Study, Cardiovascular Health Study, British 1958 Birth Cohort, Framingham Heart Study, and Rotterdam Study. All subjects had genome-wide single-nucleotide polymorphism (SNP) scans and at least 1 phenotype measured: FVII activity/antigen, FVIII activity, and vWF antigen. Each study used its genotype data to impute to HapMap SNPs and independently conducted association analyses of hemostasis measures using an additive genetic model. Study findings were combined by meta-analysis. Replication was conducted in 7604 participants not in the discovery cohort. For FVII, 305 SNPs exceeded the genome-wide significance threshold of 5.0X10(-8) and comprised 5 loci on 5 chromosomes: 2p23 (smallest P value 6.2X10(-24)), 4q25 (3.6X10(-12)), 11q12 (2.0X10(-10)), 13q34 (9.0X10(-259)), and 20q11.2 (5.7X10(-37)). Loci were within or near genes, including 4 new candidate genes and F7 (13q34). For vWF, 400 SNPs exceeded the threshold and marked 8 loci on 6 chromosomes: 6q24 (1.2X10(-22)), 8p21 (1.3X10(-16)), 9q34 (<5.0X10(-324)), 12p13 (1.7X10(-32)), 12q23 (7.3X10(-10)), 12q24.3 (3.8X10(-11)), 14q32 (2.3X10(-10)), and 19p13.2 (1.3X10(-9)). All loci were within genes, including 6 new candidate genes, as well as ABO (9q34) and VWF (12p13). For FVIII, 5 loci were identified and overlapped vWF findings. Nine of the 10 new findings were replicated.
   Conclusions-New genetic associations were discovered outside previously known biological pathways and may point to novel prevention and treatment targets of hemostasis disorders. (Circulation. 2010; 121: 1382-1392.)
C1 [Smith, Nicholas L.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98101 USA.
   [Basu, Saonli; Kong, Xiaoxiao] Univ Minnesota, Div Biostat, Minneapolis, MN USA.
   [Pankow, James S.; Folsom, Aaron R.; Tang, Weihong] Univ Minnesota, Div Epidemiol, Minneapolis, MN USA.
   [Pankow, James S.; Folsom, Aaron R.; Tang, Weihong] Univ Minnesota, Div Community Hlth, Minneapolis, MN USA.
   [Aleksic, Nena] Univ Texas Hlth Sci Ctr Houston, DNA Lab, Ctr Human Genet, Houston, TX USA.
   [Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX USA.
   [Strachan, David P.] Univ London, Div Community Hlth Sci, London WC1E 7HU, England.
   [Rumley, Ann] Univ Glasgow, Royal Infirm, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
   [McArdle, Wendy L.] Univ Bristol, ALSPAC Lab, Bristol BS8 1TH, Avon, England.
   [Bis, Joshua C.; Wiggins, Kerri L.; Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
   [Psaty, Bruce M.; Lumley, Thomas] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Psaty, Bruce M.] Univ Washington, Hlth Serv, Seattle, WA 98195 USA.
   [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
   [Cushman, Mary; Bovill, Edwin G.] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA.
   [Cushman, Mary] Univ Vermont, Dept Med, Burlington, VT 05405 USA.
   [Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
   [Chen, Ming-Huei; Yang, Qiong; Johnson, Andrew D.; Kathiresan, Sekar; Larson, Martin G.; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
   [Yang, Qiong] Boston Univ, Dept Biostat, Boston, MA 02215 USA.
   [Chen, Ming-Huei] Boston Univ, Dept Neurol, Boston, MA 02215 USA.
   [Larson, Martin G.] Boston Univ, Dept Math, Boston, MA 02215 USA.
   [Johnson, Andrew D.; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA.
   [Meigs, James B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med, Boston, MA USA.
   [Kathiresan, Sekar; O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Cardiol, Boston, MA USA.
   [Tofler, Geoffrey H.] Royal N Shore Hosp, Sydney, NSW, Australia.
   [Dehghan, Abbas; Van Duijn, Cornelia M.; Uitterlinden, Andre G.; Hofman, Albert; Witteman, Jacqueline C. M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [de Maat, Moniek P. M.; Leebeek, Frank] Erasmus MC, Dept Hematol, Rotterdam, Netherlands.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Soranzo, Nicole] Wellcome Trust Sanger Inst, Hinxton, England.
   [Soranzo, Nicole; Williams, Frances M. K.; Spector, Timothy D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England.
   [Hayward, Caroline; Vitart, Veronique; Wright, Alan F.] Inst Genet & Mol Med, Human Genet Unit, MRC, Edinburgh, Midlothian, Scotland.
   [Rudan, Igor] Univ Split, Sch Med, Croatian Ctr Global Hlth, Soltanska, Croatia.
   [Rudan, Igor; Campbell, Harry; Wilson, James F.] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland.
   [Sabater-Lleal, Maria; Maelarstig, Anders; Silveira, Angela; Hofman, Albert] Karolinska Inst, Dept Med, Atherosclerosis Res Unit, Stockholm, Sweden.
   [Peden, John F.] Univ Oxford, Dept Cardiovasc Med, Oxford, England.
   [Peters, Annette] German Res Ctr Environm & Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany.
   [Koenig, Wolfgang] Univ Ulm, Ulm, Germany.
RP Smith, NL (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.
EM nlsmith@u.washington.edu; odonnellc@nhlbi.nih.gov
RI Meigs, James/P-3927-2019; Johnson, Andrew D/G-6520-2013; Lleal, Maria
   Sabater/I-5832-2013; Yang, Qiong/G-5438-2014; Campbell,
   Harry/E-2959-2010; Hayward, Caroline/M-8818-2016; Wilson, James F
   F/A-5704-2009; Rudan, Igor/I-1467-2012; Spector, Tim D/F-6533-2012;
   Peters, Annette/A-6117-2011; Dehghan, Abbas/B-9896-2008
OI Meigs, James/0000-0002-2439-2657; Lleal, Maria
   Sabater/0000-0002-0128-379X; Campbell, Harry/0000-0002-6169-6262;
   Hayward, Caroline/0000-0002-9405-9550; Wilson, James F
   F/0000-0001-5751-9178; Rudan, Igor/0000-0001-6993-6884; Peters,
   Annette/0000-0001-6645-0985; Williams, Frances/0000-0002-2998-2744;
   Basu, Saonli/0000-0003-1200-4546; Dehghan, Abbas/0000-0001-6403-016X;
   Cushman, Mary/0000-0002-7871-6143; Larson, Martin/0000-0002-9631-1254;
   Pankow, James/0000-0001-7076-483X; Soranzo, Nicole/0000-0003-1095-3852
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [N01-HC-55015, N01-HC55016, N01-HC-55018,
   N01-HC-55019, N01-HC-55020, N01-HC55021, N01-HC-55022, R01-HL-087641,
   R01-HL59367]; National Human Genome Research InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Human Genome Research Institute (NHGRI)
   [U01-HG-004402]; National Institutes of Health (NIH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [HHSN268200625226C, UL1-RR-025005]; Medical Research
   CouncilMedical Research Council UK (MRC) [G0000934]; Wellcome
   TrustWellcome Trust [068545/Z/02]; National Institute of Neurological
   Disorders and StrokeUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS); National Center for Research
   ResourcesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [M01-RR00425]; National Institute of Diabetes and
   Digestive and Kidney DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK063491, K24
   DK080140]; NHLBI's FHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [N01-HC-25195, N02-HL-6-4278]; Robert Dawson
   Evans Endowment of the Department of Medicine at Boston University
   School of Medicine; Boston Medical Center; Erasmus Medical Center;
   Erasmus University Rotterdam; Netherlands Organization for Scientific
   Research (NWO)Netherlands Organization for Scientific Research (NWO)
   [175.010.2005.011, 911.03.012]; Netherlands Organization for Health
   Research and Development (ZonMw)Netherlands Organization for Health
   Research and Development; Research Institute for Diseases in the
   Elderly; Netherlands Heart FoundationNetherlands Heart Foundation;
   Ministry of Education, Culture and ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT); Ministry of
   Health Welfare and Sports; European CommissionEuropean Commission Joint
   Research Centre; Municipality of Rotterdam; Research Institute for
   Diseases in the Elderly (RIDE) [94800022]; Netherlands Genomics
   Initiative (NGI)/NWONetherlands Organization for Scientific Research
   (NWO) [050-060-810]; Wellcome TrustWellcome Trust; European
   CommunityEuropean Community (EC) [FP-6/2005-2008]; FP7/2007-2013
   [HEALTH-F4-2007-201413]; FP-5 GenomEUtwin Project [QLG2-CT-2002-01254];
   Department of Health via a National Institute for Health Research
   (NIHR)National Institute for Health Research (NIHR); Biotechnology and
   Biological Sciences Research CouncilBiotechnology and Biological
   Sciences Research Council (BBSRC) [G20234]; National Eye Institute via
   an NIH/Center for Inherited Disease ResearchUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Eye Institute (NEI); Medical Research Council UKMedical
   Research Council UK (MRC); Ministry of Science, Education and Sport of
   the Republic of CroatiaMinistry of Science, Education and Sports,
   Republic of Croatia [108-1080315-0302]; European UnionEuropean Union
   (EU) [LSHG-CT-2006-018947]; Chief Scientist Office of the Scottish
   Government; Royal SocietyRoyal Society of London; ECEuropean Commission
   Joint Research CentreEuropean Community (EC) [LSHM-CT-2007-037273];
   Swedish Research CouncilSwedish Research Council [8691]; Knut and Alice
   Wallenberg FoundationKnut & Alice Wallenberg Foundation; Swedish
   Heart-Lung FoundationSwedish Heart-Lung Foundation; Leducq Foundation,
   ParisLeducq Foundation; Stockholm County CouncilStockholm County Council
   [560283]; AstraZenecaAstraZeneca; Sanofi-AventisSanofi-Aventis;
   GlaxoSmithKlineGlaxoSmithKline; NHLBI contractsUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01-HL-086694,
   N01-HC-85079, N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222,
   N01-HC-75150, N01-HC-45133, U01 HL080295, R01 HL 087652, HL073410,
   HL095080]; Biotechnology and Biological Sciences Research
   CouncilBiotechnology and Biological Sciences Research Council (BBSRC)
   [G20234/2]; Medical Research CouncilMedical Research Council UK (MRC)
   [MC_U127561128, MC_qA137934]; Chief Scientist Office [CZB/4/710]
FX ARIC is supported by NHLBI contracts N01-HC-55015, N01-HC55016,
   N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC55021, and N01-HC-55022
   and grants R01-HL-087641, R01-HL59367, and R01-HL-086694; National Human
   Genome Research Institute contract U01-HG-004402; and National
   Institutes of Health (NIH) contract HHSN268200625226C. The
   infrastructure was supported in part by grant No. UL1-RR-025005, a
   component of the NIH and NIH Roadmap for Medical Research. We
   acknowledge use of phenotype and genotype data from the B58C DNA
   collection, funded by Medical Research Council grant G0000934 and the
   Wellcome Trust grant 068545/Z/02 (http://www.b58cgene.sgul.ac.uk/). The
   CHS is supported by contract Nos. N01-HC-85079 through N01-HC-85086,
   N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, and N01-HC-45133
   and grant Nos. U01 HL080295 and R01 HL 087652 from the NHLBI, with
   additional contribution from the National Institute of Neurological
   Disorders and Stroke. A full list of principal CHS investigators and
   institutions can be found at http://www.chs-nhlbi.org/pi.htm. Support
   was also provided by NHLBI grants HL073410 and HL095080 and the Leducq
   Foundation, Paris, France, for the development of Transatlantic Networks
   of Excellence in Cardiovascular Research. DNA handling and genotyping
   was supported in part by National Center for Research Resources grant
   M01-RR00425 to the Cedars-Sinai General Clinical Research Center
   genotyping core and National Institute of Diabetes and Digestive and
   Kidney Diseases grant DK063491 to the Southern California Diabetes
   Endocrinology Research Center. This research was conducted in part with
   data and resources from the FHS of the NHLBI of the NIH and Boston
   University School of Medicine. The analyses reflect intellectual input
   and resource development from the FHS investigators participating in the
   SNP Health Association Resource (SHARe) project. Partial investigator
   support was provided by National Institute of Diabetes and Digestive and
   Kidney Diseases grant K24 DK080140 (Dr Meigs). This work was supported
   in part by the NHLBI's FHS (contract No. N01-HC-25195) and its contract
   with Affymetrix Inc for genotyping services (contract No.
   N02-HL-6-4278). A portion of this research used the Linux Cluster for
   Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment
   of the Department of Medicine at Boston University School of Medicine
   and Boston Medical Center. The Rotterdam Study is supported by the
   Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands
   Organization for Scientific Research; the Netherlands Organization for
   Health Research and Development (ZonMw); the Research Institute for
   Diseases in the Elderly; the Netherlands Heart Foundation; the Ministry
   of Education, Culture and Science; the Ministry of Health Welfare and
   Sports; the European Commission; and the Municipality of Rotterdam.
   Support for genotyping was provided by the Netherlands Organization for
   Scientific Research (NWO; 175.010.2005.011, 911.03.012) and Research
   Institute for Diseases in the Elderly (RIDE). This study was further
   supported by the Netherlands Genomics Initiative (NGI)/NWO project No.
   050-060-810. Dr Dehghan is supported by NWO, RIDE (94800022).; The Twins
   UK study was funded by the Wellcome Trust; European Community's Sixth
   and Seventh Framework Programmes (FP-6/2005-2008) Life Sciences & Health
   (Ref 005268, genetic regulation of the end-stage clotting process that
   leads to thrombotic stroke: The EuroClot Consortium) and FP7/2007-2013,
   ENGAGE project HEALTH-F4-2007-201413, and the FP-5 GenomEUtwin Prject
   (QLG2-CT-2002-01254). The study also received support from the
   Department of Health via a National Institute for Health Research (NIHR)
   comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS
   Foundation Trust in partnership with King's College London. Dr Spector
   is an NIHR Senior Investigator. The project also received support from a
   Biotechnology and Biological Sciences Research Council project grant
   (G20234). The authors acknowledge the funding and support of the
   National Eye Institute via an NIH/Center for Inherited Disease Research
   genotyping project (principal investigator: Terri Young). The VIS study
   in the Croatian island of Vis was supported through grants from the
   Medical Research Council UK and Ministry of Science, Education and Sport
   of the Republic of Croatia (No. 108-1080315-0302) and the European Union
   framework program 6 EUROSPAN project (contract No. LSHG-CT-2006-018947).
   ORCADES was supported by the Chief Scientist Office of the Scottish
   Government, the Royal Society, and the European Union framework program
   6 EUROSPAN project (contract No. LSHG-CT-2006-018947). DNA extractions
   were performed at the Wellcome Trust Clinical Research Facility in
   Edinburgh. The PROCARDIS program was funded by the EC Sixth Framework
   Programme (LSHM-CT-2007-037273), the Swedish Research Council (8691),
   the Knut and Alice Wallenberg Foundation, the Swedish Heart-Lung
   Foundation, the Leducq Foundation, Paris, the Stockholm County Council
   (560283), and AstraZeneca. Genotyping of Swedish PROCARDIS control
   samples was performed at the SNP Technology Platform (head: Professor
   Ann-Christine Syvanen), Department of Medical Sciences, Uppsala
   University, Sweden.; Dr Meigs reports receiving grant support from
   Sanofi-Aventis and GlaxoSmithKline and serving as a consultant/advisor
   to Interleukin Genetics and Eli Lilly. The remaining authors report no
   conflicts.
CR Abecasis GR, 2001, GENET EPIDEMIOL, V21, pS341, DOI 10.1002/gepi.2001.21.s1.s341
   Acharya SS, 2004, J THROMB HAEMOST, V2, P248, DOI 10.1111/j.1538-7836.2003.t01-1-00553.x
   Andrew T, 2001, Twin Res, V4, P464, DOI 10.1375/1369052012803
   ANTONARAKIS SE, 1987, MOL BIOL MED, V4, P81
   Broadbent HM, 2008, HUM MOL GENET, V17, P806, DOI 10.1093/hmg/ddm352
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Chambless L E, 1992, Ann Epidemiol, V2, P723
   Clayton D, 2008, BIOSTATISTICS, V9, P593, DOI 10.1093/biostatistics/kxn007
   CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380
   Cooper DN, 1997, THROMB HAEMOSTASIS, V78, P151
   Cushman M, 1996, AM J EPIDEMIOL, V143, P665
   DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279
   de Lange M, 2001, LANCET, V357, P101, DOI 10.1016/S0140-6736(00)03541-8
   Devlin B, 2001, THEOR POPUL BIOL, V60, P155, DOI 10.1006/tpbi.2001.1542
   FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7
   Feng DL, 2000, ARTERIOSCL THROM VAS, V20, P593, DOI 10.1161/01.ATV.20.2.593
   Folsom AR, 2007, J THROMB HAEMOST, V5, P1674, DOI 10.1111/j.1538-7836.2007.02620.x
   Folsom AR, 1997, CIRCULATION, V96, P1102, DOI 10.1161/01.CIR.96.4.1102
   FOLSOM AR, 1991, ATHEROSCLEROSIS, V91, P191, DOI 10.1016/0021-9150(91)90167-2
   Folsom AR, 2001, THROMB HAEMOSTASIS, V86, P366
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   Fu J, 2005, J BIOL CHEM, V280, P3178, DOI 10.1074/jbc.M410044200
   Ghosh S, 2007, J BIOL CHEM, V282, P11849, DOI 10.1074/jbc.M609283200
   GILL JC, 1987, BLOOD, V69, P1691
   Girelli D, 2000, NEW ENGL J MED, V343, P774, DOI 10.1056/NEJM200009143431104
   Harris EN, 2008, GLYCOBIOLOGY, V18, P638, DOI 10.1093/glycob/cwn045
   Hines LM, 2001, NEW ENGL J MED, V344, P549, DOI 10.1056/NEJM200102223440802
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Hofman A, 2007, EUR J EPIDEMIOL, V22, P819, DOI 10.1007/s10654-007-9199-x
   Humphries S, 1996, THROMB HAEMOSTASIS, V75, P567
   James PD, 2007, BLOOD, V109, P145, DOI 10.1182/blood-2006-05-021105
   Kathiresan S, 2006, ARTERIOSCL THROM VAS, V26, P1405, DOI 10.1161/01.ATV.0000222011.13026.25
   KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3
   Li Y, 2006, AM J HUM GENET S, VS79, P2290
   Liang YH, 2001, IMMUNOGENETICS, V53, P357, DOI 10.1007/s002510100339
   Lopez-Sagaseta J, 2007, J THROMB HAEMOST, V5, P1817, DOI 10.1111/j.1538-7836.2007.02648.x
   Lowenstein CJ, 2005, TRENDS CARDIOVAS MED, V15, P302, DOI 10.1016/j.tcm.2005.09.005
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   Mazurier C, 2001, BEST PRACT RES CL HA, V14, P337, DOI 10.1053/beha.2001.0138
   McQuillan R, 2008, AM J HUM GENET, V83, P359, DOI 10.1016/j.ajhg.2008.08.007
   Mennen LI, 1997, AM J CLIN NUTR, V65, P732
   Morelli VM, 2005, J THROMB HAEMOST, V3, P183, DOI 10.1111/j.1538-7836.2004.01071.x
   Nichols WC, 1997, MEDICINE, V76, P1, DOI 10.1097/00005792-199701000-00001
   Olsson ML, 2001, TRANSFUSION MED, V11, P295, DOI 10.1046/j.1365-3148.2001.00320.x
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Psaty BM, 2009, CIRC-CARDIOVASC GENE, V2, P73, DOI 10.1161/CIRCGENETICS.108.829747
   Ridker PM, 2008, AM J HUM GENET, V82, P1185, DOI 10.1016/j.ajhg.2008.03.015
   Rudnicka AR, 2007, CIRCULATION, V115, P996, DOI 10.1161/CIRCULATIONAHA.106.635169
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Servin B, 2007, PLOS GENET, V3, P1296, DOI 10.1371/journal.pgen.0030114
   SKARTLIEN AH, 1989, ARTERIOSCLEROSIS, V9, P798, DOI 10.1161/01.ATV.9.6.798
   Smith A, 2005, CIRCULATION, V112, P3080, DOI 10.1161/CIRCULATIONAHA.105.557132
   Souto JC, 2000, CIRCULATION, V101, P1546, DOI 10.1161/01.CIR.101.13.1546
   Spiel AO, 2008, CIRCULATION, V117, P1449, DOI 10.1161/CIRCULATIONAHA.107.722827
   Strachan DP, 2007, INT J EPIDEMIOL, V36, P522, DOI 10.1093/ije/dyl309
   Tofler GH, 2005, AM J CARDIOL, V96, P1280, DOI 10.1016/j.amjcard.2005.06.072
   Vitart V, 2008, NAT GENET, V40, P437, DOI 10.1038/ng.106
   Vossen CY, 2007, J THROMB HAEMOST, V5, P1325, DOI 10.1111/j.1538-7836.2007.02554.x
   Wiggins KL, 2009, J THROMB HAEMOST, V7, P263, DOI 10.1111/j.1538-7836.2008.03243.x
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Ye Z, 2006, LANCET, V367, P651, DOI 10.1016/S0140-6736(06)68263-9
   Younis J, 2005, ATHEROSCLEROSIS, V180, P225, DOI 10.1016/j.atherosclerosis.2004.12.010
NR 62
TC 217
Z9 222
U1 1
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAR 30
PY 2010
VL 121
IS 12
BP 1382
EP U45
DI 10.1161/CIRCULATIONAHA.109.869156
PG 30
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 575RD
UT WOS:000276084400003
PM 20231535
OA Bronze, Green Accepted
DA 2020-08-12
ER

PT J
AU Paterson, AD
   Waggott, D
   Boright, AP
   Hosseini, SM
   Shen, EQ
   Sylvestre, MP
   Wong, I
   Bharaj, B
   Cleary, PA
   Lachin, JM
   Below, JE
   Nicolae, D
   Cox, NJ
   Canty, AJ
   Sun, L
   Bull, SB
AF Paterson, Andrew D.
   Waggott, Daryl
   Boright, Andrew P.
   Hosseini, S. Mohsen
   Shen, Enqing
   Sylvestre, Marie-Pierre
   Wong, Isidro
   Bharaj, Bhupinder
   Cleary, Patricia A.
   Lachin, John M.
   Below, Jennifer E.
   Nicolae, Dan
   Cox, Nancy J.
   Canty, Angelo J.
   Sun, Lei
   Bull, Shelley B.
CA Meta Anal Glucose Insulin Related
   Diabet Control Complications Trial
TI A Genome-Wide Association Study Identifies a Novel Major Locus for
   Glycemic Control in Type 1 Diabetes, as Measured by Both A1C and Glucose
SO DIABETES
LA English
DT Article
ID FASTING GLUCOSE; QUANTITATIVE TRAIT; CARDIOVASCULAR-DISEASE; GENE;
   NEPHROPATHY; HBA1C; SCAN; INTERVENTIONS; HERITABILITY; VARIANTS
AB OBJECTIVE-Glycemia is a major risk factor for the development of long-term complications in type 1 diabetes; however, no specific genetic loci have been identified for glycemic control in individuals with type 1 diabetes. To identify such loci in type 1 diabetes, we analyzed longitudinal repeated measures of A1C from the Diabetes Control and Complications Trial.
   RESEARCH DESIGN AND METHODS-We performed a genome-wide association study using the mean of quarterly A1C values measured over 6.5 years, separately in the conventional (n = 667) and intensive (n = 637) treatment groups of the DCCT. At loci of interest, linear mixed models were used to take advantage of all the repeated measures. We then assessed the association of these loci with capillary glucose and repeated measures of multiple complications of diabetes.
   RESULTS-We identified a major locus for A1C levels in the conventional treatment group near SORCS1 (10q25.1, P = 7 X 10(-10)), which was also associated with mean glucose (P = 2 X 10(-5)). This was confirmed using A1C in the intensive treatment group (P = 0.01). Other loci achieved evidence close to genome-wide significance: 14q32.13 (GSC) and 9p22 (BNC2) in the combined treatment groups mid 15q21.3 (WDR72) in the intensive group. Further, these loci gave evidence for association with diabetic complications, specifically, SORCS1 with hypoglycemia and BNC2 with renal and retinal complications. We replicated the SORCS1 association in Genetics of Diabetes in Kidneys (GoKinD) study control subjects (P = 0.01) and the BNC2 association with A1C in nondiabetic individuals.
   CONCLUSIONS-A major locus for A1C and glucose in individuals with diabetes is near SORCS1. T his may influence the design and analysis of genetic studies attempting to identify risk factors for long-term diabetic complications. Diabetes 59:539-549, 2010
C1 [Paterson, Andrew D.; Hosseini, S. Mohsen; Wong, Isidro; Bharaj, Bhupinder] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada.
   [Waggott, Daryl; Shen, Enqing; Sylvestre, Marie-Pierre; Bull, Shelley B.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Prosserman Ctr Hlth Res, Toronto, ON M5G 1X5, Canada.
   [Boright, Andrew P.] Univ Toronto, Dept Med, Univ Hlth Network, Toronto, ON, Canada.
   [Paterson, Andrew D.; Sun, Lei; Bull, Shelley B.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Cleary, Patricia A.; Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD USA.
   [Canty, Angelo J.] McMaster Univ, Dept Math & Stat, Hamilton, ON, Canada.
   [Sun, Lei] Univ Toronto, Dept Stat, Toronto, ON, Canada.
   [Below, Jennifer E.; Nicolae, Dan; Cox, Nancy J.] Univ Chicago, Dept Med, Med Genet Sect, Chicago, IL 60637 USA.
RP Paterson, AD (corresponding author), Hosp Sick Children, Program Genet & Genome Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM andrew.paterson@utoronto.ca
RI Bull, Shelley B/A-1920-2013; Paterson, Andrew D/A-4088-2011; Paterson,
   Andrew/AAQ-7511-2020; Below, Jennifer E/W-2179-2018; Hosseini,
   Mohsen/K-7133-2013
OI Paterson, Andrew D/0000-0002-9169-118X; Paterson,
   Andrew/0000-0002-9169-118X; Below, Jennifer E/0000-0002-1346-1872;
   Lachin, John/0000-0001-9838-2841; Hosseini, Mohsen/0000-0003-3626-9928;
   Nicolae, Dan/0000-0002-0918-4630; Below, Jennifer/0000-0002-6372-6402
FU National Institute of Diabetes and Digestive and Kidney Diseases
   (NIDDK)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK); National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA; Canadian Institutes of Health Research
   (CIHR)Canadian Institutes of Health Research (CIHR); National Institute
   of Diabetes and Digestive and Kidney DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [N01-DK-6-2204, R01-DK-077510, R01-DK077489, P60-DK20595]; Canadian
   Network of Centres of Excellence in Mathematics and Genome Canada
   through the Ontario Genomics Institute; Juvenile Diabetes Research
   FoundationJuvenile Diabetes Research Foundation; U.S. Centers for
   Disease Control and PreventionUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA
FX The DCCT/EDIC Research Group is sponsored through research contracts
   from the National Institute of Diabetes, Endocrinology and Metabolic
   Diseases of the National Institute of Diabetes and Digestive and Kidney
   Diseases (NIDDK) and the National Institutes of Health. S.B.B. held a
   Canadian Institutes of Health Research (CIHR) Senior Investigator award
   (2002-2007). A.D.P. holds a Canada Research Chair in the Genetics of
   Complex Diseases. This work received support from National Institute of
   Diabetes and Digestive and Kidney Diseases contract N01-DK-6-2204,
   National Institute of Diabetes and Digestive and Kidney Diseases Grants
   R01-DK-077510, R01-DK077489, and P60-DK20595 and support from the
   Canadian Network of Centres of Excellence in Mathematics and Genome
   Canada through the Ontario Genomics Institute. Clinical data and DNA
   from the DCCT/EDIC study will be made available through the National
   Institute of Diabetes and Digestive and Kidney Diseases repository at
   https://www.niddkrepository.org/niddk/home.do. The GoKinD study sample
   collection was supported by the Juvenile Diabetes Research Foundation in
   collaboration with the Joslin Diabetes Center and George Washington
   University and by the U.S. Centers for Disease Control and Prevention.
CR Al-Kateb H, 2008, DIABETES, V57, P218, DOI 10.2337/db07-1059
   Albers JW, 1995, ANN NEUROL, V38, P869, DOI 10.1002/ana.410380607
   An P, 2005, DIABETES, V54, P909, DOI 10.2337/diabetes.54.3.909
   Beavis William D., 1998, P145
   Bonnefond A, 2009, DIABETES, V58, P2687, DOI 10.2337/db09-0652
   BORCHJOHNSEN K, 1992, KIDNEY INT, V41, P719, DOI 10.1038/ki.1992.112
   Bouatia-Naji N, 2008, SCIENCE, V320, P1085, DOI 10.1126/science.1156849
   Bouatia-Naji N, 2009, NAT GENET, V41, P89, DOI 10.1038/ng.277
   Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a
   Chen WM, 2008, J CLIN INVEST, V118, P2620, DOI 10.1172/JCI34566
   Cleary PA, 2006, DIABETES, V55, P3556, DOI 10.2337/db06-0653
   Clee SM, 2006, NAT GENET, V38, P688, DOI 10.1038/ng1796
   DCCT Res Grp, 1986, DIABETES, V35, P530
   *DIAB CONTR COMPL, 1993, MAN OP DIAB CONTR CO
   Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703
   Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894
   Diabet Control Complications Trial Res Grp, 1998, ANN INTERN MED, V128, P517, DOI 10.7326/0003-4819-128-7-199804010-00001
   Diabet Control Complications Trial Res Grp, 1997, DIABETES, V46, P1829
   Diabet Control Complications Trial Res Grp, 1998, DIABETOLOGIA, V41, P416
   Diggle P. J., 2002, ANAL LONGITUDINAL DA
   DUBREY SW, 1994, DIABETES, V43, P831, DOI 10.2337/diabetes.43.6.831
   Dudbridge F, 2008, GENET EPIDEMIOL, V32, P227, DOI 10.1002/gepi.20297
   EDIC Res Grp, 1999, DIABETES, V48, P383
   Florez JC, 2007, DIABETES, V56, P3063, DOI 10.2337/db07-0451
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Gauderman WJ, 2003, GENET EPIDEMIOL, V25, P327, DOI 10.1002/gepi.10262
   Genuth S, 2002, JAMA-J AM MED ASSOC, V287, P2563
   Gerstl EM, 2008, EUR J PEDIATR, V167, P447, DOI 10.1007/s00431-007-0586-9
   Goodarzi MO, 2007, DIABETES, V56, P1922, DOI 10.2337/db06-1677
   Granhall C, 2006, GENETICS, V174, P1565, DOI 10.1534/genetics.106.062208
   Hietala K, 2008, DIABETES, V57, P2176, DOI 10.2337/db07-1495
   LI Y, 2006, ANN M AM SOC HUM GEN
   Lyssenko V, 2009, NAT GENET, V41, P82, DOI 10.1038/ng.288
   Meigs JB, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S16
   Meigs JB, 2002, DIABETES, V51, P833, DOI 10.2337/diabetes.51.3.833
   Mueller PW, 2006, J AM SOC NEPHROL, V17, P1782, DOI 10.1681/ASN.2005080822
   Nathan DM, 2003, NEW ENGL J MED, V348, P761
   Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187
   Orho-Melander M, 2008, DIABETES, V57, P3112, DOI 10.2337/db08-0516
   Pare G, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000312
   Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190
   Pezzolesi MG, 2009, DIABETES, V58, P1403, DOI 10.2337/db08-1514
   Prokopenko I, 2009, NAT GENET, V41, P77, DOI 10.1038/ng.290
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Sabatti C, 2009, NAT GENET, V41, P35, DOI 10.1038/ng.271
   SANNA S, 2009, AM SOC HUM GEN ANN M
   SHAMOON H, 1995, DIABETES CARE, V18, P361
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shannon H, 2000, NEW ENGL J MED, V342, P381
   Simonis-Bik AMC, 2008, TWIN RES HUM GENET, V11, P597, DOI 10.1375/twin.11.6.597
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Snieder H, 2001, DIABETES, V50, P2858, DOI 10.2337/diabetes.50.12.2858
   Sosenko JM, 2004, DIABETES, V53, pA425
   Steffes M, 2005, CLIN CHEM, V51, P753, DOI 10.1373/clinchem.2004.042143
   Steffes MW, 2003, JAMA-J AM MED ASSOC, V290, P2159, DOI 10.1001/jama.290.16.2159
   1995, ANN INTERN MED, V122, P561
NR 56
TC 77
Z9 78
U1 0
U2 8
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD FEB
PY 2010
VL 59
IS 2
BP 539
EP 549
DI 10.2337/db09-0653
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 554LG
UT WOS:000274435900026
PM 19875614
OA Green Published, Other Gold
DA 2020-08-12
ER

PT J
AU Oczkowicz, M
   Piestrzynska-Kajtoch, A
   Piorkowska, K
   Rejduch, B
   Rozycki, M
AF Oczkowicz, Maria
   Piestrzynska-Kajtoch, Agata
   Piorkowska, Katarzyna
   Rejduch, Barbara
   Rozycki, Marian
TI Expression of DLK1 and MEG3 genes in porcine tissues during postnatal
   development
SO GENETICS AND MOLECULAR BIOLOGY
LA English
DT Article
DE DLK1; imprinting; MEG3; pigs; polar overdominance
ID GROWTH; GTL2; RNA
AB The Drosophila-like homolog 1 (DLK1), a transmembrane signal protein similar to other members of the Notch/Delta/Serrate family, regulates the differentiation process in many types of mammalian cells. Callipyge sheep and DLK1 knockout mice are excellent examples of a fundamental role of the gene encoding DLK1 in muscle growth and fat deposition. DLK1 is located within co-regulated imprinted clusters (the DLK1/DIO3 domain), along with other imprinted genes. Some of these, e. g. the RNA coding MEG3 gene, presumedly interfere with DLK1 transcription. The aim of our study was to analyze DLK1 and MEG3 gene expression in porcine tissues (muscle, liver, kidney, heart, brain stem) during postnatal development. The highest expression of both DLK1 and MEG3 variant 1 (MEG3 var.1) was observed in the brain-stem and muscles, whereas that of MEG3 variant 2 (MEG3var.2) was the most abundant in muscles and the heart. During development (between 60 and 210 days of age) expression of analyzed genes was down-regulated in all the tissues. An exception was the brain-stem, where there was no significant change in MEG3 (both variants) mRNA level, and relatively little decline (2-fold) in that of DLK1 transcription. This may indicate a distinct function of the DLK1 gene in the brain-stem, when compared with other tissues.
C1 [Oczkowicz, Maria; Piorkowska, Katarzyna; Rozycki, Marian] Natl Res Inst Anim Prod, Dept Anim Breeding & Genet, PL-32083 Balice, Poland.
   [Piestrzynska-Kajtoch, Agata; Rejduch, Barbara] Natl Res Inst Anim Prod, Dept Immuno & Cytogenet, PL-32083 Balice, Poland.
RP Oczkowicz, M (corresponding author), Natl Res Inst Anim Prod, Dept Anim Breeding & Genet, Ul Krakowska 1, PL-32083 Balice, Poland.
EM majawrzeska@o2.pl
RI Oczkowicz, Maria/M-8649-2015; Oczkowicz, Maria/L-3715-2019; Piorkowska,
   Katarzyna/M-2697-2019; Piestrzynska-Kajtoch, Agata/F-8110-2014;
   Piorkowska, Katarzyna/M-8646-2015
OI Oczkowicz, Maria/0000-0001-8975-0200; Piestrzynska-Kajtoch,
   Agata/0000-0002-8238-257X; Piorkowska, Katarzyna/0000-0002-4368-9624
FU National Research Institute for Animal Production [1130.1]
FX This work was supported by the National Research Institute for Animal
   Production. Statutory activity No. 1130.1.
CR Abdallah BM, 2007, ENDOCRINOLOGY, V148, P3111, DOI 10.1210/en.2007-0171
   Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118
   Andersen DC, 2009, STEM CELLS, V27, P898, DOI 10.1634/stemcells.2008-0826
   Ansell PJ, 2007, MOL CELL ENDOCRINOL, V271, P55, DOI 10.1016/j.mce.2007.04.002
   Byrne K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008638
   Charlier C, 2001, NAT GENET, V27, P367, DOI 10.1038/86856
   CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532
   Cockett NE, 1996, SCIENCE, V273, P236, DOI 10.1126/science.273.5272.236
   Deiuliis JA, 2006, COMP BIOCHEM PHYS B, V145, P50, DOI 10.1016/j.cbpb.2006.06.003
   Georges M, 2003, TRENDS GENET, V19, P248, DOI 10.1016/S0168-9525(03)00082-9
   JENSEN CH, 1994, EUR J BIOCHEM, V225, P83, DOI 10.1111/j.1432-1033.1994.00083.x
   Jiang CD, 2009, AGR SCI CHINA, V8, P216, DOI 10.1016/S1671-2927(09)60029-8
   Khatib H, 2007, BIOESSAYS, V29, P1022, DOI 10.1002/bies.20637
   Kim KS, 2004, MAMM GENOME, V15, P552, DOI 10.1007/s00335-004-2341-0
   Labialle S, 2008, HUM MOL GENET, V17, P15, DOI 10.1093/hmg/ddm281
   Li XP, 2008, ANIM GENET, V39, P189, DOI 10.1111/j.1365-2052.2007.01693.x
   Lui JC, 2008, AM J PHYSIOL-REG I, V295, pR189, DOI 10.1152/ajpregu.00182.2008
   Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002
   Nueda ML, 2007, J MOL BIOL, V367, P1281, DOI 10.1016/j.jmb.2006.10.043
   Samulin J, 2009, ANIM GENET, V40, P239, DOI 10.1111/j.1365-2052.2008.01812.x
   Shin J, 2009, POULTRY SCI, V88, P1427, DOI 10.3382/ps.2008-00529
   Smas CM, 1996, INT J OBESITY, V20, pS65
   Smit M, 2003, GENETICS, V163, P453
   Sul HS, 2009, MOL ENDOCRINOL, V23, P1717, DOI 10.1210/me.2009-0160
   Takahashi N, 2009, HUM MOL GENET, V18, P1879, DOI 10.1093/hmg/ddp108
NR 25
TC 12
Z9 12
U1 0
U2 10
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
   RIBEIRAO PRET, BRAZIL
SN 1415-4757
EI 1678-4685
J9 GENET MOL BIOL
JI Genet. Mol. Biol.
PY 2010
VL 33
IS 4
BP 790
EP 794
DI 10.1590/S1415-47572010000400030
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 707WI
UT WOS:000286321000030
PM 21637593
OA DOAJ Gold, Green Published
DA 2020-08-12
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Why do I still have a bruise around my knee?
SO LABMEDICINE
LA English
DT Article
AB Patient
   A 45-year-old African-American female.
   Chief Complaint
   The patient presented to the emergency. department with the chief complaint of a bruise around her right knee, which occurred after a fall approximately 10 days prior to presentation.
   History of Present Illness
   In addition to her persistent right knee bruise, she reported fatigue and shortness of breath. after mild exertion of approximately 3 months' duration.
   Past Medical History
   Non-smoker with no history of alcohol abuse, and no chronic medical conditions.
   Physical Exam
   Vital signs: temperature, 36.6 degrees C; heart rate, 119 beats/minute; respiratory rate, 19 per minute; blood pressure, 122/66 mm Hg. Pertinent physical examination findings included labile mood, sinus tachycardia, conjunctival pallor, and hepatomegaly (liver span of 10 cm).
   Principal Laboratory Findings
   See Table 1. The abnormal CBC and coagulopathy were of. paramount concern and peripheral blood smear and mixing studios were performed. There was partial correction on mixing studies suggesting the presence of, inhibitors.
   Peripheral Blood Smear Findings
   Anemia, leukocytosis, thrombocytopenia with, 28% atypical cells with basophilic cytoplasm and occasional eccentrically-placed nucleus with the chromatin and nucleoli (Figure 1)
   Bone Marrow
   Bone marrow aspirate and core biopsy demonstrated a hypercellular marrow diffusely infiltrated by blasts with irregular nuclear contour, basophilic cytoplasm, and prominent nucleoli (Figure 2). The CD 138 immunohistochemical staining of the biopsy specimen highlighted the plasmablasts that are cytoplasmic kappa restricted (Figure 3A, 3B, and 3C). The Ki-67 (proliferation index marker was approximately 5%.
   Flow Cytometry
   Immunophenotypic analysis by flow cytometry demostrated an abnormal plasma cell population expressing CD45 negative/CD19 negative/CD38 positive/CD138 positive/CD56 negative/kappa restricted immunophenotype (Figure 4).
   Cytogenetic Study
   Three (20%) of the cells examined were normal. The remaining 80% exhibited complex aberrations and contained 78 to 83 (hypertriploid) range. A composite karyotype of 12 cells was generated with the aid of interphase fluorescence in situ hybridization (FISH) studies using probes for IGH (14q32)/CCND1 (11q13), IGH/FGFR3 (4p16), IGH/MAF(16q23), TP53(17p13.1), D13S319 (13q143), CEP 9 (9 centromere),CEP 15 (15 centromere), and D5S23/D5S721 (5p15.2), all from Vysis/Abbott Molecular (Des Plaines, IL).The karyotype, described with respect to triploidy, was: 78 similar to 90 3n>XXX[12],+X[6],del(1)(p11p31)[12],der(?)t(1,?)(q12,?)[6], +2[5],+3[11],+4[7],+6[2],(6)(p10)[4],+7[7],+7[4],+add(7)(p12)[4],add(8)(q24.3)[12],+add(8)(q24.3) [11],+9[10],10[3],+11[12],+11 [3],+12[4],-13[12],-14[12],+15[2],-16[12],i(16)(p10)[9],dup(16)(q11.1q21)[8], del(17)(q11.2)[12],+del(17)(q11.2) [11],+der(17)t(1;17)(q21;q25) [3],+der(17)t(1;17)[3], +18[7],+18[3],+19[8],-20[12],+21[7],+?dup(21) (q22q22)[12],+?dup(21)[11],-22[6], +22[2],+1 similar to 10mar[cp12] (Fig 5A). Salient among the abnormalities were gains of chromosomes 3, 7, 9, 11, and 19; structural abnormalities of chromosome 1; and relative loss of chromosome 13. Notably, FISH analysis using the IGH/MAF probes was positive for translocation (Figure 5B).
   Additional Diagnostic Procedures
   Computed tomography scan showed hepatomegaly and diffusely heterogeneous, moth-eaten appearance of the osseous structures with focal lytic lesions in T7 and L4 vertebral bodies (Figure 6). The echocardiogram showed normal cardiac function with an ejection fraction of 56%.
   Follow Up of this Patient
   The patient was treated with bortezomib, a proteasome inhibitor, liposomal doxorubicin, and steroids. Her renal failure improved in concordance with improvement in primary disease and dialysis was prevented. She developed severe dilated cardiomyopathy (CMP) precluding further treatment with lisosomal doxorubicin. Fortunately, CMP reversed with time. She is currently doing well and awaiting definitive treatment while on a new treatment regimen that includes cyclophosphamide, etoposide, cisplatin, and bortezomib. Thalidomide was held after a single cycle due to grade 3 reversible neuropathy.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL PATHOLOGY
PI CHICAGO
PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA
SN 0007-5027
J9 LABMEDICINE
JI Labmedicine
PD MAR
PY 2008
VL 39
IS 3
BP 147
EP 152
DI 10.1309/JONQAHLCMEUKJRHL
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 266TB
UT WOS:000253458800005
DA 2020-08-12
ER

PT J
AU Nagel, S
   Meyer, C
   Quentmeier, H
   Kaufmann, M
   Drexler, HG
   MacLeod, RAF
AF Nagel, S.
   Meyer, C.
   Quentmeier, H.
   Kaufmann, M.
   Drexler, H. G.
   MacLeod, R. A. F.
TI MEF2C is activated by multiple mechanisms in a subset of T-acute
   lymphoblastic leukemia cell lines
SO LEUKEMIA
LA English
DT Article
DE t(5;14); NK-like; microdeletion
ID TRANSCRIPTION FACTOR; HOMEOBOX GENE; NUCLEAR RECEPTORS; GATA FACTORS;
   EXPRESSION; TARGET; NKX2-5; APOPTOSIS; TINMAN; HOX11L2
AB In T-cell acute lymphoblastic leukemia (T-ALL) the cardiac homeobox gene NKX2-5 (at 5q35) is variously deregulated by regulatory elements coordinating with BCL11B (at 14q32.2), or the T-cell receptor gene TRD (at 14q11.2), respectively. NKX2-5 is normally expressed in developing spleen and heart, regulating fundamental processes, including differentiation and survival. In this study we investigated whether NKX2-5 expression in T-ALL cell lines reactivates these embryonal pathways contributing to leukemogenesis. Among 18 known targets analyzed, we identified three genes regulated by NKX2-5 in TALL cells, including myocyte enhancer factor 2C (MEF2C). Knockdown and overexpression assays confirmed MEF2C activation by NKX2-5 at both the RNA and protein levels. Direct interactions between NKX2-5 and GATA3 as indicated by co-immunoprecipitation data may contribute to MEF2C regulation. In T-ALL cell lines LOUCY and RPMI-8402 MEF2C expression was correlated with a 5q14 deletion, encompassing noncoding proximal gene regions. Fusion constructs with green fluorescent protein permitted subcellular detection of MEF2C protein in nuclear speckles interpretable as repression complexes. MEF2C consistently inhibits expression of NR4A1/NUR77, which regulates apoptosis via BCL2 transformation. Taken together, our data identify distinct mechanisms underlying ectopic MEF2C expression in T-ALL, either as a downstream target of NKX2-5, or via chromosomal aberrations deleting proximal gene regions.
C1 [Nagel, S.; Meyer, C.; Quentmeier, H.; Kaufmann, M.; Drexler, H. G.; MacLeod, R. A. F.] Deutsch Sammlung Mikroorganism Zellkultur GmbH, Human & Anim Cell Cultures, D-38124 Braunschweig, Germany.
RP Nagel, S (corresponding author), Deutsch Sammlung Mikroorganism Zellkultur GmbH, Human & Anim Cell Cultures, Inhoffenstr 7B, D-38124 Braunschweig, Germany.
EM sna@dsmz.de
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Ballerini P, 2002, BLOOD, V100, P991, DOI 10.1182/blood-2001-11-0093
   Bernard OA, 2001, LEUKEMIA, V15, P1495, DOI 10.1038/sj.leu.2402249
   Borghi S, 2001, J CELL SCI, V114, P4477
   Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543
   Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115
   De Keersmaecker K, 2005, HAEMATOLOGICA, V90, P1116
   De Val S, 2004, DEV BIOL, V275, P424, DOI 10.1016/j.ydbio.2004.08.016
   Dodou E, 2004, DEVELOPMENT, V131, P3931, DOI 10.1242/dev.01256
   Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3
   DREXLER HG, 2005, GUIDE LEUKEMIA LYMPH
   Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840
   DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G, P13
   Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687
   Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1
   Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515
   Gajewski K, 2001, DEV BIOL, V233, P425, DOI 10.1006/dbio.2001.0220
   Ganga M, 2003, J BIOL CHEM, V278, P22437, DOI 10.1074/jbc.M210163200
   Garcia-Fernandez J, 2005, NAT REV GENET, V6, P881, DOI 10.1038/nrg1723
   Graux C, 2006, LEUKEMIA, V20, P1496, DOI 10.1038/sj.leu.2404302
   Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06
   Guo L, 2001, J BIOL CHEM, V276, P2797, DOI 10.1074/jbc.C000822200
   Han Z, 2005, DEVELOPMENT, V132, P3525, DOI 10.1242/dev.01899
   Hansen-Hagge TE, 2002, LEUKEMIA, V16, P2205, DOI 10.1038/sj.leu.2402671
   HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542
   He YW, 2002, J LEUKOCYTE BIOL, V72, P440
   Hoffmann K, 2004, GENE CHROMOSOME CANC, V41, P309, DOI 10.1002/gcc.20104
   Holland PWH, 2001, J ANAT, V199, P13
   Jay PY, 2005, FASEB J, V19, P1495, DOI 10.1096/fj.04-3064fje
   KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900
   Kieusseian A, 2006, BLOOD, V107, P492, DOI 10.1182/blood-2005-02-0529
   Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980
   Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X
   LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1
   LINTS TJ, 1993, DEVELOPMENT, V119, P419
   Liu TH, 2005, CURR APPL PHYS, V5, P218, DOI 10.1016/j.cap.2003.11.089
   Luciano F, 2007, BLOOD, V109, P3849, DOI 10.1182/blood-2006-11-056879
   MacLeod RAF, 2003, GENE CHROMOSOME CANC, V37, P84, DOI 10.1002/gcc.10194
   MacLeod RAF, 2007, NAT PROTOC, V2, P372, DOI 10.1038/nprot.2007.29
   MacLeod Roderick A F, 2005, Methods Mol Biol, V290, P51
   Mullican SE, 2007, NAT MED, V13, P730, DOI 10.1038/nm1579
   Nagel S, 2005, LEUKEMIA, V19, P841, DOI 10.1038/sj.leu.2403716
   Nagel S, 2003, CANCER RES, V63, P5329
   Nagel S, 2007, CANCER RES, V67, P1461, DOI 10.1158/0008-5472.CAN-06-2615
   Nagel S, 2007, BLOOD, V109, P3015, DOI 10.1182/blood-2006-08-044347
   Olson EN, 2006, SCIENCE, V313, P1922, DOI 10.1126/science.1132292
   OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903
   Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2
   Prima V, 2005, LEUKEMIA, V19, P806, DOI 10.1038/sj.leu.2403684
   Przybylski GK, 2006, HAEMATOLOGICA, V91, P317
   Quentmeier H, 1998, LEUKEMIA, V12, P1603, DOI 10.1038/sj.leu.2401170
   Real PJ, 2004, CANCER RES, V64, P7947, DOI 10.1158/0008-5472.CAN-04-0945
   Ryan KM, 2007, DEV BIOL, V302, P694, DOI 10.1016/j.ydbio.2006.10.025
   Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904
   Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900
   Speleman F, 2005, LEUKEMIA, V19, P358, DOI 10.1038/sj.leu.2403657
   Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107
   Strizzi L, 2005, ONCOGENE, V24, P5731, DOI 10.1038/sj.onc.1208918
   Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3
   Verzi MP, 2007, DEV CELL, V12, P645, DOI 10.1016/j.devcel.2007.03.007
   von Both I, 2004, DEV CELL, V7, P331, DOI 10.1016/j.devcel.2004.07.023
   Watt PM, 2000, GENE CHROMOSOME CANC, V29, P371, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1050>3.0.CO;2-Y
   Williams O, 2001, TRENDS IMMUNOL, V22, P107, DOI 10.1016/S1471-4906(00)01797-X
   Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9
   Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200
   Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323
   Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790
   Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8
   Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x
   Zhao M, 1999, MOL CELL BIOL, V19, P21
NR 70
TC 39
Z9 42
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD MAR
PY 2008
VL 22
IS 3
BP 600
EP 607
DI 10.1038/sj.leu.2405067
PG 8
WC Oncology; Hematology
SC Oncology; Hematology
GA 273UP
UT WOS:000253957500018
PM 18079734
OA Bronze
DA 2020-08-12
ER

PT J
AU Muller, AMS
   Geibel, A
   Neumann, HPH
   Kuhnemund, A
   Schmitt-Graff, A
   Bohm, J
   Engelhardt, M
AF Mueller, Antonia M. S.
   Geibel, Annette
   Neumann, Hartmut P. H.
   Kuehnemund, Alexander
   Schmitt-Graeff, Annette
   Boehm, Joachim
   Engelhardt, Monika
TI Primary (AL) amyloidosis in plasma cell disorders
SO ONCOLOGIST
LA English
DT Article
DE AL amyloidosis; proliferative plasma cell disorder; light chain multiple
   myeloma
ID PRIMARY SYSTEMIC AMYLOIDOSIS; BRAIN NATRIURETIC PEPTIDE; LIGHT-CHAIN
   MEASUREMENTS; MULTIPLE-MYELOMA; CHROMOSOMAL-ABNORMALITIES; CARDIAC
   TROPONINS; SERUM; FEATURES; DELETION; 14Q32
AB Primary (AL) amyloidosis is the most common form of systemic amyloidosis. The morbidity arises from extracellular deposition of immunoglobulin light chain (LC) fibrils in major organs, such as the kidneys, heart, and bowel. Organ dysfunction contributes to a high mortality and poor prognosis, with a median survival time of 1-2 years from diagnosis. Here, we present a 46-year-old man with an exceptional clinical course of an LC multiple myeloma with generalized amyloidosis, causing renal insufficiency, congestive heart failure, and complete intestinal necrosis. We have summarized recent knowledge on AL amyloidosis, its association with monoclonal gammopathies, clinical presentations, diagnostic tools, and treatment strategies. Our comprehensive overview of this rare and often fatal disease aims to increase the awareness of AL amyloidosis. This may facilitate earlier diagnosis, and thus allow initiation of prompt and specific therapies, which are indispensable in order to improve disease prognosis.
C1 Univ Freiburg, Med Ctr, Dept Hematol Oncol, D-79106 Freiburg, Germany.
   Univ Freiburg, Med Ctr, Dept Cardiol Angiol, D-79106 Freiburg, Germany.
   Univ Freiburg, Med Ctr, Dept Nephrol, D-79106 Freiburg, Germany.
   Univ Freiburg, Med Ctr, Dept Pathol, D-79106 Freiburg, Germany.
RP Engelhardt, M (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.
EM monika.engelhardt@uniklinik-freiburg.de
CR Abraham RS, 2005, BLOOD, V105, P794, DOI 10.1182/blood-2004-04-1424
   Abraham RS, 2003, BLOOD, V101, P3801, DOI 10.1182/blood-2002-09-2707
   Avet-Loiseau H, 2002, BLOOD, V99, P2185, DOI 10.1182/blood.V99.6.2185
   Barosi G, 2004, HAEMATOLOGICA, V89, P717
   Bourne PC, 2002, ACTA CRYSTALLOGR D, V58, P815, DOI 10.1107/S0907444902004183
   Bradwell AR, 2005, CLIN CHEM, V51, P805, DOI 10.1373/clinchem.2005.048017
   Bradwell AR, 2001, CLIN CHEM, V47, P673
   Bradwell AR, 2003, LANCET, V361, P489, DOI 10.1016/S0140-6736(03)12457-9
   BUXBAUM JN, 1990, ANN INTERN MED, V112, P455, DOI 10.7326/0003-4819-76-3-112-6-455
   Chang SS, 2001, J CLIN GASTROENTEROL, V32, P161, DOI 10.1097/00004836-200102000-00015
   Cohen AD, 2005, BLOOD, V106, p340A
   Dispenzieri A, 2004, BLOOD, V104, P1881, DOI 10.1182/blood-2004-01-0390
   Dispenzieri A, 2004, J CLIN ONCOL, V22, P3751, DOI 10.1200/JCO.2004.03.029
   Drayson M, 2001, BLOOD, V97, P2900, DOI 10.1182/blood.V97.9.2900
   Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306
   Gafumbegete E, 2004, VIRCHOWS ARCH, V445, P531, DOI 10.1007/s00428-004-1084-3
   GERTZ MA, 1992, ARCH INTERN MED, V152, P2245, DOI 10.1001/archinte.152.11.2245
   Harrison CJ, 2002, BRIT J HAEMATOL, V117, P427, DOI 10.1046/j.1365-2141.2002.03438.x
   Kaufmann H, 2003, EUR J HAEMATOL, V71, P179, DOI 10.1034/j.1600-0609.2003.00111.x
   Koyama J, 2003, CIRCULATION, V107, P2446, DOI 10.1161/01.CIR.0000068313.67758.4F
   Kroger N, 2004, BLOOD, V103, P4056, DOI 10.1182/blood-2003-12-4435
   Kumar S, 2001, BONE MARROW TRANSPL, V28, P381, DOI 10.1038/sj.bmt.1703155
   Kurusu A, 2004, NEPHROLOGY, V9, P122, DOI 10.1111/j.1440-1797.2004.00246.x
   KYLE RA, 1995, SEMIN HEMATOL, V32, P45
   Kyle RA, 1999, BLOOD, V93, P1062, DOI 10.1182/blood.V93.3.1062.403k34_1062_1066
   Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
   Lachmann HJ, 2003, BRIT J HAEMATOL, V122, P78, DOI 10.1046/j.1365-2141.2003.04433.x
   Lacy MQ, 2004, HEMATOLOGIC MALIGNANCIES: MULTIPLE MYELOMA AND RELATED PLASMA CELL DISORDERS, P257
   Mead GP, 2004, BRIT J HAEMATOL, V126, P348, DOI 10.1111/j.1365-2141.2004.05045.x
   Ng SB, 2002, J CLIN PATHOL, V55, P876, DOI 10.1136/jcp.55.11.876
   Rajkumar SV, 1998, CANCER-AM CANCER SOC, V82, P1501, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1501::AID-CNCR11>3.0.CO;2-8
   Swan N, 2003, AM J CLIN PATHOL, V120, P610, DOI 10.1309/PFUGHBX0TY20E08U
NR 32
TC 23
Z9 25
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JUL-AUG
PY 2006
VL 11
IS 7
BP 824
EP 830
DI 10.1634/theoncologist.11-7-824
PG 7
WC Oncology
SC Oncology
GA 070OQ
UT WOS:000239532800012
PM 16880241
DA 2020-08-12
ER

PT J
AU Greenwood, TA
   Rao, FW
   Stridsberg, M
   Mahapatra, NR
   Mahata, M
   Lillie, EO
   Mahata, SK
   Taupenot, L
   Schork, NJ
   O'Connor, DT
AF Greenwood, Tiffany A.
   Rao, Fangwen
   Stridsberg, Mats
   Mahapatra, Nitish R.
   Mahata, Manjula
   Lillie, Elizabeth O.
   Mahata, Sushil K.
   Taupenot, Laurent
   Schork, Nicholas J.
   O'Connor, Daniel T.
TI Pleiotropic effects of novel trans-acting loci influencing human
   sympathochromaffin secretion
SO PHYSIOLOGICAL GENOMICS
LA English
DT Article
DE exocytosis; chromaffin
ID INHIBITORY PEPTIDE CATESTATIN; REGION-SPECIFIC RADIOIMMUNOASSAYS; B
   SECRETOGRANIN-I; QUANTITATIVE-TRAIT LOCI; CHROMOGRANIN-A; CATECHOLAMINE
   RELEASE; LINKAGE ANALYSIS; PHEOCHROMOCYTOMA CELLS; GENETIC-HYPERTENSION;
   GENERAL PEDIGREES
AB Family studies have suggested a genetic contribution to variation in blood pressure, but the genes responsible have thus far eluded identification. The use of intermediate phenotypes associated with hypertension, such as chromogranin plasma concentrations, may assist the discovery of hypertension-predisposing loci. We measured the concentrations of four chromogranin A (CHGA) and B (CHGB) peptides in 742 individuals from 235 nuclear families. The CHGA- and CHGB-derived peptides displayed significant heritability and revealed significant genetic correlations, most strikingly observed between CHGA(361-372) (catestatin) and CHGB(439 -451). A 5-cM microsatellite genome scan revealed significant and suggestive evidence for linkage on several chromosomes for three of the peptides. Subsequent bivariate linkage analysis for peptides CHGA(361-372) and CHGB(439-451), which showed evidence for convergent linkage peaks on chromosomes 2, 7, and 13, resulted in increased evidence for linkage to these regions, suggesting pleiotropic effects of these three loci on multiple chromogranin traits. Because CHGA itself is on chromosome 14q32, and CHGB itself is on chromosome 20pter-p12, the pleiotropic regions on chromosomes 2, 7, and 13 must represent trans-acting quantitative trait loci coordinately affecting CHGA/CHGB biosynthesis and/or exocytotic secretion, likely by regulating efferent sympathetic outflow, a conclusion consistent with the in vitro studies presented here of the dual control of both exocytosis and transcription of these peptides by secretory stimuli in chromaffin cells. The results suggest a new approach to heritable autonomic control of circulation and the genetic basis of cardiovascular diseases such as systemic hypertension.
C1 Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Ctr Human Genet & Genom, La Jolla, CA 92093 USA.
   Vet Affairs San Diego Healthcare Syst 0838, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Polymorphism Res Lab, La Jolla, CA 92093 USA.
   Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
   Univ Uppsala Hosp, Dept Med Sci, Uppsala, Sweden.
RP O'Connor, DT (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
EM nschork@ucsd.edu; doconnor@ucsd.edu
RI Greenwood, Tiffany A/F-6356-2012; Mahapatra, Nitish R/D-4123-2014
OI Greenwood, Tiffany A/0000-0002-6080-6503; Mahapatra, Nitish
   R/0000-0002-0695-3510; Taupenot, Laurent/0000-0003-2316-3825; Schork,
   Nicholas/0000-0003-0920-5013
FU NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [RR-00827, M01 RR000827, M01 RR000827-346233]; NHLBI
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [P01 HL058120-10, P01 HL058120-100004, P01
   HL058120-109006, P01 HL058120]
CR AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x
   Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Abecasis GR, 2001, BIOINFORMATICS, V17, P742, DOI 10.1093/bioinformatics/17.8.742
   Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844
   AMOS CI, 1994, AM J HUM GENET, V54, P535
   BANKS P, 1965, BIOCHEM J, V97, P40
   BARBOSA JA, 1991, ENDOCRINOLOGY, V128, P174, DOI 10.1210/endo-128-1-174
   BARGSTEN G, 1992, J HISTOCHEM CYTOCHEM, V40, P1147, DOI 10.1177/40.8.1352316
   BENJANNET S, 1987, FEBS LETT, V224, P142, DOI 10.1016/0014-5793(87)80438-6
   Cordell HJ, 2004, AM J HUM GENET, V74, P1294, DOI 10.1086/421476
   Drayna D, 2003, HUM GENET, V112, P567, DOI 10.1007/s00439-003-0911-y
   Eskeland NL, 1996, J CLIN INVEST, V98, P148, DOI 10.1172/JCI118760
   Falconer DS, 1996, INTRO QUANTITATIVE G
   FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461
   Feitosa MF, 2002, AM J HUM GENET, V70, P72, DOI 10.1086/338144
   FERRIER C, 1993, CLIN SCI, V84, P225, DOI 10.1042/cs0840225
   Franke D, 2005, AM J HUM GENET, V77, P230, DOI 10.1086/432378
   Fries RS, 2004, HYPERTENSION, V43, P1301, DOI 10.1161/01.HYP.0000127708.96195.E6
   Friese RS, 2005, AM J HYPERTENS, V18, P633, DOI 10.1016/j.amjhyper.2004.11.037
   GILL BM, 1991, REGUL PEPTIDES, V33, P223, DOI 10.1016/0167-0115(91)90216-4
   GORR SU, 1989, AM J PHYSIOL, V257, P247
   Greenwood TA, 2004, PHYSIOL GENOMICS, V18, P119, DOI 10.1152/physiolgenomics.00104.2003
   Hall MA, 2002, AM J HUM GENET, V70, P1172, DOI 10.1086/340090
   HELLE KB, 1966, MOL PHARMACOL, V2, P298
   IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N
   JUDY WV, 1979, HYPERTENSION, V1, P598, DOI 10.1161/01.HYP.1.6.598
   Kailasam M T, 1996, Ethn Health, V1, P117
   Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7
   Kroesen S, 1996, EUR J NEUROSCI, V8, P2679, DOI 10.1111/j.1460-9568.1996.tb01563.x
   LEE RWH, 1983, J BIOL CHEM, V258, P1326
   Mahapatra NR, 2000, ENDOCRINOLOGY, V141, P3668, DOI 10.1210/en.141.10.3668
   Mahapatra NR, 2005, J CLIN INVEST, V115, P1942, DOI 10.1172/JCI24354
   Mahata SK, 2004, MOL PHARMACOL, V66, P1180, DOI 10.1124/mol.104.002139
   Mahata SK, 1996, GENOMICS, V33, P135, DOI 10.1006/geno.1996.0171
   Mahata SK, 1999, J BIOL CHEM, V274, P2920, DOI 10.1074/jbc.274.5.2920
   Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686
   Malhotra A, 2005, J HUM GENET, V50, P69, DOI 10.1007/s10038-004-0222-8
   Metz-Boutigue MH, 1998, CELL MOL NEUROBIOL, V18, P249, DOI 10.1023/A:1022573004910
   Natori S, 1996, P NATL ACAD SCI USA, V93, P4431, DOI 10.1073/pnas.93.9.4431
   O'Connor D T, 2000, Curr Hypertens Rep, V2, P16, DOI 10.1007/s11906-000-0053-8
   O'Connor DT, 2005, J CLIN ENDOCR METAB, V90, P5414, DOI 10.1210/jc.2005-0408
   O'Connor DT, 1999, BLOOD PRESSURE, V8, P285, DOI 10.1080/080370599439508
   O'Connor DT, 2002, J HYPERTENS, V20, P1335, DOI 10.1097/00004872-200207000-00020
   O'Connor DT, 1985, HYPERTENSION S1, V7, pI76
   Portela-Gomes GM, 2002, ANN NY ACAD SCI, V971, P341, DOI 10.1111/j.1749-6632.2002.tb04491.x
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   SCHOBER M, 1989, HYPERTENSION, V13, P469, DOI 10.1161/01.HYP.13.5.469
   SCHORK NJ, 1993, AM J HUM GENET, V53, P1306
   Schork NJ, 2004, AM J HUM GENET, V75, P723, DOI 10.1086/424758
   Schork NJ, 2004, AM J HUM GENET, V74, P306, DOI 10.1086/381714
   SCHORK NJ, 1993, BIOMETRICAL J, V35, P387, DOI 10.1002/bimj.4710350402
   Sham PC, 2002, AM J HUM GENET, V71, P238, DOI 10.1086/341560
   SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712
   Stridsberg M, 2000, J ENDOCRINOL, V165, P703, DOI 10.1677/joe.0.1650703
   Stridsberg M, 2005, REGUL PEPTIDES, V125, P193, DOI 10.1016/j.regpep.2004.08.027
   Stridsberg M, 2004, REGUL PEPTIDES, V117, P219, DOI 10.1016/j.regpep.2003.10.023
   Stridsberg M, 2000, ADV EXP MED BIOL, V482, P319
   STRIDSBERG M, 1995, J ENDOCRINOL, V144, P49, DOI 10.1677/joe.0.1440049
   STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x
   TAKIYYUDDIN MA, 1995, HYPERTENSION, V26, P213, DOI 10.1161/01.HYP.26.1.213
   TAKIYYUDDIN MA, 1990, HYPERTENSION, V15, P237, DOI 10.1161/01.HYP.15.3.237
   Tang KC, 1997, J CLIN INVEST, V100, P1180, DOI 10.1172/JCI119630
   Tang KC, 1996, J BIOL CHEM, V271, P28382, DOI 10.1074/jbc.271.45.28382
   TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0
   Taupenot L, 2000, REGUL PEPTIDES, V95, P9, DOI 10.1016/S0167-0115(00)00135-X
   Taupenot L, 1998, J CLIN INVEST, V101, P863, DOI 10.1172/JCI1129
   Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405
   Taupenot L, 1999, HYPERTENSION, V34, P1152, DOI 10.1161/01.HYP.34.5.1152
   Taylor CV, 2000, J BIOL CHEM, V275, P22905, DOI 10.1074/jbc.M001232200
   VIDEEN JS, 1992, J BIOL CHEM, V267, P3066
   WARD R, 1990, HYPERTENSION PATHOPH, P81
   WATKINSON A, 1992, REGUL PEPTIDES, V40, P51, DOI 10.1016/0167-0115(92)90083-7
   Wen G, 2004, AM J HUM GENET, V74, P197, DOI 10.1086/381399
   WESTERMANN R, 1988, FEBS LETT, V239, P203, DOI 10.1016/0014-5793(88)80917-7
   WHITE R, 1985, NATURE, V313, P101, DOI 10.1038/313101a0
   WU HJ, 1994, J CLIN INVEST, V94, P118, DOI 10.1172/JCI117297
   Yoo SH, 2002, ANN NY ACAD SCI, V971, P300, DOI 10.1111/j.1749-6632.2002.tb04484.x
   Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7
   YOO SH, 1991, J BIOL CHEM, V266, P7740
   Zhang L, 2004, PHYSIOL GENOMICS, V19, P277, DOI 10.1152/physiolgenomics.00151.2004
NR 81
TC 16
Z9 17
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1094-8341
EI 1531-2267
J9 PHYSIOL GENOMICS
JI Physiol. Genomics
PD MAY 16
PY 2006
VL 25
IS 3
BP 470
EP 479
DI 10.1152/physiolgenomics.00295.2005
PG 10
WC Cell Biology; Genetics & Heredity; Physiology
SC Cell Biology; Genetics & Heredity; Physiology
GA 054KN
UT WOS:000238375600012
PM 16554546
DA 2020-08-12
ER

PT J
AU Jin, F
   Dai, JF
   Ji, CN
   Gu, SH
   Wu, MQ
   Qian, J
   Xie, Y
   Mao, YM
AF Jin, F
   Dai, JF
   Ji, CN
   Gu, SH
   Wu, MQ
   Qian, J
   Xie, Y
   Mao, YM
TI A novel human gene (WDR25) encoding a 7-WD40-containing protein maps on
   14q32
SO BIOCHEMICAL GENETICS
LA English
DT Article
DE WDR25; WD40 repeat; RT-PCR
ID BETA-SUBUNIT; MOLECULAR-CLONING; WD-REPEAT; YEAST; CONSERVATION;
   ASSOCIATION; HOMOLOG
AB Members of the large family of WD-repeat proteins are involved in diverse functions such as RNA-procession, signal transduction, vesicular trafficking, cytoskeletal assembly, and cell cycle control. By large-scale-sequencing analysis of a human fetal brain cDNA library, we isolated a novel human cDNA encoding a 7-WD40-repeat protein. This cDNA is 2004 bp in length and it codes for a 544-amino-acid protein. We term it human WD40-repeat-containing gene 25 (WDR25) and this gene shows significant similarity with human pre-mRNA splicing factor 17. The WDR25 gene is mapped to chromosome 14q32 and contains seven exons. RT-PCR analysis shows that the WDR25 gene is widely expressed in human tissues and the expression levers in heart, muscle, testis, ovary, uterus, and prostate are relatively high.
C1 Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
RP Mao, YM (corresponding author), Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
EM ymmao@fudan.edu.cn
CR Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3
   GRIGORIEVA G, 1982, FEMS MICROBIOL LETT, V13, P367, DOI 10.1111/j.1574-6968.1982.tb08289.x
   HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C
   HU J, 1994, NUCLEIC ACIDS RES, V22, P1727
   KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4
   Li QZ, 2001, GENE, V273, P275, DOI 10.1016/S0378-1119(01)00582-0
   Lindsey LA, 1998, J BIOL CHEM, V273, P32771, DOI 10.1074/jbc.273.49.32771
   NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0
   NEER EJ, 1993, NAT GENET, V5, P3, DOI 10.1038/ng0993-3
   SIMON TP, 1995, SOUTHWEST NAT, V40, P208
   Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5
   TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471
   Terol J, 2000, GENE, V260, P45, DOI 10.1016/S0378-1119(00)00446-7
   WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144
   WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223
   YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341
   Zhou ZL, 1998, EMBO J, V17, P2095, DOI 10.1093/emboj/17.7.2095
NR 17
TC 2
Z9 3
U1 0
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0006-2928
EI 1573-4927
J9 BIOCHEM GENET
JI Biochem. Genet.
PD DEC
PY 2004
VL 42
IS 11-12
BP 419
EP 427
DI 10.1023/B:BIGI.0000043954.64202.61
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 860EJ
UT WOS:000224325000004
PM 15587985
DA 2020-08-12
ER

PT J
AU Mukhopadhyay, N
   Weeks, DE
AF Mukhopadhyay, N
   Weeks, DE
TI Linkage analysis of adult height with parent-of-origin effects in the
   Framingham Heart Study
SO BMC GENETICS
LA English
DT Article; Proceedings Paper
CT 13th Genetic Analysis Workshop
CY NOV 11-14, 2002
CL NEW ORLEANS, LA
ID PEDIGREE ANALYSIS; STATURE; INHERITANCE; HERITABILITY; FAMILIES; REGIONS
AB Current linkage analysis methods for quantitative traits do not usually incorporate imprinting effects. Here, we carried out genome- wide linkage analysis for loci influencing adult height in the Framingham Heart Study subjects using variance components while allowing for imprinting effects. We used a sex-averaged map for the 22 autosomes, while chromosomes 6, 14, 18, and 19 were also analyzed using sex-specific maps. We compared results from these four analyses: 1) nonimprinted with sex-averaged maps, 2) imprinted with sex-averaged maps, 3) non-imprinted with sex-specific maps, and 4) imprinted with sex-specific maps. We found four regions on three chromosomes (14q32, 18p11-q21, 18q21-22, and 19q13) with LOD scores above 2.0, with a maximum LOD score of 3.12, allowing for imprinting and sex-specific maps, at D18S1364 on 18q21. While we obtained significant evidence of imprinting effects in both the 18p11- q21 and 19q13 regions when using sex-averaged maps, there were no significant differences between the imprinted and non-imprinted LOD scores when we used sex-specific maps. Our results illustrate the importance of allowing for gender-specific effects in linkage analyses, whether these are in the form of gender-specific recombination frequencies, or in the form of imprinting effects.
C1 Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
RP Weeks, DE (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
EM nandita@pitt.edu; weeks@pitt.edu
RI Weeks, Daniel E/B-2995-2012
OI Weeks, Daniel E/0000-0001-9410-7228
FU NIMH NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [9R01MH064205-04, R01 MH064205]
CR Daw EW, 2000, GENET EPIDEMIOL, V19, P366, DOI 10.1002/1098-2272(200012)19:4<366::AID-GEPI8>3.0.CO;2-F
   DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279
   Deng HW, 2002, AM J MED GENET, V113, P29, DOI 10.1002/ajmg.10742
   Hanson RL, 2001, AM J HUM GENET, V68, P951, DOI 10.1086/319508
   Hirschhorn JN, 2001, AM J HUM GENET, V69, P106, DOI 10.1086/321287
   KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813
   KAUR DP, 1981, ANN HUM BIOL, V8, P333, DOI 10.1080/03014468100005131
   LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611
   Lindsay RS, 2002, HUM GENET, V110, P503, DOI 10.1007/s00439-002-0718-2
   Lindsay RS, 2001, DIABETES, V50, P2850, DOI 10.2337/diabetes.50.12.2850
   Pearson K, 1902, BIOMETRIKA, V2, P357
   Perola M, 2001, AM J HUM GENET, V69, P117, DOI 10.1086/321286
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   ROBERTS DF, 1978, ANN HUM GENET, V42, P15, DOI 10.1111/j.1469-1809.1978.tb00928.x
   Shete S, 2002, AM J HUM GENET, V70, P751, DOI 10.1086/338931
   Sobel E, 2001, HUM HERED, V52, P121, DOI 10.1159/000053366
   Sobel E, 1996, AM J HUM GENET, V58, P1323
   SOLOMON PJ, 1983, ANN HUM BIOL, V10, P247, DOI 10.1080/03014468300006411
   Spencer HG, 2002, GENETICS, V161, P411
   Strichman-Almashanu LZ, 2002, GENOME RES, V12, P543, DOI 10.1101/gr.224102
   THOMPSON DB, 1995, AM J MED GENET, V59, P495, DOI 10.1002/ajmg.1320590417
   Wiltshire S, 2002, AM J HUM GENET, V70, P543, DOI 10.1086/338760
   Xu JF, 2002, AM J HUM GENET, V71, P646, DOI 10.1086/342216
NR 23
TC 16
Z9 16
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2156
J9 BMC GENET
JI BMC Genet.
PD DEC 31
PY 2003
VL 4
SU 1
AR S76
DI 10.1186/1471-2156-4-S1-S76
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 765ZL
UT WOS:000188320900076
PM 14975144
OA DOAJ Gold, Green Published
DA 2020-08-12
ER

PT J
AU Nagel, S
   Kaufmann, M
   Drexler, HG
   MacLeod, RAF
AF Nagel, S
   Kaufmann, M
   Drexler, HG
   MacLeod, RAF
TI The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with
   BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2)
SO CANCER RESEARCH
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; MOLECULAR-CLONING; HEART; HOX11L2;
   T(5/14)(Q35,Q32); IDENTIFICATION; TRANSLOCATION; EXPRESSION; SURVIVAL;
   SPLEEN
AB A cryptic chromosome rearrangement, t(5;14)(q35.1;q32.2), recently identified in pediatric acute lymphoblastic leukemia (ALL), targets activation of TLX3 at 5q35.1 by juxtaposition with a region downstream of BCL11B at 14q32.2. We describe a novel variant t(5;14) whereby NKX2-5, a related (NK-like family) homeobox gene located similar to2 Mb telomeric of TLX3, juxtaposes BCL11B in a subset of T-cell ALL cell lines. In this t(5;14) variant, NKX2-5 is expressed instead of TLX3 at both RNA and protein levels. Subsequent expression screening failed to detect involvement of additional NK-like genes in T-cell ALL cells. Our data pinpoint a regulatory region far downstream of BCL11B effecting ectopic homeobox gene activation. This study also identifies in vitro models for both t(5;14) variants and raises questions about diagnostic fluorescence in situ hybridization/reverse transcription-PCR screening in ALL.
C1 DSMZ, Dept Human & Anim Cell Cultures, D-38124 Braunschweig, Germany.
RP MacLeod, RAF (corresponding author), DSMZ, Dept Human & Anim Cell Cultures, Mascheroder Weg 1B, D-38124 Braunschweig, Germany.
CR Ballerini P, 2002, BLOOD, V100, P991, DOI 10.1182/blood-2001-11-0093
   Bernard OA, 2001, LEUKEMIA, V15, P1495, DOI 10.1038/sj.leu.2402249
   BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X
   Brake RL, 1998, ONCOGENE, V17, P1787, DOI 10.1038/sj.onc.1202078
   DEAR TN, 1995, DEVELOPMENT, V121, P2909
   Drexler H.G., 2001, LEUKEMIA LYMPHOMA CE
   Drexler HG, 2003, LEUKEMIA, V17, P416, DOI 10.1038/sj.leu.2402799
   Hansen-Hagge TE, 2002, LEUKEMIA, V16, P2205, DOI 10.1038/sj.leu.2402671
   Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212
   Helias C, 2002, LEUKEMIA, V16, P7, DOI 10.1038/sj.leu.2402347
   Holland PWH, 2001, J ANAT, V199, P13
   Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V250, P252, DOI 10.1006/bbrc.1998.9300
   Kasahara H, 1999, MOL CELL BIOL, V19, P526
   KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716
   Lindeskog M, 1997, J GEN VIROL, V78, P2575, DOI 10.1099/0022-1317-78-10-2575
   LINTS TJ, 1993, DEVELOPMENT, V119, P419
   Lopez-Borges S, 2000, ONCOGENE, V19, P3656, DOI 10.1038/sj.onc.1203709
   MacLeod RAF, 2003, GENE CHROMOSOME CANC, V37, P84, DOI 10.1002/gcc.10194
   MACLEOD RAF, 2003, CANC CELL CULTURE ME
   Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588
   Reecy JM, 1999, DEVELOPMENT, V126, P839
   ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0
   Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413
   Shiojima I, 1996, CIRC RES, V79, P920, DOI 10.1161/01.RES.79.5.920
   Toko H, 2002, J BIOL CHEM, V277, P24735, DOI 10.1074/jbc.M107669200
NR 25
TC 92
Z9 95
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2003
VL 63
IS 17
BP 5329
EP 5334
PG 6
WC Oncology
SC Oncology
GA 722XD
UT WOS:000185402600025
PM 14500364
DA 2020-08-12
ER

PT J
AU Shaughnessy, J
AF Shaughnessy, J
TI Primer on medical genomics - Part IX: Scientific and clinical
   applications of DNA microarrays - Multiple myeloma as a disease model
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; GROWTH-FACTOR-I; GLOBAL GENE-EXPRESSION;
   UNDETERMINED SIGNIFICANCE; CHROMOSOME-13 DELETION; MONOCLONAL
   GAMMOPATHY; DOWN-REGULATION; PLASMA-CELLS; LONG-TERM; PREDICTION
AB Multiple myeloma (MM) is a poorly understood and uniformly fatal malignancy of antibody-secreting plasma cells. Although several key molecular events in disease initiation or progression have been confirmed (eg, 14q32 translocations) or implicated (eg, chromosome 13 deletion), a unifying mechanism of myelomagenesis has eluded investigators. Furthermore, although MM is generally indistinguishable morphologically, it exhibits a tremendous degree of variability clinically with some patients surviving only months and others many years, suggesting that MM is composed of distinct clinical entities. Given that abnormal gene expression lies at the heart of most, if not all, cancers, high-throughput global gene expression profiling has become a powerful tool for investigating the molecular biology and clinical behavior of cancer. DNA microarray technology has facilitated the simultaneous quantification of thousands of cellular messenger RNAs (ie, gene expression). This review discusses progress made in the development of molecular-based diagnostics and prognostics for MM through the dissection of the transcriptome of plasma cells from healthy individuals and patients with MM and other plasma cell dyscrasias.
C1 Univ Arkansas Med Sci, Dept Med, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA.
RP Shaughnessy, J (corresponding author), Univ Arkansas Med Sci, Dept Med, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA.
CR Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   BARLOGIE B, 2001, WILLIAMS HEMATOLOGY, P1279
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   DeRisi J, 1996, NAT GENET, V14, P457
   Flactif M, 1995, LEUKEMIA, V9, P2109
   FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438
   Ge NL, 2000, BLOOD, V96, P2856
   GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340
   Gruber SB, 2002, SCIENCE, V297, P2013, DOI 10.1126/science.1074399
   Jacobson J, 2002, BLOOD, V100, p316A
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   Kyle RA, 2002, NEW ENGL J MED, V346, P564, DOI 10.1056/NEJMoa01133202
   LATREILLE J, 1980, BLOOD, V55, P403
   Lin H, 2002, INT J CANCER, V97, P121, DOI 10.1002/ijc.1570
   Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447
   Mabuchi H, 2001, CANCER RES, V61, P2870
   McSweeney PA, 1996, BLOOD, V88, P622, DOI 10.1182/blood.V88.2.622.bloodjournal882622
   Medina F, 2002, BLOOD, V99, P2154, DOI 10.1182/blood.V99.6.2154
   Mertens D, 2002, BLOOD, V99, P4116, DOI 10.1182/blood.V99.11.4116
   Migliazza A, 2001, BLOOD, V97, P2098, DOI 10.1182/blood.V97.7.2098
   MUNSHI NC, 2001, CANC PRINCIPLES PRAC, P2465
   Qiang YW, 2002, BLOOD, V99, P4138, DOI 10.1182/blood.V99.11.4138
   SanMiguel JF, 1995, BAILLIERE CLIN HAEM, V8, P735, DOI 10.1016/S0950-3536(05)80257-4
   Santra M, 2003, BLOOD, V101, P2374, DOI 10.1182/blood-2002-09-2801
   Shaughnessy J, 2000, BLOOD, V96, P1505, DOI 10.1182/blood.V96.4.1505.h8001505_1505_1511
   Shaughnessy J, 2002, BLOOD, V100, p390A
   Shaughnessy J, 2003, BLOOD, V101, P3849, DOI 10.1182/blood-2002-09-2873
   Shaughnessy J, 2003, BRIT J HAEMATOL, V120, P44, DOI 10.1046/j.1365-2141.2003.03948.x
   Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217
   Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68
   Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2
   Standal T, 2002, BLOOD, V100, P3925, DOI 10.1182/blood-2002-05-1406
   Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122
   Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6
   Zhan FH, 2002, BLOOD, V100, p307A
   Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737
   Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745
NR 41
TC 12
Z9 12
U1 0
U2 3
PU MAYO CLINIC PROCEEDINGS
PI ROCHESTER
PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA
SN 0025-6196
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD SEP
PY 2003
VL 78
IS 9
BP 1098
EP 1109
DI 10.4065/78.9.1098
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 717HZ
UT WOS:000185084200007
PM 12962165
DA 2020-08-12
ER

PT J
AU Sutton, VR
   Coveler, KJ
   Lalani, SR
   Kashork, CD
   Shaffer, LG
AF Sutton, VR
   Coveler, KJ
   Lalani, SR
   Kashork, CD
   Shaffer, LG
TI Subtelomeric FISH uncovers trisomy 14q32: Lessons for imprinted regions,
   cryptic rearrangements and variant acrocentric short arms
SO AMERICAN JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE uniparental disomy; imprinting; trisomy 14q; chromosome 14; chromosome
   22; telomere; telomere FISH; acrocentric chromosome; p-arm variant;
   MEG3; DLK1
ID MATERNAL UNIPARENTAL DISOMY; INTRAUTERINE GROWTH-RETARDATION; IDIOPATHIC
   MENTAL-RETARDATION; CHROMOSOMAL REARRANGEMENTS; ISODISOMY; DELETIONS;
   PHENOTYPE; TELOMERES; DIAGNOSIS; CHILDREN
AB The recent development of a set of chromosome-specific, subtelomeric probes has proved useful in diagnosis and recurrence risk counseling of patients and families with mental retardation and in further characterization of known chromosomal abnormalities. Cases of cryptic, subtelomeric rearrangements may account for up to 7.5% of cases of idiopathic moderate-severe mental retardation. We present the molecular cytogenetic studies of trisomy 14q detected by subtelomeric fluorescence in situ hybridization (FISH). Our patient is a 3-year-old girl with growth and developmental delay, myelomeningocele, partial agenesis of the corpus callosum, hypertelorism, tented mouth, simple ears, small mandible, and congenital heart disease (atrial and ventricular septal defects with subaortic conus). G-banded chromosome analysis was apparently normal. A set of FISH-based, subtelomeric, region-specific probes revealed trisomy for 14q in the child. Parental FISH studies established that the mother is a balanced carrier for a half-cryptic translocation between the distal long arm of chromosome 14 and the short arm of chromosome 22. FISH analysis using two BAC clones that contain the imprinted genes MEG3 and DLK1, which localize to 14q32, established that our patient has two maternal. copies of these genes. Because the child does not have features of the maternal UPD 14 syndrome, this case suggests that it is absence of expression of a paternally expressed gene, rather than overexpression of a maternally expressed gene, that is responsible for the maternal UPD 14 phenotype. (C) 2002 Wiley-Liss, Inc.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
RP Sutton, VR (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Pl,BCM-225, Houston, TX 77030 USA.
RI Lalani, Seema/AAI-5090-2020
FU NICHD NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R03 HD38433, K23
   HD40843-01]
CR ANTONARAKIS SE, 1993, AM J HUM GENET, V52, P1145
   Ballif BC, 2000, EUR J HUM GENET, V8, P764, DOI 10.1038/sj.ejhg.5200536
   Ballif BC, 2000, AM J HUM GENET, V67, P1356
   Benzacken B, 2001, PRENATAL DIAG, V21, P96, DOI 10.1002/1097-0223(200102)21:2<96::AID-PD986>3.0.CO;2-O
   Berends MJW, 1999, AM J MED GENET, V84, P76, DOI 10.1002/(SICI)1096-8628(19990507)84:1<76::AID-AJMG16>3.0.CO;2-F
   Coviello D. A., 1996, Acta Geneticae Medicae et Gemellologiae, V45, P169
   ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207
   Engelen JJM, 2001, AM J MED GENET, V99, P48, DOI 10.1002/1096-8628(20010215)99:1<48::AID-AJMG1128>3.0.CO;2-T
   FLINT J, 1995, NAT GENET, V9, P132, DOI 10.1038/ng0295-132
   Fokstuen S, 1999, J PEDIATR-US, V134, P689, DOI 10.1016/S0022-3476(99)70282-9
   Georgiades P, 1998, J MED GENET, V35, P821, DOI 10.1136/jmg.35.10.821
   HEALEY S, 1994, AM J MED GENET, V51, P147, DOI 10.1002/ajmg.1320510213
   Hordijk R, 1999, J MED GENET, V36, P782, DOI 10.1136/jmg.36.10.782
   Knight SJL, 1999, LANCET, V354, P1676, DOI 10.1016/S0140-6736(99)03070-6
   Knight SJL, 1997, EUR J HUM GENET, V5, P1
   Kotzot D, 1999, AM J MED GENET, V82, P265, DOI 10.1002/(SICI)1096-8628(19990129)82:3<265::AID-AJMG14>3.0.CO;2-6
   LEDBETTER DH, 1995, HUM MOL GENET, V4, P1757, DOI 10.1093/hmg/4.suppl_1.1757
   Miyoshi N, 2000, GENES CELLS, V5, P211, DOI 10.1046/j.1365-2443.2000.00320.x
   Miyoshi O, 1998, J HUM GENET, V43, P138, DOI 10.1007/s100380050056
   PAPENHAUSEN PR, 1995, AM J MED GENET, V59, P271, DOI 10.1002/ajmg.1320590302
   PENTAO L, 1992, AM J HUM GENET, V50, P690
   Sanlaville D, 2000, J MED GENET, V37, P525, DOI 10.1136/jmg.37.7.525
   Shaffer LG, 1998, AM J MED GENET, V79, P366, DOI 10.1002/(SICI)1096-8628(19981012)79:5<366::AID-AJMG7>3.0.CO;2-H
   Shaffer LG, 1997, AM J MED GENET, V69, P325, DOI 10.1002/(SICI)1096-8628(19970331)69:3<325::AID-AJMG20>3.0.CO;2-S
   Slavotinek A, 1999, J MED GENET, V36, P405
   Splitt MP, 1997, AM J MED GENET, V72, P239, DOI 10.1002/(SICI)1096-8628(19971017)72:2<239::AID-AJMG21>3.0.CO;2-N
   Sutton VR, 2000, AM J MED GENET, V93, P381, DOI 10.1002/1096-8628(20000828)93:5<381::AID-AJMG7>3.0.CO;2-9
   TEMPLE IK, 1991, J MED GENET, V28, P511, DOI 10.1136/jmg.28.8.511
   Tomkins DJ, 1996, EUR J HUM GENET, V4, P153
   WONG AC, 1997, AM J HUM GENET, V6, P113
   Wu YQ, 1999, HUM MOL GENET, V8, P313, DOI 10.1093/hmg/8.2.313
   Wylie AA, 2000, GENOME RES, V10, P1711, DOI 10.1101/gr.161600
NR 32
TC 18
Z9 19
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0148-7299
J9 AM J MED GENET
JI Am. J. Med. Genet.
PD SEP 15
PY 2002
VL 112
IS 1
BP 23
EP 27
DI 10.1002/ajmg.10703
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 588CW
UT WOS:000177684000005
PM 12239715
DA 2020-08-12
ER

PT J
AU Kelberman, D
   Tyson, J
   Chandler, DC
   McInerney, AM
   Slee, J
   Albert, D
   Aymat, A
   Botma, M
   Calvert, M
   Goldblatt, J
   Haan, EA
   Laing, NG
   Lim, J
   Malcolm, S
   Singer, SL
   Winter, RM
   Bitner-Glindzicz, M
AF Kelberman, D
   Tyson, J
   Chandler, DC
   McInerney, AM
   Slee, J
   Albert, D
   Aymat, A
   Botma, M
   Calvert, M
   Goldblatt, J
   Haan, EA
   Laing, NG
   Lim, J
   Malcolm, S
   Singer, SL
   Winter, RM
   Bitner-Glindzicz, M
TI Hemifacial microsomia: progress in understanding the genetic basis of a
   complex malformation syndrome
SO HUMAN GENETICS
LA English
DT Article
ID AUTOSOMAL-DOMINANT ANIRIDIA; T-CELL MALIGNANCIES; KLINEFELTER-SYNDROME;
   GOLDENHAR SYNDROME; GOOSECOID GENE; HUMAN GENOME; BODY-WALL;
   ABNORMALITIES; FAMILY; MUTATION
AB Hemifacial microsomia (HFM) is a common birth defect involving first and second branchial arch derivatives. The phenotype is extremely variable. In addition to craniofacial anomalies there may be cardiac, vertebral and central nervous system defects. The majority of cases are sporadic, but there is substantial evidence for genetic involvement in this condition, including rare familial cases that exhibit autosomal dominant inheritance. As an approach towards identifying molecular pathways involved in ear and facial development, we have ascertained both familial and sporadic cases of HFM. A genome wide search for linkage in two families with features of HFM was performed to identify the disease loci. In one family data were highly suggestive of linkage to a region of approximately 10.7 cM on chromosome 14q32, with a maximum multipoint lod score of 3.00 between microsatellite markers D14S987 and D14S65. This locus harbours the Goosecoid gene, an excellent candidate for HFM based on Mouse expression and phenotype data, Coding region mutations were sought in the familial cases and in 120 sporadic cases, and gross rearrangements of the gene were excluded by Southern blotting. Evidence for genetic heterogeneity is provided by the second family, in which linkage was excluded from this region.
C1 Inst Child Hlth, Clin & Mol Genet Unit, London WC1N 1EH, England.
   QE II Med Ctr, Australian Neuromuscular Res Inst, Nedlands, WA, Australia.
   Great Ormond St Hosp Sick Children, Maxillofacial & Dent Dept, London WC1N 3JH, England.
   Womens & Childrens Hosp, S Australian Clin Genet Serv, Adelaide, SA, Australia.
   Princess Margaret Hosp Children, Dept Dent, Subiaco, WA, Australia.
RP Bitner-Glindzicz, M (corresponding author), Inst Child Hlth, Clin & Mol Genet Unit, 30 Guilford St, London WC1N 1EH, England.
EM m.bitner-glindzicz@ich.ucl.ac.uk
RI Bitner-Glindzicz, Maria/A-4231-2009; McInerney-Leo, Aideen
   M/D-8302-2016; McInerney-Leo, Aideen M/E-1788-2018; Kelberman,
   Daniel/K-3411-2013
OI McInerney-Leo, Aideen M/0000-0002-0059-5732; Kelberman,
   Daniel/0000-0003-0583-5237; Laing, Nigel/0000-0001-5111-3732
CR Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157
   BLUM M, 1994, GENOMICS, V21, P388, DOI 10.1006/geno.1994.1281
   BURCK U, 1983, HUM GENET, V64, P291, DOI 10.1007/BF00279415
   BYTH BC, 1993, HUM MOL GENET, V2, P1752, DOI 10.1093/hmg/2.10.1752-a
   Castilla EE, 1999, AM J MED GENET, V86, P9, DOI 10.1002/(SICI)1096-8628(19990903)86:1<9::AID-AJMG3>3.0.CO;2-X
   Cousley RRJ, 1997, BRIT J PLAST SURG, V50, P536, DOI 10.1016/S0007-1226(97)91303-5
   Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744
   Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0
   Ewart-Toland A, 2000, AM J MED GENET, V90, P303, DOI 10.1002/(SICI)1096-8628(20000214)90:4<303::AID-AJMG8>3.3.CO;2-H
   FERRELL RE, 1980, P NATL ACAD SCI-BIOL, V77, P1580, DOI 10.1073/pnas.77.3.1580
   FERRELL RE, 1987, CYTOGENET CELL GENET, V46, P614
   Garavelli L, 1999, GENET COUNSEL, V10, P321
   GASTIER JM, 1995, HUM MOL GENET, V4, P1829, DOI 10.1093/hmg/4.10.1829
   GAUNT SJ, 1993, DEVELOPMENT, V117, P769
   Gorlin RJ, 1990, SYNDROMES HEAD NECK, P641
   GRAHAM JM, 1995, PEDIATR RES, V37, pA83
   GREENBERG F, 1988, AM J MED GENET S, V4, P170
   Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418
   Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095
   Hathout EH, 1998, AM J MED GENET, V76, P71, DOI 10.1002/(SICI)1096-8628(19980226)76:1<71::AID-AJMG13>3.0.CO;2-M
   HERMAN GE, 1988, AM J MED GENET, V29, P909, DOI 10.1002/ajmg.1320290423
   HODES ME, 1981, J CRAN GENET DEV BIO, V1, P49
   JURILOFF DM, 1987, J CRAN GENET DEV BIO, V7, P27
   Kleinjan DJ, 1998, HUM MOL GENET, V7, P1611, DOI 10.1093/hmg/7.10.1611
   KOBRYNSKI L, 1993, AM J MED GENET, V46, P68, DOI 10.1002/ajmg.1320460111
   KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0
   LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401
   LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177
   LYONS LA, 1992, GENOMICS, V13, P925, DOI 10.1016/0888-7543(92)90002-A
   Morton NE, 1998, AM J HUM GENET, V62, P690, DOI 10.1086/301741
   NAORA H, 1994, GENOMICS, V23, P515, DOI 10.1006/geno.1994.1537
   NEU KW, 1982, J CRAN GENET DEV BIO, V2, P295
   Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938
   OTT J, 1999, ANAL HUMAN GENETIC L
   Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949
   POONAWALLA HH, 1980, CLEFT PALATE J, V17, P194
   Poswillo D, 1975, Birth Defects Orig Artic Ser, V11, P61
   REGENBOGEN L, 1982, CLIN GENET, V21, P161
   RIVERAPEREZ JA, 1995, DEVELOPMENT, V121, P3005
   ROLLNICK BR, 1983, AM J MED GENET, V15, P233, DOI 10.1002/ajmg.1320150207
   RYAN CA, 1988, AM J MED GENET, V29, P755, DOI 10.1002/ajmg.1320290404
   Sensi A, 1996, CLIN GENET, V49, P300
   SINGER SL, 1994, AUST DENT J, V39, P287, DOI 10.1111/j.1834-7819.1994.tb05564.x
   SMITHELLS RW, 1992, J MED GENET, V29, P719
   SOLTAN HC, 1986, J PEDIATR-US, V108, P112, DOI 10.1016/S0022-3476(86)80783-1
   Stoll C, 1998, AM J MED GENET, V78, P345, DOI 10.1002/(SICI)1096-8628(19980724)78:4<345::AID-AJMG8>3.0.CO;2-K
   TOWNES PL, 1978, AM J DIS CHILD, V132, P498, DOI 10.1001/archpedi.1978.02120300058012
   Trumpp A, 1999, GENE DEV, V13, P3136, DOI 10.1101/gad.13.23.3136
   VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530
   WILSON GN, 1983, J CRAN GENET DEV BIO, V3, P313
   YAMADA G, 1995, DEVELOPMENT, V121, P2917
   Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0
NR 54
TC 80
Z9 89
U1 0
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD DEC
PY 2001
VL 109
IS 6
BP 638
EP 645
DI 10.1007/s00439-001-0626-x
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 510FD
UT WOS:000173197300009
PM 11810276
DA 2020-08-12
ER

PT J
AU Zhao, Y
   Yu, L
   Fu, Q
   Chen, WJ
   Jiang, JM
   Gao, J
   Zhao, SY
AF Zhao, Y
   Yu, L
   Fu, Q
   Chen, WJ
   Jiang, JM
   Gao, J
   Zhao, SY
TI Cloning and characterization of human DDX24 and mouse Ddx24 two novel
   putative DEAD-box proteins, and mapping DDX24 to human chromosome 14q32
SO GENOMICS
LA English
DT Article
ID INITIATION FACTOR-4A; RNA HELICASES; BINDING; FAMILY; VASA
AB DEAD-box proteins are a large group of putative RNA helicases that exist ubiquitously in organisms ranging from bacteria to humans. They are likely to play important roles in many different RNA metabolic processes. In this paper, we report the cloning of human DDX24, a putative DEAD-box protein, and its ortholog, Ddx24 in mouse. The deduced proteins encoded by these two cDNAs share 78.7% identity at the amino acid level and possess all the well-conserved motifs of DEAD-box proteins. However, little homology can be found between them and other DEAD-box proteins, even in their core? region (identity <40%). Northern blot analysis showed that a 3.0-kb transcript of human DDX24 exists ubiquitously in the 16 human tissues examined and was most abundant in heart and brain, but with lowest levels in thymus and small intestine. The mouse Ddx24, whose transcript is 4.0 kb, was also expressed widely in 10 tissues tested with the highest level in heart and testis, By radiation hybrid mapping, the human DDX24 gene was localized to human chromosome 14q32 between the markers D14S81 and D14S265. Moreover, the gene structure of DDX24 was determined by comparing its cDNA and genomic sequence from BAC R-1089B7, which showed that the gene spanned a 30-kb region and consisted of at least nine exons. (C) 2000 Academic Press.
C1 Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
RP Yu, L (corresponding author), Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, 220 Handan Rd, Shanghai 200433, Peoples R China.
CR de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6
   GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2
   HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4
   LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0
   Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233
   PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789
   PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x
   SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x
   WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x
NR 9
TC 12
Z9 17
U1 0
U2 3
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
J9 GENOMICS
JI Genomics
PD AUG 1
PY 2000
VL 67
IS 3
BP 351
EP 355
DI 10.1006/geno.2000.6255
PG 5
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 343ZF
UT WOS:000088732600012
PM 10936056
DA 2020-08-12
ER

PT J
AU Nakamura, T
   Ruiz-Lozano, P
   Lindner, V
   Yabe, D
   Taniwaki, M
   Furukawa, Y
   Kobuke, K
   Tashiro, K
   Lu, ZJ
   Andon, NL
   Schaub, R
   Matsumori, A
   Sasayama, S
   Chien, KR
   Honjo, T
AF Nakamura, T
   Ruiz-Lozano, P
   Lindner, V
   Yabe, D
   Taniwaki, M
   Furukawa, Y
   Kobuke, K
   Tashiro, K
   Lu, ZJ
   Andon, NL
   Schaub, R
   Matsumori, A
   Sasayama, S
   Chien, KR
   Honjo, T
TI DANCE, a novel secreted RGD protein expressed in developing,
   atherosclerotic, and balloon-injured arteries
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SIGNAL SEQUENCE TRAP; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR;
   EXTRACELLULAR-MATRIX; CALCIUM-BINDING; GENE; RECEPTOR; DOMAIN;
   LOCALIZATION; FIBULIN-1
AB We have identified and characterized mouse, rat, and human cDNAs that encode a novel secreted protein of 448 amino acids named DANCE (developmental arteries and neural crest epidermal growth factor (EGF)-like). DANCE contains six calcium-binding EGF-like domains, one of which includes an RGD motif. Overexpression studies of recombinant DANCE protein document that DANCE is a secreted 66-kDa protein. DANCE and recently described protein S1-5 comprise a new EGF-like protein family. The human DANCE gene was mapped at chromosome 14q32.1. DANCE mRNA is mainly expressed in heart, ovary, and colon in adult human tissues. Expression profile analysis by in situ hybridization revealed prominent DANCE expression in developing arteries. DANCE is also expressed in neural crest cell derivatives, endocardial cushion tissue, and several other mesenchymal tissues. In adult vessels, DANCE expression is largely diminished but is reinduced in balloon-injured vessels and atherosclerotic lesions, notably in intimal vascular smooth muscle cells and endothelial cells that lose their ability to proliferate in late stage of injury. DANCE protein was shown to promote adhesion of endothelial cells through interaction of integrins and the RGD motif of DANCE. DANCE is thus a novel vascular ligand for integrin receptors and may play a role in vascular development and remodeling.
C1 Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 606, Japan.
   Kyoto Univ, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 606, Japan.
   Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA.
   Maine Med Ctr, Res Inst, S Portland, ME 04106 USA.
   Kyoto Prefectural Univ Med, Dept Internal Med 3, Kamigyo Ku, Kyoto 602, Japan.
   Genet Inst Inc, Cambridge, MA 02140 USA.
RP Honjo, T (corresponding author), Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Yoshida Konoe Cho, Kyoto 606, Japan.
RI Yabe, Daisuke/J-6682-2014; Honjo, Tasuku/N-4470-2016
OI Yabe, Daisuke/0000-0002-5334-7687; 
CR Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244
   ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155
   CLOWES AW, 1983, LAB INVEST, V49, P208
   CORNHILL JF, 1976, ATHEROSCLEROSIS, V23, P489, DOI 10.1016/0021-9150(76)90009-5
   DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0
   GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431
   GIDDENS DP, 1993, J BIOMECH ENG-T ASME, V115, P588, DOI 10.1115/1.2895545
   HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Ikegawa S, 1996, GENOMICS, V35, P590, DOI 10.1006/geno.1996.0402
   ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179
   Jacobs KA, 1997, GENE, V198, P289, DOI 10.1016/S0378-1119(97)00330-2
   KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125
   KUROO M, 1991, J BIOL CHEM, V266, P3768
   Landry DB, 1997, AM J PATHOL, V151, P1085
   LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120
   LINDNER V, 1993, CIRC RES, V73, P589, DOI 10.1161/01.RES.73.3.589
   MARKWALD RR, 1977, AM J ANAT, V148, P85, DOI 10.1002/aja.1001480108
   MATTEI MG, 1994, GENOMICS, V22, P437, DOI 10.1006/geno.1994.1406
   NAKAMURA T, 1995, GENOMICS, V30, P312, DOI 10.1006/geno.1995.9872
   PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269
   RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4
   REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6
   RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X
   Ruoslahti E, 1997, J CLIN INVEST, V99, P1149, DOI 10.1172/JCI119269
   SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642
   Shattil SJ, 1997, J CLIN INVEST, V100, pS91
   TANIWAKI M, 1994, BLOOD, V83, P2962, DOI 10.1182/blood.V83.10.2962.2962
   TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023
   Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4
   VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4
   ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404
NR 32
TC 140
Z9 148
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 6
PY 1999
VL 274
IS 32
BP 22476
EP 22483
DI 10.1074/jbc.274.32.22476
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 223YD
UT WOS:000081868400053
PM 10428823
OA Bronze
DA 2020-08-12
ER

PT J
AU Tsui, SKW
   Chan, PPK
   Cheuk, CW
   Liew, CC
   Waye, MMY
   Fung, KP
   Lee, CY
AF Tsui, SKW
   Chan, PPK
   Cheuk, CW
   Liew, CC
   Waye, MMY
   Fung, KP
   Lee, CY
TI A novel cDNA encoding for a LIM domain protein located at human
   chromosome 14q32 as a candidate for leukemic translocation
SO BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL
LA English
DT Article
DE Homo sapiens; heart cDNA; chromosome 14; leukemia
ID CYSTEINE-RICH PROTEIN; ZINC-FINGER MOTIF; ATAXIA TELANGIECTASIA; CHAIN
   LOCUS; PATIENT; FAMILY; BREAKPOINT; EFFICIENT; MEMBER; GENES
AB A full-length cDNA clone encoding a zinc finger protein was isolated and sequenced. This full-length clone consists of 728 bp and has a predicted open reading frame (ORF) encoding 208 amino acids. The ORF of this polypeptide codes for the human cysteine-rich protein 2 (HCRP2) and has an amino acid sequence that is 92.8% identical to its rat homolog (RCRP2). HCRP2 was mapped to chromosome 14q32, which is a hot spot of translocation in tumor development, by fluorescent in situ hybridization (FISH).
C1 UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA.
RP Tsui, SKW (corresponding author), CHINESE UNIV HONG KONG,DEPT BIOCHEM,SHATIN,HONG KONG.
RI 韋妙宜教授, Mary Miu Yee Waye/A-9674-2008; Tsui, Stephen
   Kwok-Wing/E-4385-2015; Waye, Mary/U-9129-2019; Fung, Kwok
   Pui/R-9708-2018
OI 韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917; Tsui, Stephen
   Kwok-Wing/0000-0003-0686-4259; Waye, Mary/0000-0002-2582-4917; Fung,
   Kwok Pui/0000-0001-6214-5123
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9
   BERTNESS VL, 1990, CANCER GENET CYTOGEN, V44, P47, DOI 10.1016/0165-4608(90)90196-H
   BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516
   BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367
   DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287
   FUNG YW, 1995, GENOMICS, V28, P602, DOI 10.1006/geno.1995.1200
   HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275
   HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509
   HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z
   LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871
   LIEW CC, 1993, J MOL CELL CARDIOL, V25, P891, DOI 10.1006/jmcc.1993.1101
   LIEW CC, 1994, P NATL ACAD SCI USA, V91, P10645, DOI 10.1073/pnas.91.22.10645
   MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171
   OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3
   RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641
   RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3
   SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573
   SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5
   Staal SP, 1988, GENOMICS, V2, P96, DOI 10.1016/0888-7543(88)90114-0
   TAKAYAMA H, 1992, ONCOGENE, V7, P1185
   TSUI SKW, 1994, BIOCHEM BIOPH RES CO, V205, P497, DOI 10.1006/bbrc.1994.2693
   TSUI SKW, 1995, BIOTECHNIQUES, V19, P577
   WANG XK, 1992, J BIOL CHEM, V267, P9176
NR 24
TC 19
Z9 20
U1 0
U2 0
PU ACADEMIC PRESS AUST
PI MARRICKVILLE
PA LOCKED BAG 16, MARRICKVILLE NSW 2204, AUSTRALIA
SN 1039-9712
J9 BIOCHEM MOL BIOL INT
JI Biochem. Mol. Biol. Int.
PD JUL
PY 1996
VL 39
IS 4
BP 747
EP 754
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA VA368
UT WOS:A1996VA36800013
PM 8843343
DA 2020-08-12
ER

PT J
AU CHANG, H
   MESSNER, HA
   WANG, XH
   YEE, C
   ADDY, L
   MEHARCHAND, J
   MINDEN, MD
AF CHANG, H
   MESSNER, HA
   WANG, XH
   YEE, C
   ADDY, L
   MEHARCHAND, J
   MINDEN, MD
TI A HUMAN LYMPHOMA CELL-LINE WITH MULTIPLE IMMUNOGLOBULIN REARRANGEMENTS
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE CANCER; CHROMOSOME TRANSLOCATION; HEMATOPOIESIS
ID CARDIAC-TRANSPLANT RECIPIENTS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC
   LYMPHOCYTIC-LEUKEMIA; HUMAN FOLLICULAR LYMPHOMAS; BREAKPOINT-CLUSTER
   REGION; CHROMOSOME-TRANSLOCATION; GENE REARRANGEMENTS; RICHTERS
   SYNDROME; CHAIN GENES; ORIGIN
AB The development of a cell culture system efficient in the establishment of lymphoma cell lines has made it possible to dissect basic biological and molecular aspects of lymphoma cells. We have established a lymphoma cell line from a patient with B cell lymphoma. The cell line has a complex karyotype with translocations involving bands 8q24, 14q32, and 18q21. Molecular analysis revealed that the Myc gene was rearranged; we were unable to demonstrate rearrangement of the Bcl-2 gene. Evaluation of the structure of the heavy chain Ig genes revealed that the cell line carried the same rearrangements as the cells from which the cell line was derived. The pattern of rearrangement, however, was unsual in that there were at least four rearranged bands when DNA cut with HindIII was probed with a fragment of the heavy chain joining region. To further characterize the cell line, subclones were derived. Individual subclones had the same pattern of rearrangement as the parent cell line. The results of these studies provide evidence that multiple rearranged Ig genes may be present in a single clone of cells.
C1 PRINCESS MARGARET HOSP, ONTARIO CANC INST, DEPT MED & MED BIOPHYS, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA.
   WELLESLEY COLL HOSP, CYTOGENET LAB, TORONTO M4X 1K9, ONTARIO, CANADA.
CR ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559
   ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9
   ANDIMAN W, 1983, J INFECT DIS, V148, P967, DOI 10.1093/infdis/148.6.967
   ARNOLD A, 1983, NEW ENGL J MED, V309, P1593, DOI 10.1056/NEJM198312293092601
   BAKHSHI A, 1983, NEW ENGL J MED, V309, P826, DOI 10.1056/NEJM198310063091404
   BEISHUIZEN A, 1991, LEUKEMIA, V5, P657
   BERTOLI LF, 1987, BLOOD, V70, P45
   BERTOLI LF, 1988, BLOOD, V72, P94
   BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229
   CARTER M, 1991, LEUKEMIA, V5, P668
   CLEARY ML, 1984, NEW ENGL J MED, V310, P477, DOI 10.1056/NEJM198402233100801
   CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315
   CLEARY ML, 1984, P NATL ACAD SCI-BIOL, V81, P593, DOI 10.1073/pnas.81.2.593
   CLEARY ML, 1984, LANCET, V2, P489
   CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439
   CLEARY ML, 1988, J EXP MED, V167, P582, DOI 10.1084/jem.167.2.582
   DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   FOA R, 1984, J CLIN INVEST, V74, P1756, DOI 10.1172/JCI111594
   GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548
   GAUWERKY CE, 1988, ONCOGENE, V2, P431
   HIETER PA, 1981, NATURE, V294, P536, DOI 10.1038/294536a0
   HIETER PA, 1982, J BIOL CHEM, V257, P1516
   KIEM HP, 1990, ONCOGENE, V5, P1815
   KITCHINGMAN GR, 1986, BLOOD, V67, P698
   KORSMEYER SJ, 1981, P NATL ACAD SCI-BIOL, V78, P7096, DOI 10.1073/pnas.78.11.7096
   KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770
   LEVY R, 1987, IMMUNOL REV, V96, P43, DOI 10.1111/j.1600-065X.1987.tb00508.x
   MATSUZAKI H, 1990, ACTA HAEMATOL-BASEL, V84, P156
   OSTROWSKI M, 1989, AM J CLIN PATHOL, V91, P215, DOI 10.1093/ajcp/91.2.215
   PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166
   RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1
   SIEGELMAN MH, 1985, J EXP MED, V161, P850, DOI 10.1084/jem.161.4.850
   SKLAR J, 1984, NEW ENGL J MED, V311, P20, DOI 10.1056/NEJM198407053110104
   TWEEDDALE ME, 1987, BLOOD, V69, P1307
   VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210
   WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904
   YEE C, 1989, BLOOD, V74, P798
NR 38
TC 12
Z9 12
U1 0
U2 1
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR
PY 1992
VL 89
IS 3
BP 1014
EP 1020
DI 10.1172/JCI115642
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA HH513
UT WOS:A1992HH51300039
PM 1311715
OA Bronze, Green Published
DA 2020-08-12
ER

EF